

NATIONAL TOXICOLOGY PROGRAM  
US Department of Health and Human Services



# Center For The Evaluation Of Risks To Human Reproduction

---

# DRAFT

**NTP-CERHR EXPERT PANEL REPORT on the  
REPRODUCTIVE and DEVELOPMENTAL  
TOXICITY of METHYLPHENIDATE**

---

November, 2004

NTP-CERHR - -

---

## **PREFACE**

To be added after meeting.

**Reports can be obtained from the web site (<http://cerhr.niehs.nih.gov>) or from:**

Michael D. Shelby, Ph.D.  
NIEHS EC-32  
PO Box 12233  
Research Triangle Park, NC 27709  
919-541-3455  
[shelby@niehs.nih.gov](mailto:shelby@niehs.nih.gov)

### **A Report of the CERHR Expert Panel:**

Mari Golub, chair	University of California at Davis
Lucio Costa	University of Washington
Kevin Crofton	U.S. Environmental Protection Agency
Deborah Frank	Boston Medical Center
Peter Fried	Carleton University
Beth Gladen	National Institute of Environmental Health Sciences
Rogene Henderson	Inhalation Toxicology Research Institute
Erica Liebelt	University of Alabama at Birmingham School of Medicine
Shari Lusskin	New York University School of Medicine
Sue Marty	The Dow Chemical Company
Andrew Rowland	University of New Mexico
John Scialli	Phoenix, Arizona
Mary Vore	University of Kentucky

### **With the Support of CERHR Staff:**

#### **NTP/NIEHS**

Michael Shelby, Ph.D.	Director, CERHR
Christopher Portier, Ph.D.	Associate Director, National Toxicology Program

#### **Sciences International, Inc.**

Anthony Scialli, M.D.	Principal Scientist
Annette Iannucci, M.S.	Toxicologist
Gloria Jahnke, D.V.M.	Toxicologist
Jessie Poulin, B.A.	Associate

### **Note to Reader:**

This report is prepared according to the Guidelines for CERHR Panel Members established by NTP/NIEHS. The guidelines are available on the CERHR web site (<http://cerhr.niehs.nih.gov/>). The format for Expert Panel Reports includes synopses of studies reviewed, followed by an evaluation of the Strengths/Weaknesses and Utility (Adequacy) of the study for CERHR evaluation. Statements and conclusions made under Strengths/Weaknesses and Utility evaluations are those of the Expert Panel and are prepared according to the NTP/NIEHS guidelines. In addition, the Panel often makes comments or notes limitations in the synopses of the study. Bold, square brackets are used to enclose such statements. As discussed in the guidelines, square brackets are used to enclose key items of information not provided in a publication, limitations noted in the study, conclusions that differ from those of the authors, and conversions or analyses of data conducted by the Panel.

## Abbreviations

ADHD	attention/deficit-hyperactivity disorder
ANCOVA	analysis of covariance
ANOVA	analysis of variance
AUC	area under the concentration versus time curve
BMD <sub>10</sub>	benchmark dose, 10% effect level
BMDL	benchmark dose 95 <sup>th</sup> percentile lower confidence limit
BMI	body-mass index
BUN	blood urea nitrogen
bw	body weight
CAS RN	Chemical Abstracts Service Registry Number
CERHR	Center for the Evaluation of Risks to Human Reproduction
CI	confidence interval
C <sub>max</sub>	maximum concentration
CNS	central nervous system
CYP	cytochrome P450
DAPI	4',6-diamidino-2-phenylindole
EEG	electroencephalogram
EKG	electrocardiograph
EPA	Environmental Protection Agency
Eq	equivalent
f	female
F <sub>0</sub>	parental generation
F <sub>1</sub>	first filial generation
F <sub>2</sub>	second filial generation
FDA	Food and Drug Administration
FIFRA	Federal Insecticide, Fungicide, Rodenticide Act
g	gram(s)
FSH	follicle stimulating hormone
GABA	γ-amino-butyric acid
GC	gas chromatography
GD	gestation day(s)
GLP	Good Laboratory Practice
GSH	glutathione
h	hour(s)
HPLC	high performance liquid chromatography
HSDB	Hazardous Substances Data Bank
IGHD	idiopathic growth hormone deficiency
ip	intraperitoneal
ISS	idiopathic short stature
iv	intravenous
kg	kilogram(s)
K <sub>ow</sub>	octanol-water partition coefficient
L	liter(s)
LD <sub>50</sub>	lethal dose, 50% mortality
LH	luteinizing hormone

LOAEL	low observed adverse effect level
m	male
M	molar
MAOI	monoamine oxidase inhibitor
max	maximum
mM	millimolar
mmol	millimole(s)
mol	mole
mRNA	messenger ribonucleic acid
n or no	number
N/A	non-applicable
ND	not determined
ng	nanogram(s)
NIEHS	National Institute of Environmental Health Sciences
NIH	National Institutes of Health
NIOSH	National Institute of Occupational Safety and Health
nmol	nanomole(s)
NOAEL	no observed adverse effect level
NOEL	no observed effect level
ns	non-significant
NS	not specified
NTP	National Toxicology Program
OR	odds ratio
PND	postnatal day
PND	postnatal day(s)
ppm	parts per million
PRL	prolactin
RIA	radioimmunoassay
RR	relative risk
sc	subcutaneous
SD	standard deviation
SE	standard error
SEM	standard error of the mean
SMVCE	sperm morphology and vaginal cytology examinations
$t_{1/2}$	half-life of elimination
$T_{max}$	maximum time
U.S.	United States
USP	United States Pharmacopoeia
v	volume
$V_d$	volume of distribution
wk	week(s)
$\mu\text{g}$	microgram(s)
$\mu\text{L}$	microliter(s)
$\mu\text{m}$	micrometer(s)
$\mu\text{M}$	micromolar
$\mu\text{mol}$	micromole(s)

## TABLE OF CONTENTS

<b>PREFACE</b> .....	<b>II</b>
<b>LIST OF TABLES</b> .....	<b>VIII</b>
<b>LIST OF FIGURES</b> .....	<b>VIII</b>
<b>1.0 CHEMISTRY, USE, AND HUMAN EXPOSURE</b> .....	<b>1</b>
1.1 CHEMISTRY .....	1
Nomenclature .....	1
1.1.2 Formula and molecular mass.....	1
1.1.3 Chemical and physical properties .....	2
1.1.4 Technical products and impurities .....	2
1.2 USE AND HUMAN EXPOSURE.....	4
1.2.1 Production information .....	4
1.2.2 Use .....	4
1.2.3 Human Exposure .....	6
1.3 UTILITY OF EXPOSURE DATA .....	7
1.4 SUMMARY OF HUMAN EXPOSURE DATA .....	7
<b>2.0 GENERAL TOXICOLOGY AND BIOLOGIC EFFECTS</b> .....	<b>8</b>
2.1 PHARMACOKINETICS AND PHARMACODYNAMICS .....	8
2.1.1 Human .....	8
2.1.1.1 Pharmacodynamics .....	8
2.1.1.2 Absorption .....	9
2.1.1.3 Distribution.....	13
2.1.1.4 Metabolism .....	13
2.1.1.5 Excretion.....	15
2.1.1.6 Stereoselective pharmacokinetics.....	16
2.1.2 Experimental Animal .....	18
2.1.2.1 Pharmacodynamics .....	18
2.1.2.2 Pharmacokinetics .....	19
2.2 GENERAL TOXICITY .....	24
2.2.1 Human .....	24
2.2.1.1 Side effects of medication therapy.....	24
2.2.1.2 Overdose symptoms .....	26
2.2.1.3 Drug Interactions .....	27
2.2.1.4 Drug Abuse.....	28
2.2.2 Experimental Animal .....	28
2.3 GENETIC TOXICOLOGY .....	33
2.4 CARCINOGENICITY .....	37
2.4.1 Human.....	37
2.4.2 Experimental animal .....	37
2.5 POTENTIALLY SENSITIVE SUBPOPULATIONS .....	40
2.5.1 Pharmacogenetics.....	40
2.5.2 Sex-related differences.....	40
2.5.3 Children and Juvenile Mice.....	41
2.6 SUMMARY OF GENERAL TOXICOLOGY AND BIOLOGIC EFFECTS .....	42
2.6.1 Pharmacodynamics and pharmacokinetics.....	42
2.6.2 General toxicity .....	44
2.6.2.1 Humans.....	44
2.6.2.2 Experimental Animal .....	45

2.6.3 Genetic toxicology .....	45
2.6.4 Carcinogenicity .....	45
2.6.5 Potentially sensitive subpopulations .....	46
<b>3.0 DEVELOPMENTAL TOXICITY DATA .....</b>	<b>47</b>
3.1 HUMAN DATA .....	47
3.1.1 Methylphenidate Exposure During Pregnancy.....	47
3.1.2. Adverse Effects of Methylphenidate Therapy in Children .....	47
3.1.2.1 <i>Controlled Side Effect Evaluations</i> .....	48
3.1.2.2 <i>Clinical laboratory findings</i> .....	54
3.1.2.3 <i>Cardiovascular function</i> .....	57
3.1.2.4 <i>Seizures</i> .....	62
3.1.2.5 <i>Psychotic symptoms</i> .....	63
3.1.2.6 <i>Onset or Worsening of Tics on Methylphenidate</i> .....	63
3.1.2.7 <i>Substance Use Disorders</i> .....	71
3.1.2.8 <i>Effects on height and weight</i> .....	81
3.2 EXPERIMENTAL ANIMAL DATA .....	95
3.2.1 Prenatal toxicity endpoints .....	95
3.2.2 Postnatal development and behavior .....	97
3.2.3 Postnatal neurochemical effects .....	105
3.2.4 Unpublished studies .....	106
3.3 UTILITY OF DEVELOPMENTAL TOXICITY DATA.....	107
3.4 SUMMARY OF DEVELOPMENTAL TOXICITY DATA .....	108
3.4.1 Human Data .....	108
3.4.2 Experimental Animal Data.....	109
<b>4.0 REPRODUCTIVE TOXICITY DATA .....</b>	<b>115</b>
4.1 HUMAN DATA .....	115
4.2 EXPERIMENTAL ANIMAL DATA .....	115
4.3 UTILITY OF REPRODUCTIVE TOXICITY DATA .....	119
4.4 SUMMARY OF REPRODUCTIVE TOXICITY DATA .....	120
4.4.1 Human Data .....	120
4.4.2 Experimental Animal Data.....	120
<b>5.0 SUMMARIES, CONCLUSIONS, AND CRITICAL DATA NEEDS .....</b>	<b>122</b>
5.1 DEVELOPMENTAL TOXICITY .....	122
5.2 REPRODUCTIVE TOXICITY .....	122
5.3 SUMMARY OF HUMAN EXPOSURES .....	122
5.4 OVERALL CONCLUSIONS .....	122
5.5 CRITICAL DATA NEEDS .....	122
<b>6.0 REFERENCES .....</b>	<b>123</b>

## List of Tables

Table 1. Active and Inactive Ingredients in Various Methylphenidate Hydrochloride Brands .....	3
Table 2. Pharmacokinetics in humans for Various Brands of Methylphenidate.....	10
Table 3. Summary of Pharmacokinetic Data for Racemic Methylphenidate in Children Given Single Oral Doses .....	12
Table 4. Methylphenidate Urinary Metabolites in Humans, Rats, and Dogs .....	14
Table 5. Pharmacokinetic Parameters in Children Orally Administered <i>d,l</i> -Methylphenidate.....	16
Table 6. Pharmacokinetic Parameters in Children Orally Dosed with Sustained-Release <i>d,l</i> - Methylphenidate .....	17
Table 7. Pharmacokinetics in Children Orally Administered <i>d,l</i> -, <i>d</i> -, or <i>l</i> -Methylphenidate.....	17
Table 8. Pharmacokinetics of Methylphenidate and Ritalinic Acid in Adults.....	18
Table 9. Pharmacokinetic Results in Pregnant Rats Given <i>d</i> - or <i>d,l</i> -Methylphenidate.....	21
Table 10. Pharmacokinetic Results in Pregnant New Zealand White Rabbits Given <i>d</i> - or <i>d,l</i> - Methylphenidate .....	22
Table 11. Pharmacokinetic Results for <i>d</i> -Methylphenidate in Nonpregnant Rats Given <i>d</i> - or <i>d,l</i> - Methylphenidate .....	23
Table 12. Pharmacokinetic Results in Dogs Given <i>d</i> - or <i>d,l</i> -Methylphenidate .....	24
Table 13. Treatment-Emergent Adverse Effects in $\geq 1\%$ of Patients in Double-blind Methylphenidate Studies .....	25
Table 14. Adverse Events in Published Studies of Methylphenidate in Children .....	26
Table 15. Symptoms Reported in Methylphenidate Poisonings.....	27
Table 16. LD <sub>50</sub> Values for Methylphenidate.....	29
Table 17. <i>In vitro</i> Genetic Toxicity Studies of Methylphenidate .....	35
Table 18. Incidence of Liver Lesions or Tumors in Mice Treated With <i>d,l</i> -Methylphenidate in the Diet ...	39
Table 19. Pharmacokinetic Parameters of in Boys and Girls Administered a Single 10 mg dose of <i>d</i> - Methylphenidate, FDA.....	40
Table 20. Pharmacokinetic Parameters in Men and Women Administered a Single 20 mg dose of <i>d</i> - Methylphenidate under Fasting or Fed Conditions.....	41
Table 21. Comparison of Pharmacokinetics in Children and Adults Orally Administered 0.30 mg/kg bw Methylphenidate .....	41
Table 22. Comparison of C <sub>max</sub> and AUC Values for <i>d</i> -Methylphenidate in Adults and Children.....	42
Table 23. Frequency of Side Effects on Placebo or Methylphenidate.....	50
Table 24. Comparison of Growth Hormone, Prolactin, and Somatomedin Levels in Children During and Following Abstinence from Methylphenidate Therapy .....	56
Table 25. Growth Hormone Response to a Clonidine Challenge in Boys Before, During, and After Methylphenidate Treatment.....	56
Table 26. Reports of Tics in Children Treated with Stimulant Medication.....	65
Table 27. Meta-analyses for Studies Examining Substance Abuse in Subjects Who Were or Were Not Medicated for ADHD .....	80
Table 28. Methylphenidate Growth Studies .....	82
Table 29. Height and Weight Change in Children in the Multimodal Treatment Study During the 14-Month Treatment Phase .....	94
Table 30. Height and Weight Change in Children in the Multimodal Treatment Study According to Self- Identified Medication Exposure .....	94
Table 31. Postnatal Methylphenidate Treatment Studies in Rats .....	100
Table 32. Sensitization Responses in Rats Treated with Methylphenidate .....	103
Table 33. Summary of Animal Developmental Toxicity Studies.....	113

## List of Figures

Figure 1. Methylphenidate structure.....	1
Figure 2. Metabolic Pathways of Methylphenidate in Human, Rat, and Dog.....	15



## 1.0 CHEMISTRY, USE, AND HUMAN EXPOSURE

This section is initially based on secondary review sources. Primary study reports are addressed by the Expert Panel if they contain information that is highly relevant to a CERHR evaluation of potential human developmental or reproductive toxicity or if the studies were released subsequent to the reviews.

### 1.1 Chemistry

#### *Nomenclature*

Methylphenidate drugs consist of a 50/50 mixture of the *d*-threo- and *l*-threo-enantiomers (1) or only the *d*-threo-enantiomer (2). The chemical name is methyl alpha-phenyl-2-piperidineacetate (CAS RN 113-45-1). Synonyms listed in ChemIDplus (3) include:


2-Piperidineacetic acid, alpha-phenyl-, methyl ester  
Methyl (2-phenyl-2-(2-piperidyl)acetate)  
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate  
Methyl phenidylacetate  
Methylofenidan  
Methylphenidan  
Methylphenidate  
alpha-Phenyl-2-piperidineacetic acid methyl ester

*d,l*-Methylphenidate hydrochloride (CAS RN 298-59-9) is marketed under the names of Ritalin®, by Novartis Pharmaceuticals Corporation (4), Metadate® by Celltech Pharmaceuticals, Inc. (5), Methylin® by Mallinckrodt, Inc. (6), and Concerta® by Alza Corporation (7). The products are available as immediate-acting and/or extended-release formulations. *d*-Methylphenidate is marketed under the name of Focalin™ by Novartis Pharmaceuticals Corporation (2). The Expert Panel recognizes that the active medicinal compound in all these formulations is methylphenidate.

#### *1.1.2 Formula and molecular mass*

The chemical formula for methylphenidate is C<sub>14</sub>H<sub>19</sub>NO<sub>2</sub> (4). The molecular mass is 233.31. The structure is shown in Figure 1. The chemical formula for methylphenidate hydrochloride is C<sub>14</sub>H<sub>19</sub>NO<sub>2</sub>·HCl and it has a molecular mass of 269.77.

**Figure 1. Methylphenidate structure.**  
The *d*-enantiomer is shown with the chiral centers numbered.



### ***1.1.3 Chemical and physical properties***

As stated above, methylphenidate used in drug therapy consists of a 50/50 racemic mixture of *d*- and *l*-enantiomers or the *d*-enantiomer. The *d*-enantiomer has greater pharmacologic potency than the *l*-enantiomer. Unless specified otherwise, the information in this exposure section applies to both enantiomers.

Methylphenidate hydrochloride is a white, odorless, crystalline powder (4). Solutions of the compound are acidic to litmus. Methylphenidate hydrochloride has a pK<sub>a</sub> of 8.5 and it is relatively stable in acidic solutions (Reviewed in (8)). Methylphenidate hydrochloride is freely soluble in methanol and water, soluble in alcohol, and slightly soluble in chloroform and acetone (4). The melting point for methylphenidate hydrochloride is 212–216°C (8).

### ***1.1.4 Technical products and impurities***

Methylphenidate hydrochloride medications are available as capsules, tablets, and solutions. Table 1 summarizes the amount of active ingredient and lists the inactive ingredients in each marketed brand of methylphenidate hydrochloride tablets or capsules. Mallinckrodt Baker markets solutions under the name of Methylin® (9). Solutions contain methylphenidate hydrochloride at 5 mg/mL and 10 mg/mL. Information on inactive ingredients is not available.

**Table 1. Active and Inactive Ingredients in Various Methylphenidate Hydrochloride Brands**

Brand	Enantiomers	Methylphenidate hydrochloride	Inactive ingredients	Reference
Ritalin®	50/50 <i>d,l</i> -	5, 10, or 20 mg	D&C Yellow No. 10, FD&C Green no. 3, lactose, magnesium stearate, polyethylene glycol, starch, sucrose, talc, and/or tragacanth	Novartis (4)
Ritalin®SR	50/50 <i>d,l</i> -	20 mg	Cellulose compounds, cetostearyl alcohol, lactose, magnesium stearate, mineral oil, povidone titanium dioxide, and zein.	Novartis (4)
Ritalin®LA	50/50 <i>d,l</i> -	20, 30, or 40 mg	Ammonio methacrylate copolymer, black iron oxide, gelatin, methacrylic acid copolymer, polyethylene glycol, red iron oxide, sugar spheres, talc, titanium dioxide, triethyl citrate, and/or yellow iron oxide	Novartis (10)
Metadate® ER	50/50 <i>d,l</i> -	10 or 20 mg	Cetyl alcohol, ethylcellulose, anhydrous lactose, and magnesium stearate	Celltech (11)
Metadate®CD	50/50 <i>d,l</i> -	10, 20, or 30 mg	Sugar spheres, povidone, hydroxypropylmethylcellulose and polyethylene glycol, ethylcellulose aqueous dispersion, dibutyl sebacate, gelatin, titanium dioxide, FD&C Blue No. 2, FDA/E172 Yellow Iron Oxide, and/or FDA/E172 Red Iron Oxide	Celltech (5)
Methylin®	50/50 <i>d,l</i> --	5, 10, or 20 mg	Lactose, monohydrate NF, magnesium stearate NF, microcrystalline cellulose NF, and talc USP	Mallinckrodt (6)
Methylin® chewable tablets	50/50 <i>d,l</i> -	2.5, 5, or 10 mg	Aspartame NF, maltose, microcrystalline cellulose NF, guar gum NF, grape flavor, pregelatinized starch NF, and stearic acid NF	Mallinckrodt (12)
Methylin®ER	50/50 <i>d,l</i> -	10 or 20 mg	Hydroxypropyl methylcellulose 2208 USP, magnesium stearate NF, microcrystalline cellulose NF, and talc USP	Mallinckrodt (6)
Concerta®	50/50 <i>d,l</i> -	18, 27, 36, or 54 mg	Butylated hydroxytoluene, carnauba wax, cellulose acetate, hypromellose lactose, phosphoric acid, poloxamer, polyethylene glycol, polyethylene oxides, povidone, propylene glycol, sodium chloride, stearic acid, succinic acid, synthetic iron oxides, titanium dioxide, and triacetin	ALZA (7)
Focalin™	<i>d</i> -	2.5, 5, or 10 mg	Pregelatinized starch, lactose monohydrate, sodium starch glycolate, microcrystalline cellulose, magnesium stearate, FD&C Blue No. 1 #5516 aluminum lake, and/or D&C Yellow Lake #10.	Novartis (2)

## 1.2 Use and Human Exposure

### 1.2.1 Production information

Manufacture of methylphenidate hydrochloride begins with hydrolysis of  $\alpha$ -phenyl-2-pyridineacetonitrile in dilute sulfuric acid (reviewed in (8)). The hydrolysis product,  $\alpha$ -phenyl-2-pyridineacetamide, is hydrogenated to form a diastereoisomeric mixture of  $\alpha$ -phenyl-2-piperidineacetamide. The diastereoisomeric mixture is heated in sodium hydroxide to convert it to a threo racemic mixture; in the same reaction, it is hydrolyzed to  $\alpha$ -phenyl-2-piperidineacetic acid and reacted with methanol to form the methyl ester free base. The free base is converted to methylphenidate hydrochloride. **[No information was located on manufacture or isolation of the *d*-enantiomer.]**

Companies that are FDA-approved to manufacture brand name methylphenidate drugs include Novartis Pharmaceuticals Corporation, Celltech Pharmaceuticals, Inc., Mallinckrodt, Inc.; Alza Corporation Novartis Pharmaceuticals' Focalin™ and Ritalin®LA brands and Celltech Pharmaceuticals' Metadate®CD brand are currently under patent (9).

Companies that have FDA approval to produce unbranded (generic) methylphenidate include Able, Purepac Pharma, Watson Labs, Celltech MFG, and Mallinckrodt (9).

The U.S. Drug Enforcement Agency (DEA) determines a yearly aggregate production quota based on sales and inventory data from manufacturers and information provided by the Food and Drug Administration (FDA) (13). The production quota for methylphenidate was reported at 1768 kg [**3898 pounds**] in 1990 and at 14,957 kg [**32,975 pounds**] in 2000. The United Nations (14) reported U.S. methylphenidate production at 12,638 kg [**27,862 pounds**] in 2000, 15,009 kg [**33,089 pounds**] in 2001, and 20,725 kg [**45,690 pounds**] in 2002. From 2000 to 2002, no methylphenidate was imported into the U.S., but exports totaled 193 kg [**425 pounds**] in 2000, 329 kg [**725 pounds**] in 2001, and 501 kg [**1105 pounds**] in 2002 (14). The DEA (13) stated that according to a UN report, the U.S. produced and consumed about 85% of the global supply of methylphenidate in 1999. U.S. sales of methylphenidate remained stable at ~2000 kg [**4409 pounds**] prior to 1991, but increased nearly 500% by 1999 (13).

### 1.2.2 Use

Methylphenidate is a central nervous system (CNS) stimulant that is approved by the FDA for treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy in persons 6 years and older. Safety and efficacy have not been established in children younger than 6 years old. In 2000, the DEA (13) stated that "After sharp increases in the use of methylphenidate in the early 1990s, methylphenidate prescriptions have leveled off at about 11 million per year for the past four years." Most methylphenidate prescriptions are written for treatment of children diagnosed with ADHD. Although the product label recommends against the use of medication in children younger than 6 years of age, in 1998 it was estimated that 4000 prescriptions were written for children 2 years old and younger and that 40% of all prescriptions for ADHD were written for 3–9 year olds, reflecting a difference between approved labeling and clinical practice (Scialli JV, personal communication October 18, 2004). Boys are about four times more likely than girls to be diagnosed with ADHD and prescribed stimulant medication. The DEA (13) found the use of methylphenidate to vary greatly among states and communities within each state. While estimates of the prevalence of ADHD in the U.S. are 3–5%, analysis of prescription data and epidemiologic studies found some communities with almost no methylphenidate use and others in which 10–20% of students were given methylphenidate. It has been stated that 10–60% of people with childhood ADHD will have the full or residual syndrome persisting into adulthood (15-17). Methylphenidate could potentially be used to treat ADHD or narcolepsy in pregnant women, but there is no information on the numbers of pregnant women prescribed the drug.

The Expert Panel is aware of off-label uses of methylphenidate to treat depression, primarily as an adjunct to antidepressant medication, and to treat patients with post-stroke cognitive impairment (Scialli JV, Lusskin S, personal communication, September 22, 2004). Similar uses have been documented in reviews (18). While depression is common in men and women of reproductive age, strokes most often occur in older individuals. The number of prescriptions written for off-label use is not known.

The National Institute on Drug Abuse (NIDA) (19) states that addiction to stimulant medications does not occur when medicines are taken in the form and dosage prescribed. However, there is potential for methylphenidate abuse due to its stimulant-related effects such as appetite suppression, increased wakefulness, improved focus/attentiveness, and euphoria associated with somatic sensations called “tweaking.” Under the Controlled Substances Act, methylphenidate is listed as a Schedule II drug, a medically utilized drug with high potential for abuse (13).

Methylphenidate is available for illegal use only through diversion from legitimate channels, not through illicit manufacture (13). Diversion occurs through drug thefts, illegal sale, prescription forgery, and fraudulent presentation with ADHD symptoms to multiple doctors. The DEA reports incidences of methylphenidate stolen from pharmacies or schools, teachers or school nurses personally using methylphenidate prescribed for students, children selling or giving their prescribed methylphenidate to other children, and children taken to numerous physicians by parents in order to obtain the drug for themselves or for “therapeutic trials” for other children at home. The DEA presents the following statistics on methylphenidate diversion:

- Methylphenidate was one of the ten most frequently reported stolen controlled drugs from January 1990 to May 1995;
- About 700,000 dosage units of methylphenidate were reported to the DEA drug theft database from January 1996 to December 1997;
- In 1998, there were 376 reported thefts of methylphenidate from pharmacies.

The DEA (13) receives anecdotal reports of methylphenidate misuse in children on a daily basis. The following survey data was reported by the DEA (13):

- A 1999 national high school survey reported that about 3% of U.S. high school seniors illicitly used methylphenidate;
- A 1998 university survey reported that almost 7% of high school students illicitly used methylphenidate at least once and 2.5% used it more often;
- In 1998, the Drug Abuse Warning Network reported 1727 methylphenidate emergencies, 56% for 10–17 year olds;
- A 1996 DEA survey of 3 states found that 30–50% of adolescents in treatment centers reported “non-medicinal” use of methylphenidate, although it was not the primary drug of abuse.

There are concerns that students are using methylphenidate to prolong study time (20). In a 1993 survey of 48,500 students in grades 8–12 of 392 U.S. schools, methylphenidate use during the past year was reported by ~3–4% of students methylphenidate during the past month was reported by 1–2% of students (21). Usage rates were higher among students not planning to attend college. However, compared to age peers, college students reported a higher usage rate for

methylphenidate, with use during the past year reported at 5% for college students and 3% for young adults.

Although methylphenidate is abused, it is less likely to be abused than other, more bioavailable euphorogenic drugs such as cocaine; emergency room mentions for methylphenidate in the Drug Abuse Warning Network are 1/40<sup>th</sup> of those for cocaine (reviewed in (22)).

### **1.2.3 Human Exposure**

For the treatment of ADHD or narcolepsy, dose levels for methylphenidate range from 10 to 60 mg/day in children older than 6 years and in adults (4-7). Average doses in adults range from 20 to 30 mg/day. Manufacturers recommend an initial dose of 10 mg/day in children with weekly incremental increases of 5–10 mg/day until optimal dosages are obtained. According to the American Academy of Pediatrics (23), the recommended dosage for methylphenidate in children [age unspecified] is 0.3 mg/kg bw twice daily, gradually increased to 0.6–0.8 mg/kg bw twice daily. It has been reported that children continue to respond to the same dose of methylphenidate and there is little evidence that tolerance or behavioral sensitization develops (reviewed in (18, 22)). Methylphenidate is administered 1–3 times daily, depending on the required dose and the form of medication (24). Methylphenidate is available in short-acting, intermediate-acting (e.g. Ritalin®SR, Metadate®ER, and Methylin®ER), and extended-release (e.g., Concerta™, Metadate®CD, and Ritalin®LA) formulations (24). Generally, dosing occurs 2–3 times/day with short-acting formulations, 1–2 times/day with intermediate-acting formulations, and 1 time/day with extended-release formulations. Dose schedules can be individualized to meet the need of the patient. For example, if symptom relief is required only during school hours, dosing 5 days/week may be sufficient.

The AAP (24) notes that studies examining the safety and efficacy of stimulants involve a period of weeks to months. Due to the lack of long-term studies, manufacturers of methylphenidate recommend occasional discontinuation of treatment and evaluation of symptoms in children (4-7). Manufacturers report that treatment can often be discontinued at puberty. According to a 1988 report, average methylphenidate therapy durations are 2, 4, and 7 years when treatments commence during elementary, middle, and high school stages, respectively (reviewed in (8)). However, it has been reported that 10–60% of patients may continue to have symptoms of ADHD as adults (reviewed in (15-17)).

As stated in Section 1.2.2, methylphenidate is also encountered as a drug of abuse. In addition to orally ingesting methylphenidate, abusers often intranasally inhale crushed tablets or inject themselves with a solution of methylphenidate dissolved in water (19). Some users inject methylphenidate with cocaine or heroin. Typical abuse patterns include increased dosing, bingeing followed by depression, and an overpowering urge to continue drug use despite medical or social consequences (13).

An information sheet published by Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) (undated (25)), and the web site of The National Center for Gender Issues and AD/HD (NCGI) (26) indicate that ADHD is under-diagnosed in girls and women. To the extent that these organizations and other educational efforts increase the diagnosis of ADHD in women, prescription of methylphenidate and other stimulants to women of childbearing potential may increase. **[The Expert Panel recognizes that neither CHADD nor NCGI recommend medication therapy in preference to other management strategies for ADHD in adults.]**

### 1.3 Utility of Exposure Data

Human exposure data include dose ranges for approved therapeutic uses of methylphenidate. Blood levels of methylphenidate measured in children on therapy are presented in Section 2. There are no data on blood levels in pregnant women or blood or milk values in nursing women using the drug. It is not known how many pregnant or nursing women are exposed. There are no data on human exposures resulting from unapproved use or abuse of methylphenidate.

### 1.4 Summary of Human Exposure Data

Methylphenidate is a medication marketed for treatment of ADHD and narcolepsy in children 6 years and older and in adults. It is available as a 50/50 mixture of the *d*-threo- and *l*-threo-enantiomers (1) or only the *d*-threo-enantiomer (2). It is believed that human exposures are primarily through medication use and to a lesser extent, drug abuse. No information was identified on possible environmental or occupational exposure. Recommended oral doses are 10–60 mg/day for children older than 6 years and for adults. Methylphenidate is available in short-acting, intermediate-acting, and extended-release formulations and is administered 1–3 times daily, depending on the required dose and the form of medication. Dose schedules can be individualized according to patient needs. For example, if symptom relief is required only during school hours, dosing 5 days/week may be sufficient or discontinuation over the summer months is possible. In some cases of ADHD, treatment can be discontinued at puberty; in other cases, continued treatment through adulthood is recommended due to persistence of symptoms.

In 2000, the DEA (13) stated that about 11 million methylphenidate prescriptions were written in the past 4 years, most for treatment of ADHD in children. According to the DEA (13), production of methylphenidate was reported at 14,957 kg [32,975 pounds] in 2000. The United Nations (14) reported U.S. methylphenidate production at 12,638 kg [27,862 pounds] in 2000, 15,009 kg [33,089 pounds] in 2001, and 20,725 kg [45,690 pounds] in 2002.

The Expert Panel is aware of off-label uses of methylphenidate, such as treatment of depression with or without concomitant antidepressant therapy. Since depression is common in men and women of reproductive age, there is a potential for methylphenidate exposure in that population. Methylphenidate could potentially be used to treat ADHD or narcolepsy in pregnant women, but there is no information on the numbers of pregnant women prescribed the drug.

The DEA is aware of cases of methylphenidate diversions for illicit use, including by children or adolescents (13). One review reported that methylphenidate is less likely to be abused than drugs that induce euphoria, such as cocaine; emergency room mentions for methylphenidate in the Drug Abuse Warning Network are 1/40<sup>th</sup> those for cocaine (reviewed in (22)). In addition to orally ingesting methylphenidate, abusers often inhale crushed tablets or inject themselves with a solution of methylphenidate dissolved in water (19).

## 2.0 GENERAL TOXICOLOGY AND BIOLOGIC EFFECTS

Information in Section 2 is initially based upon reviews. The Panel reviewed primary studies if the information in reviews was inadequate; if the information presented in the primary studies is highly relevant for the evaluation of developmental or reproductive effects; or if the studies were published subsequent to reviews.

### 2.1 Pharmacokinetics and Pharmacodynamics

Unless otherwise specified, the information discussed in this section pertains to the racemic mixture of methylphenidate. Information on stereospecificity is discussed when available.

Pharmacokinetic information obtained from drug labels is summarized in Table 2. Details on protocols and results presented in drug labels are very limited. In addition, it is not known if the values presented are for *d*- or *d,l*-methylphenidate. Most likely, the majority of information in Table 2 is for racemic methylphenidate. Due to the limited amount of information presented in drug labels, and because children are a highly relevant population for this CERHR evaluation, the Expert Panel reviewed primary data on pharmacokinetics of methylphenidate in children. Information on pharmacokinetics in children given single oral doses of racemic methylphenidate is summarized in Table 3. The information in Table 3 is not specific for either enantiomer and represents the *d*- and *l*-enantiomers combined. In addition to the information in Table 3, one study reported that methylphenidate treatment of boys twice daily for 1 week resulted in mean plasma methylphenidate levels of 10.95 ng/mL at 0.25 mg/kg bw, 19.39 ng/mL at 0.50 mg/kg bw, and 41.75 at 1.0 mg/kg bw (27) [the time period between dosing and sampling was not specified]. A limited number of studies reported pharmacokinetic information for the *d*- and *l*-enantiomers separately, and those studies are reviewed in detail below.

#### 2.1.1 Human

##### 2.1.1.1 Pharmacodynamics

Methylphenidate is classified as a non-catecholamine sympathomimetic that is a direct and indirect adrenergic agonist (reviewed in (28)). No information was found on therapeutic mode of action for treatment of narcolepsy. Stimulatory effects presumably occur through methylphenidate activation of the brain stem arousal system and cortex (11, 12). The mode of action for therapeutic treatment of ADHD is not known. It is thought that methylphenidate blocks reuptake of norepinephrine and dopamine by the presynaptic neuron, thus increasing levels of these monoamine neurotransmitters in the extraneuronal space (5, 7, 10, 12). A study in adults demonstrated that orally administered methylphenidate occupies the dopamine transporter in the striatal region of the brain, but binds the transporter at a slower rate than observed with intravenous (iv) cocaine exposure (reviewed in Greenhill et al. (22)). Methylphenidate may also inhibit monoamine oxidase to a limited extent (reviewed in (29)).

Although stimulants decrease locomotor activity in children, an increase in activity is observed in experimental animal studies. A review by Solanto (29) discussed possible reasons for discordance between children and laboratory animals. One theory is that reduced activity and increased attention in children compares to decreased activity as a secondary effect of stereotypy in experimental animals given high doses of methylphenidate. However, several studies examining divergent thinking and cognitive perseverance indicated no or inconsistent associations between therapeutic effects and cognitive constriction or stereotypic thinking. (reviewed in (29, 30)). An alternate theory of mechanism of action in children is that stimulation of inhibitory presynaptic autoreceptors decreases dopamine activity, thus compensating for excessive dopamine activity those children with ADHD (reviewed in (29)).



Because most pharmacodynamic information was developed from experimental animal studies, more information is presented below in Section 2.1.2.

#### 2.1.1.2. Absorption

Methylphenidate is available in immediate-release and long-acting formulations. Some long-acting formulations consist of capsules containing a mixture of immediate-release and enteric-coated delayed released beads (5, 31). One long-acting preparation is also available as a tablet containing an outer membrane of drug for immediate release and a layered core of drug and osmotically-active component (7).

Immediate-release formulations of methylphenidate are rapidly absorbed and reach peak values within 1–3 hours following oral ingestion (2, 10, 12, 32). Extended-release (long-acting) formulations usually produce two peak blood levels in children with ADHD and in healthy adults (7, 10). A sharp initial slope to reach peak levels occurs during the first 1–3 hours and is similar to that for immediate-release formulations. A more gradual peak occurs 3–4 hours later. Extended-release formulations minimize variability between peak and trough levels that occur with multiple dosing of immediate-release formulations.

Intermediate-acting formulations, such as Ritalin®SR and Metadate® are absorbed more slowly but as completely as immediate-acting formulations (4). Bioavailability was reported to be the same upon administration of equivalent doses of immediate- or intermediate-acting formulations.

Data on the effects of food on absorption are variable. While one manufacturer reported that a high fat breakfast does not affect pharmacokinetics (7), other manufacturers reported that a high fat breakfast may slow absorption (4, 5, 10, 12). Although food may slow the absorption of methylphenidate, it appears to have little to no effect on  $C_{max}$  and AUC (2, 32). One study reported that ingestion of food accelerated methylphenidate absorption in hyperactive children ( $T_{max} = 1.60 \pm 0.42$  versus  $1.00 \pm 0.38$  hours [mean  $\pm$  SD] when taken while fasting versus with a meal) without reducing bioavailability (33). However, the FDA (31) noted that studies reporting no effects or more rapid absorption with food had design flaws including use of low calorie and low fat meals, very few subjects, and inadequate blood sampling.

Dosing with *d*-methylphenidate resulted in plasma *d*-methylphenidate levels similar to those obtained with twice the dose of *d,l*-methylphenidate (32). The pharmacokinetics of *d*-methylphenidate were not different from those of the racemic mixture (32, 34).

**Table 2. Pharmacokinetics in humans for Various Brands of Methylphenidate**

Brand name (reference) <ul style="list-style-type: none"> <li>• dose</li> <li>• activity</li> <li>• test subjects (n)</li> </ul>	C <sub>max1</sub> Mean±SD (range), ng/mL	C <sub>max2</sub> Mean±SD (range), ng/mL	T <sub>max1</sub> Mean±SD (range), hours	T <sub>max2</sub> Mean±SD (range), hours	AUC <sub>0-∞</sub> Mean±SD (range), ng-h/mL	Half-life Mean±SD (range), hours
Ritalin® (10) <ul style="list-style-type: none"> <li>• 20 mg (2 10-mg doses, 4 hours apart)</li> <li>• immediate-acting</li> <li>• children</li> </ul>	10.2±4.2 (4.2–20.2)	15.3±7.0 (6.2–32.8)	1.8±0.6 (1–3)	5.6±0.7 (5–8)	102.4±54.6 (40.5–261.6)	2.5±0.8 (1.8–5.3)
Ritalin® (10) <ul style="list-style-type: none"> <li>• 20 mg (2 10-mg doses, 4 hours apart)</li> <li>• immediate-acting</li> <li>• adults</li> </ul>	4.3±2.3 (1.8–7.5)	5.3±1.4 (3.6–7.2)	1.9±0.4 (1.3–2.7)	5.9±0.5 (5.0–6.5)	37.8±21.9 (14.3–85.3)	3.5±1.9 (1.3–7.7)
Methylin® Chewable Tablets (12) <ul style="list-style-type: none"> <li>• 20 mg</li> <li>• immediate-acting</li> <li>• NS except for half-life in adults</li> </ul>	10 (NS)	N/A	(NS) 1–2	N/A	NS	3
Ritalin®LA (10) <ul style="list-style-type: none"> <li>• 20 mg</li> <li>• long acting</li> <li>• children</li> </ul>	10.3±5.1 (5.5–26.6)	10.2±5.9 (4.5–31.1)	2.0±0.8 (1–3)	6.6±1.5 (5–11)	86.6±64.0 (43.3–301.44)	2.4±0.7 (1.5–4.0)
Ritalin®LA (10) <ul style="list-style-type: none"> <li>• 20 mg</li> <li>• long acting</li> <li>• adults</li> </ul>	5.3±0.9 (3.8–6.9)	6.2±1.6 (3.9–8.3)	2.0±0.9 (1.3–4.0)	5.5±0.8 (4.3–6.5)	45.8±10.0 (34.0–61.6)	3.3±0.4 (3.0–4.2)
Concerta® (7) <ul style="list-style-type: none"> <li>• 18 mg</li> <li>• long acting</li> <li>• adults</li> </ul>	NS	3.7±1.0	NS	6.8±1.8	41.8±13.9	3.5±0.4

Brand name (reference) • dose • activity • test subjects (n)	C <sub>max1</sub> Mean±SD (range), ng/mL	C <sub>max2</sub> Mean±SD (range), ng/mL	T <sub>max1</sub> Mean±SD (range), hours	T <sub>max2</sub> Mean±SD (range), hours	AUC <sub>0-∞</sub> Mean±SD (range), ng-h/mL	Half-life Mean±SD (range), hours
Metadate®CD (5) • 20 mg • long acting • children	8.6±2.2 <sup>b</sup>	10.9±3.9 <sup>b</sup>	~1.5	~4.5	63.0±16.8 (AUC <sub>0-9</sub> )	6.8 hours (age NS)
Metadate®CD (5) • 40 mg • long acting • children	16.8±5.1 <sup>b</sup>	15.1±5.8 <sup>b</sup>	~1.5	~4.5	120±39.6 (AUC <sub>0-9</sub> )	6.8 hours (age NS)
Focalin™ (32) <sup>c</sup> • 2.5 mg • immediate-acting • children	5.2±1.5	N/A	1.7±1.1	N/A	23.9±6.7	2.4±0.4
Focalin™ (32) <sup>c</sup> • 5 mg • immediate-acting • children	10.5±3.4	N/A	1.3±0.7	N/A	50.1±15.5	2.5±0.5
Focalin™ (32) <sup>c</sup> • 10 mg • immediate-acting • children	20.6±7.7	N/A	1.8±1.3	N/A	98.7±27.7	2.4±0.4
Focalin™ (2, 32) <sup>c</sup> • 20 mg • immediate-acting • adults	22.1±6.9 (fed) <sup>d</sup> 23.7±9.9 (fasting)	N/A	2.9±0.8 (fed) 1.5±0.5 (fasting) <sup>a</sup>	N/A	131.9±49.7 (fed) 120.9±55.3 (fasting)	2.8±0.3 (fed) 2.7±0.3 (fasting)

NS = Not specified; N/A = Not applicable

<sup>a</sup>Values for adults administered 2 10-mg doses

<sup>b</sup>Values are questionable because the text and figure in product label do not appear to correspond

<sup>c</sup>Focalin™ consists solely of the *d*-enantiomer

<sup>d</sup>Values were measured following ingestion of a high fat breakfast or in the fasting state

**Table 3. Summary of Pharmacokinetic Data for Racemic Methylphenidate in Children Given Single Oral Doses**

Number of children	Dosage	Half-life Mean±SD (range), hours	T <sub>max</sub> Mean±SD (range), hours	C <sub>max</sub> Mean±SD (range), ng/mL	AUC <sub>0-∞</sub> Mean±SD (range), ng-h/mL	Clearance Mean±SD (range), L/h/kg	Reference
6 <sup>b</sup>	0.3 mg/kg bw	2.43	1.5±0.2 <sup>a</sup>	10.8±1.9 <sup>a</sup>	NS	10.2±2.2	(35)
8–14	0.34 mg/kg bw	2.53±0.59	2.5±0.65	11.2±2.7	59.5±13.9	NS	(36)
5	10 mg [0.21–0.41 mg/kg bw]	3.15±1.04 (2.17–4.62)	NS	NS	33.48±10.38 (18.32–44.06)	9.22±3.56 (7.27–15.26)	(37)
5	0.25–0.68 mg/kg bw (taken while fasting)	2.10±0.36 (1.6–2.6)	1.60±0.42 (1.0–2.0)	NS	NS	NS	(33)
5	0.25–0.68 mg/kg bw (taken with meal)	2.14±0.32 (1.7–2.5)	1.0±0.35 (0.5–1.5)	NS	NS	NS	(33)
4	10–15 mg [0.30–0.48 mg/kg bw]	2.56±0.162 (2.37–2.75)	NS	17.6±6.0 (7.71–22.5)	86.93±34.55 (36.26–133.82)	NS	(38)
4–5	0.65 mg/kg bw	2.61±0.29	1.90±0.82	20.2±9.1	103.7±55.9	NS	(36)
8	0.89±0.14–0.91±0.7 <sup>c</sup>	3.33±0.65–4.09±1.8 <sup>c</sup>	[1.63±0.77–1.67±0.68] <sup>c</sup>	20.17±6.4–23.2±14.4 <sup>c</sup>	116.3±45.4–126.9±47.2 <sup>c</sup>	8.6±2.9–8.5±4.9 <sup>c</sup>	(39)

NS = Not specified

<sup>a</sup>Errors are SE

<sup>b</sup>One child was given 2 mg/kg bw methylphenidate; though not explicitly stated, it does not appear that that the child was included in the analysis.

<sup>c</sup>Values were obtained following 0 and 6 months on methylphenidate

### 2.1.1.3 Distribution

Apparent volume of distribution following iv exposure to methylphenidate is 6 L/kg (reviewed in (10, 40)). Volume of distribution was reported as 10.7–33.2 L/kg in 4 children given 10–15 mg methylphenidate orally (38) and ~40 L/kg in children given ~0.9 mg/kg bw (~28 mg) orally (39). According to information presented in a review article (40), a volume of distribution exceeding extracellular fluid and total body water suggests substantial tissue binding. Binding of methylphenidate to plasma protein is low (10–33%) (30); reviewed in (1, 10). Methylphenidate disposition is stereospecific, resulting in higher plasma levels of the *d*- versus the *l*-enantiomer (reviewed in (1)). Peak plasma levels of the *d*-enantiomer are reportedly 8 times higher than the *l*-enantiomer following oral dosing with 10 mg methylphenidate (reviewed in (8)). Following iv or oral administration, total body clearance is higher for the *l*-enantiomer, while mean residence time, volume of distribution, AUC, and half-life are higher for the *d*-enantiomer (reviewed in (1)).

The proportionality of pharmacokinetic parameters to administered dose was reported in children administered 2.5–10 mg *d*-methylphenidate or 5–20 mg *d,l*-methylphenidate (32). One manufacturer reported that  $C_{\max}$  and AUC values increased proportionally to dose in children given once-daily oral doses of 20 or 40 mg for 1 week or adults given single oral doses of 10–60 mg (5). However, a study in 4 healthy individuals and 1 narcolepsy patient reported disproportionate increases in AUC (corrected to a 10-mg dose) between 20 and 40 mg and dose-related decreases in oral clearance, most likely due to saturated presystemic metabolism, at doses between 10 and 60 mg methylphenidate (41). **[The Panel notes that author conclusions are reasonable but with so few humans involved, firm conclusions cannot be made.]** The FDA (31) reported the possibility of “nonlinearity” at a dose of 60 mg. Modi et al. (42) postulated that linearity may be affected by drug formulation due to higher blood concentrations obtained with immediate versus sustained-release formulations.

Human studies demonstrated uptake of radiolabeled *d,l*-methylphenidate in the striatum of the brain, with peak concentrations occurring 5–15 minutes following iv injection (reviewed by (1)). Following iv dosing, methylphenidate has a half-life of ~90 minutes, much shorter than the half-life of cocaine in the brain (20 minutes) (reviewed in (43)).

Because methylphenidate is a basic compound ( $pK_a$  8.8), accumulation in the acid environment of the stomach due to ion trapping has been observed, even following iv exposure (reviewed in (16)).

### 2.1.1.4 Metabolism

Figure 2 illustrates the metabolism of methylphenidate. In the predominant human metabolic pathway for methylphenidate, nonmicrosomal hydrolytic esterases found throughout the body rapidly biotransform methylphenidate to  $\alpha$ -phenyl-piperidine acetic acid (PPA; commonly called ritalinic acid) (10). The metabolite is believed to have little to no pharmacologic activity (8). The *d*- and *l*- enantiomers are converted to their respective *d*- and *l*-metabolite enantiomers, with no substantial interconversion between enantiomers (32). Less than 2% of methylphenidate is metabolized in minor pathways involving aromatic hydroxylation to *p*-hydroxy compounds, microsomal oxidation to oxo- compounds, and conjugation; none of the minor metabolites are believed to be pharmacologically active (reviewed in (1, 8)). Small amounts of hydroxylated metabolites, such as hydroxymethylphenidate and hydroxyritalinic acid have been detected in plasma (10). Table 4 lists metabolites detected in humans, rats, and dogs. The metabolite ethylphenidate was recently identified in overdose victims and volunteers given methylphenidate in combination with alcohol (reviewed in (16)). Ethylphenidate, which is possibly formed through a transesterification reaction, is of unknown pharmacodynamic significance. No metabolism by or inhibition of cytochrome P450 isoenzymes was observed in *in vitro* studies with the *d,l*-


enantiomer (5). A lack of cytochrome P450 (CYP) isoenzyme inhibition *in vitro* was also reported for the *d*-enantiomer (2). However, a recent review of drug interaction reports concluded that methylphenidate is involved in pharmacokinetic interactions that suggest inhibition of one or more hepatic CYP enzymes (44).

The low absolute oral bioavailability of methylphenidate in children (~30%, range: ~10–52%) implies extensive presystemic biotransformation (10, 33). There is evidence of stereospecific differences in oral bioavailability of methylphenidate, reported at 23% for the *d*-enantiomer and 5% for the *l*-enantiomer (reviewed in (1)).

**Table 4. Methylphenidate Urinary Metabolites in Humans, Rats, and Dogs**

Species/Dose	Route	Time (hours)	Percent Drug or Metabolite in Urine
Human 20 mg/kg bw	Oral or iv	0–24	Ritalinic acid (80%); <i>p</i> -hydroxyritalinic acid (2%); 6-oxoritalinic acid (< 1%, 1.5% iv); methylphenidate, <i>p</i> -hydroxymethylphenidate, 6-oxomethylphenidate, and <i>p</i> -hydroxyritalinic acid glucuronide (all < 1%)
Rat 20 mg/kg bw	Oral	0–24	Ritalinic acid (35–40%); methylphenidate (1%); 6-oxomethylphenidate (1.5%); 6-oxoritalinic acid (7–10%); 5-hydroxy-6-oxomethylphenidate (2%); 5-hydroxy-6-oxoritalinic acid (15–17%); carbamide methylphenidate (1%); <i>p</i> -hydroxyritalinic acid glucuronide (10%); unknown (20%)
		0–48	Ritalinic acid (36%); 6-oxoritalinic acid (1.8%); <i>p</i> -hydroxymethylphenidate (3%); <i>p</i> -hydroxyritalinic acid (19%); <i>p</i> -hydroxyritalinic acid glucuronide (10%); methylphenidate and 6-oxomethylphenidate (both < 1%)
	ip	0–48	Ritalinic acid (27%); 6-oxomethylphenidate (1.2%); 6-oxoritalinic acid (3%); <i>p</i> -hydroxymethylphenidate (15%); <i>p</i> -hydroxyritalinic acid (20%); <i>p</i> -hydroxyritalinic acid glucuronide (10%); methylphenidate (< 1%)
Dog 5 mg/kg bw	Oral	0–8	Ritalinic acid (23%); 6-oxomethylphenidate (1%); 6-oxoritalinic acid (26.5%); 6-oxoglucuronide (20%); 5-hydroxy-6-oxomethylphenidate glucuronide (12%); 4-hydroxy-6-oxomethylphenidate glucuronide (1%); 5-hydroxy-6-oxoritalinic acid (4%); carbamide methylphenidate (1%); <i>p</i> -hydroxy-6-oxoglucuronide (2–3%); <i>p</i> -hydroxy-6-oxosulfonic acid (1%); unknown (3%); methylphenidate (0.3%)
	iv	0–5	Ritalinic acid (44%); <i>p</i> -hydroxymethylphenidate (1.2%); <i>p</i> -hydroxyritalinic acid (2%); 6-oxomethylphenidate (7%); 6-oxoritalinic acid (30%); methylphenidate and <i>p</i> -hydroxyritalinic acid glucuronide (both < 1%)

Adapted from NTP (8)



\* Minor pathways in human. Adapted from NTP (8)

**Figure 2. Metabolic Pathways of Methylphenidate in Human, Rat, and Dog.**

#### 2.1.1.5 Excretion

Methylphenidate half-lives of ~2–8 hours (mean ~2.5–3.5 hours) were reported for oral administration of immediate- or extended-release *d*- or *d,l*-formulations after doses of up to 20 mg in adults and children (2, 5, 7, 10, 12, 32). Celltech (5) stated that half-life for Metadate®CD (6.8 hours) is longer than the half-life for sustained-release tablets (3.4 hour) and immediate-release tablets (2.9 hours); it was suggested that differences in half-life resulted from controlled release from extended-release tablets and absorption as the rate-limiting process. Mean total body clearance was calculated at 2.52 L/kg-hour in children administered 10–15 mg methylphenidate by iv infusion (reviewed in (40)); according to study authors, a total body clearance value exceeding average blood flow to the liver (1.4 L/kg-hour) suggests extrahepatic metabolism. Mean clearance rates of ~9–10 L/kg-hour were reported in children orally exposed to methylphenidate at up to 0.41 mg/kg bw (35, 37) and 0.9 mg/kg bw (39).

Oral dosing with radiolabeled methylphenidate results in recovery of 80–90% of the radioactivity in urine (7, 12). Novartis (10) reports that 78–97% of a methylphenidate dose is excreted in urine and 1–3% is excreted in feces as metabolites within 48–96 hours. Ritalinic acid is the main urinary metabolite and represents about 60–86% of the dose (7, 10). Less than 1% of the methylphenidate dose is excreted unchanged in urine (10). Due to the small percentage of methylphenidate excreted unchanged, urinary pH is not expected to affect excretion (16).

The half-life of ritalinic acid is 3–5 hours following dosing with racemic methylphenidate (10, 33) and ~3–8 hours with intake of *d*-methylphenidate (32). One study reported a half-life of ~9 hours for *d*-ritalinic acid and ~7 hours for *l*-ritalinic acid following oral intake of sustained-release racemic methylphenidate at doses of 18–54 mg (42). Repeated dosing of children with *d*-methylphenidate did not result in significant accumulation (32).

#### 2.1.1.6 Stereoselective pharmacokinetics

A series of studies from the laboratory of Srinivas examined the stereoselective pharmacokinetics of methylphenidate in children. A study in adults was also reviewed in detail because it examined linearity of pharmacokinetic parameters at multiple doses.

In a pilot study by Srinivas et al. (37), 6 boys (ages 8–13 years) took their regular dose of methylphenidate (10 mg for 5 subjects and 5 mg for 1 subject) prior to eating a light breakfast. Results from the child taking 5 mg were not used in calculations of mean values. Based on the reported body weights for the children, the doses ranged from 0.21 to 0.41 mg/kg bw in the children taking 10 mg and the dose was 0.21 mg/kg bw in the child taking 5 mg. Blood samples were collected prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, or 8 hours following dosing. Plasma levels of *d*-, and *l*-methylphenidate were measured using capillary column GC with electron capture detection. Results of the study are listed in Table 5. Plasma *d*-methylphenidate levels were 5 or more times higher than plasma *l*-methylphenidate levels in all children.

**Table 5. Pharmacokinetic Parameters in Children Orally Administered *d,l*-Methylphenidate**

Parameter	Enantiomer	Results
C <sub>max</sub> (ng/mL)	<i>d</i>	7.07±1.23
	<i>l</i>	1.00±0.19
T <sub>max</sub> (hours)	<i>d</i>	2.15±0.50
	<i>l</i>	2.01±1.16
AUC <sub>0-∞</sub> (ng-h/mL)	<i>d</i>	30.46±9.57
	<i>l</i>	6.66±1.38
Half-life (hours)	<i>d</i>	3.10±1.07
	<i>l</i>	5.59±1.07

Results presented as mean±SD for 5 children given 10 mg methylphenidate. From Srinivas et al. (37)

Hubbard et al. (45) examined enantioselective pharmacokinetics of sustained-release *d,l*-methylphenidate. Six children (5 boys and 1 girl 8–14 years old; mean age 11) received an oral dose of 20 mg methylphenidate. Doses on a body weight basis ranged from 0.34 to 0.88 mg/kg bw. Blood samples were taken prior to dosing and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.5, 6, 8, and 12 hours after dosing. Methods of analysis were referenced, but not described in this paper. Results are listed in Table 6. Peak plasma levels of the *d*-enantiomer were 8- to 10-fold higher than the *l*-enantiomer. Plasma levels of both *d*- and *l*-methylphenidate were sustained for at least 8 hours. Clearance and volume of distribution were greater for the *l*-enantiomer. Citing a study that found



higher levels of *d*- versus *l*-enantiomer in the urine of a human dosed with racemic methylphenidate, the study authors postulated that lower systemic exposure to the *l*-enantiomer is most likely due to reduced bioavailability and not selective urinary excretion of the *l*-enantiomer.

**Table 6. Pharmacokinetic Parameters in Children Orally Dosed with Sustained-Release *d,l*-Methylphenidate**

Parameter	Enantiomer	Results
$C_{\max}$ (ng/mL)	<i>d</i>	18.79±9.92
	<i>l</i>	1.60±1.23
$T_{\max}$ (hours)	<i>d</i>	2.83±1.69
	<i>l</i>	3.13±1.86
$AUC_{0-\infty}$ (ng-h/mL)	<i>d</i>	132.78±92.47
	<i>l</i>	12.73±7.37
Oral clearance	Ratio of <i>l</i> : <i>d</i> -enantiomer	10.18±3.08
Apparent volume of distribution	Ratio of <i>l</i> : <i>d</i> -enantiomer	14.91±13.19

Results presented as mean ± SD for 6 children given 20 mg methylphenidate. From Hubbard et al. (45)

Srinivas et al. (34) conducted a double blind, four-way, randomized, crossover study to further examine enantioselective pharmacokinetics in children. Nine boys (mean age 11 years) orally received 10 mg *d,l*-methylphenidate, 5 mg *d*-methylphenidate, and 5 mg *l*-methylphenidate on 3 separate days, separated by a 1-week interval. Blood was collected prior to dosing and at 1, 2, 3, 4, 5, 6, and 7 hours after dosing. Plasma levels of *d*-, and *l*-methylphenidate were measured using a capillary column GC with electron capture detection. Results are listed in **Table 7**. The study authors reported no evidence of interconversion between enantiomers. Administration of the racemic compound resulted in higher plasma levels of *d*- than *l*-methylphenidate [**3–8 times higher**], but  $T_{\max}$  and half-life were similar for the two enantiomers. Citing a manuscript in press, the authors attributed the lower level of *l*-methylphenidate to preferential presystemic metabolism. Pharmacokinetic parameters for *d*-methylphenidate did not differ significantly when the drug was administered in racemic or pure form. However,  $C_{\max}$  and AUC for *l*-methylphenidate were significantly lower when the drug was administered in pure versus racemic form. Sustained attention of the children was improved only upon administration of *d*- or *d,l*-methylphenidate.

**Table 7. Pharmacokinetics in Children Orally Administered *d,l*-, *d*-, or *l*-Methylphenidate**

Parameter	Enantiomer	Result for each treatment regimen		
		10 mg <i>d,l</i>	5 mg <i>d</i>	5 mg <i>l</i>
$C_{\max}$ (ng/mL)	<i>d</i>	6.42±2.17	5.60±2.79	N/A
	<i>l</i>	1.27±0.53	N/A	0.78±0.55
$T_{\max}$ (hours)	<i>d</i>	2.3±0.5	2.44±0.53	N/A
	<i>l</i>	2.4±0.5	N/A	2.1±0.3
$AUC_{0-\infty}$ (ng-h/mL)	<i>d</i>	27.71±9.53	23.55±12.14	N/A
	<i>l</i>	4.61±1.77	N/A	2.0±1.16
Half-life (hours)	<i>d</i>	1.87±0.65	1.84±0.83	N/A
	<i>l</i>	1.43±0.76	N/A	0.98±0.21

Results presented as mean±SD for nine children receiving each treatment. From (34)

N/A = non-applicable

Modi et al. (42) conducted a randomized three-way cross-over study to examine pharmacokinetics of *d*- and *l*-methylphenidate in adults (n = 35) orally administered continuous-

release methylphenidate (Concerta™) at doses of 18, 36 (2 × 18), and 54 (3 × 18) mg/kg bw. Blood samples were collected over a 30-hour period for measurement of methylphenidate and ritalinic acid levels. Pharmacokinetic parameters are summarized in Table 8. Plasma levels of *d*-methylphenidate were ~40-fold higher than *l*-methylphenidate. In contrast, plasma levels of *d*- and *l*-ritalinic acid were similar. Dose-normalized pharmacokinetics for methylphenidate and ritalinic acid demonstrated linear and dose-proportional values. The ratio of AUC for *d*-methylphenidate to *d*-ritalinic acid was similar in all dose groups (~0.04), indicating no dose-related effects on metabolism.

Modi et al. (42) noted that nonlinear pharmacokinetics were observed at doses of 10–60 mg methylphenidate (immediate-release) in a study by Aoyama et al. (41). Modi et al. postulated that nonlinearity may have resulted from the higher blood levels obtained with the immediate-release formulation versus continuous-release formulations.

**Table 8. Pharmacokinetics of Methylphenidate and Ritalinic Acid in Adults**

Parameter	Enantiomer	Results at each dose level		
		18 mg	36 mg	54 mg
<b>Methylphenidate</b>				
C <sub>max</sub> (ng/mL)	<i>d</i>	3.87±1.8	7.28±2.8	10.6±3.4
	<i>l</i>	0.095±0.2	0.17±0.2	0.36±0.5
T <sub>max</sub> (hours)	<i>d</i>	7.9±2	7.5±1	7.2±1.5
	<i>l</i>	7.1±2	7.0±2	6.1±1
Half-life (hours)	<i>d</i>	3.8±0.8	3.9±0.7	3.9±0.7
	<i>l</i>	-	-	-
AUC <sub>0-∞</sub> (ng-h/mL)	<i>d</i>	42.2±16	80.9±31	120±46
	<i>l</i>	0.43±0.7	0.96±1	1.82±2.7
<b>Ritalinic acid</b>				
C <sub>max</sub> (ng/mL)	<i>d</i>	53.3±14	105±36	155±37
	<i>l</i>	69.7±19	132±36	192±31
T <sub>max</sub> (hours)	<i>d</i>	8.8±2	8.8±1	8.5±2
	<i>l</i>	8.1±2	7.6±1	7.8±2
Half-life (hours)	<i>d</i>	9.1±2	8.8±2	9.1±2
	<i>l</i>	6.9±2	6.7±1	6.8±1
AUC <sub>0-∞</sub> (ng-h/mL)	<i>d</i>	989±240	1880±360	2880±660
	<i>l</i>	961±130	1870±260	2780±350

Data presented as mean±SD. From (42)

- = Insufficient data for calculation

## 2.1.2 Experimental Animal

### 2.1.2.1 Pharmacodynamics

The NTP (8) reviewed experimental animal studies modeling the pharmacologic action of methylphenidate in the treatment of human ADHD. Methylphenidate stimulatory effects in rodents are thought to occur through stimulation of dopaminergic neurons, releasing stored catecholamines into the synaptic cleft. In neonatal rats, methylphenidate ameliorated hyperactivity induced by depletion of brain dopamine. Dosing of rats with methylphenidate metabolites (ritalinic acid, *p*-hydroxymethylphenidate, and 6-oxomethylphenidate) resulted in no pharmacologic activity, thus indicating that the parent compound is most likely the pharmacologically active species.

A series of studies using dopamine transporter knock-out mice demonstrated that reduction of hyperactivity was modulated through the serotonergic system; however, the relevance of the studies to humans was questioned because serotonin reuptake inhibitors were found to be ineffective in the treatment of children with ADHD (reviewed in (18)).

The experimental animal studies suggesting that *d*-methylphenidate is the active enantiomer were reviewed by Teo et al. (46). A rat locomotive activity study demonstrated that potency of *d*-methylphenidate is greater than *d,l*-methylphenidate, which in turn is greater than *l*-methylphenidate. In a rat behavioral study, *d*-methylphenidate was more potent than *l*-methylphenidate, which produced little effect. One study demonstrated that depletion of catecholamine stores in brain neurons reduced locomotive response to *d*-methylphenidate. Studies in human and baboon brains revealed specific binding and uptake of *d*- but not *l*-methylphenidate in the striatum. *d*-Methylphenidate and *d,l*-methylphenidate, but not *l*-methylphenidate, reduced motor hyperactivity in juvenile rats with dopamine projection lesions induced during the neonatal period; *d*-methylphenidate was more potent than *d,l*-methylphenidate (47).

#### 2.1.2.2 Pharmacokinetics

Methylphenidate is readily absorbed and distributed in rats, mice, and monkeys. In rats, 19% of a 10 mg/kg bw methylphenidate hydrochloride dose given orally was absorbed within 1 hour and the peak plasma concentration within that hour was 200 ng/mL (reviewed by (8)). Methylphenidate was found at the highest levels in liver, kidney, and lung of rats gavaged with 7–70 mg/kg bw and mice gavaged with 2.1–35 mg/kg bw methylphenidate. In rats given 1 mg/kg bw methylphenidate hydrochloride orally or iv, the brain tissue to serum ratio of methylphenidate was 8 within 1–5 minutes. In another study, the brain to plasma ratio of methylphenidate in rats was 3.4 (reviewed by (1)). Methylphenidate brain levels in baboons peaked at 8–10 minutes following iv administration and 60–120 minutes following oral administration (reviewed in (43)).

Methylphenidate metabolites in rats and dogs exposed by various routes are outlined in Table 4. Major biotransformation pathways in rats and dogs exposed orally or parenterally are microsomal oxidation of methylphenidate to oxomethylphenidate and aromatic hydroxylation to *p*-hydroxymethylphenidate, in addition to esterification to ritalinic acid (Figure 2) (reviewed by (8)). More than 50% of metabolites in rats and dogs are derived from microsomal oxidation or aromatic hydroxylation reactions. Percentage of orally administered methylphenidate believed to be biotransformed to ritalinic acid is ~35–40% in rats and 23% in dogs. Less than 1% of methylphenidate is excreted unchanged in all species. Many of the metabolites undergo further conjugation and deesterification reactions. It was reported that one dog study demonstrated evidence of CYP inhibition by methylphenidate (reviewed in (44)).

Elimination half-life of methylphenidate from plasma was reported at 2–3 hours in rats orally administered 10 mg/kg bw and monkeys orally administered 3 mg/kg bw (reviewed in (8)). Urinary excretion is the major elimination route in mice, dogs, and rats (reviewed in (8)). Oral dosing of rats with radiolabeled methylphenidate resulted in urinary elimination of 50–60% of a  $\leq 20$  mg/kg bw dose over an unspecified time period and 80% of a  $\leq 70$  mg/kg bw dose over 24 hours. Oral dosing studies in mice and dogs demonstrated 50–60% urinary elimination of an unspecified dose over 48 hours. In another mouse study, 80% of an oral methylphenidate dose  $\leq 35$  mg/kg bw was excreted in urine over 24 hours. In rats dosed with 10–20 mg/kg bw methylphenidate orally or by ip injection, 30–40% of elimination occurred through feces and a significant amount of the dose was also excreted in bile (reviewed in (8)).

A brief section in the FDA medical review for Focalin™ reported similar pharmacokinetic values for *d*-methylphenidate in rats, rabbits, and dogs when drug was administered as the *d*- or *d,l*-enantiomer at equimolar concentrations of *d*-enantiomer (32).  $T_{max}$  for *d*-methylphenidate was 30 minutes at doses providing up to 25 mg/kg bw *d*-enantiomer. AUC of *d*-methylphenidate was comparable at equimolar concentrations of *d*- or *d,l*-enantiomers and plasma half-life was reported at 1–2 hours in rats, rabbits, and dogs. Plasma half-life for *d*-ritalinic acid was reported at 1–3 hours in rats and 4–8 hours in rabbits.

A number of studies were described in detail because they examined pharmacokinetics of methylphenidate in pregnant animals. Also notable in these studies is that the *d*- and *l*-enantiomers were analyzed separately.

Teo et al. (48) performed a perinatal/postnatal toxicology study of *d*-methylphenidate (98–102% pure) and *d,l*-methylphenidate (chiral purity 50/50) in Sprague-Dawley rats, discussed in Section 3. Satellite groups of pregnant rats were used for pharmacokinetic assessment. Equal treatments were given by gavage twice/day, 6 hours apart, for total daily doses of *d*-methylphenidate of 2 and 20 mg/kg bw/day and a total daily dose of *d,l*-methylphenidate of 40 mg/kg bw/day from GD 7–17. An unspecified number of animals were evaluated on GD 7 and 17 with plasma sampled just prior to the morning dose and at times 0, 0.25, 0.5, 0.75, 1, 2, 4, and 12 hours post-dose (the afternoon dose was omitted on the day of sampling). *d*-Methylphenidate determinations were by liquid chromatography-tandem mass spectroscopy. AUC exposures to *d*-methylphenidate were 500 ng-h/mL after dosing with 20 mg/kg bw/day *d*-methylphenidate and 800 ng-h/mL after dosing with 40 mg/kg bw/day *d,l*-methylphenidate **[It is not stated whether these data were from GD 7 or 17 samples and no data were given for the 2 mg/kg bw/day dose of *d*-methylphenidate.]** The authors stated that both compounds behaved in a dose-proportional manner without evidence of accumulation **[No data were shown; the Expert Panel questions whether dose-proportionality could be shown for *d,l*-methylphenidate for which only a single dose appears to have been used.]**

A subsequent developmental toxicity study from the same group (48) also included satellite pharmacokinetic assessments in Sprague-Dawley rats and New Zealand White rabbits. The developmental toxicity results are discussed in Section 3. In the pharmacokinetic component, pregnant rats (n = 4/group/time point) were given twice daily gavage doses of *d*-methylphenidate and *d,l*-methylphenidate at the same doses and on the same days of pregnancy (GD 7–17) as in the first study (49). Pregnant rabbits (n = 4/group/time point) were given 4 or 100 mg/kg bw/day *d*-methylphenidate or 200 mg/kg bw/day *d,l*-methylphenidate on GD 6–18. As in the rat study, the rabbits received the total daily dose in 2 equal doses 6 hours apart. On the last day of treatment, only the morning dose was given and plasma was sampled 0, 0.25, 0.5, 0.75 (in the rabbits), 1, 2, 4, 8, and 24 hours after the dose. Samples were assayed by liquid chromatography-tandem mass spectroscopy for *d*-, *l*-, and *d,l*-methylphenidate. **[The authors indicated that based on unpublished data, there is no interconversion of the *d*- and *l*-enantiomers in human plasma.]**

Results are given in Table 9. and Table 10. **[The Expert Panel notes that the methods of Teo et al. (48) do not describe the collection of some of the data presented in the paper; these data correspond to the methods given in Teo et al. (49).]** The authors called attention to the higher concentrations of *d*-methylphenidate after administration of *d,l*-methylphenidate than after administration of *d*-methylphenidate, in spite of equal amounts of administered *d*-enantiomer. The lower concentration of *l*- compared to *d*-methylphenidate after administration of *d,l*-methylphenidate in a 50/50 ratio was attributed by the authors to a possible greater rate of

elimination of the *l*-enantiomer. [The Expert Panel notes that the half-life data do not support the hypothesis of a greater rate of elimination of the *l*-enantiomer.]

Bakhtiar and Tse (50) of the Novartis Institute for Biomedical Research performed a pharmacokinetic study in pregnant Sprague-Dawley rats and New Zealand white rabbits. Treatments were by single daily gavage with “high purity” racemic methylphenidate on GD 6–17 in rats (plug = GD 0) and GD 7–2- in rabbits. Doses in rats were 0, 7, 25, or 75 mg/kg bw/day, and in rabbits 0, 20, 60, or 200 mg/kg bw/day, with 5 animals in each dose group. Blood was obtained from the retro-orbital sinus in rats and the marginal ear artery or vein in rabbits 0.5, 1, 3, 8, and 24 hours after the last dose. Analysis of *d*- and *l*-methylphenidate was performed using chiral liquid chromatography-tandem mass spectroscopy. No methylphenidate was detected in any of the samples from control animals. Pharmacokinetic parameters are shown in Table 9 and Table 10. [These tables display data from Teo et al. (48) and Bakhtiar and Tse (50); the Expert Panel notes that there were differences between these studies in dosing intervals (twice/day versus daily dosing) and rat strain, pregnancy days of administration and sampling, and sampling intervals.] The authors reported  $C_{max}$  corrected for dose in rats as ranging from 9.69 to 12.6 (ng/mL)/(mg/kg bw/day) for *d*-methylphenidate and 3.29 to 5.50 (ng/mL)/(mg/kg bw/day) for *l*-methylphenidate. In rabbits, the  $C_{max}$  corrected for dose ranged from 0.127 to 2.83 (ng/mL)/(mg/kg bw/day) for *d*-methylphenidate and 0.193 to 0.400 (ng/mL)/(mg/kg bw/day) for *l*-methylphenidate. The authors considered  $C_{max}$  to be dose-proportional in rats with respect to both enantiomers and in rabbits with respect to *l*-methylphenidate. AUC, however, was not dose-proportional in either species, with increases in AUC for both enantiomers in rats and for *d*-methylphenidate in rabbits greater than would have been predicted based on dose-proportionality. The authors believed these findings were consistent with saturability of metabolic processes.

**Table 9. Pharmacokinetic Results in Pregnant Rats Given *d*- or *d,l*-Methylphenidate**

Treatment (mg/kg bw/dose)	GD	Enantiomer measured	$T_{max}$ (h)	$C_{max}$ (ng/mL)	$t_{1/2}$ (h)	AUC (ng-h/mL)
<i>d</i> -Methylphenidate						
2 <sup>a</sup>	7	<i>d</i>	0.25	13.90	0.23	4.93
	17	<i>d</i>	0.25	11.08	0.80	8.15
20 <sup>a</sup>	7	<i>d</i>	0.25	463	0.83	356
	17	<i>d</i>	0.25	546	0.66	519
<i>d,l</i> -Methylphenidate						
7 <sup>b</sup>	17	<i>d</i>	0.5	88.4±16.7	1 <sup>c</sup>	120±18.5
		<i>l</i>	0.5	38.5±4.14	1 <sup>c</sup>	65.7±9.14
25 <sup>b</sup>	17	<i>d</i>	0.5	293±28.8	1.5	781±128
		<i>l</i>	0.5	134±35.6	1 <sup>c</sup>	329±92.5
40 <sup>a</sup>	7	<i>d</i>	0.25	536	0.72	674
		<i>l</i>	0.25	488	0.65	500
	17	<i>d</i>	0.25	390	1.17	792
		<i>l</i>	0.25	313	0.95	554
75 <sup>b</sup>	17	<i>d</i>	1.33	727±533	4 <sup>c</sup>	3104±2469
		<i>l</i>	1.33	247±164	4 <sup>c</sup>	1139±802

<sup>a</sup>Dose divided, given twice daily, GD 7–17, Sprague-Dawley strain. Results were from pooled plasma from 4 rats/group. *l*-Methylphenidate was undetectable after administration of *d*-methylphenidate. From Teo et al. (48).

<sup>b</sup>Dose given once daily GD 6–17, Wistar-Hannover IGS strain. Data from 5 rats/group expressed as mean ± SD. From Bakhtiar and Tse (50). <sup>c</sup>Estimated from a graph.

**Table 10. Pharmacokinetic Results in Pregnant New Zealand White Rabbits Given *d*- or *d,l*-Methylphenidate**

Treatment (mg/kg bw/day)	GD	Enantiomer measured <sup>b</sup>	T <sub>max</sub> (h)	C <sub>max</sub> (ng/mL)	t <sub>1/2</sub> (h)	AUC (ng-h/mL)
<i>d</i> -Methylphenidate						
4 <sup>a</sup>	6	<i>d</i>	0.25±0.00	1.63±0.53	1.09 (n = 2)	3.25 (n = 2)
	18	<i>d</i>	0.31±0.13	3.13±1.49	1.23±0.27	5.84±0.26
100 <sup>a</sup>	6	<i>d</i>	0.44±0.38	39±34	1.88±0.37	88±50
	18	<i>d</i>	0.31±0.13	101±78	1.19±0.08	146±73
<i>d,l</i> -Methylphenidate						
20 <sup>b</sup>	20	<i>d</i>	0.90	3.98±1.70	2 <sup>c</sup>	8.40±4.53
		<i>l</i>	0.90	8.00±3.08	3 <sup>c</sup>	47.9±11.6
60 <sup>b</sup>	20	<i>d</i>	2.3	7.60±2.26	4.5 <sup>c</sup>	63.1±22.6
		<i>l</i>	1.4	11.6±1.70	3.5 <sup>c</sup>	83.3±11.3
200 <sup>b</sup>	20	<i>d</i>	0.50	565±213	1 <sup>c</sup>	776±124
		<i>l</i>	0.50	86.3±35.1	2 <sup>c</sup>	263±50.5
200 <sup>a</sup>	6	<i>d</i>	0.38±0.14	142±91	1.38±0.45	268±166
		<i>l</i>	0.44±0.13	16.28±9.84	1.39±0.40	35.85±9.51
	18	<i>d</i>	0.25±0.00	158±61	1.27±0.32	253±50
		<i>l</i>	0.56 = 0.31	16.10±3.20	1.66±0.51	36.85±4.22

<sup>a</sup>Dose divided, given twice daily, GD 6–18. *l*-Methylphenidate was undetectable after administration of *d*-methylphenidate. Mean±SD (n = 4 except where noted). From Teo et al. (48). <sup>b</sup>Dose given once daily GD 7–20, Wistar-Hannover IGS strain. Data from 5 rats/group expressed as mean ± SD. From Bakhtiar and Tse (50).

<sup>c</sup>Estimated from a graph

Teo et al. (46) conducted a satellite pharmacokinetic assessment as part of a subchronic study in Sprague-Dawley rats. The subchronic toxicity results are discussed in Section 2.2.2. In the pharmacokinetic component, rats (n = 4/group/sex/time point) were given twice daily gavage doses of *d*-methylphenidate (1 or 25 mg/kg bw/dose) or *d,l*-methylphenidate (50 mg/kg bw/dose), except on sampling days (day 1 and 80 of the dosing period), when only one dose was given. During the two days of sampling, blood was collected before dosing and at 0.25, 0.5, 0.75, 1, 2, 4, and 12 hours after dosing. Plasma samples from four rats/time period were pooled and assayed for *d*-methylphenidate by liquid chromatography-tandem mass spectroscopy. Pharmacokinetic endpoints were modeled using noncompartmental analysis. Results are listed in Table 11. Data indicate no accumulation of *d*-methylphenidate. The authors stated that rats dosed with *d,l*- versus *d*-methylphenidate had higher exposure to the *d*-enantiomer.

**Table 11. Pharmacokinetic Results for *d*-Methylphenidate in Nonpregnant Rats Given *d*- or *d,l*-Methylphenidate**

Treatment (mg/kg bw/dose) <sup>a</sup>	Sex	T <sub>max</sub> (h)	C <sub>max</sub> (ng/mL)	t <sub>1/2</sub> (h)	AUC (ng-h/mL)
<i>d</i> -Methylphenidate					
1	M	ND	ND	ND	ND
	F	0.50/0.25	2.78/9.95	1.53/1.42	3.34/6.57
25	M	0.50/0.50	460/599	0.81/0.74	367/788
	F	0.50/0.50	668/612	0.75/0.72	699/880
<i>d,l</i> -Methylphenidate					
50	M	0.50/0.25	675/574	0.74/0.72	692/890
	F	0.25/0.50	946/621	0.72/0.71	1224/1657

n = 1 since data were pooled for 4 rats/sex/time period; ND = not determined since concentrations below limit of quantification (< 1ng/mL). <sup>a</sup>Dose given twice daily except on the day of sampling when given once daily; results are listed for day 1/day 80 of dosing. From (46).

Teo et al. (51) also conducted a satellite pharmacokinetic assessment as part of a subchronic study in Beagle dogs. The subchronic toxicity results are discussed in Section 2.2.2. In the pharmacokinetic component, dogs (n = 4/group/sex/time point) were given twice daily gavage doses of *d*-methylphenidate (0.5 or 5 mg/kg bw/dose) or *d,l*-methylphenidate (10 mg/kg bw/dose), except on days of sampling (day 1 and the first day of week 12 of dosing), when only one dose was given. During the two days of sampling, blood was collected before dosing and at 0.25, 0.5, 0.75, 1, 2, 4, and 12 hours after dosing. Plasma samples were assayed for *d*-, and *l*-methylphenidate by liquid chromatography-tandem mass spectroscopy. Pharmacokinetic endpoints were modeled using noncompartmental analysis. **[Again, the authors indicated that based on unpublished data there is no interconversion of the *d*- and *l*-enantiomers in human plasma.]** Results are listed in Table 12. Data indicate no accumulation of *d*- or *l*-methylphenidate. According to further analyses presented in a manuscript in preparation, pharmacokinetic parameters were reported to be proportional to dose. Differences in AUC according to sex could not be evaluated due to large standard deviations.

**Table 12. Pharmacokinetic Results in Dogs Given *d*- or *d,l*-Methylphenidate**

Treatment (mg/kg bw/dose) <sup>a</sup>	Sex	Enantiomer measured <sup>b</sup>	T <sub>max</sub> (h)	C <sub>max</sub> (ng/mL)	t <sub>1/2</sub> (h)	AUC (ng-h/mL)
<i>d</i> -Methylphenidate						
0.5	M	<i>d</i>	0.42±0.14/ 0.50±0.25	2.40±1.21/ 3.53±3.02	0.43 <sup>c</sup> / 1.31 <sup>c</sup>	1.27±0.83/ 2.43±1.89
	F	<i>d</i>	0.38±0.14/ 0.50 <sup>c</sup>	11.25±13.89/ 1.85 <sup>c</sup>	0.42 <sup>c</sup> / ND	7.72±11.60/ / 0.64 <sup>c</sup>
5	M	<i>d</i>	1.50±1.67/ 2.31±1.95	85.40±55.14/ 10.15±6.16	0.85±0.25/ 2.67 <sup>c</sup>	114±59/ 19±15
	F	<i>d</i>	1.25±1.84/ 1.00±0.87	71.25±68.25/ 38.00±44.50	0.89±0.32/ 3.64±5.09	77±70/ 45±44
	M	<i>d</i>	1.38±1.75/ 1.44±1.74	255±147/ 183±229	0.85±0.11/ 0.83 <sup>c</sup>	346±195/ 132±130
<i>d,l</i> -Methylphenidate						
10	M	<i>l</i>	1.25±1.84/ 1.44±1.74	333±174/ 252±286	1.23±0.34/1 .74±0.94	479±238/ 218±162
	F	<i>d</i>	1.69±1.72/ 5.13±4.87	136±95/ 27.53±29.10	1.42±0.87/N D	155±79/ 41±26
	F	<i>l</i>	1.69±1.72/ 5.13±4.87	215±133/ 58±62	1.45±0.78/N D	262±119/ 95±60

Mean±SD (n = 4 except where noted); ND = not determined because concentrations below limit of quantification (< 1ng/mL). <sup>a</sup>Dose given twice daily except on the day of sampling when given once daily; results are listed for day 1/week 12 of dosing. <sup>b</sup>*l*-Methylphenidate was undetectable after administration of *d*-methylphenidate. <sup>c</sup>No SD reported. From (51).

The Teo et al. (51) study in dogs indicated that administration of the racemic mixture resulted in higher blood levels of the *l*-enantiomer. The findings are consistent with a study that also demonstrated higher levels of the *l*-enantiomer in one dog orally administered 1.0 mg/kg bw *d,l*-methylphenidate (52). AUCs were 5.96 ng-hr/mL for the *d*-enantiomer and 7.77 ng-hr/mL for the *l*-enantiomer. In contrast to the earlier study, the half-life for the *d*-enantiomer was longer (half-life = 3.07 hours for *d*-enantiomer versus 2.86 hours for the *l*-enantiomer). The relevancy of using dogs to study methylphenidate toxicity in humans was questioned by Srinivas et al. (52), who noted that levels of the *d*-enantiomer are higher in humans following ingestion of racemic methylphenidate (See Section 2.1.1.6).

## 2.2 General Toxicity

### 2.2.1 Human

#### 2.2.1.1 Side effects of medication therapy

Adverse effects emerging in ≥1% of patients treated with *d*- or *d,l*-methylphenidate were included in an FDA (32) review and those effects are summarized in Table 13. A meta-analysis of published placebo controlled studies of methylphenidate effectiveness for ADHD included an evaluation of adverse effects (Table 14) (53). [The Expert Panel notes that the meta-analysis was acceptable but it is not clear if publication bias was addressed.] Briefer reports of adverse effects were presented in methylphenidate product labels (5, 7), but the incidence of effects appears similar to the values reported by the FDA (32). Methylphenidate manufacturers report nervousness and insomnia as the most common adverse effects (4, 5, 7, 12). The adverse effects



occurring most frequently in children include reduced appetite, abdominal pain, weight loss with prolonged therapy, insomnia, and tachycardia (4, 7, 11, 12). The American Academy of Pediatrics (24) also reported jitteriness and social withdrawal as common side effects associated with stimulant treatment. Irritability, anxiety, and proneness to crying were reported as common side effects of methylphenidate therapy in a review by Kimko et al. (1). The AAP (24) states that most effects associated with stimulant treatment occur during early therapy and are mild and transient. However, it has also been reported that some adverse effects such as anorexia, weight loss, headaches, insomnia, and tics may not resolve during methylphenidate treatment in children (reviewed in (22)). An effect that has been inconsistently documented in controlled studies of stimulants is “cognitive constriction” which is characterized by interference of cognitive tasks requiring divergent thinking (reviewed by (30)). Controlled studies on adverse medication effects in children are discussed in detail in Section 3.1.2.1.

According to drug labels for methylphenidate, its use is contraindicated in individuals with marked anxiety, tension, and agitation, since the drug may aggravate such symptoms (4, 5, 7, 12). Use of methylphenidate is also contraindicated in individuals with glaucoma, motor tics, or family history of Tourette’s syndrome, and hypersensitivity to the drug.

**Table 13. Treatment-Emergent Adverse Effects in  $\geq 1\%$  of Patients in Double-blind Methylphenidate Studies**

Body system/adverse effect	Percentage of unique patients reporting the effect		
	<i>d</i> -methylphenidate (n = 79)	<i>d,l</i> -methylphenidate (n = 46)	Placebo (n = 82)
Body as whole			
Abdominal pain	15.2	4.3	6.1
Accidental injury	5.1	8.7	6.1
Chest pain	2.5	0	0
Fever	5.1	6.5	1.2
Flu syndrome	2.5	0	3.7
Headache	12.7	23.9	8.5
Pain	5.1	2.2	3.7
Viral infection	2.5	8.7	6.1
Digestive			
Anorexia	6.3	10.9	1.2
Diarrhea	3.8	2.2	1.2
Gastroenteritis	0	0	2.4
Nausea	8.9	13.0	1.2
Vomiting	5.1	6.5	3.7
Metabolic			
Ketosis	2.5	0	0
Musculoskeletal			
Myalgia	0	2.2	2.4
Nervous			
Emotional lability	3.8	4.3	1.2
Insomnia	2.5	4.3	3.7
Nervousness	2.5	2.2	1.2
Personality disorder	2.5	2.2	0
Somnolence	3.8	4.3	2.4

Body system/adverse effect	Percentage of unique patients reporting the effect		
	<i>d</i> -methylphenidate (n = 79)	<i>d,l</i> -methylphenidate (n = 46)	Placebo (n = 82)
Respiratory			
Increased cough	2.5	4.3	1.2
Epistaxis	3.8	2.2	1.2
Pharyngitis	2.5	4.3	2.4
Rhinitis	10.1	4.3	7.3
Skin and appendages			
Eczema	2.5	0	0
Herpes simplex	0	0	2.4
Special senses			
Ear pain	0	0	2.4

Adapted from FDA (32).

**Table 14. Adverse Events in Published Studies of Methylphenidate in Children**

Symptom	Total subjects	Percent parent/self reporting side effect (95% CI)		
		Methylphenidate	Placebo	Methylphenidate–placebo difference
Decreased appetite	675	44.8 (36.8–52.7)	14.4 (5.1–23.8)	30.3 (18.0–42.6)
Insomnia	663	47.7 (42.1–53.3)	30.7 (23.9–37.5)	17.0 (8.3–25.8)
Headache	581	18.4 (15.3–21.5)	12.5 (8.9–16.0)	5.9 (1.4–10.4)
Stomachache	290	24.0 (19.0–28.9)	14.9 (8.7–21.1)	9.0 (1.2–16.9)
Drowsiness	201	24.3 (16.6–32.0)	14.5 (4.5–24.6)	9.8 (–2.8–22.3)
Anxiety	482	31.1 (24.8–37.5)	38.4 (29.9–46.8)	–7.2 (–17.8–3.3)
Dizziness	383	7.3 (5.5–9.1)	2.2 (0.0–4.6)	5.1 (2.2–8.1)

From (53). Total subjects does not distinguish patients randomized to placebo versus methylphenidate; however, most studies used a cross-over design. The number of studies reporting individual symptoms ranged from 4 to 10. Differences between treated and placebo groups were not statistically significant.

#### 2.2.1.2 Overdose symptoms

Symptoms of methylphenidate overdose are similar to those of other amphetamine-like drugs. Signs and symptoms result primarily from overstimulation of the CNS and include vomiting, headache, agitation, confusion, euphoria, delirium, tremors, muscle twitching, hyperreflexia, seizures, and possibly coma. Cardiovascular manifestations include tachycardia, chest pain, hypertension, and dysrhythmia. Patients also present with mydriasis, diaphoresis, fever, and abdominal pain. Severe intoxication can result in hyperthermia, dysrhythmia, and seizures(5, 7, 10, 12)).

Abuse of methylphenidate by iv injection can result in intoxication. Many of the complications and toxicity of iv administration are related to insoluble excipients in methylphenidate tablets. Reported toxicity has included retinopathy, emphysema, hepatic dysfunction, and multiple organ system failure (54-58).

Symptoms observed with methylphenidate overdose in various age groups were reported in a retrospective review of reports submitted to a certified regional poison information center during 1998 (Table 15) (59). As noted in Table 15, some of the patients ingested other drugs in

combination with methylphenidate and the clinical findings were not discussed in terms of methylphenidate exposures alone. More severe effects were observed in patients  $\geq 13$  years, who had larger mean exposures, increased time between overdose and contact with a poison control center, and more frequent co-exposure to other drugs. Known outcomes in patients were classified as no effects to moderate effects. There was no significant morbidity or mortality.

**Table 15. Symptoms Reported in Methylphenidate Poisonings**

Patient ages (years)	N	Intake, mg (mean $\pm$ SD)	Mean dose, mg/kg bw	Percent with Clinical Symptoms	Percent Co-exposed to Other Drugs <sup>a</sup>	Symptoms
< 6	35	13.6 $\pm$ 8.2	0.94	16	1	Drowsiness or hyperactivity
6–12	26	26.8 $\pm$ 18.7	0.89	30.8	37.5	Drowsiness, hyperactivity, hyperventilation, and/or “feeling hot”
13–19	30	106.8 $\pm$ 177	1.70	50.0	46.7	Tachycardia, agitation, uncontrolled movements, hydriasis, confusion, hyperactivity, hypertension, drowsiness, and/or hypokalemia
> 19	22	70.0 $\pm$ 73.9	Unknown	54.5	~53	Tachycardia, agitation, uncontrolled movements, confusion, hyperactivity, hypertension, drowsiness, psychosis, and/or slurred speech

<sup>a</sup>Percentages based on number of patients with clinical signs, with the exception of the >19 year-old group which is based on number of patients admitted to emergency room.

### 2.2.1.3 Drug Interactions

Methylphenidate may decrease the hypotensive effect of guanethidine and may inhibit metabolism of coumarin anticoagulants, anticonvulsants (e.g., phenobarbital, diphenylhydantoin, and primidone), phenylbutazone, and tricyclic drugs (e.g., imipramine, clomipramine, and desipramine); although causality has not been established, coadministration of methylphenidate with clonidine may lead to serious adverse effects (4-6, 10, 16). Possible inhibition of sertraline (an serotonin reuptake inhibitor) metabolism and possible interactions with phenytoin and antipsychotics (haloperidol and thioridazine) have also been reported (44). Hypertensive crises could occur if methylphenidate is used concurrently or within 14 days of treatment with monoamine oxidase inhibitors (5, 12).

Gastrointestinal pH changes resulting from antacid or acid suppressant use could potentially alter methylphenidate release from Ritalin®LA tablets, but the effect of gastrointestinal pH on absorption has not been studied (10).

#### 2.2.1.4 Drug Abuse

Chronic methylphenidate abuse can lead to tolerance, psychic dependence, and abnormal behavior (11). Methylphenidate abuse has resulted in symptoms similar to those observed with amphetamine toxicity, including psychotic episodes, paranoid delusions, hallucinations, and bizarre behavior (13). Abuse has resulted in death. Depression and symptoms of underlying disorders can be unmasked during withdrawal (11).

Experimental animal and human studies indicate that methylphenidate can substitute for methamphetamine and cocaine in models used to predict abuse potential (60). There has been concern that methylphenidate use by children will increase susceptibility to abuse of stimulants in later life. Evidence for and against this proposition is summarized in Section 3.1.

#### 2.2.2 Experimental Animal

An FDA review (32) of Focalin™ summarized toxicity in rat and dog studies. Weight loss was reported as a consistent finding in dog studies. In rats, decreased platelet count, increased prothrombin time in males, and increased eosinophils in females were reported following dosing with *d*- or *d,l*-methylphenidate for 14 but not 90 days. No observed effect levels (NOELs) for *d*-methylphenidate were identified at < 20 mg/kg bw/day in rats and 1 mg/kg bw/day in dogs. NOELs for *d,l*-methylphenidate were < 40 mg/kg bw/day for rats and 2 mg/kg bw/day for dogs. A maximum tolerated dose of 100 mg/kg bw/day for *d*-methylphenidate in rats was based upon hyperactivity, hypersensitivity, and self-mutilation. The maximum tolerated dose of 10 mg/kg bw/day in dogs was based upon hyperactivity, salivation, and elevated body temperature.

A review by Greenhill (30) reported hyperactivity and hyperexcitability but no signs of reduced appetite, growth suppression, convulsions, or changes in liver tissue in dogs treated with 120 mg/kg bw/day methylphenidate for 120 days.

Unlike amphetamine and methamphetamine, there is no evidence that methylphenidate damages neurons (reviewed in (61)).

LD<sub>50</sub> values are summarized in Table 16. Death following exposure to high dose levels of methylphenidate is most probably due to “excessive central adrenergic stimulation” [**not otherwise specified**] (8). Additional effects reported in experimental animals exposed to methylphenidate include lowered brain and serum cholesterol levels and serum thyroxine and triiodothyronine (reviewed in (8)).

A review by Greenhill (30) reports that methylphenidate has a 100:1 margin of safety for an approximate single human therapeutic dose and a dose producing lethality in two species of animals.

**Table 16. LD<sub>50</sub> Values for Methylphenidate**

Species	Exposure route	LD <sub>50</sub> (mg/kg bw)
Mouse	oral	60–450 <sup>a,b</sup>
	ip	32–96.5 <sup>a,c</sup>
	sc	150–218 <sup>a,c</sup>
	iv	41 <sup>a</sup>
Rat	oral	180–350 <sup>b</sup>
	ip	430 <sup>a</sup>
	sc	170 <sup>c</sup>
	iv	50 <sup>c</sup>
Rabbit	oral	900 <sup>c</sup>
	sc	170 <sup>c</sup>
	iv	30 <sup>c</sup>

Reviewed in <sup>a</sup>HSDB (62), <sup>b</sup>NTP (8), <sup>c</sup>NIOSH (63).

**[The enantiomers were not specified, but based on the CAS RNs provided (298-59-9 or 113-45-1) and the listing of Ritalin as a synonym, it appears that *d,l*-methylphenidate was used in these studies]**

NTP toxicity studies and studies by Teo et al. (51) were reviewed in detail because reproductive organs were examined in a subchronic and in a carcinogenicity study and growth was measured in the subchronic study. The carcinogenicity study is described in Section 2.4.2.

The NTP (8) conducted 14-day and 13-week studies to examine toxicity of *d,l*-methylphenidate in F344/N rats and B6C3F<sub>1</sub> mice. The studies used pharmacopoeia grade methylphenidate hydrochloride, which has a purity of >99%. The drug was mixed in feed and stability, homogeneity, and target concentrations were verified. Statistical analyses included Cox method and Tarone life table test for survival, Fisher Exact test and Cochran-Armitage trend test for lesion incidence, and the Dunnet, Williams, Dunn, or Shirley test for continuous variables.

In a 14-day study, no toxicity was observed at doses up to 1000 ppm (80 mg/kg bw in rats and 160 mg/kg bw in mice, as determined by study authors). The study was repeated by exposing 7-week-old animals (5/sex/group) to 0, 16, 62, 250, 1000, or 4000 ppm methylphenidate hydrochloride in feed for 14 days. Doses were 0, 1, 5, 20, 90, or 380 mg/kg bw/day in male rats and 1, 5, 20, 90, and 360 mg/kg bw/day in female rats. The highest dose in rats was approximately equal to the LD<sub>50</sub> for methylphenidate. Doses in mice were 0, 2, 10, 40, 120, or 460 mg/kg bw/day in males and 0, 2, 10, 40, 140, or 410 mg/kg bw/day in females. Animals were observed daily and weighed before, during, and after treatment. Clinical chemistry and histopathology of liver and kidney were examined in all animals.

In male and female rats exposed for 14 days, body weight gain and final body weight were significantly reduced in the 4000-ppm group. Slightly lower feed intake was only observed during the first 5 days of the study. Clinical signs included hyperactivity in females exposed to  $\geq 250$  ppm and males exposed to 4000 ppm. Significant, treatment-related changes in clinical chemistry included decreased serum creatinine levels ( $\geq 16$ -ppm males), increased serum urea nitrogen ( $\geq 62$ -ppm females,  $\geq 1000$ -ppm males), and decreased aspartate aminotransferase activity (4000-ppm males). In the 4000-ppm group, significant increases were observed for absolute and relative (to body weight) liver weight in males and females, and relative kidney weights in males. Other

significant organ weight changes indicated in Table F1 of the NTP report were increased relative brain weight (4000-ppm males and females) and increased absolute heart weight ( $\geq 1000$ -ppm males). Centrilobular hepatocellular hypertrophy was observed in males and females of the 4000-ppm group [**data not shown**].

In mice exposed for 14 days, body weight gain was reduced in males and females administered  $\geq 1000$  ppm. Final body weight of females in the 4000-ppm group was lower than controls. Feed intake was decreased in the 1000- and 4000-ppm groups only during the first week of the study. During the second week of the study, hyperactivity was observed in some males from the 4000-ppm group. Three males from the 4000-ppm group died during the study. Treatment had no effect on clinical chemistry. Significant, treatment-related effects on organ weights included increased absolute and relative (to body weight) liver weight ( $\geq 16$ -ppm males, 4000-ppm females) and decreased absolute and relative thymus weight (4000-ppm females). According to Table F5 in the NTP report, relative liver weights were significantly increased and absolute thymus weights were significantly decreased in female mice from the 1000-ppm group. Centrilobular hepatocellular hypertrophy was observed in males exposed to  $\geq 250$  ppm and females exposed to  $\geq 1000$  ppm; the effect was dose-related and more severe in males. Two males that died during the study had slight multifocal tubule epithelial cell degeneration and necrosis in the kidneys. [**Histopathologic data not shown.**]

The 13-week NTP study was conducted according to FDA Good Laboratory Practices (GLP). Six-week-old rats and mice (10/sex/group) were fed diets containing 0, 125, 250, 500, 1000, or 2000 ppm methylphenidate hydrochloride; exposures occurred for 90 days in rats and 92 days in mice. Study authors estimated doses at 0, 7, 15, 30, 70, or 130 mg/kg bw/day in male rats and 0, 9, 18, 30, 70, and 150 mg/kg bw/day in female rats. Author-estimated doses in mice were 0, 15, 30, 70, 115, and 230 mg/kg bw/day in males and 0, 15, 30, 70, 125, and 260 mg/kg bw/day in females. Dose selection was based on results of the 14-day study. Animals were examined daily and weighed before, during, and after treatment. Growth was assessed in rats by measuring crown-rump length and bone density. After rats were killed they were necropsied and organs were weighed. Livers and kidneys from all animals, major systems organs from control and 2000-ppm animals, and animals that died before the study ended were collected and fixed in 10% neutral buffered formalin for histopathologic evaluation. Included in the organs examined were clitoral gland (rat only), mammary gland, ovary, prostate gland, testis, epididymis, seminal vesicle, and uterus.

In the 13-week rat study, 4 deaths in the 125-ppm group and 1 death in the 250-ppm group were not believed by authors to be treatment-related. Body weight gain was significantly reduced in females exposed to  $\geq 250$  ppm and males exposed to  $\geq 500$  ppm, but final body weights did not differ significantly from controls. Feed intake was lower in the 2000-ppm group during the first week of the study. During weeks 1 and 2 of the study, females exposed to  $\geq 1000$  ppm were slightly hypersensitive to touch and displayed increased activity and vocalization. Increased activity was observed in female rats of the 2000-ppm group during weeks 9–13 of the study. Significant organ weight changes included increased absolute liver weight (2000-ppm male and female), relative liver weight ( $\geq 1000$ -ppm male and female), relative kidney weight ( $\geq 1000$  male and female), absolute brain weight ( $\geq 500$ -ppm male), and relative brain weight ( $\geq 500$ -ppm male,  $\geq 1000$ -ppm female). Also reported was a decrease in absolute heart weight in female rats exposed to  $\geq 1000$  ppm and an increase in relative testis weight at  $\geq 1000$  ppm. No increase in histopathologic lesions was observed at the high dose [**data not shown**]. Methylphenidate did not decrease nose-rump length, bone length, or bone density in males or females.

In the 13-week mouse study, body weight gain was significantly reduced in males exposed to  $\geq 125$  ppm and females exposed to  $\geq 2000$  ppm. Final body weight was significantly lower in males exposed to  $\geq 250$  ppm and females exposed to 2000 ppm according to Table 11 in the NTP report. According to Table F6 in the NTP report, necropsy body weights were significantly reduced in males of all dose groups but there were no significant effects in females. Relative liver weights were reduced in males exposed to  $\geq 250$  ppm and absolute and relative liver weights were significantly increased in mice of both sexes exposed to  $\geq 1000$  ppm. The study authors stated that only relative weights increased in other organs and the effect was attributed to reduced body weight. **[According to Table F6 in the NTP report, absolute and relative brain weights were increased in the 2000-ppm males.]** Liver lesions were significantly increased in males exposed to  $\geq 500$  ppm and the lesions included centrilobular hypertrophy, degeneration, and necrosis.

The NTP tables reporting organ weight effects contain a footnote about organ collection for sperm morphology and vaginal cytology examinations. The results for sperm analyses and male organ weight measurements are addressed in a separate publication (64), discussed in Section 4.2.

Teo et al. (46) examined the subchronic toxicity of *d,l*- and *d*-methylphenidate in Sprague-Dawley rats. In a 14-day dose range-finding study, 10 rats/sex/group were gavaged with 0, 1, 10, or 50 mg/kg bw *d*-methylphenidate or 0, 2, 20, 100 mg/kg bw *d,l*-methylphenidate twice daily, 6 hours apart, for a total dosage of 0, 2, 20, or 100 mg/kg bw/day *d*-methylphenidate or 0, 4, 40, or 200 mg/kg bw/day *d,l*-methylphenidate. Significant differences in body weight changes **[not specified but assumed reduced]** and reduced feed consumption were observed in the 200 mg/kg bw/day *d,l*-methylphenidate and 100 mg/kg bw/day *d*-methylphenidate groups. There were two moribund rats in the 200 mg/kg bw/day *d,l*-methylphenidate group and clinical signs in that group included self-mutilation, abrasions, and missing portions of front paws. Similar clinical signs were observed in females of the 100 mg/kg bw/day *d*-methylphenidate group, but at a lower incidence and lesser severity. Changes in hematology and clinical chemistry endpoints occurred in the  $\geq 40$  mg/kg bw/day *d,l*-methylphenidate and 100 mg/kg bw/day *d*-methylphenidate groups, but the effects were not specified. Organ weight changes included increased absolute and relative liver weight in females of the 200 mg/kg bw/day *d,l*-methylphenidate group and decreased absolute spleen weights in females of the 20 mg/kg bw/day and males of the 100 mg/kg bw/day **[*d*-methylphenidate]** group. Based on the findings of this study, the authors selected high doses of 50 mg/kg bw/day for *d*-methylphenidate and 100 mg/kg bw/day for *d,l*-methylphenidate in the subchronic study.

For the subchronic study, 7-week-old Sprague-Dawley rats were gavaged with hydrochloride salts of *d*- or *d,l*-methylphenidate (98–102% purity) in water for 90 days. Doses (number of rats/sex/dose) were 0 (15), 1.0 (10), 10.0 (10), and 25.0 (15) mg/kg bw for *d*-methylphenidate and 50 (15) mg/kg bw for *d,l*-methylphenidate. Doses were administered twice daily, 6 hours apart, for total dosages of 0, 2.0, 20.0, or 50.0 mg/kg bw/day *d*-methylphenidate or 100 mg/kg bw/day *d,l*-methylphenidate. Animals were observed daily and measurements included feed intake, body weight, ophthalmology examination, and body temperature. Blood was collected before and during the study, and just prior to kill for hematologic and clinical chemistry evaluations. After rats were killed, organs were weighed and major organs were collected for a histopathologic evaluation of all animals. The organs analyzed were not generally specified, but testes were reportedly collected and fixed in Bouin solution. Ten rats/sex/group were killed 1–2 days after the last treatment. Five rats/sex group in the control, 50 mg/kg bw/day *d*-methylphenidate, and 100 mg/kg bw/day *d,l*-methylphenidate groups were killed following a 30-day recovery period. Statistical analyses included ANOVA followed by Dunnett test.

One male and 1 female in the 50 mg/kg bw/day *d*-methylphenidate group and 1 male in the 100 mg/kg bw/day *d,l*-methylphenidate died during the study. Clinical signs stated to be most likely treatment-related included material around eyes or nose, scabbing, foot swelling, localized alopecia, and abrasions in rats treated with 50 mg/kg bw/day *d*-methylphenidate or 100 mg/kg bw/day *d,l*-methylphenidate. Dose-related reductions in body weight changes were observed in males with statistical significance obtained at numerous time points with  $\geq 20$  mg/kg bw/day *d*-methylphenidate and 100 mg/kg bw/day *d,l*-methylphenidate. There were no consistent reductions in female body weight gain or feed intake in males or females. There were no eye lesions or significant changes in body temperature. No significant hematologic changes were observed [**data not shown**]. Significant changes in clinical chemistry parameters in males of the 50 mg/kg bw/day *d*-methylphenidate and 100 mg/kg bw/day *d,l*-methylphenidate groups included increased blood urea nitrogen, sodium, and chloride and decreased albumin, creatinine, and triglycerides; changes in females from the same dose groups included increased chloride and decreased albumin and albumin/globulin ratio. In the 20 mg/kg bw/day *d*-methylphenidate group, significant reductions were observed for triglyceride levels in males and albumin levels in females. Protein in urine was increased in 1 male from the 100 mg/kg bw/day *d,l*-methylphenidate group and 4 females from the 50 mg/kg bw/day *d*-methylphenidate group [**data not shown**]. The only absolute organ weight changes were observed in rats treated with *d,l*-methylphenidate and they included increased pituitary (male only) and ovary weight and decreased prostate weight [**data not shown**]. Significant increases in organ to body weight ratios were observed in rats treated with the high dose of either compound and organs affected included brain, heart, kidney, and liver in *d*-methylphenidate-treated males, liver, ovary, and spleen in *d*-methylphenidate-treated females, adrenals, brain, heart, kidneys and pituitary in *d,l*-methylphenidate treated males, and brain, kidney, liver, ovary, and spleen in *d,l*-methylphenidate-treated females. When expressed as percent brain weight, only ovarian weights in rats treated with both drugs and prostate and pituitary weights in rats treated with *d,l*-methylphenidate remained increased [**data not shown**]. No abnormal histopathologic changes were observed [**data not shown**]. All effects were resolved or improved during the 30-day recovery period in control and high-dose animals. Based upon body weight changes, the authors identified a no observed adverse effect level (NOAEL) of 20 mg/kg bw/day for *d*-methylphenidate; they concluded that toxicity of *d*- and *d,l*-methylphenidate is comparable at equimolar doses of the *d*-enantiomer under the conditions of this study.

Teo et al. (51) examined the subchronic toxicity of *d,l*- and *d*-methylphenidate in Beagle dogs. In a 14-day dose range-finding study, an unspecified number of dogs were treated with 0, 0.5, 1.5, or 5 mg/kg bw *d*-methylphenidate or 1, 3, or 10 mg/kg bw *d,l*-methylphenidate twice daily, 6 hours apart, for a total dosage of 0, 1, 3, or 10 mg/kg bw/day *d*-methylphenidate or 2, 6, or 20 mg/kg bw/day *d,l*-methylphenidate. Hyperactivity and increased salivation were observed in dogs dosed with  $\geq 3$  mg/kg bw/day *d*-methylphenidate and 20 mg/kg bw/day *d,l*-methylphenidate. Reduced body weight and food intake were reported for dogs exposed to  $\geq 3$  mg/kg bw/day *d*-methylphenidate and  $\geq 6$  mg/kg bw/day *d,l*-methylphenidate. The maximum tolerated dose was considered to be 10 mg/kg bw/day for *d*-methylphenidate and 20 mg/kg bw/day for *d,l*-methylphenidate; those dose levels were selected as the high dose for the 90-day study.

In the GLP-compliant subchronic study, Teo et al. (51) gavaged 6-month-old Beagle dogs (6/sex/group) for 93 days with vehicle [**unspecified**]; 0.5, 1.5, or 5.0 mg/kg bw *d*-methylphenidate; or 10 mg/kg bw *d,l*-methylphenidate twice daily, 6 hours apart for total doses of 1, 3, or 10 mg/kg bw/day *d*-methylphenidate or 20 mg/kg bw/day *d,l*-methylphenidate. Drug purities were reported to be 98–102%. Animals were observed daily and measurements included feed intake, body weight, ophthalmology, body temperature, and EKG. Blood was collected before and during the study, and just prior to kill for hematologic and clinical chemistry



evaluation. After animals were killed, organs were weighed and major organs were collected for a histopathologic evaluation of all animals. The organs analyzed were not generally specified, but testes were reported to have been collected and fixed in 3% glutaraldehyde. Four dogs/sex/group were killed at the end of treatment, while 2 dogs/sex/group were killed following a 1-month recovery period. Statistical analyses included ANOVA followed by Dunnett test.

No mortality was observed in the 93-day study. Clinical signs in dogs dosed with 10 mg/kg bw/day *d*-methylphenidate or 20 mg/kg bw *d,l*-methylphenidate included salivation, hyperactivity, and loose stool or diarrhea. Significant reductions were observed for feed intake in males during the first 3–4 weeks of the study and male body weights in the 10 mg/kg bw/day *d*-methylphenidate and 20 mg/kg bw *d,l*-methylphenidate groups; weight loss was also observed in dogs from the top *d*- and *d,l*-methylphenidate dose groups during the first few weeks of the study. Significant effects on hematology included reduced hemoglobin and hematocrit in males from the 10 mg/kg bw/day *d*-methylphenidate and 20 mg/kg bw/day *d,l*-methylphenidate groups; red blood cell count was also reduced in the males given 20 mg/kg bw/day *d,l*-methylphenidate. **[The results section reported that the only clinical chemistry findings were significant decreases in serum albumin and albumin/globulin ratio at week 4 in males given *d,l*-methylphenidate. However, Table 4 of the report indicates significantly increased blood urea nitrogen in females dosed with 10 mg/kg bw/day *d*-methylphenidate and reduced creatine phosphokinase (CPK) in males dosed with 20 mg/kg bw/day *d,l*-methylphenidate.]**

Significant decreases in absolute organ weights (*d*-: lung; *d,l*-: lung and spleen), increases in organ to body weight ratios (*d*-: brain, heart and testes; *d,l*-: brain and liver), or decreases in organ to brain weight ratios (*d*-: lung; *d,l*-: lung and spleen) were observed in high-dose males treated with both drugs, but the study authors did not consider the changes to be treatment-related. No abnormal urinalysis results or histopathology were observed **[data not shown]**. Ophthalmologic and EKG testing was also reported to be normal. All effects were reversed or improved during the recovery period **[data not shown]**. The study authors selected a NOAEL of 3 mg/kg bw/day for *d*-methylphenidate based on body weight changes; they concluded that at equimolar concentrations of *d*-methylphenidate, the repeat dose toxicity of *d*-methylphenidate was slightly less than or similar to that of *d,l*-methylphenidate.

### 2.3 Genetic toxicology

Results and details of study protocols for *in vitro* genetic toxicity tests are summarized in Table 17.

Based on results of their mutagenicity studies in *Salmonella* and chromosomal aberration and sister chromatid exchange tests in Chinese hamster ovary cells (Table 17), the NTP (8) concluded that methylphenidate “. . . is not a gene mutagen in bacteria or mammalian cells, but . . . might have some potential for inducing clastogenic damage in mammalian cells.” However, it was noted that increases in sister chromatid exchange occurred at doses causing severe toxicity and increases in chromosomal aberrations did not correlate well with dose.

Additional genetic toxicity studies were identified. Teo et al. (28) demonstrated that *d,l*-, *d*-, and *l*-methylphenidate do not induce mutations in *Salmonella typhimurium*, *Escherichia coli*, or mouse lymphoma cells (Table 17). In an *in vitro* study available only as an abstract, therapeutic doses of methylphenidate caused a slight but significant increase in sister chromatid exchanges in lymphocytes in 2 of 4 pediatric patients **[presumably without metabolic activation]** (65). Methylphenidate tested negative in a cell transformation assay (66).

One *in vivo* genetic toxicity study was identified. In that study, no increase in bone marrow cell micronucleus formation was observed in 6–8 week old male and female CD-1 mice treated orally

with 25–250 mg/kg bw *d*-methylphenidate, 125–500 mg/kg bw *l*-methylphenidate, or 50–250 mg/kg bw *d,l*-methylphenidate (28). The study included vehicle and positive controls.

**Table 17. *In vitro* Genetic Toxicity Studies of Methylphenidate**

Reference	Enantiomers tested/concentration	Testing with metabolic activation	Species or cell type/strain	Endpoint	Results
NTP (8)	<i>d,l</i> ≤ 10,000 µg/plate	Yes	<i>Salmonella typhimurium</i> strains TA100, TA1535, TA1537, TA98	Mutagenicity at the histidine operon	↔ with and without metabolic activation
NTP (8)	<i>d,l</i> ≤ 4000 µg/plate	Yes	<i>Salmonella typhimurium</i> strain TA97	Mutagenicity at the histidine operon	↔ with and without metabolic activation
Teo et al. (28)	<i>d,l</i> , and <i>d,l</i> ≤ 5000 µg/plate	Yes	<i>Salmonella typhimurium</i> strains TA98, TA100, TA1535, TA1537	Mutagenicity at the histidine operon	↔ with and without metabolic activation
Teo et al. (28)	<i>d,l</i> , and <i>d,l</i> ≤ 5000 µg/plate	Yes	<i>Escherichia coli</i> strain WP2 <i>uvrA</i>	Mutagenicity at the tryptophan operon	↔ with and without metabolic activation
Teo et al. (28)	<i>d</i> ≤ 500 µg/mL; <i>l</i> ≤ 800 µg/mL; <i>d,l</i> ≤ 600 µg/mL	Yes	<i>L5178Y/TK</i> <sup>+/-</sup> mouse lymphoma cells	Mutagenicity	↔ with and without metabolic activation
NTP (8)	<i>d,l</i> ≤ 5000 µg/mL	Yes	Chinese hamster ovary cells	Chromosomal aberration	Equivocal, weakly positive to positive results obtained in some trials with ≥ 1750 µg/mL without metabolic activation and ≥ 1000 µg/mL with metabolic activation; results in other trials were negative

Reference	Enantiomers tested/concentration	Testing with metabolic activation	Species or cell type/strain	Endpoint	Results
NTP (8)	<i>d,l</i> , ≤2000 µg/mL	Yes	Chinese hamster ovary cells	Sister chromatid exchange	↑ at ≥702 µg/mL without metabolic activation; equivocal with metabolic activation (trials in two labs produced negative or weakly positive results at ≥1600 µg/mL)
Walker and Dumars (65) (abstract)	NS (assumed to be <i>d,l</i> ) / “therapeutic levels”	NS	Human pediatric lymphocytes	Sister chromatid exchange	Small but significant ↑ in lymphocytes from 2 of 4 subjects
Matthews et al. (66)	NS (assumed to be <i>d,l</i> ) / 2.09–8.36 mM [488–1950 µg/mL]	No	A-31-1-13 BALB/c-3T3 cells	Transformation	↔

↔ no change; ↑significant increase

## 2.4 Carcinogenicity

### 2.4.1 Human

Review of pharmacy and medical records from 1969 to 1973 for a cohort of 143,574 patients in a medical care program indicated that the number of cancers was lower than expected in 529 patients taking methylphenidate (67). Whereas 32.7 cases of cancer were expected, only 15 cases were observed ( $P < 0.002$ ). Study authors urged caution in the interpretation of the finding because the small sample size limited the power to detect modest increases in cancer and the study covered a relatively short time period ( $< 20$  years).

### 2.4.2 Experimental animal

Drug manufacturers reported no evidence of carcinogenicity in male or female p53+/- transgenic mice exposed to up to 60–74 mg/kg bw/day racemic methylphenidate through feed for 24 weeks (2, 5, 7); the transgenic mouse strain is reportedly sensitive to genotoxic carcinogens. CERHR was not able to locate the original study report.

The NTP (8, 68) examined the carcinogenicity of *d,l*-methylphenidate in F344/N rats and B6C3F<sub>1</sub> mice in studies conducted according to FDA GLP. The studies used pharmacopoeia grade *d,l*-methylphenidate hydrochloride, which has a purity of  $>99\%$ . The drug was mixed in feed, and stability, homogeneity, and target concentrations were verified. Animals were 6 weeks old at the start of the study and 70 animals/sex/group were randomly assigned to dose groups. Rats were fed diets containing 0, 100, 500, or 1000 ppm methylphenidate hydrochloride and mice were fed diets containing 0, 50, 250, or 500 ppm methylphenidate hydrochloride. Males were exposed for 104 weeks and females for 105 weeks. Male rats received estimated methylphenidate doses of 4, 20, and 42 mg/kg bw/day and females received estimated doses of 0, 4, 22, and 47 mg/kg bw/day. Doses estimated in mice were 0, 5, 28, or 56 mg/kg bw/day in males and 0, 7, 34, or 66 mg/kg bw/day in females. Dose selection was based on results of the 13-week study described in Section 2.2.2. According to study authors, doses in this study were 40–60 times higher than therapeutic human doses. Animals were examined daily and weighed before, during, and after treatment. Interim killings were conducted in 10 animals/sex/group at 9 and 15 months to examine hematology, clinical chemistry, and organ weights. At terminal kill, rats were necropsied. Organs from major systems were collected from all animals and fixed in 10% neutral buffered formalin for histopathologic evaluation. Among the organs examined were clitoral gland (rat only), mammary gland, ovary, prostate gland, testis, epididymis, seminal vesicle, and uterus. Statistical analyses included the Cox method and Tarone life table test for survival, Fisher exact test and Cochran-Armitage trend test for lesion incidence, and the Dunnett, Williams, Dunn, or Shirley test for continuous variables.

In rats, survival of treated groups was similar to controls. Starting at week 30 of the study, mean body weights of rats in the 500- and 1000-ppm groups were lower than controls. Body weights of female rats were significantly lower than controls at 9 and 15 months. Final body weights in the 100-, 500-, and 1000-ppm groups were 102, 95, and 90% of control values in males and 96, 89, and 78% of control values in females. Feed intake of treated animals was similar to controls. The only clinical sign was increased fighting in males of the 1000-ppm group. At the 9-month kill, leukocyte and lymphocyte numbers were generally increased in males and females. **[The results section reports that statistical significance for leukocyte and lymphocyte increases was obtained at the 1000-ppm dose. While tables in the NTP report support the statement for statistical significance in lymphocytes, the tables indicate that statistical significance for leukocytes was obtained at most dose levels in males and at  $\geq 500$  ppm in females.]** No differences in white blood cell numbers were observed at 15 months. Clinical chemistry findings reported in the results section include decreased serum alanine aminotransferase activity in males from the 500- and 1000-ppm groups at 9 months and in males from all treatment groups at 15

months. **[Other significant effects listed in NTP tables included reduced aspartate aminotransferase levels in the 1000-ppm males at 9 months, increased creatinine levels in 1000-ppm females at 9 months, and increased blood urea nitrogen levels in females at 15 months.]** In the results section it was reported that absolute and relative brain weights were increased in females exposed to 1000 ppm and relative brain weights were significantly increased in females exposed to  $\geq 500$  ppm. **[According to Table F3 and F4 in the report, statistically significant organ weight changes at the 9-month kill included increased relative kidney weight ( $\geq 500$ -ppm males), relative liver weight (1000-ppm males), testis weight (1000 ppm), absolute brain weight (1000-ppm female), and relative brain weight ( $\geq 100$  ppm), and decreased absolute liver weight ( $\geq 500$ -ppm female). Statistically significant organ weight changes at the 15-month kill included increased relative kidney weight (1000-ppm male), relative liver weight ( $\geq 500$ -ppm male and female), and relative brain weight ( $\geq 500$ -ppm females) and decreased absolute kidney weight (1000-ppm female) and absolute liver weight ( $\geq 500$ -ppm female).]** There were no increases in the incidence of neoplastic or non-neoplastic lesions in males or females. Negative trends were reported for neoplastic lesions in male adrenal gland and female mammary gland. Incidence of benign pheochromocytomas was significantly reduced in males of all dose groups, but the effect was not dose-related. Incidence of mammary gland fibroadenomas was significantly reduced in the 500- and 1000-ppm groups. In females, there were also dose-related reductions in incidence of galactoceles and lactation.

In the mouse study, methylphenidate did not affect survival. Mean body weights of treated groups were 3–11% lower than controls throughout the study. Final body weights of the respective low to high-dose treatment groups were 97, 89, and 93% of control values in males and 98, 93, and 97% of control values in females. Although some significant but minor effects were observed for hematologic and clinical chemistry parameters at 9 and 15 months, the study authors stated the differences were not biologically significant. According to NTP tables, significant organ weight changes at 9 months included increased relative liver weight ( $\geq 50$ -ppm females, 500-ppm males), relative brain weights ( $\geq 250$ -ppm males), and relative kidney and testis weight (500-ppm males). **[The results section of the NTP report only describes weight effects in liver.]** At 15 months, relative liver weight was significantly increased in males and females from all dose groups. In males and females of the 500-ppm group, the incidences of eosinophilic foci and all foci were increased in liver. Hepatic neoplastic findings are summarized in Table 18. Treatment with 500 ppm methylphenidate resulted in significantly increased incidences of hepatocellular adenoma and carcinoma in males and females of the 500-ppm group. The incidence of hepatoblastoma, a rare neoplasm, was increased in males of the 500-ppm group. According to study authors, progression of hepatic foci from cellular alteration to adenoma to carcinoma may represent a spectrum of proliferative liver lesions. Because methylphenidate is not mutagenic in *Salmonella* tests, the study authors postulated that liver tumorigenesis may have been due to a nongenotoxic mechanism, such as increased cell proliferation. According to study authors, a decreased trend for alveolar/bronchial adenomas in males and increased trend in females was apparently due to variances in control animals and incidences in treated groups were within historical control values; therefore, the authors did not consider the effects to be treatment-related.

The study authors concluded that under the conditions of this study, there was *no evidence of carcinogenic activity* in F344/N rats and *some evidence of carcinogenic activity* of methylphenidate hydrochloride in male and female B6C3F<sub>1</sub> mice, based on hepatocellular neoplasms.

**Table 18. Incidence of Liver Lesions or Tumors in Mice Treated With *d,l*-Methylphenidate in the Diet**

Tumor types and parameters	Dose (ppm)			
	0	50	250	500
<b>Females:</b> Values presented as incidence/number examined (%) or [%] <sup>a</sup>				
Eosinophilic foci	3/49 [6.1%]	3/48 [6.3%]	8/49 [16.3%]	25/50** [50%]
All foci	5/49 [10%]	8/48 [17%]	11/49 [22%]	26/50** [52%]
Hepatocellular adenoma (multiple)	2/49 [4.1%]	0/48	3/49 [6.1%]	15/50** [30%]
Hepatocellular adenoma (single or multiple)				
Overall rate <sup>b</sup>	6/49 (12%)	10/48 (21%)	10/49 (20%)	28/50 (56%)***
Adjusted rate <sup>c</sup>	16.2%	26.6%	26.1%	62.2%***
Terminal rate <sup>d</sup>	6/37 (16%)	8/35 (23%)	9/37 (24%)	27/44 (61%)***
Hepatocellular carcinoma				
Overall rate <sup>b</sup>	5/49 (10%)	3/48 (6%)	2/49 (4%)	6/50 (12%)
Adjusted rate <sup>c</sup>	13.5%	8.3%	5.4%	13.2%
Terminal rate <sup>d</sup>	5/37 (14%)	2/35 (6%)	2/37 (5%)	5/44 (11%)
Hepatocellular carcinoma or adenoma				
Overall rate <sup>b</sup>	9/49 (18%)	11/48 (23%)	11/49 (22%)	30/50 (60%)***
Adjusted rate <sup>c</sup>	24.3%	28.7%	28.7%	65.2%**
Terminal rate <sup>d</sup>	9/37 (24%)	8/35 (23%)	10/37 (27%)	28/44 (64%)***
<b>Males:</b> values presented as incidence/number examined (%) or [%] <sup>a</sup>				
Eosinophilic foci	6/50 [12%]	8/50 [16%]	9/50 [18%]	14/50* [28%]
All foci	9/50 [18%]	12/50 [24%]	14/50 [28%]	18/50* [36%]
Hepatocellular adenoma (multiple)	5/50 [10%]	10/50 [20%]	6/50 [12%]	14/50* [28%]
Hepatocellular adenoma (single or multiple)				
Overall rate <sup>b</sup>	18/50 (36%)	18/50 (36%)	16/50 (32%)	29/50 (58%)†
Adjusted rate <sup>c</sup>	39.1%	39.1%	35.5%	64.2%†
Terminal rate <sup>d</sup>	17/45 (38%)	17/45 (38%)	15/44 (34%)	25/41 (61%)†
Hepatocellular carcinoma				
Overall rate <sup>b</sup>	10/50 (20%)	9/50 (18%)	17/50 (34%)	11/50 (22%)
Adjusted rate <sup>c</sup>	20.7%	19.5%	34.7%	23.4%
Terminal rate <sup>d</sup>	7/45 (16%)	8/45 (18%)	12/44 (27%)	6/41 (15%)
Hepatoblastoma				
Overall rate <sup>b</sup>	0/50	1/50 (2%)	1/50 (2%)	5/50 (10%)††
Adjusted rate <sup>c</sup>	0%	2.2%	2.3%	12.2%††

Tumor types and parameters	Dose (ppm)			
	0	50	250	500
Terminal rate <sup>d</sup>	0/45	1/45 (2%)	1/44 (2%)	5/41 (12%)††
Hepatocellular adenoma, carcinoma, or hepatoblastoma				
Overall rate <sup>b</sup>	24/50 (48%)	23/50 (46%)	26/50 (52%)	34/50 (68%)†††
Adjusted rate <sup>c</sup>	49.9%	48.9%	53.0%	70.7%
Terminal rate <sup>d</sup>	21/45 (47%)	21/45 (47%)	21/44 (48%)	27/41 (66%)†††

From (8, 68).

\* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; † $P = 0.02$ ; †† $P = 0.026$ ; ††† $P = 0.037$

<sup>a</sup>( ) = study author calculations, [ ] = CERHR calculations; <sup>b</sup>Total number; <sup>c</sup>Kaplan-Meier estimated incidence adjusted for intercurrent mortality; <sup>d</sup>Observed incidence at terminal kill

## 2.5 Potentially sensitive subpopulations

### 2.5.1 Pharmacogenetics

Information on ethnic variation is not available (32).

### 2.5.2 Sex-related differences

An FDA review of Focalin™ reported no difference in pharmacokinetics of *d*-methylphenidate in boys and girls following single or repeat dosing in a small sample ( $n = 4$ – $5$ /sex) (32). Table 19 lists results for the single dose exposure. Similar effects were observed following repeat dosing.

**Table 19. Pharmacokinetic Parameters of in Boys and Girls Administered a Single 10 mg dose of *d*-Methylphenidate, FDA**

Parameter <sup>a</sup>	Girls ( $n = 4$ )	Boys ( $n = 5$ )
Age (years)	9.5±2.1	10.4±2.9
Height (cm)	138.3±9.8	146.6±19.4
Weight (kg)	32.8±6.5	40.6±13.8
$C_{\max}$ (ng/mL)	22.7±7.8	20.4±5.6
$T_{\max}$ (hours)	1.0±0.4	1.3±0.4
$AUC_{0-12h}$ (ng-hour/mL)	85.2±25.5	80.1±18.6
$AUC_{0-\infty}$ (ng-hour/mL)	89.1±26.6	88.1±17.0
Half-life (hours)	2.0±0.3	2.5±0.4

<sup>a</sup>Results presented as mean±SD. From (32)

The FDA review of Focalin™ reported that *d*-methylphenidate  $C_{\max}$  was 20–35% higher and AUC was 26–37% higher in adult female ( $n = 6$ ) compared to male ( $n = 9$ ) volunteers when adjusted for body weight, possibly indicating higher bioavailability in females (32). The FDA noted that the clinical significance of the finding is not clear.  $T_{\max}$  and half-life did not differ between males and females. The study is summarized in Table 20.

An FDA review of Ritalin®LA reported higher weight-adjusted volume of distribution and clearance in women compared to men, but similar plasma level profiles (31). The FDA stated that there appears to be a gender-related but clinically insignificant effect.

No difference in mean dose-adjusted  $AUC_{0-\infty}$  values for Concerta® was reported in healthy adult men (36.7 ng-hour/mL) and women (37.1 ng-hour/mL) (7).



**Table 20. Pharmacokinetic Parameters in Men and Women Administered a Single 20 mg dose of *d*-Methylphenidate under Fasting or Fed Conditions**

Parameter <sup>a</sup>	Fasting		Fed	
	Females (n = 6)	Males (n = 9)	Females (n = 6)	Males (n = 9)
Body weight (kg)	60.4±4.7	79.2±12.4	See fasting	See fasting
Dose/kg	0.33±0.03	0.26±0.04	See fasting	See fasting
C <sub>max</sub> (ng/mL)	32.0±9.4 (+76%)	18.2±5.6	28.1±4.8 (+55%)	18.1±4.9
C <sub>max</sub> /(dose/kg)	96.0±28.3 (+35%)	71.8±19.3	84.4±12.5 (+20%)	70.6±15.9
T <sub>max</sub> (hours)	1.4±0.4	1.7±0.6	2.6±0.7	3.1±0.9
AUC <sub>0-12h</sub> (ng-hour/mL)	159.7±55.9	88.1±31.0	167.4±45.3	101.4±30.4
AUC <sub>0-∞</sub> (ng-hour/mL)	164.3±56.3 (+79%)	91.9±31.9	172.0±45.9 (+64%)	105.2±31.7
AUC <sub>0-∞</sub> /(dose/kg)	488.2±148.8 (+37%)	355.2±100.9	511.6±106.3(+26%)	407.0±98.1
Half-life (hours)	2.7±0.3	2.7±0.3	2.8±0.5	2.8±0.2

<sup>a</sup>Results presented as mean±SD. The percentage figures in parentheses are the changes in females compared to the comparable parameter in males. From (32)

### 2.5.3 Children and Juvenile Mice

Pharmacokinetic parameters in children and adults orally administered 0.30 mg/kg bw methylphenidate are listed in Table 21 (35). The study authors concluded that results were similar in adults and children.

**Table 21. Comparison of Pharmacokinetics in Children and Adults Orally Administered 0.30 mg/kg bw Methylphenidate**

Subjects	T <sub>max</sub> (hours)	C <sub>max</sub> (ng/mL)	Clearance (L-hr/kg)	Half-life (hours)
Adults (n = 10)	2.1 ± 0.3	7.8 ± 0.8	10.5 ± 1.7	2.14
Children (n = 6) <sup>a</sup>	1.5 ± 0.2	10.8 ± 1.9	10.2 ± 2.2	2.43

From (35). Results presented as mean±SEM

<sup>a</sup>One child was given 2 mg/kg bw methylphenidate; although not explicitly stated, it does not appear that that the child was included in the analysis.

Dosing with 20 mg methylphenidate resulted in about twice the plasma level of methylphenidate in children aged 7–12 years compared to adults aged 18–35 years (10). Because apparent clearance normalized to body weight was found to be independent of age, higher blood levels in children are thought to be almost exclusively due to lower body weights and volumes of distribution (10). In an FDA review for Ritalin®LA, a slightly shorter half-life was reported for children versus adults (~2.6 versus 3.4 hours) (31).

In a study summarized in an FDA review for Focalin™, C<sub>max</sub> and AUC were compared in adults and children administered similar doses of *d*-methylphenidate on a mg/kg bw basis (32). *d*-Methylphenidate C<sub>max</sub> values were similar but AUC values were slightly lower in adults (Table 22). [CERHR notes that the conclusion was based on data from two separate studies.]

**Table 22. Comparison of C<sub>max</sub> and AUC Values for *d*-Methylphenidate in Adults and Children**

Age group	Number	Dose (mg/kg bw) <sup>c</sup>	C <sub>max</sub> (ng/mL) <sup>c</sup>	AUC (ng-hour/mL) <sup>c</sup>
Children (< 12 years) <sup>a</sup>	7	0.31±0.09	26.04±10.79	94.51±26.0
Adults	15	0.29±0.05	23.72±9.91	120.9±55.3

From (32)

<sup>a</sup>Children were dosed with 10 mg *d*-methylphenidate twice daily

<sup>b</sup>Adults were dosed with 2 × 10 mg *d*-methylphenidate as a single dose

<sup>c</sup>Errors were not specified. Based on other data in this report, the values are most likely mean±SD

**[Data were obtained from two separate studies.]**

Fukui et al. (69) conducted an *in vitro* study to investigate methylphenidate effects on dopamine signaling in neostriatal slices from young (14–15- or 21–22-day old) or adult (6–8 week old) male C57BL/6 mice. The slices were incubated in 100 μM methylphenidate [**23.3 μg/mL, assuming that values were provided for the free base**] for 2 or 5 minutes and an immunoblotting technique was used to measure dopamine and cAMP-regulated phosphoprotein M<sub>r</sub> 32 kDa (DARPP-32) phosphorylation at the Thr34 and Thr5 sites. In adult animals, methylphenidate increased Thr34- DARPP-32 phosphorylation, but decreased Thr75- DARPP-32 phosphorylation at both time periods. In the two younger groups, there was no increased in Thr34-DARPP-32 phosphorylation and a reduction in Thr75-DARPP-32 phosphorylation only occurred in slices from the 21–22-day old animals at 5 minutes. Similar results were seen with cocaine, but methamphetamine regulation of DARPP-32 phosphorylation was similar in adult and young animals. Incubation of neostriatal slices with SKF81297, a dopamine D1 receptor agonist increased Thr34-DARPP-32 and decreased Thr75-DARPP-32 phosphorylation in both young and mature animals at a similar level. According to study authors, “These results suggest that the dopamine D1-type receptor signaling pathway in neostriatal medium spiny neurons is fully functional in young mice, but that the machinery for dopamine release and/or reuptake, or its regulation at presynaptic dopaminergic terminals is immature in young mice.”

## 2.6. Summary of General Toxicology and Biologic Effects

### 2.6.1 Pharmacodynamics and pharmacokinetics

Stimulatory effects of methylphenidate presumably occur through activation of the brain stem arousal system and cortex (11, 12). The mode of action for therapeutic treatment of ADHD is not known. It is thought that methylphenidate blocks reuptake of norepinephrine and dopamine by the presynaptic neuron, thus increasing levels of these monoamine neurotransmitters in the extraneuronal space (5, 7, 10, 12). A limited inhibition of monoamine oxidase activity may also occur (reviewed in (29)). Dosing of rats with methylphenidate metabolites (ritalinic acid, *p*-hydroxymethylphenidate, and 6-oxomethylphenidate) resulted in no pharmacologic activity, thus indicating that the parent compound is most likely the pharmacologically active species (reviewed in (8)). Numerous studies in rats demonstrated that the *d*-enantiomer is the pharmacologically active component (reviewed by Teo et al. (46)).

Methylphenidate is available in immediate-release, long-acting, and intermediate-acting formulations. In humans, immediate-release-formulations reach peak blood levels within 1–3 hours following oral ingestion (See Sections 2.1.1.2 and 2.1.1.6). Extended-release (long-acting) formulations usually result in a sharp initial slope to peak level during the first 1–3 hours after ingestion followed by a more gradual peak occurring 3–4 hours later. Intermediate-acting formulations were reported to have the same bioavailability as immediate-acting formulations but

are absorbed more slowly. Maximum blood levels of methylphenidate in children given therapeutic doses of the drug in the racemic or *d*-enantiomer form were within a similar range when presented as total or *d*-enantiomer; and that range was ~5–20 ng/mL (See Sections 2.1.1.2 and 2.1.1.6).

Consistent with humans, rapid absorption of methylphenidate was demonstrated in rats, mice, and monkeys (reviewed in NTP (8)). Studies in rats and rabbits demonstrated  $T_{\max}$  values of ~0.25–2 hours following dosing with up to 75 mg/kg bw/day *d,l*-methylphenidate or up to 100 mg/kg bw/day *d*-methylphenidate (46, 48, 50).  $T_{\max}$  was reported at 0.5–5 hours in dogs dosed with 10 mg/kg bw/day *d,l*-methylphenidate or up to 5 mg/kg bw/day *d*-methylphenidate (51). In those same studies maximum blood levels of *d*-methylphenidate were dependent on dose and ranged from ~3 to 946 ng/mL in rats, ~2 to 565 ng/mL in rabbits, and 2 to 333 ng/mL in dogs.

Apparent volumes of distribution for methylphenidate in humans have been reported at 6 L/kg following iv exposure (10, 40), at 7–33.2 L/kg in 4 children given 10–15 mg methylphenidate orally (38), and at ~40 L/kg in children given ~0.9 mg/kg bw (~28 mg) orally (39). Binding of methylphenidate to plasma protein is low (10–33%) ((30); reviewed in (1, 10)). Methylphenidate disposition is stereospecific, resulting in higher plasma levels of the *d*- versus the *l*-enantiomer in humans (reviewed in (1)). Peak plasma levels of the *d*-enantiomer were 5–8 times higher than the *l*-enantiomer in children dosed with 10–20 mg methylphenidate (34, 37, 45). Two studies in pregnant rats also demonstrated higher blood levels of the *d*-enantiomer (~2 times higher) at doses of 7–75 mg/kg bw/day (48, 50). In pregnant rabbits, the *l*-enantiomer was ~1.5–6 times higher than the *d*-enantiomer at doses of 20–60 mg/kg bw/day, while the *d*-enantiomer was ~3–9 times higher than the *l*-enantiomer at 200 mg/kg bw/day (48, 50). Higher levels of the *l*-enantiomer (~1.3–2 times higher than the *d*-enantiomer) were observed in non-pregnant dogs dosed with 10 mg/kg bw/day methylphenidate.

The FDA (32) reported proportionality of pharmacokinetic parameters to administered dose in children given 2.5–10 mg *d*-methylphenidate or 5–20 mg *d,l*-methylphenidate (32). One manufacturer reported that  $C_{\max}$  and AUC values increased proportionally to dose in children given once-daily oral doses of 20 or 40 mg for 1 week or adults given single oral doses of 10–60 mg (5). However, a study in 4 healthy individuals and 1 narcolepsy patient reported disproportionate increases in AUC (corrected to a 10-mg dose) between 20 and 40 mg and dose-related decreases in oral clearance, most likely due to saturated presystemic metabolism, at doses between 10 and 60 mg methylphenidate (41). **[The Panel notes that author conclusions are reasonable but with so few humans involved, firm conclusion cannot be made]** The FDA (31) reported the possibility of “nonlinearity” at a dose of 60 mg. Modi et al. (42) postulated that linearity may be affected by drug formulation due to higher blood concentrations obtained with immediate- versus sustained-release formulations. In an experimental animal study, disproportionate increases in AUC for both enantiomers in pregnant rats dosed with 7–75 mg/kg bw/day and for the *d*-enantiomer in rabbits dosed with 20–200 mg/kg bw/day led study authors to suggest saturation of metabolic processes (50).

In the predominant human metabolic pathway for methylphenidate, nonmicrosomal hydrolytic esterases found throughout the body rapidly biotransform methylphenidate to  $\alpha$ -phenyl-piperidine acetic acid (PPA; commonly called ritalinic acid) (10), a metabolite believed to have little to no pharmacologic activity (8). The low absolute oral bioavailability of methylphenidate in children (~30%, range: ~10–52%) implies extensive presystemic biotransformation (10, 33). There appears to be no substantial interconversion between the *d*- and *l*- enantiomers (32). Less than 2% of methylphenidate is metabolized in minor pathways involving aromatic hydroxylation to *p*-hydroxy compounds, microsomal oxidation to oxo- compounds, and conjugation, the minor

metabolites are not believed to be pharmacologically active (Reviewed in (1, 8)). Though no metabolism by or inhibition of CYP isoenzymes has been observed in *in vitro* studies (2, 5), a review of drug interaction reports concluded that methylphenidate is involved in pharmacokinetic interactions suggesting inhibition of one or more hepatic CYP enzymes (44).

In contrast to humans who metabolize the majority of methylphenidate to ritalinic acid, less than half (~23–40%) of a methylphenidate dose is esterified to form ritalinic acid following oral or parenteral exposure of rats and dogs (reviewed by (8)). More than 50% of metabolites in rats and dogs are derived from microsomal oxidation or aromatic hydroxylation reactions. Many of the metabolites undergo further conjugation and de-esterification reactions. Less than 1% of methylphenidate is excreted unchanged in all species. It was reported that one dog study demonstrated evidence of CYP inhibition by methylphenidate (reviewed in (44)).

Methylphenidate half-lives of ~2–8 hours were reported for oral administration of immediate- or extended-release *d*- or *d,l*-formulations at doses up to 20 mg in adults and children (2, 5, 7, 10, 12, 32). Half-lives for extended-release products are expected to be longer than immediate-release formulations due to slower absorption as the rate limiting process (5). Mean total body clearance in children administered 10–15 mg methylphenidate by iv infusion was reported at 2.52 L/kg-hour, a value exceeding average blood flow to the liver (1.4 L/kg-hour) and suggesting extrahepatic metabolism (reviewed in (40)). Mean clearance rates of ~9–10 L/kg-hour were reported in children orally exposed to methylphenidate at up to 0.41 mg/kg bw (35, 37) and 0.9 mg/kg bw (39). Oral dosing with radiolabeled methylphenidate results in recovery of 80–97% of the radioactivity in human urine (7, 10, 12) and 1–3% in feces (10). Ritalinic acid is the main urinary metabolite and represents about 60–86% of the dose in humans (7, 10). Less than 1% of the methylphenidate dose is excreted unchanged in urine {Novartis, 2001 #2173}.

Methylphenidate elimination half-lives were reported at ~1–4 hours in rats, rabbits, and dogs dosed with up to 75 mg/kg bw/day *d,l*-methylphenidate {Teo, 2003 #78; Bakhtiar, 2004 #3056; Teo, 2002 #120; Teo, 2003 #79} and ~0.2–4 hours in rats, rabbits, and dogs dosed with up to 100 mg/kg bw/day *d*-methylphenidate (46, 48, 51). Consistent with humans, urinary excretion is the major elimination route in mice, dogs, and rats (reviewed in (8)). Studies in rats, mice, and dogs demonstrated 50–80% of methylphenidate doses excreted in urine over 24–48 hours (8). In rats dosed with 10–20 mg/kg bw methylphenidate orally or by ip injection, 30–40% of elimination occurred through feces and a significant amount of the dose was also excreted in bile (reviewed in (8)).

## **2.6.2 General toxicity**

### **2.6.2.1 Humans**

Common side effects associated with methylphenidate treatment have been reported as nervousness, insomnia, reduced appetite, abdominal pain, weight loss, and tachycardia, jitteriness, social withdrawal, irritability, anxiety, and proneness to crying. The effects may be transient or persistent. Following overdose with methylphenidate, symptoms result primarily from overstimulation of the CNS and include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions possibly followed by coma, euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and/or dry mucous membranes. Chronic methylphenidate abuse can lead to tolerance and symptoms similar to those observed with amphetamine toxicity including psychic dependence, abnormal behavior, psychotic episodes, paranoid delusions, or hallucinations (11, 13).

### 2.6.2.2 Experimental Animal

LD<sub>50</sub> values for various species are summarized in Table 16. Death following exposure to high dose levels of methylphenidate is most probably due to excessive adrenergic stimulation (8). The most common signs of toxicity observed in methylphenidate repeat dose studies in rats, mice, and dogs were weight loss, reduced feed intake, and clinical signs such as hyperactivity. In a review by the FDA (32), maximum tolerated doses for *d*-methylphenidate were identified as 100 mg/kg bw/day in rats, based upon hyperactivity, hypersensitivity, and self-mutilation, and 10 mg/kg bw/day in dogs, based upon hyperactivity, salivation, and elevated body temperature. NOELs for *d*-methylphenidate were identified at < 20 mg/kg bw/day in rats and 1 mg/kg bw/day in dogs. NOELs for *d,l*-methylphenidate were < 40 mg/kg bw/day for rats and 2 mg/kg bw/day for dogs. Subchronic studies available for Expert Panel review suggested *d*-methylphenidate LOAELs of 50 mg/kg bw/day in rats (46) and 10 mg/kg bw/day in dogs (51) based upon reduced body weight gain. In addition, those studies in rats and dogs found similar toxicity of *d*- and *d,l*-methylphenidate at equimolar concentrations of the *d*-enantiomer and found that effects reversed or improved following a recovery period. Though not consistently observed, some repeat dose studies reported liver lesions in rats and mice (8) and clinical chemistry or hematological changes in rats or dogs (46, 51); in most cases the effects occurred at or above doses causing weight changes or clinical signs of toxicity.

### 2.6.3 Genetic toxicology

As noted in Section 2.3, negative results were obtained in most methylphenidate genetic toxicity tests including *in vitro* mutagenicity tests in *S. typhimurium*, *E. coli*, and mouse lymphoma cells, a transformation assay in A-31-1-13 BALB/c-3T3 cells, and an *in vivo* micronucleus study in mice. However, equivocal or positive results were obtained in other *in vitro* tests including a chromosomal aberration assay in Chinese hamster ovary cells, and sister chromatid exchange assays in Chinese hamster ovary cells or human pediatric lymphocytes. Based on results of their mutagenicity studies in *S. typhimurium* and chromosomal aberration and sister chromatid exchange tests in Chinese hamster ovary cells (Table 17), the NTP (8) concluded that methylphenidate “. . . is not a gene mutagen in bacteria or mammalian cells, but . . . might have some potential for inducing clastogenic damage in mammalian cells.” However, it was noted that increases in sister chromatid exchange occurred at doses causing severe toxicity and increases in chromosomal aberrations did not correlate well with dose.

### 2.6.4 Carcinogenicity

One study of 529 patients exposed to methylphenidate that included a < 20 year follow-up, reviewed pharmacy and medical records from 1969 to 1973 for a cohort of 143,574 patients in a medical care program and reported that the number of cancers in patients exposed to methylphenidate was lower than expected, 15 versus an expected 32.7 cases (67).

Labels from drug manufacturers reported no evidence of carcinogenicity in male or female p53+/- transgenic mice exposed to up to 60–74 mg/kg bw/day racemic methylphenidate through feed for 24 weeks. In a 2-year GLP dietary carcinogenicity study, there was no evidence of neoplasia at *d,l*-methylphenidate doses up to 47 mg/kg bw/day in rats (8, 68). However, significant increases in hepatic neoplasms (adenomas or adenomas and carcinomas) were observed in mice receiving 500 ppm *d,l*-methylphenidate (56–66 mg/kg bw/day). With the exception of an increase in hepatic foci there were no other treatment-related increases in non-neoplastic lesions, including in reproductive organs. The study authors concluded that under the conditions of this study, there was no evidence of carcinogenic activity in F344/N rats and some evidence of carcinogenic activity of methylphenidate hydrochloride in male and female B6C3F<sub>1</sub> mice, based on hepatocellular neoplasms.

### ***2.6.5 Potentially sensitive subpopulations***

There is no information on genetic or ontological differences that could affect metabolism or disposition of methylphenidate. In FDA reviews of methylphenidate drug studies, slight differences in some pharmacokinetic parameters were noted between men and women and between adults and children.

A study in mouse neostriatal medium spiny neurons slices demonstrated that young mice (14–22 days old) have an intact dopamine D1-type receptor signaling pathway but that the regulation of the pathway following *in vitro* exposure to methylphenidate is different in young versus adult mice (69).

### 3.0 DEVELOPMENTAL TOXICITY DATA

#### 3.1 Human Data

##### *3.1.1 Methylphenidate Exposure During Pregnancy*

**Debooy et al. (70)**, support not indicated, reported on 39 infants (1 set of twins) born to 38 women in a 2-year period in Manitoba for whom there was evidence in the maternal record of iv use of pentazocine (an opioid) and methylphenidate. **[The authors indicate that biochemical drug testing was not performed, so the evidence is presumably based on maternal report.]** All the mothers smoked cigarettes and 10 women (26%) abused other drugs. Eight of the infants (21%) were born prior to 37 gestational weeks and 12 infants (31%) had a birth weight lower than the 10<sup>th</sup> percentile for gestational age. Eleven infants (28%) were diagnosed with withdrawal **[criteria not specified]**. There were four infants (10%) with malformations: one with a ventricular septal defect, one with polydactyly, and two (the twins) with fetal alcohol syndrome. One infant died of extreme prematurity. Follow-up information was available on 30 children. Twelve of the children were readmitted to the hospital, 11 were diagnosed with behavioral problems, and 5 had failure to thrive. Child abuse and neglect was suspected in eight children.

**Strengths/Weaknesses:** The strength of this paper is the evaluation of the pentazocine-methylphenidate combination, which is of clinical importance. The evaluation of a mixed exposure, however, is a weakness in attempting to understand the toxicity of methylphenidate itself. The iv exposure route is not relevant to therapeutic methylphenidate exposure. Other weaknesses include the many other potential harmful exposures such as sexually transmitted diseases, cigarettes, ethanol, and child abuse. Much of the information was obtained from medical records, and there appeared to be no controls.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is not useful in the evaluation process.

**The National Collaborative Perinatal Project (71)** reported on 50,282 mother-child pairs in which pregnancy had lasted at least 5 lunar months. Information on medication exposure during pregnancy was collected at the time of the first prenatal visit and recorded prospectively thereafter. Outcome information was based on physical examination of the child up to the age of 1 year in 91% of the sample and for up to 4 years of age in an unspecified proportion of the sample. There were 11 pregnancy exposures (first 4 lunar months) to methylphenidate, which were analyzed as part of 96 pregnancies exposed to “other sympathomimetics,” which included 16 other agents. Relative risks were calculated using the entire sample as a reference group. There were 7 malformations in the other sympathomimetic group, giving a crude relative risk of 1.13 **[95% CI not provided]**.

**Strengths/Weaknesses:** The National Collaborative Perinatal Project was a good study that was properly analyzed; however, this study contains only 11 methylphenidate exposures.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is not useful in the evaluation process.

##### *3.1.2. Adverse Effects of Methylphenidate Therapy in Children*

There are several issues to take into account when reviewing studies on side effects in children. These issues may account for the inconsistent and sometimes contradictory results of different reports. Studying side effects is especially problematic because of the subjective nature of the outcome measure. Specific considerations are as follows:

- Side Effect Check Lists deal with subjective qualities such as headache and dizziness.
- Parents and teachers may observe different side effects in the home versus school environment; some studies include one assessment while others include both.
- Parent reports may be biased because parents want to see their children feel better and may over report symptoms at the beginning of a study.
- Children may not accurately report on many of the effects (i.e., headache, dizziness, anorexia) and may not understand some of them because of their cognitive age.
- Different durations of drug treatment may give rise to different side effects.
- Different drug doses may give rise to different side effects.
- Drug compliance is not documented in these studies.
- Many of these studies lack control groups or have inadequate control groups. When placebo controls are available, it is noteworthy how commonly side effects occur on placebo.

Side effects of methylphenidate reported to the FDA were listed in Table 13 in Section 2.2.1.1. In the Concerta™ product label, treatment-emergent events in a 4-week placebo-controlled trial in children included headache in 15/106 children on methylphenidate and 10/99 on placebo [***P* = 0.40, Fisher Exact test**]. Abdominal pain occurred in 7/106 children on methylphenidate and 1/99 on placebo [***P* = 0.07, Fisher Exact test**], and anorexia occurred in 4/106 children on methylphenidate and 0/99 on placebo [***P* = 0.12, Fisher Exact test**]. There were smaller differences between methylphenidate and placebo for other adverse effects.

#### 3.1.2.1 Controlled Side Effect Evaluations

Published studies were identified in which methylphenidate was compared with placebo with regard to adverse effects (72-78). Some controlled study data on side effects were summarized in Table 14 in Section 2.2.1.1. Additional details will be presented here.

**Rapoport et al. (72)** performed a randomized controlled trial, supported by NIMH, using 76 children age 6–12 years (mean = 9 years) referred for persistent distractibility or motor restlessness and impulsivity. Subjects were randomized in a blinded manner to treatment with methylphenidate 10 mg in the morning (n = 29), imipramine 25 mg morning and evening (n = 29), or placebo (n = 18). The focus of the study was effectiveness [**not discussed here**], but side effect data were also reported [**method of obtaining side effect information not specified; the Expert Panel assumes that side effects were recorded at the end of the study at 6 weeks**]. The authors concluded that compared to placebo, children on methylphenidate were more likely to have stomachache (7 of 29 on methylphenidate compared to 0 of 18 on placebo [***P* = 0.034, Fisher Exact test by CERHR**]), drowsiness (5 of 29 on methylphenidate compared to 0 of 18 on placebo [***P* = 0.141, Fisher Exact test by CERHR**]), and increased blood pressure (> 10 mm Hg increase in diastolic pressure in 8 of 29 on methylphenidate and 0 of 18 on placebo [***P* = 0.017, Fisher Exact test by CERHR**]). There were no differences between the methylphenidate and placebo groups in the incidence of appetite change or sleep disturbance.

**Strengths/Weaknesses:** Weaknesses in this study include inadequate delineation of the method of assessing side effects and the possibility of a multiple comparison problem leading to a greater chance of Type I error.

**Utility (Adequacy) for CERHR Evaluation Process:** This study has marginal utility for the evaluation process; because of the missing methodologic information, confidence in the study is low.



**Conners and Taylor (73)**, supported by NIMH and Abbott Laboratories, randomized 60 children (3 girls, 57 boys) with “hyperkinesis due to minimal brain dysfunction” to pemoline (n = 19), methylphenidate (n = 20), or placebo (n = 21). The children ranged from 6 to 11 years old (mean 7 years, 11 months). Medication or placebo capsules were given twice daily permitting the blind to be maintained while dosing pemoline once daily and methylphenidate twice daily. Medication doses were increased each week as necessary for clinical response. The mean final doses were pemoline 2.25 mg/kg bw/day and methylphenidate 0.82 mg/kg bw/day. Side effect information was recorded by a physician on a standard 49-item form at baseline and 4 and 8 weeks after initiation of therapy **[efficacy endpoints were also evaluated, but are not presented here]**. The most common side effect of methylphenidate was difficulty sleeping, occurring in 13/20 children on medication and 5/21 on placebo [***P* = 0.01, Fisher Exact test**]. Appetite problems occurred in 8/20 children on methylphenidate and 5/21 on placebo [***P* = 0.33, Fisher Exact test**]. Increased crying was noted in 10/20 children on methylphenidate and 5/19 children on placebo [***P* = 0.11, Fisher Exact test**]. Headache occurred in 5/20 children on methylphenidate and 2/21 children on placebo [***P* = 0.24, Fisher Exact test**]. The remainder of the side effects occurred in 0, 1, or 2 children on methylphenidate.

**Strengths/Weaknesses:** Strengths include the blinded placebo control and the ratings prior to and during therapy. The use of parent as well as physician ratings is a strength. A weakness is the absence of efficacy endpoints.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is useful for the evaluation process.

**Barkley et al. (74)**, support not indicated, gave 83 children, 5–13 years old, a 7–10 day trial of twice-daily placebo, methylphenidate 0.3 mg/kg bw/dose, or methylphenidate 0.5 mg/kg bw/dose. Each child was crossed over to each treatment in random order. Evaluations, performed on 80 children who completed the study, included effectiveness endpoints **[not discussed here]** and side effects, derived from a behavior questionnaire completed by parents at the end of each treatment period. A list of 17 common side effects was presented on the questionnaire with a Likert scale for the evaluation of severity ranging from 0 (not present) to 9 (severe). Side effects were evaluated with regard to whether they were present or absent at each evaluation, whether they were “severe” (Likert rank of 7 or higher), and with regard to mean Likert score **[the Expert Panel questions the use of parametric statistics for Likert scale results]**. The frequency of the most common side effects on each treatment are given in Table 23. The authors concluded that decreased appetite and sleep problems were the most common symptoms of stimulant therapy. They noted, however, that most children in whom these side effects occurred rated them as mild (a Likert score of  $\leq 3$ ).

**Table 23. Frequency of Side Effects on Placebo or Methylphenidate**

Symptom	Number of affected children (of 80)			[ <i>P</i> value from 2 × 3 chi squared]
	Placebo	Methylphenidate 0.3 mg/kg bw/dose	Methylphenidate 0.5 mg/kg bw/dose	
Decreased appetite	12	42 <sup>a</sup>	45 <sup>a</sup>	[0.001]
Severe	1	6	10 <sup>a</sup>	[0.021]
Insomnia	32	50 <sup>a</sup>	54 <sup>a</sup>	[0.009]
Severe	6	14	14	[NS]
Stomachache	14	31 <sup>a</sup>	28 <sup>b</sup>	[0.011]
Severe	0	1	5	[0.028]
Headache	9	21 <sup>b</sup>	17	[0.052]
Severe	0	1	3	[NS]
Prone to crying	39	47	43	[NS]
Severe	8	13	8	[NS]

NS = not significant. [<sup>a</sup>*P* < 0.001, <sup>b</sup>*P* < 0.05 compared to placebo, Fisher Exact test performed by CERHR].

From (74).

**Strengths/Weaknesses:** The use of a triple-blind placebo controlled design is a strength as is completion of rating scales by parents and teachers. The short duration of treatment (10 days) and the inappropriate statistical evaluation of the Likert scales are weaknesses.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is useful in the evaluation process.

**Handen et al. (75)**, supported by NICHD, the Edith L. Trees Foundation, and Children’s Hospital of Pittsburgh, enrolled 27 children with a diagnosis of ADHD and an IQ of 48–74 (mean 64). The children were observed without stimulant medication for 2 weeks (some of them had previously been on medication), followed by three 1-week periods on placebo, methylphenidate 0.3 mg/kg bw/dose, and methylphenidate 0.6 mg/kg bw/dose. The treatments were given twice daily. **[It is not clear whether the order of treatments was randomized.]** The presence of side effects was evaluated by teachers using a 13-item questionnaire based on the side effects reported in the methylphenidate product label. For 14 of the children, a Likert scale was used to rank side effect severity. Two children were discontinued from the study due to social withdrawal on methylphenidate 0.3 mg/kg bw/dose and were not evaluated at the 0.6 mg/kg bw/dose level. None of the 13 side effects were reported in a significantly larger proportion of children on methylphenidate than placebo. Three side effects were more common on placebo than on at least one of the methylphenidate regimens: irritability, anxiety, and high activity. **[The statistical methods given in the paper include ANOVA, which is not appropriate for proportions; however, Fisher Exact test by CERHR confirmed the significant differences identified by the authors in proportion of children with side effects on each treatment. The Likert ranks were given as means and were not amenable to further evaluation by CERHR.]** The authors concluded that many of the side effects attributed to methylphenidate may be symptoms of ADHD. They noted, for example, that appetite problems appear to be common in children with ADHD and were not increased with the use of methylphenidate in their study.

**Strengths/Weaknesses:** It is difficult to assess somatic complaints in mentally retarded children, whose responses can be influenced by whomever questions them. This study does not provide

assurance that the assessment of side effects was reliable. In addition, the statistical handling of the Likert scales was not appropriate.

**Utility (Adequacy) for CERHR Evaluation Process:** Confidence in the findings of this report is low.

**Ahmann et al. (77)** treated 206 children aged 5–15 with methylphenidate 0 or 0.3 mg/kg bw/dose 3 times daily for 7 days (week 1) followed by 7 days of the opposite treatment (0.3 or 0 mg/kg bw/dose methylphenidate, week 2). Subjects were then either randomized to methylphenidate 0 or 0.5 mg/kg bw/dose 3 times/day (n = 46) or were given placebo in week 3 if the week 2 treatment was methylphenidate 0.3 mg/kg bw/dose and methylphenidate 0.5 mg/kg bw/dose if the week 2 treatment was placebo. The week 4 regimen was the opposite of week 3 (methylphenidate 0.5 or 0 mg/kg bw/day). Thus, all children received 2 weeks of placebo (methylphenidate 0 mg/kg bw/dose), and 1 week each of methylphenidate 0.3 and 0.5 mg/kg bw/dose, with the higher dose regimen always later in time than the lower dose regimen. **[The Expert Panel notes that the change in randomization scheme after the first 46 patients was to avoid the possibility of 2 successive weeks of methylphenidate.]** The children were evaluated by their parents using an 18-item side effect inventory. Four children did not complete the study due to side effects on methylphenidate. A comparison of the presence of side effects on methylphenidate or on placebo was expressed as an odds ratio with 95% CI. Weeks 1 and 2 were analyzed separately from weeks 3 and 4; that is, each methylphenidate dose condition had its own placebo period for comparison. Of the 18 side effects, 5 were more prevalent on methylphenidate, 4 were more prevalent on placebo, and 9 did not significantly differ by treatment condition. The 5 side effects and odds ratios (95% CI) that increased on methylphenidate were insomnia 3.13 (1.80–5.42), appetite disturbance 19.00 (9.18–39.31), stomachache 7.00 (3.29–14.89), headache 5.29 (2.51–11.15), and dizziness 7.50 (1.93–29.13). The 4 side effects and odds ratios that were less prevalent on methylphenidate were staring and daydreaming 0.47 (0.27–0.84), irritability 0.33 (0.18–0.61), anxiety 0.42 (0.23–0.76), and nail biting 0.19 (0.07–0.53). The authors found that the prevalence of appetite disturbance was dose-related. Separate analyses did not show age or sex to be significantly associated with medication side effects. The authors concluded that many of the symptoms attributed to methylphenidate therapy in anecdotal reports may be ADHD symptoms, some of which improve on stimulant therapy. Insomnia, decreased appetite, stomachache, headache, and dizziness, which were increased in this study, were also increased in other studies and may have been medication effects, according to the authors.

**Strengths/Weaknesses:** Strengths include the large sample size and the randomized, double-blinded, placebo-controlled design. Weaknesses include evaluation by parents only. The dosing schedule (3 times/day, 7 days/week) may limit comparability to other studies. It is of interest that the number of patients reporting side effects was greater at baseline than on the placebo treatment.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is useful in the evaluation process.

**Fine and Johnston (76)**, supported by CIBA-Geigy Canada, randomized 24 children with ADHD to received methylphenidate 0, 0.3, or 0.6 mg/kg bw/dose twice/daily for 1 week each. **[The Expert Panel assumes the randomization was to the order of treatment and that all children received all treatments for 1 week; the methods are not clear.]** Parents evaluated side effects using a 16-item questionnaire on which each symptom was scored using a 0–9 Likert scale. The results were presented and analyzed as means of Likert ranks; the authors concluded that trouble sleeping, decreased appetite, and nail biting occurred “significantly more frequently”

on active drug than placebo based on higher mean ranks for these three symptoms [**the Expert Panel questions the use of parametric analysis of means of Likert ranks**].

**Strengths/Weaknesses:** Use of a placebo arm is a strength. Weaknesses include the small sample size, limited number of days of assessment, and the statistical handling of the Likert scores.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is not useful for the evaluation process.

**Kent et al. (79)** evaluated the effect of a third daily dose of methylphenidate at 4 PM on sleep, noting that typical therapy involves only morning and midday dosing in order to avoid sleep disturbance. Twelve children with ADHD, aged 5.5–11.25 years (mean  $\pm$  SD  $9.0 \pm 2$  years) were studied in an inpatient setting. Methylphenidate dosing was begun using 5 mg at 7 AM and noon, with these doses titrated up to 15 or 20 mg/dose twice/day based on clinical response. The titration phase was completed within 14 days, following which children were given an additional dose at 4:00 PM of 0, 10, or 15 mg methylphenidate. Each child received each of the 3 dose regimens for a 4-day trial, in random order. Sleep latency was evaluated by checking the subject every 10 minutes at bedtime until sleep was identified. Sleep adequacy was evaluated by subjective report and by staff evaluation of the child's appearance during the daytime. There were no differences between treatments in sleep latency. The proportion of children who were evaluated as being tired or who said they were tired during the day was not different by treatment. The authors concluded that there was no evidence of sleep disturbance with an afternoon dose of methylphenidate, although they acknowledged that the structured inpatient setting may not be generalizable to home environments.

**Strengths/Weaknesses:** The structured setting is a strength, but also a weakness in that the inpatient situation may not be relevant to the typical outpatient treatment setting. The comorbidity for oppositional-defiant disorder or conduct disorder is a weakness, as is the subjective nature of the reports of sleepiness from the children and the lack of a control group. The very long sleep latencies (50 minutes) raise the possibility that the environment or the ADHD may have interfered with sleep.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is marginally useful in the evaluation process.

**Schachar et al. (78)**, supported by the Medical Research Council of Canada, randomized 91 children (mean age 8.3–8.4 years, range 6–12) with ADHD to methylphenidate or placebo for a planned 6-month treatment period. Side effects were evaluated at 4 months in 66 subjects who had remained on their initially assigned therapy, including 37 children on methylphenidate and 29 children on placebo. During a 3- or 4-week titration period, methylphenidate doses were increased by 10 mg/day each week to reach a target dose of 0.7 mg/kg bw/dose given twice daily. Medication dose could be increased or decreased based on therapeutic response and side effects at the discretion of a study physician [**blinding of the study physician to treatment is assumed, although the paper does not address this issue**]. Non-medication therapies were also used. Side effects were evaluated by parents and teachers using a telephone interview at baseline and 4 months. The telephone interview consisted of a list of 14 side effects to be rated on a 10-point Likert scale. Four side effect domains were constructed: physiological (insomnia, dizziness, anorexia, headache, daytime drowsiness), affective (irritability, social withdrawal, sadness, crying), tics (motor or vocal tics), and over-focusing (staring, preoccupation). Likert ranks within each domain were summed to create a score. Side effect scores were considered clinically significant if they increased more than 1 standard deviation from the baseline scores for the

sample or if any side effect increased from “absent or mild” to “moderate or severe” [**Likert ranks corresponding to these adjectives were not given in the report.**] The side effect data were presented as means and standard deviations of the four domain scores and evaluated using analysis of variance. [**The Expert Panel questions the summing and averaging of Likert ranks and the use of parametric analysis.**] The authors stated that anorexia, stomachache, withdrawal, sadness, and crying were the most common side effects to increase with methylphenidate. Ten percent of children assigned to methylphenidate discontinued the medication due to side effects. The authors suggested that the higher rate of discontinuation for side effects in their study compared to other placebo-controlled studies may reflect the longer duration of treatment in their study.

**Strengths/Weaknesses:** The large sample size and extended treatment period are strengths of this study as are the evaluation by parents and teachers and the inclusion of nonpharmacologic interventions. The inclusion of children with comorbid oppositional-defiant disorder or conduct disorder is a weakness, and assessment was only at baseline and 4 months. It is also a weakness that medications were given on weekends and holidays at the parents’ discretion. The evaluation of Likert scores using parametric statistical methods is a weakness.

**Utility (Adequacy) for CERHR Evaluation Process:** Because the data presentation relied on manipulating Likert ranks arithmetically, this report is not adequate for the evaluation process.

**Efron et al. (80)**, supported by a hospital research fund, randomized 114 boys and 11 girls with ADHD to a 2-week trial of *d*-amphetamine or methylphenidate, followed by a 24-hour wash-out period, followed by a 2-week trial of the other stimulant. The mean age (range) of the subjects was 104.8 months (60–179 months). The *d*-amphetamine dose was 0.15 mg/kg bw/dose and the methylphenidate dose was 0.30 mg/kg bw/dose, both given twice/day, rounded to the nearest tablet size. Investigators, subjects, teachers, and family members were blinded to the identity of the medication. Evaluations included effectiveness endpoints [**not discussed here**] and side effects, derived from a behavior questionnaire completed by parents at the end of each 2-week treatment period. A list of 17 common side effects was presented on the questionnaire with a Likert scale for the evaluation of severity ranging from 0 (not present) to 9 (severe). Side effects were evaluated with regard to whether they were present or absent at baseline and on treatment and with regard to mean Likert score. [**The Expert Panel questions the use of parametric statistics for Likert scale results.**] Poor appetite occurred in a larger proportion of subjects on methylphenidate (56%) than at baseline (34%) [ **$P = 0.0014$ , Fisher Exact test**]. Anxiousness, headaches, and nightmares occurred more often at baseline than on methylphenidate therapy (anxiousness: 77% at baseline, 61% on methylphenidate [ **$P = 0.0093$ , Fisher Exact test**]; headache: 41% at baseline, 24% on methylphenidate [ **$P = 0.0067$ , Fisher Exact test**]; and nightmares: 39% at baseline, 21% on methylphenidate [ **$P = 0.0023$ , Fisher Exact test**]). The remainder of the symptoms were identified as present in a similar proportions of children at baseline and on methylphenidate. The authors concluded that many side effects identified on stimulant medication may be side effects associated with the underlying disorder rather than due to the medication therapy.

**Strengths/Weaknesses:** The double-blind cross-over design is a strength of this study. The limitation of drug therapy to 2 weeks is a weakness. The use of parametric statistics for Likert scores is a weakness, although using the scores to rank symptoms as present or absent permitted nonparametric analysis.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is useful in the evaluation process.

**Connor (81)**, support not indicated, published a review of side effects reported in 2 studies with similar designs, one conducted in pre-school age children (mean age 4.1 years, n = 32) and another in school age children (mean age 8.2 years, n = 83). The types of side effects that were significantly increased compared to controls differed in each age group. Side effects reported in preschool age children were sadness, nightmares, appetite suppression, drowsiness, less talking, and lack of interest. Reported side effects in school age children were appetite suppression, insomnia, stomachache, and headache. There appeared to be a slight increase in side effects reported as severe in pre-school (10%) versus school age (3.6%) children. Connor (81) concluded that more studies are needed before firm conclusions can be made about safety and efficacy during different developmental stages.

**Strengths/Weaknesses:** This review does not add new information.

**Utility (Adequacy) for CERHR Evaluation Process:** This review is not useful in the evaluation process.

### *3.1.2.2 Clinical laboratory findings*

**Satterfield et al. (82)**, supported by NIMH, performed clinical blood chemistry determinations at baseline on an initial cohort of 115 boys aged 6–12 years who were being started on stimulant therapy. Blood testing was repeated every 6 months for up to 48 months. Of the initial cohort, 70 boys were sampled at 12 months, 44 boys at 24 months, 15 boys at 36 months, and 7 boys at 48 months. Testing included red and white blood cell counts, hemoglobin, hematocrit, eosinophils, protein-bound iodine (an estimate of thyroid hormone status), glucose, lactate dehydrogenase, alkaline phosphatase, bilirubin, calcium, phosphorus, protein, albumin, transaminase [**not otherwise specified**], urea nitrogen, uric acid, and cholesterol. Small significant changes were noted over time in some measures, attributed by the authors to normal maturational changes [**normative data not given or referenced**]. The authors concluded that there were no adverse effects of methylphenidate therapy on these clinical laboratory parameters.

**Strengths/Weaknesses:** It is a weakness that normative data were not given or referenced.

**Utility (Adequacy) for CERHR Evaluation Process:** This study can be used in the evaluation process.

**Aarskog et al. (83)** and **Shaywitz et al. (36)** examined the acute effects of oral methylphenidate treatment on growth hormone or prolactin levels in children. Treatment of 10 children with 20 mg methylphenidate resulted in an increase from a mean baseline serum growth hormone level of 3.8 ng/mL to a mean peak level of 10.6 ng/mL at 60 minutes (83). Mean plasma levels of growth hormone rose from a baseline level of 4.40 ng/mL to a peak level of 10.5 ng/mL at 2 hours in 11 children who received 0.34 mg/kg bw methylphenidate (36). Following the peak, growth hormone levels returned to baseline values in both studies. One study demonstrated that adults treated with methylphenidate also experience an acute increase in serum growth hormone levels (84). In the study by Shaywitz et al. (36), mean plasma prolactin levels in children decreased from a baseline value of 9.50 ng/mL to 3.80 ng/mL within 1.5 hours of dosing with 0.34 mg/kg bw methylphenidate.

Recognizing that *d*-amphetamine and methylphenidate are as effective as *l*-dopa in releasing growth hormone, Aarskog et al. (83) compared serum growth hormone levels at baseline and following acute administration of *l*-dopa/carbidopa and *d*-amphetamine in 7 children (ages 6–13 years), before and after 6–8 months therapy with 5–35 mg/day methylphenidate [**purity not**

**specified].** Growth hormone levels were determined using a radioimmunosorbent method. Prior to methylphenidate therapy, mean  $\pm$  SEM baseline levels of serum growth hormone were  $2.3 \pm 0.6$  ng/mL in the *l*-dopa/carbidopa study and  $3.1 \pm 0.9$  ng/mL in the *d*-amphetamine study. After methylphenidate therapy, baseline levels of growth hormone were  $4.5 \pm 1.6$  in the *l*-dopa/carbidopa and  $8.6 \pm 1.5$  ng/mL in the *d*-amphetamine groups. The increase in baseline levels of growth hormone following methylphenidate therapy in the *d*-amphetamine study were statistically significant, but there was no significant difference after the baseline values for the *l*-dopa/carbidopa and *d*-amphetamine studies were combined. Extended therapy with methylphenidate changed individual responses to acute *d*-amphetamine treatment. In most children, standard growth hormone provocation curves were obtained with acute *d*-amphetamine treatment prior to methylphenidate therapy. Subsequent to methylphenidate therapy, acute *d*-amphetamine treatment resulted in “tendencies” for delayed response and an initial fall in growth hormone concentration, with or without a subsequent rise [**the term “tendency” was not defined and statistical analyses were not presented**]. The study authors concluded that extended methylphenidate treatment may have effects on growth hormone homeostasis, but urged caution in the interpretation of results because occasional high levels of growth hormone were due to factors such as stress.

**Strengths/Weaknesses:** These studies appeared to have been appropriately performed and yield data with interesting implications. It is a weakness of the study by Aarskog et al. (83) that statistical methods were not presented.

**Utility (Adequacy) for CERHR Evaluation Process:** These studies can be used as supplemental information in the evaluation process.

**Schultz et al. (85),** in a study funded in part by NIH grants, compared diurnal concentrations of growth hormone and prolactin in children during periods with and without methylphenidate exposure. The 9 children (mean age  $11.1 \pm 1.7$  [SD] years) examined in the study were on methylphenidate therapy (20–120 mg/day) for 3 months to 4 years. During a 24-hour period, blood was collected continually for measurement of serum growth hormone and prolactin concentrations by RIA. [**It was not stated if children took methylphenidate on the day of analysis.**] Following the 24-hour analysis period, growth hormone response to insulin-arginine stimulation was examined. About half the subjects took their morning methylphenidate dose prior to the insulin-arginine tolerance test, while the other half waited until the test was completed before taking methylphenidate. The study was repeated after methylphenidate therapy was discontinued for 11 days to 10 weeks and values during treatment and the abstinence period were compared. Patterns of diurnal growth hormone and prolactin levels were similar during periods with and without methylphenidate treatment. There were normal fluctuations in levels throughout the day and peak hormone release occurred during sleep. Mean integrated concentrations of growth hormone and prolactin and fasting levels of somatomedin are listed in Table 24. There were no significant differences in values during the time periods of treatment and following the abstinence period. No significant differences in growth hormone levels were observed when subjects were stratified according to doses  $>0.90$  mg/kg bw/day ( $n = 4$ ) or  $<0.90$  mg/kg bw/day ( $n = 5$ ). A significantly higher peak level of growth hormone following insulin-arginine administration in subjects during the methylphenidate treatment period appeared to be related to the acute administration of methylphenidate prior to the insulin-arginine test in about half the subjects. The study authors concluded that these data suggest growth deficits in methylphenidate-treated children are not related to alterations in the hypothalamic-pituitary somatomedin axis.

**Table 24. Comparison of Growth Hormone, Prolactin, and Somatomedin Levels in Children During and Following Abstinence from Methylphenidate Therapy**

Measurement	Serum concentration (ng/mL except somatomedin)	
	Before methylphenidate	During methylphenidate
Integrated 24-hour growth hormone	3.82±0.39	4.38±0.35
Integrated growth hormone during sleep	5.5±0.49	6.4±0.6
Integrated 24-hour prolactin	13.0±1.7	13.7±1.9
Integrated prolactin during waking hours	7.7±1.4	9.2±1.7
Integrated prolactin during sleep	13.0±1.7	24.3±3.2
Fasting somatomedin (units/mL)	0.76±0.03	0.88±0.03

Data expressed as mean ± SEM, n=9. Data from Schultz et al. (85)

**Strengths/Weaknesses:** Strengths include the evaluation of children on long-term therapy and the use of continual measurements over 24 hours. A weakness is the small number of subjects.

**Utility (Adequacy) for the CERHR Evaluation Process:** This report is useful in the evaluation process, although confidence in the conclusions are limited by the small sample.

**Hunt et al. (86)**, in a study funded by the McArthur foundation and focusing on neurochemical mechanisms of ADHD, measured growth hormone levels in response to a clonidine challenge before, during, and 1 day after methylphenidate treatment of 8 boys (mean age 11 years) for at least 3 months with ≥0.3 mg/kg bw/day methylphenidate. **[The dose was stated to be 0.5 mg/kg bw/day in the results section. The duration of methylphenidate treatment prior to conducting the clonidine challenge during the treatment period was not specified.]** For analyses conducted during treatment, methylphenidate was given at 8:00–8:30 AM, 1 hour prior to the challenge with 3 µg/mL clonidine, an alpha adrenergic agent. In the time periods before and after methylphenidate treatment, clonidine was administered 9:00–9:30 AM. Blood was collected before clonidine administration and throughout a 4-hour period following clonidine dosing. Plasma growth hormone levels were determined in 4 or 5 subjects/time period by RIA. **[There was no discussion about methods used for statistical analyses.]** Results of growth hormone analyses are listed in Table 25, which shows an attenuation of growth hormone increase in response to clonidine challenge during and after methylphenidate treatment (the augmentation in growth hormone response to clonidine was decreased by 53% and then rebounded to 66% of control levels). The clonidine inhibition of 3-methoxy-4-hydroxyphenylethylene release tended to be more pronounced during the methylphenidate treatment period. Methylphenidate treatment resulted in no significantly or consistent effects on norepinephrine and epinephrine release following clonidine challenge.

**Table 25. Growth Hormone Response to a Clonidine Challenge in Boys Before, During, and After Methylphenidate Treatment**

Methylphenidate status	Plasma growth hormone		
	Baseline	Peak (ng/mL)	
		Following Clonidine	AUC (ng-min/mL) Following Clonidine
Before treatment	4.3±1.4	31.3±4.6	3010±823
During treatment	~7 <sup>a</sup>	14.8±3.2*	1620±353*
One day after treatment	~3 <sup>a</sup>	20.8±3.9*	2325±623

Data expressed as mean ± SEM, n=8. \*Statistically significant compared to methylphenidate pre-treatment levels. <sup>a</sup>Value estimated from a graph.

From (86)



**Strengths/Weaknesses:** It is a strength that effects on growth hormone were evaluated after relatively long-term treatment (3 months), but a weakness that subjects were in different pubertal stages. The small number of subjects is also a weakness.

**Utility (Adequacy) for CERHR Evaluation:** This report can be used in the evaluation process.

### *3.1.2.3 Cardiovascular function*

Several factors must be taken into account when reviewing the studies on the effects of methylphenidate on cardiovascular function in children. Not all of these factors were taken into account in every study reviewed. Because there are so many variables and many studies do not control for them appropriately, the results are inconsistent and contradictory.

- There is large intra-individual variability in heart rate and blood pressure. There are normal hour-to-hour and day-to-day fluctuations in heart rate and blood pressure; thus, one-time measurement does not necessarily reflect a “normal” measurement.
- There are normal ranges for both heart rate and blood pressure for different age groups of children.
- Conditions under which the children had their heart rate and blood pressure measured may affect the results—quiet environment, period of rest before measurement, etc.
- Measurement tools differ and include blood pressure machines versus sphygmomanometer measurements, and apical/radial pulse measurement versus pulse measurement by machine.
- Reliability of measurement may be questioned if different people do the measurements.
- Proper technique of blood pressure measurement is not always used. Sources of error include supine versus seated measurements and the appropriateness of cuff size.
- The anxiety effect of monitoring that has been previously documented in adults (called “white coat syndrome”) could also occur in children.
- Varying durations of methylphenidate treatment might influence study results.
- Some children were drug naïve while others were not, which could affect results if there were up- or down-regulation of receptors involved in cardiovascular modulation.
- In some studies, children’s doses were titrated up to a maximum dose before results were obtained, while others were given a set dose. There may be physiological differences between these two circumstances.
- Differences in heart rate and blood pressure that are statistically significant may not be clinically significant.

**Knights and Hinton (87)**, supported by CIBA Co. Ltd. and the Ontario Mental Health Foundation, randomized 40 children with “minimal brain dysfunction” to methylphenidate (n = 20) or placebo (n = 20). The children ranged from ages 8 to 15 with a mean age of 10.5 years. The initial methylphenidate dose was 20 mg once a day with an increase over 4 days to 20 mg twice a day. Children were examined prior to starting medication and at the end of a 6-week period. Examinations included blood pressure and heart rate. Differences between pretreatment and on-treatment values were compared by *t* tests (methylphenidate compared to placebo). The change in systolic blood pressure did not differ between the two treatment groups. Children on methylphenidate for 6 weeks had a mean 1.9 mm increase in diastolic blood pressure while children on placebo for 6 weeks had a mean 2.7 mm Hg decrease in diastolic blood pressure. Heart rate increased 15.6 beats/minute on methylphenidate and 0.9 beats/minute on placebo. The difference between treatment arms was significant at  $P < 0.1$  for diastolic blood pressure and heart rate [**variances were not given**].

**Strengths/Weaknesses:** Strengths of this study include the randomized, placebo-controlled, double-blind design. Weaknesses include the lack of information on how heart rate and blood pressure were measured, and the reporting of mean blood pressure (in mm) and heart rate (in beats/minute) to one decimal place, which is clinically meaningless. The blood pressure changes in this study were not clinically significant.

**Utility (Adequacy) for CERHR Evaluation Process:** This report can be used in the evaluation process, although confidence in the results is only moderate.

**Greenberg and Yellin (88)**, supported by NIMH, randomized 47 hyperactive children (7 girls, 40 boys; 6–13 years old) to either imipramine-placebo or methylphenidate-placebo. All subjects crossed over between their assigned medication and placebo. Children previously on methylphenidate were weaned off and had a 7-day drug-free period prior to starting study medication. The study medication was increased over a 1-week period and maintained at full dosage (100 mg imipramine, 40 mg methylphenidate) for a 1-week period. Methylphenidate did not produce a significant increase in systolic pressure, diastolic pressure, or pulse compared to placebo.

**Strengths/Weaknesses:** The use of a placebo arm is a strength. It is unclear, however, how blood pressure and heart rate measurements were taken. Subjects were studied after only one week on medication.

**Utility (Adequacy) for CERHR Evaluation Process:** This report can be used in the evaluation process, although confidence in the results is only moderate.

**Aman and Werry (89)**, supported by the Medical Research Council of New Zealand, CIBA (UK), and NIMH, performed a double-blind, placebo-controlled, crossover study with 10 boys diagnosed as hyperkinetic or subject to “unsocialized aggressive reactions.” The children ranged from 84 months to 116 months of age (mean 104 months) with weights ranging from 22 kg to 38 kg (mean 30.4 kg). Each subject received methylphenidate and placebo in random order with methylphenidate given at a dose of 0.5 mg/kg bw [**the discussion and summary indicate 0.3 mg/kg bw**]. The drugs were administered by parents 90 minutes before the subjects were to arrive at the laboratory. Each subject was tested a total of three times (no medication, placebo or methylphenidate, methylphenidate or placebo). [**It is not indicated whether subjects were tested after a single dose of medication or while being on medication for some number of days, nor is it stated how many subjects were on other medications, except for the statement, “The study was run during school vacation when most were not receiving any medication.”**] Heart rate and respiratory rate were measured for 1 minute at rest, at the end of successive 4-minute sessions of light, moderate, and heavy bicycle exercise, and after 4 minutes of post-exercise rest. Eight of the 10 subjects had their heart rates decrease from the first session (no drug) to the placebo session. The response of heart and respiratory rates to level of exercise and medication was evaluated by ANOVA. Methylphenidate produced an increase in basal and exercise-associated heart rate (a mean 3–9 beat/minute difference compared to placebo). Respiratory rate was not significantly altered by methylphenidate. The authors concluded that methylphenidate causes small but significant increases in heart rate during rest and exertion, with no increase in respiratory rate, and they postulated a vasoconstriction-associated decrease in oxygen expenditure during exercise.

**Strengths/Weaknesses:** The double-blind, placebo-controlled design is a strength. It is not known, however, whether subjects were tested after a single dose of methylphenidate or whether

they had been on methylphenidate for some period of time. The decrease in heart rate from the pre-drug to the placebo session in 8/10 subjects indicates the variability of heart rate.

**Utility (Adequacy) for CERHR Evaluation Process:** This report can be used in the evaluation process, although confidence in the results is only moderate.

**Ballard et al. (90)**, support not indicated, examined cardiovascular responses in 27 hyperactive children (24 boys, 3 girls) being treated with methylphenidate. The children had a mean age of 10.41 years and a mean weight of 37.09 kg. Subjects were tested after a dose of methylphenidate and after a dose of placebo, in random order with 1 month separating the test sessions. For the children who were tested on methylphenidate first, placebo was given for 30 days before the second test. Medication was given once daily at doses that had been optimized based on clinical response; these doses ranged from 0.13 mg/kg bw to 0.89 mg/kg bw (mean 0.48 mg/kg bw; 5–30 mg/day). One and a half hours after taking methylphenidate or placebo, a 12-lead EKG was recorded after the subject rested in bed 5 minutes and before, immediately after, and 10 minutes following a 5-minute treadmill exercise period. Heart rate was monitored with a telemetry system. Blood pressure was measured during each minute of the testing procedure using a sphygmomanometer. Oxygen consumption was measured using an open-circuit method [**citing methods in a 1968 publication**]. Data were analyzed using ANOVA. Methylphenidate significantly increased heart rate, systolic blood pressure, and mean arterial blood pressure compared to placebo during rest, exercise, and recovery. The mean increase in heart rate was 8.1 beats/minute, the mean increase in systolic blood pressure was 6.2 mm Hg, and the mean increase in mean arterial blood pressure was 4.4 mm Hg. The increases in heart rate, systolic blood pressure, and diastolic blood pressure were correlated with weight-adjusted methylphenidate dose. There were large differences among children in response to methylphenidate compared to placebo. The largest increase in heart rate during the pre-exercise rest period was 40 beats/minute, and the smallest was a 17 beat/minute decrease in heart rate on methylphenidate compared to placebo. The largest change in blood pressure (systolic/diastolic) was a 22/12 mm Hg increase, whereas other subjects had decreases of up to 7 mm Hg in blood pressure on methylphenidate compared to placebo. There was no difference in oxygen consumption on methylphenidate compared to placebo. All EKGs were reportedly normal. The authors expressed concern that some of the cardiovascular changes were large and that accommodation to the cardiovascular effects of methylphenidate had not been demonstrated. Some of the children in this study had been on medication for more than a year, and there was no difference in cardiovascular response between these children and those who had been on placebo for 30 days prior to testing, which the authors interpreted as demonstration that tolerance does not develop to the cardiovascular effects of methylphenidate. The authors also noted that increased blood pressure did not result in a slowing of heart rate, leading them to conclude that methylphenidate blocks the baroreceptor reflex.

**Strengths/Weaknesses:** This was a well-designed placebo-controlled study, although the children were not drug-naïve. The difference between placebo-treated subjects and normal controls suggests that ADHD children may have distinctive physiologic characteristics. This study does not address long-term consequences of the cardiorespiratory changes that were noted.

**Utility (Adequacy) for CERHR Evaluation Process:** This report can be used in the evaluation process.

**Conners and Taylor (73)**, supported by NIMH and Abbott Laboratories, randomized 60 children (3 girls, 57 boys) with “hyperkinesis due to minimal brain dysfunction” to pemoline (n = 19), methylphenidate (n = 20), or placebo (n = 21). The children ranged from 6 to 11 years old (mean

7 years, 11 months). Medication or placebo capsules were given twice daily permitting the blind to be maintained while dosing pemoline once daily and methylphenidate twice daily. Medication doses were increased each week as necessary for clinical response. The mean final doses were pemoline 2.25 mg/kg bw/day and methylphenidate 0.82 mg/kg bw/day. Measurement of pulse and blood pressure were recorded at weeks 0, 4, and 8. There was a greater increase in pulse rate at week 4 in the placebo group than in the stimulant groups, but by week 8 there was no difference in pulse rate between groups. There were no differences between groups in systolic blood pressure. Diastolic blood pressure decreased in the placebo and pemoline groups at week 4 and 8, but increased in the methylphenidate group by a mean of 2.4 mm Hg at week 4 [**data not shown, statistical analysis not indicated**].

**Strengths/Weaknesses:** The lack of data is an important weakness of this report.

**Utility (Adequacy) for CERHR Evaluation Process:** This report is not useful in the evaluation process.

**Satterfield et al. (82)**, supported by NIMH, evaluated blood pressure and pulse rate annually in boys aged 6–12 years who were on methylphenidate therapy (mean dose 0.47 mg/kg bw/day at 1 year and 0.52 mg/kg bw/day at 2 years). There were 74 boys at 0 and 12 months, 44 boys at 24 months, and 36 boys at 36 months. Comparisons to baseline were made by *t* tests. Systolic and diastolic blood pressure was significantly higher than baseline at 2 and 3 years and pulse rate was higher than baseline at 1 year and lower than baseline at 3 years. The mean increase in systolic blood pressure from baseline to year 3 was 7.9 mm Hg, and for diastolic blood pressure the mean increase was 4.6 mm Hg. The authors interpreted these changes as consistent with normal maturation.

**Strengths/Weaknesses:** Weaknesses include the withholding of medication on the day the measurements were performed, the lack of description of how measurements were made, and the yearly interval for the measurements. The conclusion that changes are consistent with normal maturation is inappropriate given the many other variables that were not controlled.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is not useful in the evaluation process.

**Brown et al. (91)**, supported by NIMH and NIH, evaluated 11 boys with attention deficit disorder on methylphenidate and placebo in a randomized, blinded, cross-over design. The children were all males whose ages ranged from 9 years 1 month to 12 years 1 month (mean 10 years 5 months). The methylphenidate dose was 0.3 mg/kg bw administered twice/day. At the end of each 2-week dosage period the subjects were assessed with attention tasks 1.5 hours after being given medication. During the same clinic visit, heart rate and blood pressure were measured. Analysis using multivariate analysis of variance showed no difference between in heart rate or blood pressure between methylphenidate and placebo.

**Strengths/Weaknesses:** Strengths include the randomized, blinded, placebo-controlled design and the clear definition of how measurements were made. Weaknesses include the evaluation of short-term effects (2 weeks) and the recording of heart rate for only 1 minute, with large variability among subjects.

**Utility (Adequacy) for CERHR Evaluation Process:** This report can be used in the evaluation process.

**Brown and Sexson (92)**, supported by the NIH and Emory University, evaluated 11 boys with ADHD on placebo and 3 dose levels of methylphenidate (0.15, 0.3, and 0.5 mg/kg bw given twice daily). Each boy was tested after two weeks on each of the medication regimens in random order. The children were all black males ranging from age 12 years 10 months to age 14 years 10 months (mean 13 years 7 months). Heart rate and blood pressure were assessed at least one hour after the medication dose. The relationship between dose and cardiovascular parameters was assessed using ANOVA followed by pair-wise testing of blood pressure measurements at each methylphenidate dose compared to placebo. The authors found significant effects for systolic and diastolic blood pressure and systolic blood pressure, significant on pair-wise testing only for diastolic blood pressure, which increased from a placebo mean of 69.0 mm Hg to a mean of 83.0 mm Hg with a methylphenidate dose of 0.5 mg/kg bw twice daily. The authors reported no significant effect of methylphenidate on heart rate. **[ANOVA by CERHR showed a significant effect of methylphenidate dose on heart rate ( $P < 0.001$ ) with post-hoc Dunnett test showing significant pair-wise increases in heart rate at methylphenidate doses of 0.3 and 0.5 mg/kg bw twice daily. Mean heart rate on placebo was 71.8 beats/minute, and on the high dose of methylphenidate, 82.5 beats/minute.]**

**Strengths/Weaknesses:** The use of drug-naïve subjects is a strength. Measurements were taken 1 hour after medication was given, and it is a weakness that the duration of the effects was not evaluated.

**Utility (Adequacy) for CERHR Evaluation Process:** This study can be used in the evaluation process, although its application to chronic medication use is not straightforward.

**Kelly et al. (93)**, support not indicated, investigated the response of pulse to methylphenidate in 47 drug-naïve children (3 females, 44 males) with ADHD. The children ranged from 6 to 12 years old (mean 8.3 years). Each week, subjects received a single dose of methylphenidate following which pulse was measured using a fingertip photocell. Each subject was evaluated after 5 different methylphenidate dose regimens (0, 5, 10, 15, and 20 mg) in random order; thus, the data consisted of 5 weekly measurements for each child, each weekly measurement being a response to a different methylphenidate dose. Resting pulse rate was assessed prior to and after the administration of the medication during several 5-minute measuring periods. Data were analyzed using ANOVA with post-hoc Tukey test. There was a significantly higher post-medication heart rate at 120 minutes after 15 and 20 mg of methylphenidate. Pulse rate was also increased 180 minutes after 10, 15, and 20 mg of methylphenidate. The mean response to placebo was a decrease of 4–7 beats/minute over 180 minutes, whereas the mean response to 20 mg methylphenidate was an increase of 2–6 beats/minute over the same interval.

**Strengths/Weaknesses:** The measurement protocol was rigorous with several measurements averaged over 5-minute periods in drug-naïve subjects. Measurements were made before and after medication administration, which is a strength.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is well-designed and useful for the evaluation process.

The Expert Panel notes the existence of a review article that concludes that the use of stimulant medication such as methylphenidate does not pose long-term cardiovascular risk and that the increased heart rate seen in the first months of methylphenidate therapy is modest compared to heart rate increases associated with exercise, eating a meal, or playing a competitive video game (94) **[The Expert Panel does not agree that this author conclusion is supported by the data.]**

#### 3.1.2.4. Seizures

**Knights and Hinton (87)**, supported by CIBA Co. Ltd. and the Ontario Mental Health Foundation, randomized 40 children with “minimal brain dysfunction” to methylphenidate (n = 20) or placebo (n = 20). The children ranged from ages 8 to 15 years with a mean age of 10.5 years. The initial methylphenidate dose was 20 mg once a day with an increase over 4 days to 20 mg twice a day. Children were examined prior to starting medication and at the end of a 6-week period. There were 33 children who had electroencephalograms (EEG) before and on therapy. Eleven of the children had abnormal EEGs before therapy; there was no methylphenidate-associated increase in EEG abnormalities.

**Strengths/Weaknesses:** This report is limited by the small number of children who were evaluated.

**Utility (Adequacy) for CERHR Evaluation Process:** This report is useful, with the sample size limitations noted.

**Gross-Tsur et al. (95)**, supported by the Israel Ministry of Health, studied 30 children with epilepsy and ADHD. The mean age of the children was 9.8 years (range 6.4–16.4 years). Children had baseline evaluations of seizure frequency, antiepileptic drug levels, and EEGs. They were randomized to received 8 weeks of placebo or 8 weeks of methylphenidate 0.3 mg/kg bw given once in the morning. After 8 weeks, testing was repeated and each subject crossed over to the opposite therapy. After 8 weeks on the second therapy, testing was repeated. Each child’s usual antiepileptic medication was continued throughout the study. Seizure frequency on therapy was monitored with weekly calls to the parents and monthly clinic visits. There were 25 children who were seizure-free at baseline; none of these children had seizures on methylphenidate. Of the 5 children who had seizures at baseline (1 or 2 seizures/week), 4 had seizures while on methylphenidate, and 3 of the 4 had an increase in seizure frequency on methylphenidate [**the seizure frequency on placebo was not reported**]. Abnormal EEGs were identified in 23 children prior to methylphenidate. On methylphenidate, 19 of these children had abnormal EEGs; 4 had become normal. There were three children in whom the abnormality on EEG was different on methylphenidate than it was off methylphenidate. [**Changes, if any, on placebo were not mentioned**]. Antiepileptic drug levels changed on methylphenidate and on placebo in some children. The direction of the change was not uniform with either treatment and there was no significant net effect of methylphenidate on antiepileptic drug levels. The authors concluded that methylphenidate could be used in children with a history of epilepsy, but that children who were still having seizures might experience an increase in seizure frequency while on drug therapy.

**Strengths/Weaknesses:** The strength of this study is the documentation of compliance with antiepileptic treatment. Weaknesses include lack of reporting of seizure frequency or EEG changes on placebo. It is also not clear if the children with abnormal brain imaging were those who had seizures.

**Utility (Adequacy) for CERHR Evaluation Process:** This paper is not useful for the evaluation process.

**Hemmer et al. (96)**, supported by the Crown Family, performed EEGs on 179 males (3–20 years old) and 55 females (3–19 years old) with ADHD. The mean age of the subjects was 9–10 years. Epileptiform EEGs were obtained in 36 subjects prior to stimulant therapy or up to 8 weeks after the initiation of therapy. The decision to accept stimulant therapy was made by parents and did not appear to be influenced by the EEG results. There were 175 subjects treated with stimulants

of whom 30 (17%) had had an epileptiform EEG. Of the 29 subjects who declined stimulant therapy, 6 (21%) had had an epileptiform EEG. Seizures occurred in four subjects [**follow-up period not specified**]. All of the subjects with seizures were in the stimulant group, although one child had a seizure after being off stimulant medication for two months. Three of the four children had prior epileptiform EEGs. The authors concluded that a normal EEG prior to stimulant therapy was reassuring that seizures would not occur on therapy. They were not convinced that the stimulant therapy caused the seizures that occurred based on the timing of the seizures with respect to the start of stimulant therapy, and based on the low overall incidence of seizures (2%) in the stimulant-using population. [**The specific stimulants were not named except in the four cases of seizure. The stimulants used in these cases were methylphenidate and *d*-amphetamine.**]

**Strengths/Weaknesses:** The incidence of epileptiform EEGs in this study (15.4%) is much higher than the estimated incidence of EEG abnormalities in an unselected population of children (2%), suggesting that these children may have had underlying neurologic disorders other than ADHD. The statement that children with normal EEGs are at a low risk of seizure is stating the obvious.

**Utility (Adequacy) for CERHR Evaluation Process:** This report does not add useful information for the evaluation process.

#### *3.1.2.5 Psychotic symptoms*

Psychotic symptoms developing on methylphenidate, described in case reports, include hallucinations (97, 98), delusions (99), and mania (100). Some of the case report authors have suggested that methylphenidate and other stimulants may unmask incipient psychiatric disorders in susceptible individuals (99, 100).

**Cherland and Fitzpatrick (101)**, support not indicated, performed a chart review at the Royal University Hospital in Saskatoon. Of 98 children treated with stimulant medication, 9 developed psychotic-like symptoms (7 on methylphenidate and 2 on pemoline [**It is not clear whether the children who may have become psychotic on pemoline also became psychotic on methylphenidate**]). Two of the children who developed psychotic symptoms on methylphenidate were subsequently diagnosed with bipolar disorder and one was diagnosed with a pervasive developmental disorder not otherwise specified. The authors point out that inasmuch as their study was retrospective, assessments were not fully standardized, and follow-up was not consistent.

**Strengths/Weaknesses:** In addition to the weaknesses identified by the authors, weaknesses also include the small number of children, lack of a control group, and difficulty determining which reactions were associated with which medications, and which were associated also with underlying illnesses.

**Utility (Adequacy) for CERHR Evaluation Process:** This report is of moderate utility in the evaluation process.

#### *3.1.2.6 Onset or Worsening of Tics on Methylphenidate*

Tourette disorder is a chronic neurologic disorder characterized by repeated and involuntary body movements (tics) and uncontrollable vocal sounds. Tics can include eye blinking, repeated throat clearing or sniffing, coughing, arm thrusting, kicking movements, shoulder shrugging, or jumping. A large proportion of children with Tourette disorder have comorbid ADHD (reviewed

by Leckman (102)). In 1974, a case report was published describing a 9-year-old boy treated with methylphenidate for hyperactivity who developed Tourette disorder on therapy (103); since that report, additional papers have described tics or Tourette disorder in association with stimulant therapy (Table 26). In spite of the impression expressed by some authors that stimulant therapy can be associated with the *de novo* appearance of tics or the worsening of pre-existing tic disorders, controlled studies have not demonstrated an incidence of tic appearance or worsening greater than that on placebo or at baseline (74, 77, 80, 104, 105). **[The Barkley study (74) concludes that there is a significant increase in tics associated with stimulant therapy. Statistical analysis of the Barkley data by CERHR did not confirm the authors' conclusions (see Table 26). The Expert Panel notes that in 4 of these 5 reports, support is from non-commercial sources. In the Barkley study (74), the source of support is not indicated.]**

**[The Expert Panel noted some general limitations with most tic studies. A consideration in the evaluation of tic studies is whether the subjects in placebo or stimulant treatment groups had prior drug exposure, that might in itself account for development of tics, but this issue was only addressed by the Tourette's Syndrome study group (105). Methods for rating the presence of tics need to be known. None of the studies controlled for substance abuse.]**



**Table 26. Reports of Tics in Children Treated with Stimulant Medication**

Medication	Stimulant dose (mg/day except where indicated)	Characteristics of the children	Outcome	Comments <sup>a</sup>	Reference
Methylphenidate	10	9-year-old boy	Tics developed	Tics did not resolve after medication stopped, and haloperidol was required, suggesting that the tics/Tourette disorder may have been spontaneous.	(103)
Methylphenidate	10–60	20 children, mean age 10 years, range 7–14. 18 boys, 2 girls	20/1520 (1.3%) children on methylphenidate either developed (14) or had worsening of pre-existing tics (6). Tics resolved in most with discontinuation or reduction in dose, and recurred spontaneously in 1 subject.	Strength: Large number of charts reviewed. Weaknesses: Combined anecdotal recollections of several authors, without controls or statistical analysis.	(106)
Methylphenidate, <i>d</i> -amphetamine, methamphetamine	Not reported	32 Tourette disorder patients who had been exposed to stimulants (unspecified ages)	17/32 experienced worsened symptoms when on stimulants	This report is descriptive, with no doses or ages given. Other medications in the mix were not considered. Omitted from consideration were 39 of 45 subjects with preexisting Tourette disorder that did not worsen.	(107)
Methylphenidate, imipramine	5–40	Boys aged 7, 8, and 11.5 years	Worsening of Tourette disorder	These 3 case reports do not provide useful information.	(108)
Methylphenidate	Mean 29.3, Range 7.5–70	134 with Tourette disorder, 21 treated with stimulants	Increased tics in 4/21	This paper provides evidence that Tourette disorder is not an absolute contraindication to methylphenidate use; however, a variety of stimulants were used both before and after the diagnosis of Tourette disorder.	(109)
<i>d</i> -Amphetamine, methylphenidate	Not reported	4 boys, 8–11 years old	Tourette disorder developed and continued	This paper indicates the independence of Tourette disorder from medication, but	(110)

Medication	Stimulant dose (mg/day except where indicated)	Characteristics of the children	Outcome	Comments <sup>a</sup>	Reference
<i>d</i> -amphetamine/ pemoline methylphenidate/ pemoline			after medication	includes only 4 children who used 3 medications alone and in combination with no indication of dose.	
Methylphenidate, <i>d</i> -amphetamine, pemoline	Not reported	200 children, 48 with Tourette disorder	8/48 tics worsened	Strengths: Inclusion of a fairly homogeneous population of 48 children with pre-existing Tourette disorder. Weaknesses: Retrospective review, dose range not given; there was no independent diagnosis; follow-up duration was variable.	(111)
Methylphenidate, pemoline, <i>d</i> - amphetamine	Not reported	170 twins and individuals	50% with worsening of tics, some developed tics	Strength: Twin study (In 6 monozygotic twins, discordant for medications; other twin developed Tourette disorder suggesting genetic basis) Weaknesses: Doses were not given; Tourette disorder was pre-existing; the relationship of tic worsening to therapy was vague.	(112)
Methylphenidate	10–30	4 boys, 8–11 years old	Tics not worsened	Strength: Single-blind Weakness: Only 4 subjects; all had Tourette disorder and ADHD	(113)
Methylphenidate, <i>d</i> -amphetamine	Up to 90 mg/day methylphenidate; up to 45 mg/day <i>d</i> -amphetamine	45 hyperactive boys age 6–12 years	10/45 had increase in tics or development of tics on methylphenidate; 6/45 on <i>d</i> -amphetamine.	Strengths: Compared methylphenidate and <i>d</i> -amphetamine; high doses used. Weakness: Tics were not clearly distinguished from other behavioral changes and disorders (e.g., obsessive-compulsive disorder) that developed over the course of the study.	(114)
Methylphenidate	0, 0.3, or 0.5 mg/kg bw twice/day	82 children age 5–13 years crossed over to each dose for 7–10 days	Tics occurred in 18% of subjects on placebo and on low dose and 28% of subjects on high dose; $P$ < 0.05 according to authors [ <b>statistical method not indicated;</b> <b><math>P = 0.19</math>, Fisher exact</b>	Strengths: Double-blinded, placebo controlled cross-over design; ratings by parents and teachers. Weaknesses: No measures to actively exclude new cases of Tourette disorder (there may not have been any). Rating scale used the broad term “tics/nervous movements” which may explain high rates in	(74)

Medication	Stimulant dose (mg/day except where indicated)	Characteristics of the children	Outcome	Comments <sup>a</sup>	Reference
			test by CERHR].	both placebo and active drug groups. Also, no notation of whether subjects were “drug naïve.” Time-course of exposure to drug unclear: 7–10 days on drug, followed by placebo OR two active drug phases back to back. Duration of exposure may influence frequency of tics.	
Methylphenidate	0, 0.3, 0.5 mg/kg bw 3 times/day	206 children age 5–15 years crossed over to each dose for 1 week (2 placebo weeks were included in random order)	No increase in tics on either dose of methylphenidate	Strengths: Used the dose scheme of (74); children with Tourette disorder were excluded. Weakness: The randomization scheme was changed after the first 46 children were enrolled. Used parent ratings only. Rating scale used the broad term “tics/nervous movements” which may explain high rates in both placebo and active drug groups. Also, no notation of whether subjects were “drug naïve.” Not clear if the study design was the same as Barkley, 1990, #402). Here it is 1 week on and 1 week off. Short-term exposures to drug do not necessarily reflect risks in long-term use	(77)
Methylphenidate, <i>d</i> -amphetamine, pemoline	Methylphenidate dose (mean ± SD): 21.1 ± 11.7 with tics, 24.4 ± 17.2 without tics; <i>d</i> -amphetamine dose (mean ± SD): 14.2 ± 5.2 with tics, 15.8 ± 6.8 without tics	122 children with ADHD age 3.6–15.8 years	Tic/dyskinesias occurred in 8.2% of children treated with medication	Strengths: Large study with standardized diagnosis of ADHD (DSM-III-R). Weaknesses include retrospective design, unknown weight-adjusted doses, and reliance on chart review for parental assessments of unusual tic-like movements such as “eye bugging.” Prior medication history not detailed.	(115)
Methylphenidate	0.1, 0.3, 0.5	34 children	Small increase in	Strengths: The observation of three in-school	(116, 117)

Medication	Stimulant dose (mg/day except where indicated)	Characteristics of the children	Outcome	Comments <sup>a</sup>	Reference
	mg/kg bw twice daily	with ADHD aged 6.1–11.9 years	frequency of tics (motor tics increased, verbal tics decreased). The increase occurred only on the low dose (mean 4.4 mg [ <b>likely subtherapeutic</b> ]).	settings, including lunch-room and playground, is interesting (with physician, teacher, and parent ratings) in (116). Weaknesses: The sample size is small and the observation period was only 6 weeks. The tics were clinically unimportant (e.g., the teachers did not notice them).	
Methylphenidate, <i>d</i> -amphetamine	Methylphenidate 35–90; <i>d</i> -amphetamine 10–45	20 children, mean age ± SD 9.4 ± 2.0 years	Reversible increase in tics, particularly with <i>d</i> -amphetamine. Methylphenidate-associated tics returned to placebo baseline with continued methylphenidate treatment.	Strengths: Two drugs were compared; wide range of doses; double blind. Weakness: Small sample size	(118)
Methylphenidate, <i>d</i> -amphetamine	Methylphenidate 0.6 mg/kg bw/day, <i>d</i> -amphetamine 0.3 mg/kg bw/day	125 children with ADHD, mean age ± SD 104.8 ± 27.6 months; range 60–179 months (5–15 years)	Tics present in 35% of subjects at baseline and 26–28% of subjects after 2 weeks on either drug	Strengths: Moderately high doses of two drugs were evaluated. Used Barkley scale as in the Ahmann study (77) Weaknesses: Lack of placebo control; the item scored was “tics or nervous movements,” (in this case the rating scale may overestimate prevalence of tics at baseline, confounding analysis); the duration of the study was only 2 weeks on each drug; no notation of whether subjects were “drug naïve.”	(80)
Methylphenidate	0.5 mg/kg bw/day mean dose	72 children with ADHD	10/51 developed tics, 7/21 tics worsened; incidence of new and worsened tics similar with placebo. 40% of tics developed 4–12 months after medication started.	Strengths: Placebo-controlled; identifies differences in parent and teacher evaluations; 80% of sample took their medication for 8–12 months; demonstrates waxing and waning of tics regardless of origin (but doses were adjusted if tics emerged or worsened until the tics improved somewhat). Subjects had no history of	(104)

Medication	Stimulant dose (mg/day except where indicated)	Characteristics of the children	Outcome	Comments <sup>a</sup>	Reference
Methylphenidate	0.1, 0.3, 0.5 mg/kg bw 3 times daily	34 children with ADHD and tics	Transient increase in tics; long-term methylphenidate use did not cause tics to develop or worsen.	<p>exposure to meds for ADHD or tics. Age range is small: methylphenidate group: 8.4 years (SD 1.6) and placebo group: 8.3 (1.5). Naturalistic design useful for clinical practice compared to fixed dose.</p> <p>Weaknesses: Excluded severe tics and Tourette disorder; scoring performed by research assistants based on parents' narratives; prior to medication, 30% had motor or vocal tics; parents could initiate cross-over if child's behavior worsened. Did not note whether they had prior exposure to any other psychotropic medications such as neuroleptics.</p> <p>Utility: Study adequate for evaluation process.</p> <p>Strength: 2-year prospective study.</p> <p>Weakness: Not blinded to treatment.</p>	(119)
Methylphenidate, <i>d</i> -amphetamine, pemoline	Not reported	374 children on methylphenidate, 126 children on <i>d</i> -amphetamine, 13 on pemoline	Tics present in 7.8% of children; not more frequent in any medication category	<p>Strength: Comparison of three medications.</p> <p>Weakness: Retrospective chart review.</p>	(120)
Methylphenidate, clonidine	5–60	104 children age 7–14 years	Proportion of subjects with worsening tics was similar with methylphenidate (20%: includes 8 subjects treated with	<p>Strengths: A wide range of doses was studied; followed up to 9 active treatment weeks. Excluded subjects with secondary tic disorders such as tardive tics (which can occur with use and with discontinuation of neuroleptics) and subjects with several other</p>	(105)

Medication	Stimulant dose (mg/day except where indicated)	Characteristics of the children	Outcome	Comments <sup>a</sup>	Reference
			methylphenidate alone and 6 treated with methylphenidate + clonidine), clonidine alone (26%), and placebo (22%). The greatest reduction in tic severity and ADHD severity occurred in the methylphenidate + Clonidine group.	major psychiatric disorders. Weaknesses: Because all subjects had comorbid ADHD and DSM-IV Tourette disorder, chronic motor or vocal tic disorder, cannot necessarily generalize findings to children without baseline tic disorders. Table 1 of study, "Subject Characteristics at Baseline," does list some subjects as having major depressive disorder, which appears to contradict enrollment criteria. Some subjects were on clonidine for ADHD; clonidine may suppress tics. For methylphenidate, the development of tics was dose-limiting. Severity rating scales were evaluated with <i>t</i> tests. Utility: This important and well designed study is adequate for the evaluation process.	

<sup>a</sup>None of the studies screened for substance abuse

**Strengths/Weaknesses:** The strength of the overall data set on tics in children treated with stimulant medication is the demonstration that the use of controls and blinded evaluators results in the disappearance of the association between stimulant medication and tics that was suggested by older, anecdotal reports. Weaknesses of the studies generally include small numbers of subjects and short observation periods. Worsening of tics can be due to the natural waxing phase of spontaneous tics and Tourette disorder, which has a high incidence in the ADHD population. Many studies do not discriminate between different observers (e.g., parents, teachers, records), much less evaluate inter-rater reliability.

**Utility (Adequacy) for CERHR Evaluation Process:** The data set is generally useful in the evaluation process.

### *3.1.2.7 Substance Use Disorders*

Studies examining associations between pharmacotherapy for ADHD and substance use disorders were reviewed. The studies are presented below in order of evaluations conducted during childhood, adolescence, and adulthood.

**Chilcoat and Breslau (121)**, supported by NIDA and NIMH, included a limited assessment of stimulant treatment for ADHD and risk of childhood drug use. In the longitudinal study focusing on ADHD effects on illicit drug use, 717 children were assessed at ages 6 and 11 years. The children were born between 1983 and 1985. African American children represented 46.2% of the subjects; 57.4% of all subjects had been low birth weight infants (< 2500 g). **[Subject sex was not specified.]** At ages 6 and 11 years, the children were asked about drug use and psychiatric evaluations were conducted on both the children and their mothers. A total of 146 of the children had been diagnosed with ADHD at age 6 years and 100 of those children had been low birth weight infants. At age 11, 30 of the children (20.2%) with ADHD were being treated with medication. It was stated that nearly all were receiving methylphenidate, but no information was provided about other medications used. **[Duration of treatment was not specified.]** The children were considered drug users if they had ever used tobacco, alcohol, marijuana, or inhalants. Rates of drug use were 31.0% in children receiving medication for ADHD compared to 28.2% in children not receiving pharmacotherapy for ADHD. In a group of 24 children who were not diagnosed with ADHD at age 6 but were receiving medication for treatment of ADHD at age 11, the rate of drug use (16.6%) was the same as the incidence of drug use in a group of children not receiving medication. **[The number of children not receiving medication was not specified.]** The authors stated that models were used to control for severity of ADHD. **[There was no other discussion of statistical methods used and it was not stated if statistical analyses were conducted in assessing the risk of ADHD pharmacotherapy.]** The study authors concluded that use of stimulant medications had no effect on drug use in children. Associations were found between drug use and level of externalizing problems (e.g., aggressiveness, acting out, and disruptive behavior), ADHD in combination with moderate externalization of problems, low level of parental monitoring, and drug use by peers.

**Strengths/Weaknesses:** A strength is that this was the only study that looked at very young children (6 and 11 years). Several weaknesses were noted. A paucity of information was provided for statistical procedures. Children were asked if drugs were “ever used,” which is not very useful in establishing “substance use disorder.” The study noted that over half the children were of low birth weight; this observation needs to be statistically controlled because it may underlie some of the associations noted with ADHD and externalizing behavior. Important parameters (e.g., duration of treatment) were not described.

**Utility (Adequacy) for CERHR Evaluation Process:** The study is not useful for the evaluation process.

**Beck et al. (122)**, in a study supported in part by the CIBA Corporation, examined the effects of methylphenidate treatment on substance abuse. The treatment group consisted of 30 adolescents (23 males and 7 females; 14–19 years old) with minimal brain dysfunction who had been treated with methylphenidate for  $\geq 6$  months during childhood but were not currently receiving methylphenidate treatment. The control group consisted of 30 adolescents who were comparable in age, sex, and socioeconomic background and had no chronic disabilities or previous psychiatric history. Subjects were interviewed to obtain information about use of marijuana, heroin, hashish, mescaline, glue, and a category of “other” substances at the time of interview and more than 6 months prior to the interview. In the treatment group, 1 subject reported habitual heroin use  $>6$  months prior to interview and 2 subjects reported occasional use of marijuana during both time periods. Two control subjects reported habitual use of heroin, 1 reported habitual use of marijuana, 1 reported habitual glue sniffing  $>6$  months prior to interview, and 3 reported habitual use of marijuana at the time of interview. Occasional or unspecified drug use was reported by 5–7 control subjects during each time period. **[No statistical analyses were conducted.]** The study authors concluded that methylphenidate treatment during childhood does not contribute to later substance abuse. Effects on growth were also examined and are reported in Section 3.1.2.8.

**Strengths/Weaknesses:** A strength is that this study is one of few examining methylphenidate treatment in children who may not have ADHD (i.e., subjects in treatment group defined as having minimal brain dysfunction). A weakness of the study is that the comparison group neither received stimulant treatment nor had minimal brain dysfunction. Only 2 (6%) of 30 treatment subjects reported occasional use of marijuana. This percentage appears to be very low since Monitoring the Future data suggest that in 1975, 40% of 12<sup>th</sup> graders used marijuana in the previous year (21). Thus, the reliability of the collected information is suspect.

**Utility (Adequacy) for CERHR Evaluation Process:** The study is not useful for the evaluation process.

**Biederman et al. (123)**, in a study supported by the NIMH and NIDA, evaluated the risk of substance abuse disorders associated with psychotropic medication for treatment of ADHD. Data were obtained and reanalyzed from an ADHD longitudinal genetics study conducted in 260 families. Females were not evaluated because most medicated subjects were male; subjects younger than 15 were excluded due to the significantly younger age of medicated versus non-medicated subjects. Subject groups consisted of Caucasian males who were  $\geq 15$  years old and had previously received medication for ADHD ( $n = 56$ ), had ADHD but were not medicated ( $n = 19$ ), or did not have ADHD ( $n = 137$ ). The average duration of treatment was 4.4 years. **[The types of medications used were not specified.]** Multiple logistic regression was used to correct confounding by age, socioeconomic status, lifetime risk of conduct disorder, and substance use disorders in parents. Substance use disorders were examined for alcohol, marijuana, hallucinogen, cocaine/stimulant, and tobacco. ADHD subjects who had been medicated had a significantly reduced risk of any substance abuse disorder compared to unmedicated subjects with ADHD (OR 0.15, 95% CI 0.04–0.6). Unmedicated subjects with ADHD had a significantly increased risk of any substance abuse disorder compared to controls without ADHD (OR 6.3, 95% CI 1.8–21.4). With the exception of tobacco use, the medicated group had reduced risk of all other individual substance use disorders compared to the unmedicated ADHD group, but the sample size was too small to evaluate statistical significance for individual substances. The study authors concluded



that pharmacotherapy is associated with an 85% reduction in risk for substance abuse disorders in youths with ADHD.

**Strengths/Weaknesses:** Strengths of this study include well-articulated competing hypotheses and longitudinal design, as well as masked assessment and careful definition of the sample restricted to Caucasian males older than 15 years of age. Authors pay considerable attention to quality control and structured DSM-III-R interviews were used to establish the diagnosis of substance use disorders (because of small numbers, abuse and dependence were analyzed as a single category as substance use disorder). Important variables, including comparisons of treated and untreated ADHD children, were considered in analyses. The study addresses implicitly the issue of self-medication by determining that treated groups had a diminished odds ratio for substance abuse. Other strengths include control of parental substance use disorder and presentation of outcomes as an aggregate of any substance use disorder and disaggregated by substance. Limitations include use of an exclusively tertiary referred Caucasian sample, so findings may not apply to less privileged or lower income risk groups. Other weaknesses include lack of specification of the drugs that the treated members of the cohort received. The authors correctly identified lack of power as diminishing confidence in null findings. Other weaknesses are that the age ranges of subjects and the time period they had been off medication were not specified.

**Utility (Adequacy) for CERHR Evaluation Process:** The study is useful for the evaluation process.

**Barkley et al. (124)** (also reported in **Fischer and Barkley (125)**), in a study supported by the NIMH, examined possible associations between stimulant medication therapy during childhood or adolescence and substance use during adolescence and young adulthood. During each evaluation period, subjects or their parents were asked about stimulant therapy, behavior, mental health, illicit drug use, and education history; psychological tests were conducted and subjects were rated according to scales. Groups consisted of 91% males and 9% females. Racial distribution was 94% white, 5% black, and 1% Hispanic. Subject ages were 12–20 years during the adolescent evaluation and 19–25 years during the adult evaluation. During the adolescent evaluation, 119 subjects diagnosed as hyperactive were available for interview and parents were questioned about stimulant therapy during childhood. Ninety-eight were treated with stimulants during childhood, while 21 were not. Percentages treated with each type of stimulant during childhood were 80% methylphenidate, 3% *d*-amphetamine, and 20% pemoline. Some subjects received more than one type of stimulant; *d*-amphetamine was given to 2% and pemoline to 22% of the children in the methylphenidate group. All children in the pemoline group had also received *d*-amphetamine. Mean durations of treatment during childhood were 44.8 months for methylphenidate, 32.8 months for amphetamine, 13.3 months for pemoline, and 40.2 months for stimulants in general. During the adult evaluation, 147 hyperactive subjects were questioned about stimulant treatment during high school, but were not asked to identify the specific stimulant medication taken. Thirty-two subjects were treated with stimulants and 115 were not treated with stimulants during high school. Mean duration of stimulant treatment during high school was 26.6 months. All of the subjects had also been treated during childhood and seven were receiving stimulant treatment at the time of the interview. **[Severity of ADHD symptoms and conduct disorders were the only potentially confounding factors considered.]**

At the adolescent evaluation, subjects were asked if they had ever tried cigarettes, alcohol, marijuana, hashish, cocaine, heroin, hallucinogens, unprescribed stimulants, sedatives, or tranquilizers. **[Information about frequency of use was not obtained and substance abuse/dependency was not considered.]** The proportion of hyperactive subjects who had ever

tried any of the substances were similar in the stimulant-treated and untreated groups by chi-squared analysis. No significant differences were found when all stimulants (cocaine, amphetamines) were combined or when duration of stimulant therapy was considered.

When evaluated in adulthood, subjects were questioned about their use of alcohol, marijuana, cocaine, amphetamines/speed, any stimulant, hallucinogens, narcotics, sedatives, or other drugs. Frequencies of substance use were log transformed, due to high standard deviations, and compared by ANOVA. Stimulant treatment in childhood did not significantly increase the frequency of any type of substance use in early adulthood. The frequency of cocaine use was significantly higher ( $P = 0.043$ ) in subjects who were treated with stimulant medications in high school, but the results were no longer significant when corrected for severity of ADHD and conduct disorder [**Table 3 of the study, which presents effects of high school stimulant treatment, lists group numbers for childhood treatment (n = 21 untreated, 98 treated) instead of high school treatment (n = 115 treated, 32 untreated)**]. The proportion of subjects who ever used each of the substances was analyzed by chi-squared. If statistically significant findings were observed, a binary logistic analysis was conducted to adjust for severity of ADHD symptoms and conduct disorders. A greater percentage of adults who were treated with stimulants in childhood and in high school used cocaine at least once (5% untreated compared to 26% treated in childhood,  $P = 0.037$  and 20% untreated compared to 40% treated in high school,  $P = 0.016$ ). Due to increased cocaine use, the use of any stimulant was also increased in adults treated during high school (25% in untreated compared to 47% in treated,  $P = 0.018$ ). Additional analyses indicated that risk of cocaine use was primarily mediated by severity of conduct disorder and not by use of stimulant medication. Increased duration of stimulant treatment was not found to affect adversely the risk of substance use. No significant differences in adult substance abuse/dependence rates (diagnosed by DSM-III-R criteria) were noted in hyperactive subjects who were or were not treated with stimulants in childhood or during high school. [**There was no statistical analyses for abuse/dependency in adults.**] The study authors concluded that there is no compelling evidence that stimulant treatment of children or adolescents with ADHD leads to increased risk of substance experimentation, use, dependence, or abuse by adulthood.

**Strengths/Weaknesses:** A strength of this study is that substance abuse was defined by DSM-III-R criteria. This study considered not only substance use, but also examined frequency/quantity and distinguished experimentation from problem use. Initiation and experimentation did not differ by stimulant medication exposure status. Another strength is consideration of duration of treatment, with considerable detail provided on length of time subjects received different medications. Two time frames of stimulant medication use and drug use were examined; uniquely, illicit drug use was examined while a few subjects were still receiving medication. An important study finding was that cocaine use was related to adolescent treatment but this relationship was lost when severity of ADHD was statistically controlled; this finding emphasizes the need for such control in other studies. In addition to the paucity of control variables (including family history), a major weakness noted by authors on page 100 of the *Pediatrics* article is that the assessor was not masked to stimulant exposure history. It is both a strength and a weakness that the authors specify the medications to which the children were exposed, but because of small cell sizes and a predominance of methylphenidate, stimulants were only evaluated as a single generic exposure. However, the authors did use standard instruments. Weaknesses include the fact that tobacco use was not adequately evaluated. The authors were correct in noting that it is difficult to ascertain whether the weak association between high school stimulant treatment and cocaine use was an artifact of multiple comparisons. However, another conceptual weakness they did not consider is that perhaps children who are more deviant and, therefore, with or without treatment, more prone to substance use disorders, are more likely to continue to be treated into high school. Though important, it was not stated whether subjects treated in high school received

stimulants at both ages, especially as findings were mediated by severity of ADHD. The authors themselves point out that their study design did not permit them to identify the temporal sequences of conduct disorder and substance use disorder, leading to difficulties in interpretation of the worrisome finding of a possible connection between stimulant treatment and cocaine use.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is useful for the CERHR process.

**Lambert and Hartsough (126) and Lambert (127#3053)**, in studies supported by the Tobacco-Related Disease Research Program, examined the effects of ADHD and stimulant treatment on tobacco use and substance dependency in a longitudinal sample of 492 adults. According to information provided in the Lambert study (127), subjects were born in the San Francisco area between 1962 and 1968. About 22% of the subjects were female and 23% represented ethnic minority groups. The authors reported that among subjects using stimulant medications, 69% used only methylphenidate, 16% used combinations of methylphenidate and other stimulants, and 15% used other CNS stimulants (amphetamines, pemoline). At various stages throughout their lives, the subjects were questioned about their use of tobacco, alcohol, marijuana, stimulants, and cocaine. A total of 399 subjects were said to be available for interview. **[These studies appear to have numerous discrepancies or mathematical errors in text compared to tables or in different parts of tables. In adding numbers presented in some study tables, it appears that either mathematical errors were made or more than 399 subjects were evaluated for some endpoints (i.e., Table 3 in Lambert and Hartsough (126). In other cases, fewer than 399 subjects were included in analyses and it is not clear if or why some subjects were excluded (Table 5 in Lambert and Hartsough (126).]**

In the Lambert and Hartsough study (126) subjects were placed into hyperactive or control groups. According to information presented in Lambert (127), there were 217 hyperactive subjects (136 with primary hyperactivity with no causal explanation, 31 with secondary hyperactivity possibly due to organic factors, and 50 with untreated hyperactivity). There were 182 controls (141 age controls and 41 with non-ADHD behavioral problems). Information in Lambert (127) indicates that only 80% of the primary hyperactive group and 66% of the secondary hyperactive group received stimulant treatment. **[It is not clear why untreated subjects in the primary and secondary hyperactive group were not put into the untreated hyperactive control group.]** It appears that about 3% of controls received stimulant treatment. Subgroups of individuals were grouped together based on similarity of health, familial, educational, and social background factors. **[There was no discussion of adjustment for additional confounding factors such as severity of ADHD.]** The rate of smoking in adults who had ADHD as children and who never used stimulant medication ( $n = 47$ ) was 37.0%; for adults who had used stimulant medication for up to a year ( $n = 28$ ), the rate of smoking was 22.0%; and for adults who had used stimulant medication for  $\geq 1$  year ( $n = 52$ ), the rate of smoking was 40.9% ( $P < 0.03$  for never used compared to use  $\geq 1$  year, by chi-squared). The Mantel-Haenszel test for linear trend was also significant for duration of stimulant use ( $P < 0.01$ ). Significant linear trends ( $P < 0.03$ ) were noted for rates of tobacco dependency in adults who had ADHD as children and who never used stimulant medication ( $n = 81$ ; 32.1% rate) or had used stimulant medication for up to 1 year ( $n = 9$ ; 38.5% rate) or  $\geq 1$  year ( $n = 84$ ; 48.8% rate). Significant linear trends ( $P < 0.05$ ) were also noted for rates of cocaine dependency in adults who had ADHD as children and who never used stimulant medication (15.0%) or had used stimulant medication for up to 1 year (17.9%) or  $\geq 1$  year (27.4%). **[The text states that statistical significance by chi-squared was obtained for cocaine dependency, but the legend of Table 7 in the study indicates that results of chi-squared analyses were not significant for either tobacco or cocaine dependency. It is not clear how the numbers of subjects were selected for each analysis and**

why the numbers were so different for each analysis. The number using stimulant medication for up to 1 year is listed as 9, but this figure cannot be correct based on the percentages given in the table. Assuming the correct number is 52 (based on one version of the total number of subjects in the report), Fisher Exact test by CERHR shows a significant difference for tobacco prevalence between subjects with  $\geq 1$  year use of stimulant medication and subjects without use of stimulant medication,  $P = 0.039$ ; none of the other comparisons for tobacco or cocaine use were statistically significant. The Expert Panel has little faith in these conclusions, however, given the confusion in the paper concerning the number of subjects in various comparison groups.] A comparison of subjects who had ADHD as children with subjects who did not have ADHD as children showed that subjects with ADHD began smoking regularly at a younger age and had a higher rate of smoking and cocaine dependency as adults. The study authors concluded that there is a possible link between stimulant medication and rates of smoking and tobacco and cocaine dependency in adulthood.

In the Lambert study (127#3053), subjects were divided into groups of 268 who received no CNS stimulant treatment and a group of 131 who received stimulant treatment. [According to Table 18.2 in the paper, the group with no stimulant treatment was comprised of 162 subjects without ADHD and 106 with ADHD (41 severe, 25 moderate, and 40 mild. The stimulant treatment group was comprised of 10 subjects without ADHD and 121 subjects with ADHD (62 severe, 48 moderate, and 11 mild.) The percentage of subjects who had not yet become regular smokers was significantly higher ( $P \leq 0.05$  by Lee Desu statistic) in the untreated group (~60%) compared to the treated group (45%). The same subjects were evaluated according to the age when stimulant treatment was ended: age 10, age 11–13, or after age 14. Stimulant treatment appeared to protect against smoking during childhood. However, in adulthood, smoking rates were significantly higher ( $P < 0.001$  by chi-squared) in treated groups (41%) compared to the untreated group (19%). Adjusted odds ratios were calculated. [The confounding factors considered in the analyses are not clearly identified, but it appears that childhood conduct disorders were considered in addition to socioeconomic status, cognitive ability, and ethnicity. It is not clear how many subjects were included and how the subjects were classified in calculating the odds ratios. It is assumed that as in previous analyses, subjects with and without ADHD were collapsed into the same groups based on stimulant exposure.] In the group treated with stimulants for more than 1 year, odds ratios were described as significant for daily smoking (2.817) and cocaine dependency (2.251) in adulthood. In subjects exposed  $< 1$  year, a significant odds ratio (3.951) was obtained for daily smoking in adulthood [95% confidence intervals were not listed]. ADHD severity was found to be significantly related to tobacco, cocaine, and stimulant dependency in adulthood.

**Strengths/Weaknesses:** A strength of these studies is the emphasis on cigarette consumption, which possibly indicated self-medication, as higher rates of smoking were found in untreated ADHD subjects. However, the inconsistencies in sample sizes and inaccuracies in study tables are serious and make conclusions very tenuous. Other weaknesses include the inadequate description of sample in terms of ethnicity, social class, parental substance use, severity of ADHD, and many other potential confounders. In addition, the authors tended to make sweeping conclusions on the basis of univariate analyses. All of these weaknesses make interpretation of reported findings problematic.

**Utility (Adequacy) for CERHR Evaluation Process:** These studies are not useful for the evaluation process.

**Paternite (128) and Loney (129)** (from the same group) examined the effects of stimulant medication in childhood on substance use in adulthood. One of the studies (128) was partially

supported by NIMH. Subjects were selected from 219 [listed as 285 in one study, but this figure appears to be an error] boys (98% white) who were referred to the University of Iowa child psychiatric clinic at 4–12 years of age. Boys were diagnosed as having hyperkinetic reaction (70%) or minimal brain dysfunction (30%). By more current standards, ~70% of the boys would have been diagnosed with ADHD and the term ADHD is used in the later paper for convenience. Aggressiveness was noted in 7% of the boys, who would have likely received a diagnosis of oppositional defiant disorder according to more recent terminology. Based on treatment preferences of 3 different physicians, 182 of the boys received stimulant medication and 37 were not given medication. At follow-up during adulthood (21–23 years old), 97 of 121 subjects medicated with methylphenidate in childhood were available for evaluation. **[It appears that the 121 medicated subjects were selected from the group of 182 medicated subjects. The number of untreated subjects available for evaluation in adulthood was not specified.]** The medicated subjects were treated between 1967 and 1972 at a mean age of 8.8 years. Mean methylphenidate dose was 32 mg/day (8–80 mg/day range) and mean duration of treatment was ~30 months [reported as 30.4 and 36 months in the 2 papers] with a range of 1–76 months. **[It was not stated how many untreated subjects were included in analyses.]**

In the Paternite et al. study (128), regression analyses were conducted to determine associations between methylphenidate dose, response, or treatment duration and alcoholism, drug abuse disorder, psychiatric conditions, and measurements of social function and IQ. Child age, symptom dimensions, and the two other medication variables were held constant in each analysis. Neither alcoholism nor drug abuse disorders were significantly associated with methylphenidate treatment, although there was a trend between increased dosage and fewer diagnoses of alcoholism ( $r = -0.2$ ,  $P < 0.10$ ). **[Most data were not shown since only values approaching or reaching statistical significance were listed in tables.]** The only adverse finding related to methylphenidate treatment was an association between better response to treatment and reduced likelihood of high school graduation ( $r = -0.34$ ,  $P < 0.01$ ). Additional findings included associations between increased dosage and reduced suicide attempts; better medication response with improved psychiatric outcomes and social functioning; and longer treatment duration with improved psychiatric outcomes, higher IQ, and better reading scores. Significant associations or trends were noted between inattention-overactivity and unemployment and adverse outcomes on some psychiatric or behavioral measures. Associations or trends noted for aggression were drug abuse disorder, antisocial personality disorder, and adverse outcomes on some psychiatric or behavioral measurements. **[The Expert Panel notes that a number of unique positive associations with medication were observed (e.g., reduced suicide attempts). Only one adverse significant association with medication was reported and it is surprising: “better response to treatment and reduced likelihood of high school graduation.”]**

In the study by Loney et al. (129), rates of involvement (experimentation, continuation, or escalation of use) with alcohol, tobacco, barbiturates, tranquilizers, stimulants, marijuana, glue, cocaine, LSD, and opioids were compared between ADHD subjects who either were or were not treated with methylphenidate. The analyses controlled for year of birth and inattention, overactivity, or aggressive defiance symptoms. In unmedicated compared to medicated subjects, adult involvement was significantly increased ( $P < 0.05$ ) for tobacco, stimulants, glue, and opioids. **[The unit on the Y axis of involvement graphs (Figure 17.1 and 17.2 of the study) is not specified and it is not clear what kind of analysis was conducted.]** According to the study authors' interpretation of the data, medicated subjects progressed less far along the path from experimentation to continued use. Significantly fewer ( $P < 0.05$ ) medicated versus unmedicated subjects (respective percentages) had experimented with glue (~22 vs. 38%), stimulants (38 vs. 58%), LSD (~30 vs. 49%), and opioids (~23 vs. 42%). Medicated versus unmedicated subjects (respective percentages) had significantly lower rates of alcoholism (27 vs. 56%,  $P = 0.002$ ) and

antisocial personality disorder (24 vs. 44%,  $P = 0.004$ ). Drug abuse rates were similar between the 2 groups (17 vs. 19%). Loney et al. (129) concluded that their studies did not indicate a negative effect of childhood methylphenidate treatment on future drug use, but suggested that further research is needed. [The Expert Panel notes evidence of self-medication, as non-treated subjects were more likely to be ‘involved’ with tobacco and stimulants.]

**Strengths/Weaknesses:** Strengths include a relatively lucid exposition of the technical problems in this field and an ethnically homogenous sample that consisted of all preadolescent subjects at the time of intake. Other strengths were that both treated and untreated subjects had ADHD and that inattention/hyperactivity and aggression were explored separately. In the Paternite et al. study (128), regression analyses were applied to consider many putative associations, including some that were unique (e.g., social function). Weaknesses include the need to reclassify now outdated clinical measures to fit modern criteria and the use of other outdated measures for outcomes, as well as lack of consideration of family risk factors, both genetic and environmental. The small size of the unmedicated subgroup ( $n=37$ ) would tend to bias the evaluation against finding a negative effect in the unmedicated group. It is not clear how the follow-up medicated subjects were selected or how many untreated subjects were followed to adulthood. For example, the authors failed to describe clearly in these 2 articles how an initial sample of 182 treated subjects became 121 and then 97.

Some weaknesses in the interpretation of the Loney et al. (129) study were noted. The main finding was that medicated subjects were less likely to go from “experimentation to continued use” (terms not defined). Drug abuse (not defined) was reported to be similar among treated and untreated groups but medicated subjects were less likely to “experiment” with most drugs. Therefore, the conclusion that drug abuse rates are not impacted by medication is problematic. Because fewer medicated subjects experimented, it appears that the proportion of medicated subjects who experimented and went on to continuous drug use was higher than the proportion of unmedicated subjects. A statistical control is needed for this finding.

**Utility (Adequacy) for CERHR Evaluation Process:** The Paternite et al. (128) study is of limited utility; the Loney et al. study (129) is not useful for the evaluation process.

**Mannuzza et al. (130)**, in a study supported by the NIMH and NIDA, , examined substance abuse in Caucasian adults who as children were randomly treated with methylphenidate or placebo in studies to examine the effects of methylphenidate on reading disorders. The probands in this study had reading disorders, but no other psychiatric problems. They received methylphenidate or placebo at 7–12 years of age over a period of 12–18 weeks. Average methylphenidate doses of treated subjects were 43.9–48.8 mg/day. Sixteen years later (average age 26 years), the probands were interviewed about use of substances such as alcohol; marijuana; cocaine, crack or other stimulants; barbiturates/tranquilizers; psychedelics/hallucinogens; heroin and other opioids; and other substances such as inhalants. The numbers of probands interviewed were 39 (79% male) in the methylphenidate group and 63 (70% male) in the placebo group. Results in the proband groups were compared to each other and to a comparison group of 129 Caucasian individuals (74% male) who had no behavior problems prior to 13 years of age. Dichotomous data were analyzed using logistic regression analysis and continuous data were analyzed using ANCOVA, with age and social class co-varied. Other factors such as gender, parent marital status, number of siblings, school grade, reading grade equivalent, and family stability were stated to be similar between groups. There were no significant differences in rates of substance abuse disorder. Rates of substance abuse disorder were 41% in the methylphenidate group, 37% in the placebo group, and 40% in the comparison group. For substances abusers, there were no significant group differences in age of onset, duration, number of abuse episodes,

or dependence. Significantly more subjects in the comparison group reported ever using marijuana/hashish and stimulants. Rates of stimulant use were 46% in the methylphenidate group, 41% in the placebo group, and 60% in the comparison group. The study authors concluded that results of this study failed to support the theory that treatment with stimulants during childhood increases risk for substance abuse later in life.

**Strengths/Weaknesses:** A strength of this study is that the sample of children with reading disorders was randomly assigned to methylphenidate or placebo groups. The study was well controlled for possible moderators or mediators of effect and masked interviewers were used. There was a detailed examination of abuse using a number of parameters. It is a strength in refuting the sensitization hypothesis that the sample, ethnically homogeneous Caucasian, had developmental reading disabilities not ADHD or comorbid conditions and were treated for a fixed period dictated by study design rather than clinical condition. However, these strengths also weaken the relevance to "real life" situations where methylphenidate is most often used for long duration in children already at behavioral risk. The authors document a number of potential background characteristics, although not parental history of substance use. The article would be strengthened by calculations of power to detect an effect if one did exist. A weakness of this study is that the very short treatment period (12–18 weeks) limits generalizability to populations more commonly using stimulants.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is useful for the evaluation process.

**Wilens et al. (131)** conducted a meta-analysis of studies examining possible associations between long-term medication for treatment of ADHD and substance use disorders. The studies reviewed in the analysis are listed in Table 27 and include published reports identified in a PubMed search, data presented at scientific meetings, and unpublished findings. **[Published studies are reviewed in detail above.]** Included in the analysis were prospective studies examining subjects during adolescence ((123, 131)) and young adulthood (126, 128, 129). One retrospective study examined subjects during adulthood (Huss 1999 abstract cited in (131)). A total of 674 medicated and 360 unmedicated subjects with ADHD were included in the meta-analysis. The analysis did not examine nicotine use. ORs for drug and alcohol substance abuse disorders are listed in Table 27. An OR > 1 indicates a protective effect of medication, while an OR <1 indicates an adverse effect of medication. **[According to ORs and CIs listed in Table 27, none of the studies demonstrated a significant adverse effect of medication.]** The pooled OR of 1.9 (95% CI 1.1–3.6) suggests a nearly 2-fold reduction in risk of substance abuse disorders in youths medicated versus unmedicated for treatment of ADHD. Additional analyses indicated that no one study heavily influenced outcome. Studies that controlled for baseline severity of ADHD were found to have larger ORs **[statement not consistently supported by drug data in Table 27]**. A greater protective effect of medication was found in studies examining adolescent (OR 5.8) versus adult subjects (OR 1.4) **[95% CIs were not presented]**. The study authors concluded that results suggested an association between stimulant treatment in childhood and reduced risk of subsequent drug and alcohol disorders.

**Strengths/Weaknesses:** This paper reviewed numerous studies, some of which were not published. Strengths of this study include statistical analyses (albeit of data of heterogeneous quality and composition) and care in checking that no one study heavily influenced the combined estimates, as well as attention to publication bias. Other strengths were largely conceptual. The authors raised an important issue about baseline severity of ADHD in moderating impact of stimulant treatment; unfortunately part of that analysis was based on unpublished observations (Barkley et al.). Another interesting point is that children from families with a history of

substance use may be more resistant to stimulant treatment. On the other hand, children with more severe oppositional and aggressive disorders (and thus at greater risk of later substance use disorder whether treated or untreated) are more likely to receive stimulant treatment than children at lower baseline risk. It can either be regarded as a strength or a weakness that samples were heterogeneous in the age of follow-up with two studies looking at adolescents who were presumably quite early in the substance use disorder trajectory and the remainder looking at adults. Another weakness is that the reviewed studies used differing measures of varying validity to document substance use disorder. Problems also include conflation of prospective and retrospective studies and exclusion of cigarette/tobacco use as an outcome when it was a primary outcome of a limited study that found an adverse effect of childhood stimulant treatment (126).

**Utility (Adequacy) for CERHR Evaluation Process:** This report is of marginal utility for the evaluation process.

**Table 27. Meta-analyses for Studies Examining Substance Abuse in Subjects Who Were or Were Not Medicated for ADHD**

Reference	Similar baseline severity?	Number of ADHD subjects		ORs (95% CI)	
		Medicated	Unmedicated	Drugs	Alcohol
Lambert and Hartsough, 1998 (126)	No	93	81	0.47 (0.22–1.0)	0.6 (0.32–1.1)
Biederman et al., 1999. (123)	Yes	145 <sup>b</sup>	45 <sup>b</sup>	3.9 (1.8–8.1)	8.1 (3.9–17.2)
Huss, 1999 abstract cited in (131)	No	98	21	2.2 (0.99–5.1)	No data
Loney et al. (129)	Yes	182	37	1.1 (0.46–2.8)	3.6 (1.7–7.4)
Molina and Pelham, 1999 abstract cited in (131)	Yes	53	73	4.6 (1.5–14.5)	6.6 (1.4–30.2)
Barkley unpublished data cited in (131) <sup>a</sup>	Yes	Not specified	Not specified	0.83 (0.29–2.3)	0.98 (0.36–2.7)

<sup>a</sup>This study may have been published later as (124)

<sup>b</sup>According to CERHR review of this study, there were 56 medicated and 19 unmedicated subjects with ADHD From (131)

As noted above, some studies examining the effects of ADHD medications also found associations between ADHD and/or conduct disorders and substance use (121, 126, 128). Numerous studies examined possible associations between ADHD, independent of treatment, and substance abuse [not considered here]. A review by Wilens (132) concluded, “There is a robust literature supporting a relationship between ADHD and SUD [substance use disorders]. Noncomorbid ADHD appears to confer an intermediate risk factor for SUD, although conduct and bipolar disorder appear to heighten the risk of early onset of SUD. Both family-genetic and self medication influences appear to be operational in the development and continuation of SUD in ADHD subjects.”



**[The Expert Panel noted that in general, the studies examining substance use disorders are complicated by the well-known association in pedigrees of substance use disorders, ADHD, and other psychiatric disorders and by the studies' varying sophistication in measuring true substance use disorder compared to simple experimentation or initiation. A weakness of all the studies is the use of self-report only to measure substance use without confirmation by biologic markers such as urine or hair, which might enhance accurate identification of users.]**

#### *3.1.2.8 Effects on height and weight*

A number of studies on the effects of methylphenidate therapy on height and weight of in children are summarized in Table 28. The 1992 Multimodal Treatment Study of ADHD, which included height and weight data, is summarized following the table.

There are several variables considered by the Expert Panel in reviewing these studies. Differences in study design and comparison groups may account for the inconsistent and contradictory results observed across the entire data set. The following observations were made about the data set in general:

- In some studies, control groups were absent or inadequate.
- Various medication dosages were used.
- The use of drug-naïve subjects is highly desirable.
- Duration of drug treatment, which may affect pharmacokinetics, was inadequate in some studies.
- The presence or absence of drug holidays may have affected the results of some studies.
- A wide age range, including prepubertal and pubertal children, may have affected results.
- Intervals of measurements, whether monthly, yearly, or some other interval, could influence results.
- Inexact methods to measure growth and height were used in some studies.
- Long term follow-up and consideration of normal growth and weight gain were variable among studies.
- Height does not vary linearly with age; thus the wider age range of the sample, the more vulnerable are direct comparisons of averaged height measurements.
- Methods for assessing growth deficits varied; for example, studies included absolute differences, growth percentiles from old/outdated growth charts, or other metrics.
- Some studies used growth percentiles from standardized growth charts; averages of percentiles overemphasize small differences near the mean at the expense of similar difference at the extremes.
- Many studies failed to consider parental height or body-mass index (BMI) (i.e., genetic influences).

**Table 28. Methylphenidate Growth Studies**

Parameters, mean (range)	Results and author conclusions	Comments	Reference																						
n = 29 (sex unspecified) Control: Unmedicated ADHD controls (n = 7); Anthropometric scale Age: Elementary school-aged Duration: Group 1 ≥ 9 months; Group 2 ≥ 2 years Dose: 20, 30, or 40 mg/day	<p><u>Methylphenidate and d-amphetamine combined results</u></p> <p>-The group that discontinued medication after 9 months (n = 13) gained twice as much weight in the summer as the group staying on medication (n = 7). Weight rebound was not sufficient to compensate for the initial weight suppression.</p> <p>-Over 2 years, medicated group (n = 9) had a percentile weight change of -20.38, compared to +6.79 in the control group (n = 7). For height, the medicated group percentile change was -13.45 compared to +1.29 in controls.</p> <p>-Tolerance did not develop for weight gain suppression in the 2-year group; these children had a mean weight gain of 1.8 kg, compared to the expected 3.1 kg.</p> <p>-Percentile height decrease correlated with percentile weight decrease, but was not significant compared to baseline</p> <p><u>Methylphenidate results:</u></p> <p>-Difference in weight gain between group discontinuing medication in the summer (0.41 kg/mo) and group continuing medication (0.29 kg/mo) was not significant.</p> <p>-20 mg/day did not inhibit weight gain</p> <p>-30 or 40 mg/day had a suppressive effect on weight gain</p>	<p>Strength: Control group</p> <p>Weakness (First data set): Most were in special classes for learning and behavior problems; measurements only 3 times in 9 months; 13/20 taken off medication during summer, making exposures non-uniform. (Second data set): Data obtained retrospectively from school nurse records; medication information obtained from parent or nurse reports; different medication doses for children; small number for subjects (9) and controls (7); use of percentiles.</p> <p>It is difficult to draw conclusions from these data.</p>	(133)																						
n = 20 (sex unspecified for methylphenidate group, however 44 of 49 in study were male) Control: 14 unmedicated ADHD males Age (years): 7.4 Duration: mean = 3.0 years Dose: unspecified	<table border="1"> <thead> <tr> <th rowspan="2"></th> <th rowspan="2">N</th> <th colspan="2">Percentile change in growth</th> </tr> <tr> <th>Weight</th> <th>Height</th> </tr> </thead> <tbody> <tr> <td>All doses</td> <td>20</td> <td>-6.35</td> <td>-5.20</td> </tr> <tr> <td>High dose (&gt; 20 mg/day)</td> <td>10</td> <td>-10.00</td> <td>-9.40</td> </tr> <tr> <td>Low dose (≤20 mg/day)</td> <td>10</td> <td>-2.70</td> <td>-1.00</td> </tr> <tr> <td>Control</td> <td>14</td> <td>+6.79</td> <td>+1.29</td> </tr> </tbody> </table> <p>-Low-dose group did not statistically differ from controls; high-dose group exhibited suppression of both height and weight.</p> <p>-Summer continuance did not significantly influence weight suppression. However, summer continuance was statistically related to an increased</p>		N	Percentile change in growth		Weight	Height	All doses	20	-6.35	-5.20	High dose (> 20 mg/day)	10	-10.00	-9.40	Low dose (≤20 mg/day)	10	-2.70	-1.00	Control	14	+6.79	+1.29	<p>Strength: Use of a control group</p> <p>Weakness: Evaluation performed once/year</p> <p>Growth was evaluated by total change in the normative percentiles for weight and height.</p>	(134)
	N			Percentile change in growth																					
		Weight	Height																						
All doses	20	-6.35	-5.20																						
High dose (> 20 mg/day)	10	-10.00	-9.40																						
Low dose (≤20 mg/day)	10	-2.70	-1.00																						
Control	14	+6.79	+1.29																						

Parameters, mean (range)	Results and author conclusions	Comments	Reference																												
	percentile height loss (n = 17, P = 0.05), thus indicating a recovery effect.																														
n = 30 (23 male) Control: 30 normal controls Age (years): 14–19 (Mean: boys 16.4, girls 17.8) Duration ≥ 6 months during childhood	<table border="1"> <thead> <tr> <th rowspan="2"></th> <th colspan="3">Height, mean inches (range)</th> </tr> <tr> <th>N</th> <th>Boys</th> <th>Girls</th> </tr> </thead> <tbody> <tr> <td>Methylphenidate</td> <td>30</td> <td>69.2 (64–73)</td> <td>64 (64–67)<sup>a</sup></td> </tr> <tr> <td>Control</td> <td>30</td> <td>68.7 (64–72)</td> <td>64.2 (61–65)</td> </tr> </tbody> </table> <p>No statistically significant effect on height <sup>a</sup>As in the original; however, the lower value of the range is unlikely to also be the mean.</p>		Height, mean inches (range)			N	Boys	Girls	Methylphenidate	30	69.2 (64–73)	64 (64–67) <sup>a</sup>	Control	30	68.7 (64–72)	64.2 (61–65)	Strength: Use of a control group Weakness: Retrospective data General comments: Low socioeconomic class; treatment duration ≥ 6 months; little can be concluded from this study.	(122)													
	Height, mean inches (range)																														
	N	Boys	Girls																												
Methylphenidate	30	69.2 (64–73)	64 (64–67) <sup>a</sup>																												
Control	30	68.7 (64–72)	64.2 (61–65)																												
n = 32 (sex unspecified; 4:1 male:female ratio for study as a whole) Control: Anthropometric scale (historical control) Age (years): 10.3 (range 8–13) Duration ≥ 3 years Dose: 27 (10–60) mg/day	<table border="1"> <thead> <tr> <th rowspan="2"></th> <th rowspan="2">N</th> <th colspan="2">Weight (kg/month)</th> <th colspan="2">Height (cm/month)</th> </tr> <tr> <th>School Year</th> <th>Summer</th> <th>School Year</th> <th>Summer</th> </tr> </thead> <tbody> <tr> <td>Continued</td> <td>8</td> <td>0.24 ± 0.20</td> <td>0.21 ± 0.22</td> <td>0.42 ± 0.12</td> <td>0.48 ± 0.35</td> </tr> <tr> <td>Discontinued</td> <td>2</td> <td>0.21 ± 0.20</td> <td>0.47 ± 0.38</td> <td>0.37 ± 0.21</td> <td>0.60 ± 0.52</td> </tr> <tr> <td>Expected</td> <td></td> <td></td> <td>0.28</td> <td></td> <td>0.52</td> </tr> </tbody> </table> <p>mean ± SD -Growth rate differences between school year and summer in discontinued group were statistically significant, indicating rebound for both height and weight. -Increased dose correlated with increased growth suppression, but did not affect the degree of rebound.</p>		N	Weight (kg/month)		Height (cm/month)		School Year	Summer	School Year	Summer	Continued	8	0.24 ± 0.20	0.21 ± 0.22	0.42 ± 0.12	0.48 ± 0.35	Discontinued	2	0.21 ± 0.20	0.47 ± 0.38	0.37 ± 0.21	0.60 ± 0.52	Expected			0.28		0.52	Strength: 3-year study period Weaknesses: Measurements twice/year; measurement with a yardstick is unlikely to be sensitive to 0.01 cm, as the data are expressed; potential inclusion of puberty in age group; use of historical control. General comment: Results suggest growth rebound.	(135)
	N			Weight (kg/month)		Height (cm/month)																									
		School Year	Summer	School Year	Summer																										
Continued	8	0.24 ± 0.20	0.21 ± 0.22	0.42 ± 0.12	0.48 ± 0.35																										
Discontinued	2	0.21 ± 0.20	0.47 ± 0.38	0.37 ± 0.21	0.60 ± 0.52																										
Expected			0.28		0.52																										
n = 23 (all male) Control: treatment drop out group of boys on medication ≤ 4 months (n = 12) Age (years): 8.91 ± 1.61 Duration: 12 months (continuous) Dose: 20.62 ± 8.56 mg/day [± not defined]	<table border="1"> <thead> <tr> <th rowspan="2"></th> <th rowspan="2">N</th> <th colspan="2">Percentile Scores</th> </tr> <tr> <th>Weight</th> <th>Height</th> </tr> </thead> <tbody> <tr> <td>All doses</td> <td>23</td> <td>-8.81</td> <td>+3.19</td> </tr> <tr> <td>&gt; 20 mg/day</td> <td>5</td> <td>-15.40</td> <td>-3.00</td> </tr> <tr> <td>≤ 20 mg/day</td> <td>18</td> <td>-6.88</td> <td>+5.12</td> </tr> <tr> <td>Treatment dropout group</td> <td>12</td> <td>+1.61</td> <td>-1.46</td> </tr> </tbody> </table> <p>-Statistically significant decrease in weight but not in height -Compared methylphenidate to imipramine and found similar results of decreased weight but not height in both treatment groups.</p>		N	Percentile Scores		Weight	Height	All doses	23	-8.81	+3.19	> 20 mg/day	5	-15.40	-3.00	≤ 20 mg/day	18	-6.88	+5.12	Treatment dropout group	12	+1.61	-1.46	Weaknesses: Methylphenidate compared only to imipramine; 1-year measurements only; confusing pretreatment regimen, which included placebo period. General comment: Difficult to interpret conclusion.	(136)						
	N			Percentile Scores																											
		Weight	Height																												
All doses	23	-8.81	+3.19																												
> 20 mg/day	5	-15.40	-3.00																												
≤ 20 mg/day	18	-6.88	+5.12																												
Treatment dropout group	12	+1.61	-1.46																												

Parameters, mean (range)	Results and author conclusions	Comments	Reference																						
<p>n = 60 (52 male)  Control: Iowa Growth Tables  Age (years): 9.0 (3–13.9)  Duration: 5.1 (2.0–9.7) years  Dose: 34 (10–120) mg/day</p>	<table border="1"> <thead> <tr> <th rowspan="2">Time after onset</th> <th colspan="2">Mean change in percentile<sup>a</sup></th> <th rowspan="2">Mean Dose, mg/day<sup>b</sup></th> </tr> <tr> <th>Weight</th> <th>Height</th> </tr> </thead> <tbody> <tr> <td>1 year</td> <td>-5.2 (<i>P</i> &lt; .05)</td> <td>-0.1 (<i>P</i> = NS)</td> <td>24.4</td> </tr> <tr> <td>All 60 on medication</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Final follow-up</td> <td>+11.4 (<i>P</i> &lt; .001)</td> <td>+12.8 (<i>P</i> &lt; .001)</td> <td>43.8</td> </tr> <tr> <td>30 on medication, 30 off</td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p><sup>a</sup> For all patients  <sup>b</sup> For patients still on medication</p> <p>-Some weight loss in the first 3 years compared to expected norms (statistically significant only in the first year), which recovered in later years.  -Both height and weight exhibited a statistically significant percentile increase at final follow-up.  -Patients who had discontinued medication at final follow-up showed a “larger” (not statistically significant) weight and height rebound than those still on medication.</p>	Time after onset	Mean change in percentile <sup>a</sup>		Mean Dose, mg/day <sup>b</sup>	Weight	Height	1 year	-5.2 ( <i>P</i> < .05)	-0.1 ( <i>P</i> = NS)	24.4	All 60 on medication				Final follow-up	+11.4 ( <i>P</i> < .001)	+12.8 ( <i>P</i> < .001)	43.8	30 on medication, 30 off				<p>Strength: Longer treatment period (at least 2 years).  Weaknesses: Data partly retrospective; measurements converted to percentiles for comparison.  Comments: The utility of this study is in showing that height and weight deficits are compensated in long-term treatment.</p>	(137)
Time after onset	Mean change in percentile <sup>a</sup>		Mean Dose, mg/day <sup>b</sup>																						
	Weight	Height																							
1 year	-5.2 ( <i>P</i> < .05)	-0.1 ( <i>P</i> = NS)	24.4																						
All 60 on medication																									
Final follow-up	+11.4 ( <i>P</i> < .001)	+12.8 ( <i>P</i> < .001)	43.8																						
30 on medication, 30 off																									
<p>n = 20 (17 male)  Control: 6 males off medication; 23 (20 male) age-matched controls  Duration: 12 months  Dose: 0.60 (0.24–1.35) mg/kg bw/day</p>	<p>Children in study had been treated with methylphenidate for an average of 30.3 months (range 9–47); all were treated for at least 8 of the 12 months in the study.  -Compared to controls, hyperactive children had slightly more lean body mass, a higher percent body fat, and larger muscle girths.  -Hyperactive children increased less in lean body mass, but more of their weight gain was in body fat.  -Unmedicated hyperactive children did not differ significantly from medicated children.  -Methylphenidate-treated children experienced the same amount of growth as normal children, but body composition differed.</p>	<p>Strengths: Control group of children without ADHD; use of other measures such as body fat composition and lean body mass.</p>	(138)																						
<p>n = 28 (24 boys) for 1 year; 13 (11 boys) for 2 years</p>	<p>-At 1 year of growth, no significant difference in height, weight, lean body mass, % body fat, or body girth.  -Skeletal width of medicated hyperactive children was significantly</p>	<p>Strengths: Age- and sex-matched controls; 12 and 24-month follow-up.</p>	(139)																						

Parameters, mean (range)	Results and author conclusions	Comments	Reference
Control: 24 (21 male) unmedicated hyperactive children for 1 year, 10 (9 male) unmedicated hyperactive children for 2 years; plus age- and sex-matched normal controls Age: Group means were 9.7–10.7 years Duration: 12 or 24 months Dose: 1-year group: 24.1 mg/day (10–40); 2-year group 21.9 mg/day (12–40).	increased compared to controls; however, age was significantly different as well and accounted for the increase. -No difference between medicated and unmedicated hyperactive children. -Over a 12-month period, hyperactive children had significantly slower rate of body girth increase. -Over a 24-month period, hyperactive children added more fat weight than controls. -Methylphenidate use over 1 or 2 years did not produce growth suppression.	Weakness: Excessive variation within groups, for example in drug duration. General comments: The differences in skeletal widths are probably not important because age differences could account for the skeletal differences. The results appear to be counterintuitive.	
n = 36 (sex unspecified) Duration: 16 months Dose: 10–20 mg/day	Letter to the editor. Full study results in below in (140) -No significant difference in height and weight percentile distribution before and after treatment. -Annual growth was above the norm in 23 patients. -Possible growth stimulant effect in 6 patients between 5 and 8 years of age.	The conclusions may not be reliable based on the letter format and the use of percentiles for comparisons.	(141)
n = 36 (all male) Control: pretreatment measurements; normal children (historical control) Age (years): 5-10 Duration: 16 (6–26) months (interrupted on weekends and vacations) Dose: 10–20 mg/day	-Rates of annual growth were above normal for 23 patients, below for 13. Only 2 had a significantly decreased rate, whereas 6 patients (aged 5–8 years old) had a significantly increased growth rate. -Percentile distribution for height and weight was not significantly different from controls. -64% of patients had above normal rates of annual growth. -Concluded that relatively low doses given in divided doses are well tolerated and do not suppress growth in children with minimal brain dysfunction.	Strengths: Prospective study; included growth rates, not just percentiles. Weakness: Drug therapy was interrupted on weekends and holidays; used historical controls consisting of white North American children from 1962; used varying intervals for measurements.	(140)

Parameters, mean (range)	Results and author conclusions	Comments	Reference									
<p>n = 72 (all male)  Age (years): 6–12  Duration: 1 or 2 years  Mean Dose</p> <table border="1"> <thead> <tr> <th>Year</th> <th>N</th> <th>mg/kg bw/day</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>72</td> <td>0.47</td> </tr> <tr> <td>2</td> <td>48</td> <td>0.59</td> </tr> </tbody> </table>	Year	N	mg/kg bw/day	1	72	0.47	2	48	0.59	<p>Results for Year 1:  <u>Summer medication group</u> (n = 31): significant height and weight deficit prior to summer; significant height increase in summer.  <u>No summer medication group</u> (n = 41): significant weight deficit prior to summer; significant height decrease after summer.  <u>Total</u>: Significant mean weight decrease of 0.88 kg and mean height decrease of 1.03 cm from expected.</p> <p>Results for Year 2:  -The second year of treatment showed no significant height or weight difference from expected values. However, the 2-year cumulative weight deficit was significant.  -Patients on medication for two years experienced a height deficit in the first year that was compensated by a height gain in the second year</p> <p>Conclusions:  -Growth deficits decreased with length of treatment, suggesting development of tolerance.  -Summer drug holidays had no significant effect on height but did have a minimally significant effect on weight. However, average daily dosage for patients treated in the summers was significantly higher throughout the year than patients who did not take summer medication (as much as twice the dose), which may also account for increased weight deficits.  -The temporary height reduction of less than 1% is not clinically significant.</p>	<p>Strengths: Prospective study; monthly measurements; medication compliance documented by urinalysis.  Weakness: Included boys who were theoretically in the pubertal age group, although it is difficult to predict the adolescent growth spurt.  General comments: Used predicted height and weight velocities based on Iowa norms; the decrease in growth deficits with length of treatment could represent development of tolerance or temporary developmental deviations not related to complications of stimulant treatment.</p>	(142)
Year	N	mg/kg bw/day										
1	72	0.47										
2	48	0.59										
<p>n = 85 (all male)  Control: 8 nondrug growth predicting factors  Age (years): 9.2 at referral, 14.5 (12–18) at follow-up  Duration: mean = 36 months  Dose: 33.1 (5–80) mg</p>	<p>-Retrospective analysis.  -Longer duration of treatment resulted in increased growth suppression; drug holidays decreased suppressant effects.  -Findings suggested that the presence of early side-effects such as nausea, vomiting, and appetite suppression a major predictor of growth deficit. Also found that maintenance dose was not a major predictor of growth suppression.</p>	<p>Strengths: Large sample size; controlled for parental heights and weights; controlled for nondrug growth-predicting variables; first study to use multiple regression analysis.  Weaknesses: Included adolescents in pubertal age; growth measured only once, at 3 years; large range of drug doses (5–80 mg)</p>	(143)									

Parameters, mean (range)	Results and author conclusions	Comments	Reference																																											
n = 26 (25 male) Control: 8 (all male) unmedicated ADHD; 25 (24 male) normal Age (years): 5–13 Duration: 1–3 years Dose ≤ 0.8 mg/kg bw/day	-No significant effect on growth in the first, second, or third years of treatment. -Data indicate no effect on growth of male children younger than 13 years of age with doses up to 0.8 mg/kg bw/day for 1 or 2 years or 0.6 mg/kg bw/day for 3 years. -Authors note that children in the study had not yet reached the adolescent growth spurt.	Strengths: Used unmedicated ADHD group and non-ADHD group for comparison; rigorous measurements; took parental stature into account.	(144)																																											
n = 86 (sex unspecified) Control: National Centre for Health Statistics; pretreatment percentiles Age (years): 8 Duration: up to 4 years with varying drug holidays Mean Dose: 40 mg/day	<table border="1"> <thead> <tr> <th rowspan="2"></th> <th colspan="4">Treatment Period, years (n)</th> </tr> <tr> <th>&lt; 1 (86)</th> <th>1–2 (81)</th> <th>2–3 (54)</th> <th>3–4 (42)</th> </tr> </thead> <tbody> <tr> <td>Mean duration (range), weeks</td> <td>20.7 (1–47)</td> <td>59.4 (26–85)</td> <td>99.1 (43–142)</td> <td>130.0 (51–190)</td> </tr> <tr> <td>Daily dose (range), mg</td> <td>39.9 (10.0–58.0)</td> <td>41.3 (12.4–59.4)</td> <td>41.0 (22.4–59.4)</td> <td>41.4 (16.2–62.6)</td> </tr> <tr> <td>Cumulative dose (range), g</td> <td>5.9 (0.2–18.5)</td> <td>17.2 (5.6–34.9)</td> <td>28.5 (10.5–48.0)</td> <td>37.9 (9.5–68.1)</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th rowspan="2"></th> <th colspan="4">Treatment Year</th> </tr> <tr> <th>1</th> <th>2</th> <th>3</th> <th>4</th> </tr> </thead> <tbody> <tr> <td>Height percentile decrement</td> <td>1.4 (n = 51; P = NS)</td> <td>8.1 (n = 56; P &lt; .001)</td> <td>13.4 (n = 37; P &lt; .001)</td> <td>18.1 (n = 19; P &lt; .001)</td> </tr> <tr> <td>Weight percentile decrement</td> <td>9.7 (n = 69; P &lt; .001)</td> <td>15.9 (n = 69; P &lt; .001)</td> <td>18.6 (n = 44; P &lt; .001)</td> <td>20.8 (n = 26; P &lt; .001)</td> </tr> </tbody> </table>		Treatment Period, years (n)				< 1 (86)	1–2 (81)	2–3 (54)	3–4 (42)	Mean duration (range), weeks	20.7 (1–47)	59.4 (26–85)	99.1 (43–142)	130.0 (51–190)	Daily dose (range), mg	39.9 (10.0–58.0)	41.3 (12.4–59.4)	41.0 (22.4–59.4)	41.4 (16.2–62.6)	Cumulative dose (range), g	5.9 (0.2–18.5)	17.2 (5.6–34.9)	28.5 (10.5–48.0)	37.9 (9.5–68.1)		Treatment Year				1	2	3	4	Height percentile decrement	1.4 (n = 51; P = NS)	8.1 (n = 56; P < .001)	13.4 (n = 37; P < .001)	18.1 (n = 19; P < .001)	Weight percentile decrement	9.7 (n = 69; P < .001)	15.9 (n = 69; P < .001)	18.6 (n = 44; P < .001)	20.8 (n = 26; P < .001)	General comments: This study included a very large range of treatment durations and medication doses (daily and cumulative). The height percentile decrements are of concern but the absolute height decrement was 3.3 cm over the 4 years of follow-up, demonstrating the limitations of using percentiles. It is important that all children were pre-pubertal.	(145)
	Treatment Period, years (n)																																													
	< 1 (86)	1–2 (81)	2–3 (54)	3–4 (42)																																										
Mean duration (range), weeks	20.7 (1–47)	59.4 (26–85)	99.1 (43–142)	130.0 (51–190)																																										
Daily dose (range), mg	39.9 (10.0–58.0)	41.3 (12.4–59.4)	41.0 (22.4–59.4)	41.4 (16.2–62.6)																																										
Cumulative dose (range), g	5.9 (0.2–18.5)	17.2 (5.6–34.9)	28.5 (10.5–48.0)	37.9 (9.5–68.1)																																										
	Treatment Year																																													
	1	2	3	4																																										
Height percentile decrement	1.4 (n = 51; P = NS)	8.1 (n = 56; P < .001)	13.4 (n = 37; P < .001)	18.1 (n = 19; P < .001)																																										
Weight percentile decrement	9.7 (n = 69; P < .001)	15.9 (n = 69; P < .001)	18.6 (n = 44; P < .001)	20.8 (n = 26; P < .001)																																										
	-Significant weight deficit all 4 years of treatment and significant height deficit after the first year. -Dose and duration were significantly related to growth suppression. -Children who were initially larger showed greater growth deficits. -Weight suppression appeared to plateau with time. -Onset of weight suppression occurred earlier than that of height suppression. -Authors note that all children were pre-pubertal.																																													

Parameters, mean (range)	Results and author conclusions	Comments	Reference
n = 8 (all male) Control: Pre-treatment measurements Age (years): 8.5 (6–9.5) Duration: 1 year Dose: 1.3 mg/kg bw/day; 39 (10–60) mg/day	-Weight decreased $9.5 \pm 3.3$ percentage points ( $P < 0.001$ ); weight velocity was 3.0 kg/year lower than expected ( $P < 0.005$ ). -Height decreased $2.4 \pm 1.5$ percentage points ( $P = \text{NS}$ ); height velocity 0.5 cm/year lower than expected ( $P = \text{NS}$ ). -Significant suppression of both weight and weight velocity. Authors speculate that lack of significant height suppression could be due to the short half-life of methylphenidate.	Strength: Measured height velocity. Weaknesses: Small sample size (8); lack of control group. General comment: The main objective was to look at prolactin and growth hormone.	(146)
n = 61 (all male) Control: 99 normal males Age (years): 6–12 Duration: 2.24 years (range 6 months to 5.2 years); Follow-up occurred between the ages of 16 and 23 (mean = 9 years after diagnosis) Dose: 44.9 mg/day	-Even when there was a suppressive effect on height during treatment, growth rebound after discontinuation of therapy compensated so that there was no final adverse effect on height. -Complicated by multiple pharmacologic use; 82% of children received other medications at intervals during treatment: 11% <i>d</i> -amphetamine; 25% imipramine hydrochloride; 62% thioridazine hydrochloride. However, there were no significant differences at follow-up between methylphenidate only patients and those who had taken other drugs.	Strengths: Long-term follow-up; non-ADHD controls. Weaknesses: Children received concomitant medications; incomplete histories; controls were a full year older than probands; self-reported heights in 40% of subjects, although these heights did not differ significantly from the heights that were directly measured.	(147)
n = 58 (53 male) Age (years): 9.2 (6–12) Duration: Two groups on medication for two years; the ON group continued during the summers and the OFF group had summer drug holidays	-After the first summer, the OFF group (n = 32) weighed significantly more (0.9 kg) than the ON group (n = 26) ( $P < 0.005$ ), but there was no significant difference in height. -After 2 summers, the OFF group (n = 14) was significantly taller (1.5 cm) than the ON group (n = 14) ( $P < 0.02$ ), but there was no significant difference in weight -Results suggest a reduction in growth velocity while on methylphenidate. However study did not address long term effects of treatment.	Weaknesses: Treatment received before study began; summer period not defined; used absolute height and weight measurements.	(148)
n = 29 (sex unspecified) Control: 30 random unmedicated healthy Age (years): $7.8 \pm 2.4$ Duration: mean = 14 months	-Significant height and weight deficits compared with controls. -Children with higher initial weight percentiles experienced greater weight loss. -Authors analyzed differences between methylphenidate- and desipramine-treated children and found growth suppression less pronounced with desipramine.	Strength: Control group of unmedicated healthy children; used various assessments of growth (simple growth deficits, percent deficits, frequency percentiles, growth velocity).	(149)



Parameters, mean (range)	Results and author conclusions	Comments	Reference
Dose: 31.4 ± 17.6 mg/day (1.0 ± 0.5 mg/kg bw/day) [±SD]		General comment: Primary focus was desipramine, although one group received methylphenidate.	
n = 23 (all male) Control: 23 unmedicated ADHD males Age (years): 9.0 (7–12) Duration: 21 months Dose: 23 mg/day (0.55 mg/kg bw/day)	-No statistically significant effect on weight, height, heart rate, diastolic or systolic blood pressure. -No significant weight deficit at high doses at the end of treatment period (mean 2.2 kg difference). -Authors note that the relationship between dose and decreased weight could become clinically significant if treatment with high doses is extended past 2 years.	Strengths: Untreated ADHD controls; treatment duration of almost 2 years. Comments: In the multiple regression analysis, baseline weight and height explained 88% of the variance in final weight and height.	(150)
n = 32 (29 male) Age (years): 7.5 (3.6–15.5) Duration ≥ 5 months; mean duration of follow-up = 11.2 months Dose: 25.5 mg/day (1.0 mg/kg bw/day)	-All height and weight measurements are represented as <i>z</i> scores. -Initial weight 0.7; Initial height 0.6 -Weight change at follow-up –0.4 -Height change at follow-up –0.1 -Children were divided into two groups to analyze effects of pre-treatment weight; 75% of the heavy group (n = 16) experienced decreased BMI from expected compared to 50% of the thinner group (n = 16). BMI slope analysis showed significant difference in growth deficit between heavy and thin groups. -Major predictor of decreased BMI was pre-treatment weight. No significant effect of dose, duration of follow-up, or age on degree of weight loss. -Retrospective study; did not account for drug holidays.	Strengths: No prior drug treatment; used weight-for-height curves (BMI). Weaknesses: Retrospective study; data on weekend treatment only partially available; BMI curves were from a Caucasian sample and not generalizable to non-white children.	(151)
n = 124 (all male) Control: 109 normal male controls Age (years): 14.5 (6-17) Dose: methylphenidate equivalent dose (twice the <i>d</i> -amphetamine and half the pemoline dose) = 38	-Of the 124 ADHD children, 110 were medicated at some time in their lives with either methylphenidate, <i>d</i> -amphetamine, or pemoline. At the time of the study, 53 had been treated in the preceding 2 years with a mean methylphenidate equivalent dose of 38 mg/day. -ADHD children were 4 kg lighter and 3 cm shorter than controls; neither difference was statistically significant. There was a statistically significant height deficit ( <i>P</i> = 0.03) when height was converted to a <i>z</i> score. Significantly more ADHD children were at least 2 standard	Strengths: Normal controls; used <i>z</i> scores; corrected for parental heights; performed pubertal assessments. Weaknesses: Measurements only at 4-year follow-up; missing data.	(152)

Parameters, mean (range)	Results and author conclusions	Comments	Reference
(5–120) mg/day	<p>deviations shorter than the mean (<math>P = 0.02</math>) when corrected for age and parental heights.</p> <ul style="list-style-type: none"> <li>-No significant difference was found for height or weight between unmedicated and stimulant-treated children with ADHD.</li> <li>-Modest height deficits were unrelated to weight deficits or stimulant treatment, and only evident in ADHD children in early adolescence. This result indicates that ADHD children may experience delayed growth, rather than permanent stunting of growth.</li> <li>-No evidence of weight suppression or delayed pubertal development.</li> <li>-No association between height and drug treatment, drug class, duration of treatment, or dose regimen was identified.</li> </ul>		
<p>n = 301 (260 male)  Control: Non-ADHD controls with idiopathic growth hormone deficiency or idiopathic short stature (n = 3596, 2656 male)  Age (years): 3–20  Duration: <math>\sim 3 \pm 2</math> (SD) years on growth hormone therapy (stimulant treatment duration unspecified)  Dose: Not specified</p>	<ul style="list-style-type: none"> <li>-Children with either idiopathic growth hormone deficiency (IGHD) or idiopathic short stature (ISS) on methylphenidate or pemoline for ADHD (results not separated by medication).</li> <li>-All children on growth hormone therapy and below fifth percentile for height at start of treatment.</li> <li>-No effect of stimulant medication on growth of children treated with growth hormone for ISS.</li> <li>-Small negative effect of stimulant medication on growth of children treated with growth hormone for IGHD.</li> </ul>	<p>Weakness: Stimulant treatment duration not specified.  General comment: Caution is needed in interpreting negative results, but follow-up is indicated and study results are interesting.</p>	(153)
<p>n = 9 (all male)  Control: 9 normal males  Age (years): 3–10  Duration: 1–2 years; mean <math>13 \pm 4</math> months [error not specified]  Dose: 10.0 (7.5–12.5) mg/day; 0.5 mg/kg bw/day</p>	<ul style="list-style-type: none"> <li>-No child changed height percentile during treatment.</li> <li>-No significant differences in bone mineral density, serum bone-specific alkaline phosphatase, or urinary deoxypyridinoline.</li> <li>-No effect of methylphenidate on bone mineral density turnover in children treated for 1–2 years.</li> </ul>	<p>Weaknesses: Sample size too small to anticipate seeing a difference in these bone parameters. A cohort of vulnerable children may have been preferable.</p>	(154)

Parameters, mean (range)	Results and author conclusions	Comments	Reference																		
Review of height and weight studies	<p>-Eight of 11 studies reviewing weight reported significant decreases in expected versus actual weight gain of children treated with methylphenidate. Four of 10 studies found height reductions; however, in 2 of these studies there was a subsequent significant height rebound.</p> <p>-Studies suggest that there is an association between methylphenidate treatment and decreased weight gain in some children, and this effect may be dose-dependant. Effects appear to be transient and are diminished by drug holidays, dosage adjustment, and parent education of administration timing.</p> <p>-Height effects appear dose-related and are diminished in some children by summer drug holidays. However, height decreases are not significant in follow-up studies after 4 years.</p>	General comment: The studies reviewed are included in this table.	(155)																		
<p>n = 23 (all male) Control: Norwegian population sample Age (years): 3–13 Duration: 1–5 years Dose: Range 7.5–70.0 mg/day</p> <table border="1"> <thead> <tr> <th>Year</th> <th>N</th> <th>Dose (mg/day)</th> </tr> </thead> <tbody> <tr> <td>0–1</td> <td>23</td> <td>23.9</td> </tr> <tr> <td>1–2</td> <td>22</td> <td>27.4</td> </tr> <tr> <td>2–3</td> <td>17</td> <td>30.8</td> </tr> <tr> <td>3–4</td> <td>11</td> <td>33.3</td> </tr> <tr> <td>4–5</td> <td>9</td> <td>27.8</td> </tr> </tbody> </table>	Year	N	Dose (mg/day)	0–1	23	23.9	1–2	22	27.4	2–3	17	30.8	3–4	11	33.3	4–5	9	27.8	<p>-Compared 23 boys on methylphenidate to 68 boys on a racemic mixture of <i>l</i>- and <i>d</i>-amphetamine.</p> <p>-No statistically significant difference between methylphenidate and amphetamine-treated children in height or weight except for a lower weight gain in amphetamine-treated children during the first year (<math>P &lt; 0.05</math>).</p> <p>-Twenty-one boys (31%) on amphetamine and 4 (17%) on methylphenidate either lost or did not gain weight during the first year; weight loss ranged from 0 to 9.5 kg. There was no significant dose difference between those who lost weight in the first year and those who did not. All boys who had lost weight in the first year experienced subsequent sufficient weight gains.</p> <p>-Children above the 50<sup>th</sup> percentile in weight prior to treatment had significantly increased weight loss compared to those below the 50<sup>th</sup> percentile (<math>P &lt; 0.05</math>), suggesting a slimming effect.</p> <p>-No effect on height was observed.</p> <p>-No effect of cumulative dose or age was observed.</p> <p>-Concluded that methylphenidate and amphetamine do not have adverse growth effects for most children.</p> <p>-Retrospective study; some missing data; broad age range; measurement reliability uncertainty.</p>	<p>Strengths: Large number of subjects followed for an extended time period; results and conclusions are consistent with previous studies.</p> <p>Weaknesses: Large age range of subjects; inclusion of pubertal subjects; once-yearly height and weight data, collected retrospectively; included developmentally-delayed children without reference to whether they had a growth-retarding syndrome.</p> <p>General comments: Standard Norwegian population sample comparison. Multiple regression showed that neither cumulative dose nor age had a significant effect on growth when initial weight and height were controlled.</p>	(156)
Year	N	Dose (mg/day)																			
0–1	23	23.9																			
1–2	22	27.4																			
2–3	17	30.8																			
3–4	11	33.3																			
4–5	9	27.8																			

Parameters, mean (range)	Results and author conclusions	Comments	Reference
<p>n = 84 (68 male)  Control: 87 (71 male)  normal healthy siblings  Age (years): 8.7 (5–17)  Duration ≥ 2 years  Dose: 18.0 (10–45)  mg/day for girls; 22.5 (5–85)  mg/day for boys</p>	<p>-Height velocity decreased compared to age-matched sibling controls. After 1 year of treatment, 60% had a change in SD scores [<b>probably a z-score</b>] &lt;0. After 3 years, 90% of girls and 76% of boys had SD score change &lt;0.</p> <p>-After 3 years, heights were 3–4 cm less than age- or time-matched sibling controls (0.5 SD for boys and 0.6 SD for girls)</p> <p>-Growth rates declined at both high and low doses. In boys, the change in growth velocity was inversely proportional to dose. In girls, growth rates decreased at all doses but no dose correlation was observed (possibly due to a smaller dose variance).</p> <p>-ADHD children’s growth rates prior to methylphenidate treatment were not statistically different from non-ADHD siblings, indicating that the growth deficit was due to medication rather than problems intrinsic to ADHD.</p> <p>-Retrospective study; limited dose variance in girls; no long term follow-up.</p>	<p>Strengths: Height and weight obtained every 3–6 months; evaluated height velocities and z-scores.</p> <p>Weaknesses: Retrospective study; no untreated ADHD controls.</p> <p>General comments: Community-based study in pediatricians’ offices; sibling controls (to control for genetic influence) do not appear to have added anything.</p>	(157)
<p>n = 51 (44 male)  Control: National Centre for Health Statistics  Age (years): 7.2 (3.1–11.4)  Duration: 6–32 months  Dose: 1.0 ± 0.24 mg/kg bw/day; 27.5 (10–40) mg/day</p>	<p>-After 6 months, weight was 1.7 kg less than expected; 76% lost weight. After 30 months there was a 3.0-kg deficit.</p> <p>-During the first 2 years, the height deficit was approximately 1 cm/year; the average height deficit after 42 months was 2.4 cm.</p> <p>-In the first 6 months, 86% had a decreased height velocity. However, after 30 months, the deficit attenuated and most children had normal height velocity.</p> <p>-Thirty-one percent experienced weight deficit even without reported appetite suppression.</p> <p>-Average weight deficit was 2.4 times the height deficit after 30 months.</p> <p>-Significant decrease in height and weight after 6 and 18 months (<math>P &lt; 0.001</math>) and after 30 months (<math>P &lt; 0.01</math>).</p> <p>-Retrospective study; results do not separate methylphenidate (n = 19) from dexamphetamine (n = 32) treatment; 10 patients were also on clonidine; did not account for drug holidays.</p>	<p>Strengths: Rigorous measurements, obtained every 6 months; height, weight, and height velocity corrected for age and sex using SD scores.</p> <p>Weaknesses: Retrospective study; no control group; no long-term follow-up.</p> <p>General comments: Height velocity was lowest during the first 6 months, but in most cases normalized after 3 years; results consistent with other findings.</p>	(158)

**The Multimodal Treatment Study of ADHD (MTA) (159)**, was organized in 1992 by the National Institute of Mental Health and the Department of Education. This study compared four different treatment strategies for ADHD in children aged 7–9.9 years. Assignment was random but not blinded. The treatment strategies were an intensive medication strategy, a behavioral therapy, a combination of medication and behavioral therapy, and community care. The medication-including arms initially used methylphenidate, although other medications could be used if methylphenidate failed to be effective. Nearly all of the children assigned to the medication arm and the combined arm were on methylphenidate for the 14 months of the study (159). Children in the behavioral group were not prescribed medication. Children assigned to community care were managed by their own health care providers without study-imposed restrictions. Two-thirds of these children were prescribed stimulant medication and 87% of the stimulant prescriptions in this group were for methylphenidate. **[The Expert Panel notes the opportunity for confusion in the authors’ names for their groups. Children in three groups could have received medication (the medication group, the behavioral therapy group, and the community care group), yet the authors use the term medication group to refer to a specific “carefully-crafted” regimen developed by algorithm and involving 3-times/day dosing. Although it is not directly relevant to considerations of methylphenidate toxicity, the Expert Panel notes that the results of the MTA trial showed a better response to treatment of the medication and the combined therapy groups compared to the group given behavioral therapy without medication and the community care group. Inasmuch as a majority of children in the community care group received stimulant medication, it was not clear why this group did not improve as much as the medication group. The authors postulated that the optimization of medication dose and the 3-times daily regimen in their “carefully-crafted” medication group may have been more effective than the dose regimen in the community care group.]**

Following 14 months of treatment in their randomly assigned groups, children were followed for an additional 10 months without study-prescribed interventions. Subjects and their parents were free to choose any therapy available in their communities. Assessment 24 months after randomization included changes in height and weight from baseline and from the 14-month time point (160). Analysis of height and weight change from 0 to 14 months was by intention-to-treat. Analysis from baseline to 24 months and from 14 to 24 months was by medication exposure status, based on whether any medication was reported to have been used in the interval, regardless of group assignment. There were 4 medication status groups, reflecting medication exposure during months 0–14 and months 14–24: Med-Med, No Med-No Med, Med-No Med, and No Med-Med.

During months 0–14, children assigned to received medication (either the medication group or the combined therapy group) had smaller increases in height and weight than children assigned to behavioral therapy or to community care. The reported values are given in Table 29. The authors observed that the contrast between the medication group and the behavior group may have been the most meaningful because children in the medication group were most likely to have received intensive therapy with stimulants and children in the behavioral therapy were likely to have not been exposed to stimulants during the course of the treatment period. The changes in height and weight for the treatment period (months 0–14) and the post-treatment period (months 14–24) are shown in Table 30, organized by self-identified exposure to medication. **[The Expert Panel notes that some children assigned to the medication treatment group did not receive medication, and some children assigned to the behavioral therapy group did receive medication.]** There appeared to be an association between self-reported exposure to medication and a decrease in height increase and weight gain. The authors indicated that self-selection

regarding medication status may have influenced growth outcomes, particularly because the Med-Med group started the study shorter (by 1.69 cm) and lighter (by 0.96 kg) than the No Med-No Med group. Over time, these differences by medication exposure status became larger. Age and sex of the child was not significantly related to the growth effects of stimulant exposure.

**Table 29. Height and Weight Change in Children in the Multimodal Treatment Study During the 14-Month Treatment Phase**

Treatment group (n)	Height increase (cm)	Weight increase (kg)
Medication (120)	4.25	1.64
Behavioral therapy (135)	6.19	4.53
Combined (135)	4.85	2.52
Community care (131)	5.68	3.13

[Numbers are assumed to represent means. SD and SEM not given; statistical analysis not provided.] Data from (160).

**Table 30. Height and Weight Change in Children in the Multimodal Treatment Study According to Self-Identified Medication Exposure**

Exposure group (n), expressed as months 0–14/ months 14–24	Height increase (cm), mean ± SD		Weight increase (kg), mean ± SD	
	months 0–14	months 14–24	months 0–14	months 14–24
Med-Med (222)	5.88±1.80 <sup>ac</sup>	4.53±1.61 <sup>a</sup>	2.36±3.00 <sup>a</sup>	3.81±2.84 <sup>a</sup>
No Med-No Med (106)	6.93±2.21 <sup>b</sup>	5.40±2.18 <sup>b</sup>	5.14±3.53 <sup>b</sup>	4.83±3.10 <sup>b</sup>
Med-No Med (63)	5.94±1.84 <sup>cd</sup>	4.94±2.06 <sup>ab</sup>	3.54±3.84 <sup>c</sup>	4.73±3.42 <sup>ab</sup>
No Med-Med (42)	6.64±1.49 <sup>bd</sup>	4.79±1.62 <sup>ab</sup>	4.21±3.43 <sup>bc</sup>	3.37±2.87 <sup>a</sup>

Within columns, groups with different superscripts are different by ANOVA with post-hoc Newman-Keuls Multiple Comparison Test [performed by CERHR]. Data from (160).

**Strengths/Weaknesses:** Strengths include the large sample size, the well-defined pre-pubertal age group, the use of z-scores as a secondary analysis, and consideration of the issue of regression towards the mean. Weaknesses included the lack of blinding; lack of true randomization (choice to switch off medication may have reflected family concern about growth); failure to consider mid-parental height, bone age, or normal seasonality of growth; the use of other medications if methylphenidate failed; the lack of a standard protocol in the community group of children, who could get other medication; the failure of some children in the medication group to receive medication; and the pre-study shorter and lighter status of children in the Med-Med group.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is not useful in the evaluation process because of the numerous methodologic flaws and weaknesses in design.

**Overall Assessment of Height and Weight Data:** While the observations in this area are consistent with most clinical experience, the quality of data in the older papers is suboptimal. These articles have variable but generally marginal-to-moderate utility with incomplete documentation of compliance or actual dosing regimens and with failure to consider (in most cases) basic factors that are usually assessed in growth studies, such as mid-parent height and parent BMI; family history of timing of puberty onset; the child's actual physical or endocrinologic level of puberty at start of treatment (some of the youngsters were as old as 15 when the studies were conducted); and measurement of skeletal maturity (bone age), which particularly in school-aged children is considered a useful indication of expected growth potential. The seasonal differences in expected growth (in the northern hemisphere, children grow faster in summer) are not accounted for by designs that compare children whose families chose to leave them on stimulants through the summer and children whose families did not leave them on medication during the summer. Thus, it cannot be ruled out that those who remained on the medicines also had other conditions or behavioral patterns that motivated their parents to continue the medication and might also (like fetal alcohol effects) decrease growth.

In addition, assessments of growth do not appear to be masked to stimulant exposure history. For example, in the reports of Safer et al. (133-135), the nurse who obtained the measurements was not masked to the children's drug histories and in fact in many cases actually administered the drugs herself.

Findings overall seem to suggest that appetite and growth suppression are less with methylphenidate than with amphetamines, but these findings are not conclusive. There are interesting and clinically relevant issues of mechanism that have not been fully elucidated. It is unclear whether the growth alterations that are noted are primarily related to appetite suppression (as might be expected given the widespread use of amphetamines by dieters) or by endocrine alterations as well. If the issue is only appetite suppression, it is possible to test a number of useful clinical interventions, such as feeding the child a high-calorie supplement before the first daily dose and monitoring whether this intervention alters the patterns of growth. The possible role of stimulant-associated endocrine changes cannot be addressed with the current data set because the endocrinologic data are outdated and use comparison drugs that increase the release of prolactin, creating a possible artifact of lower hormone levels with stimulants.

## 3.2 Experimental Animal Data

### 3.2.1 Prenatal toxicity endpoints

**Teo et al. (48)**, from Celgene Corporation, performed a developmental toxicity study in Sprague-Dawley rats and New Zealand White rabbits using *d*-methylphenidate (98–102% purity) and *d,l*-methylphenidate (chiral purity 50:50). Treatment was by gavage twice/day with equal doses 6 hours apart. A range-finding study in rats appeared identical to the range-finding study reported in Teo et al. (49), discussed in Section 3.2.2. The range-finding study in rabbits used 5 pregnant animals/group given *d*-methylphenidate at 0, 4, 50, or 300 mg/kg bw/day or *d,l*-methylphenidate at 8, 100, or 600 mg/kg bw/day [**days of treatment not specified, but GD 6–18 in the main study**]. Cesarean sections were performed on GD 29. Clinical signs, body weight losses, and maternal deaths occurred in the groups given 300 mg/kg bw/day *d*-methylphenidate and 600 mg/kg bw/day *d,l*-methylphenidate. Absolute and relative feed consumption were decreased in these dose groups and in the group given 50 mg/kg bw/day *d*-methylphenidate. There were no resorbed conceptuses or dead fetuses. Decreased fetal body weight occurred in pregnancies exposed to *d,l*-methylphenidate 600 mg/kg bw/day and a single fetus in the *d*-methylphenidate 300 mg/kg bw/day group had external malformations (missing digits). [**There was insufficient**

**detail in the reporting of the dose range-finding study to evaluate other outcome parameters or to determine LOAEL, NOAEL, or benchmark dose.]**

In the main rat study, 25 pregnant animals/group were treated with 2 equal daily gavage doses 6 hours apart of *d*-methylphenidate or *d,l*-methylphenidate from GD 7–17 (plug day = GD 0). Total doses were 0, 2, 6, or 20 mg/kg bw/day *d*-methamphetamine or 40 mg/kg bw/day *d,l*-methylphenidate. Dams were killed on GD 20 and all fetuses were given external examinations. Half the litters were microdissected for soft tissue examinations and half were prepared for skeletal evaluation. Data were analyzed using ANOVA with post-hoc Dunnett test or Kruskal-Wallis with Dunnett test, depending on homogeneity of variance. Clinical signs occurred in the 6 and 20 mg/kg bw/day *d*-methylphenidate groups and in the 40 mg/kg bw/day *d,l*-methylphenidate group. Some of these signs occurred more often in the 40 mg/kg bw/day *d,l*-methylphenidate group than in the 20 mg/kg bw/day *d*-methylphenidate group in spite of the 2 groups being treated with identical amounts of the active enantiomer (*d*-methylphenidate). Absolute and relative feed consumption and body weight gain during the dosing period were decreased in the 6 and 20 mg/kg bw/day *d*-methylphenidate groups and in the 40 mg/kg bw/day *d,l*-methylphenidate group. There were no treatment-related alterations in corpora lutea or implantations per dam or in litter values for live or dead fetuses, resorptions, sex ratio, fetal body weight, fetal malformations, or variations. When analyzed on a per fetus basis, there was an increase in ossification delay in the 20 mg/kg bw/day *d*-methylphenidate and 40 mg/kg bw/day *d,l*-methylphenidate groups.

**[Benchmark dose<sup>1</sup> modeling by CERHR using the *d*-methylphenidate data gave BMD<sub>10</sub> values for the various ossification delay endpoints in the 31–36 mg/kg bw/day range and BMDL values in the 23–24 mg/kg bw/day range. The Expert Panel notes, however, that this analysis was based on per fetus data and that there were no treatment-related alterations in litter parameters. Benchmark dose modeling for maternal weight gain during the treatment period or from the onset of treatment to GD 20 gave BMD<sub>10</sub> values of 26–32 mg/kg bw/day and BMDL values of 18–21 mg/kg bw/day.]** The authors concluded that the decreases in maternal feed intake and weight gain were likely due to the anorectic effect of methylphenidate and that there were no developmental effects at *d*-methylphenidate doses up to 20 mg/kg bw/day, 40 times the human dose. The authors calculated based on pharmacologic data (discussed in Section 2) that this dose was 5.6 times the human exposure (AUC basis). Similarly, *d,l*-methylphenidate was tested at 11.7 times the AUC obtained with the maximum therapeutic doses in humans.

In the main rabbit study, 20 pregnant animals/group were treated with *d*-methylphenidate or *d,l*-methylphenidate using 2 equal gavage doses 6 hours apart. Total daily doses were 0, 4, 20, or 100 mg/kg bw/day *d*-methylphenidate or 200 mg/kg bw/day *d,l*-methylphenidate. Treatment was given from GD 6–18. Does were killed on GD 29 and fetuses removed by cesarean section. All fetuses were examined externally, microdissected to evaluate soft tissues, and evaluated for skeletal malformations. Statistical analysis was similar to that used in the rat study. There were clinical signs in does in the *d*-methylphenidate 100 mg/kg bw/day group and the *d,l*-methylphenidate 200 mg/kg bw/day group. There was a higher incidence of clinical signs in the 200 mg/kg bw/day *d,l*-methylphenidate group than in the 100 mg/kg bw/day *d*-methylphenidate

---

<sup>1</sup> The BMD<sub>10</sub> is the benchmark dose associated with a 10% effect, estimated from a curve fit to the experimental data. The BMDL represents the dose associated with the lower 95% confidence interval around this estimate. Benchmark doses are used commonly in a regulatory setting; however, they are used in this report when the underlying data permit their calculation, and are only supplied to provide one kind of description of the dose-response relationship in the underlying study. Calculation of a benchmark dose in this report does not mean that regulation based on the underlying data is recommended, or even that the underlying data are suitable for regulatory decision-making.



group in spite of the 2 groups being treated with identical amounts of the active enantiomer (*d*-methylphenidate). There were no adverse effects of any treatment on mean number of corpora lutea, implantations, live or dead fetuses/litter, placental morphology, resorptions, sex ratio, fetal body weights, or fetal alterations. The authors concluded that there were no reproductive effects of *d*-methylphenidate in rabbits at maternal doses up to 100 mg/kg bw/day, 200 times the human dose. The authors calculated based on pharmacologic data (discussed in Section 2) that this dose was 1.7 times the human exposure (AUC basis). Similarly, *d,l*-methylphenidate was tested at 3.79 times the AUC obtained with the maximum therapeutic doses in humans.

**[The Expert Panel notes that neither *d*- nor *d,l*-methylphenidate were considered selective developmental toxicants based on the outcome of these studies. There was an increase in fetal alterations (primarily delayed ossification) in the 6 and 20 mg/kg bw/day *d*-methylphenidate groups, but litter incidence for these alterations was not significantly increased and fetal incidence rates were within the laboratory's historical control range.]**

**Strengths/Weaknesses:** These are standard developmental toxicity studies in CD rats and New Zealand White rabbits conducted for product safety assessment. The studies appear to have been conducted according to standard Federal Insecticide, Fungicide, Rodenticide Act (FIFRA) GLP guidelines. A strength is standardized experimental parameters that produce data sets comparable to other agents. These studies used oral gavage dosing twice/day with doses 6 hours apart, a relevant dosing scenario. The studies have sufficient group sizes, appropriate controls, and appropriate statistical analyses. The investigators controlled for litter effects. Chemical purity and stability were verified. The developmental toxicity studies included external, visceral, and skeletal examinations of term fetuses. A weakness of this study is lack of hypothesis testing related to the specific agents under study. It is not clear why the authors chose to present gestational body weight data as opposed to body weight gain data. Gestational body weights were not affected at any dose of *d*-methylphenidate, but gestational body weight gains were significantly decreased in the 6 and 20 mg/kg bw/day *d*-methylphenidate groups over the entire dosing period (GD 7–18). There appears to be an error in Table 3 of the study. “Dams with viable fetuses” is listed as 100% in the *d,l*-methylphenidate group, although the authors list 22 of 23 litters here. Aside from clinical observations, there were no other signs of maternal toxicity seen in the rabbit developmental toxicity study. The authors selected the *d*-methylphenidate high-dose (100 mg/kg bw/day) based on a probe study that found no effects at 50 mg/kg bw/day and excessive toxicity at 300 mg/kg bw/day. Higher doses in the rabbit study could have increased the exposure margin between the rabbit study and maximum therapeutic human dose AUC, which is currently 1.7×.

**Utility (Adequacy) for CERHR Evaluation Process:** The studies are adequate for the CERHR process. Gavage dosing is comparable to human oral dosing. The comparison to human doses based on AUC is valuable.

### **3.2.2 Postnatal development and behavior**

**Pizzi et al. (161)**, support not indicated, evaluated growth in hooded rat pups [**strain not otherwise indicated**] after treatment with methylphenidate 35 mg/kg bw sc twice/day on PND 5–24. Control littermates received injections of saline. Litters were standardized on PND 1 to 8 pups with a preference for males. In the first experiment, 12 males from each treatment group were killed on PND 25. Body weight and length, femur length, and weights of thyroid, pituitary, testes, adrenals, and brain were significantly reduced in the group that had been treated with methylphenidate. Body weight in the methylphenidate-treated animals was 78% that of the controls, and organ weights in the methylphenidate-treated animals ranged from 59 to 93% of corresponding control organ weights. At least 16 control animals and at least 14 animals from the

methylphenidate group were killed or died between PND 458 and 537 **[the text does not say exactly how many animals were involved and implies that a different number contributed data to each of the measurements]**. Body weight, femur length, and organ weights did not differ between the two groups of adults. In a second experiment, treatments were the same as in the first experiment. Animals (14–16/group) were killed at 25 or 35 days of age, and body weight, femur length, and weights of brain and pituitary were measured. The 25-day-old animals had similar degrees of methylphenidate-associated growth impairment as in the first experiment. At 35 days, there were no differences between the groups. The authors concluded that catch-up growth after high-dose methylphenidate treatment in juvenile animals is rapid and complete.

**Pizzi et al. (162)** further examined the effects of methylphenidate on growth of hooded rats **[strain not otherwise indicated]** in a series of studies funded by a grant from the Northeastern Illinois University Committee on Organized Research. The first study attempted to replicate the findings of the Pizzi et al. (161) study addressed above. Female rats were sc injected with saline or 35 mg/kg bw/day methylphenidate (half the dose of the previous study) on PND 5–24 and evaluated for growth on PND 25 and 55 (n = 12–15/group/time period). As was noted in the previous study in male rats, methylphenidate treatment significantly reduced body weight, femur length, and pituitary weight in PND-25 females. In contrast to the findings in male rats, brain weight was not affected. In methylphenidate-treated animals, body weight was 90.5% and femur length was 95% of control values. A rebound in growth occurred following treatment, as no significant differences in femur length or body, pituitary, or brain weight were observed in PND-55 females. In the second experiment, neonatal male rats received saline or methylphenidate 100 mg/kg bw twice daily sc for 10 days beginning on PND 5. Dosing was stopped at that time due to a 67% mortality rate in treated animals. During evaluation at PND 529–537 (n = 14–16/group), it was found that methylphenidate had no effect on femur length or weights of thyroid, pituitary, testes, adrenals, or brain. In the third experiment, peri-adolescent males and females were sc injected on PND 35–54 with methylphenidate 35 mg/kg bw/day, a dose that induced stereotypy. Twelve animals/sex/group were evaluated on PND 55. Body weight was said to be reduced in males **[90% of control values]** but not females. Methylphenidate treatment did not significantly affect femur length or weights of pituitary, cerebrum, or cerebellum in either sex on PND 55, demonstrating a growth rebound in males. Body weights were again measured in 12–17 animals/sex/group on PND 85 and found to not be affected by methylphenidate treatment. The study authors concluded that reversible growth impairment occurs with methylphenidate treatment of neonatal rats, but that no growth impairment occurs with treatment of peri-adolescent rats. **[Reduced body weight in peri-adolescent males is not considered in the conclusion made about growth in peri-adolescents. However, the Expert Panel notes that linear growth is a better index of growth than BMI]**

**Strengths/Weaknesses:** Strengths included examination of the appropriate developmental period for childhood therapeutic use and availability of multiple measures of growth. The group sizes are adequate, although the numbers of animals used for some measures is unclear. Weaknesses included no identification of enantiomer, split-litter design with vehicle controls, and no reporting of feed intake or maturational indices. In addition, simple organ weights were used as endpoints. The lack of dose-response information is a weakness.

**Utility (Adequacy) for CERHR Evaluation Process:** The studies can be used for understanding potential growth effects of childhood therapeutic use. However, potential litter effects need to be taken into account. The lack of dose-response data together with growth retardation and some lethality limits the utility of these studies, although the work generally supports the idea that there is recovery later in life from early life effects of treatment.

**Greeley and Kizer (163)**, in a series of six experiments supported by the NIMH, examined the effects of methylphenidate HCL [**chirality not specified but assumed to be *d,l*-**] on growth and endocrine function in developing Sprague-Dawley rats. Detailed descriptions of the protocols and results for each experiment are summarized in Table 31, while major findings and author conclusions are discussed in this paragraph. Repeated dosing with high levels of methylphenidate ( $\geq 35$  mg/kg bw twice daily) was found to inhibit body weight gain and skeletal growth in neonatal (5–7-day-old) and weanling rats (18–21-day-old), but the effect did not persist 12 months after treatment ended. Data obtained in pair-fed weanling control rats suggested that the inhibition in growth was due to decreased feed consumption at 35 mg/kg bw, whereas this explanation did not entirely account for decreased naso-anal length seen at 100 mg/kg. The study authors concluded that inhibition of growth was not likely related to effects on growth hormone since repeated dosing with methylphenidate reduced growth hormone levels only in female rats [**not dose-related**], where as inhibited growth was observed in both sexes. The acute dosing data demonstrating reductions in growth hormone levels in males were discounted by study authors because they did not reflect temporal fluctuations. Repeated dosing with  $\geq 35$  mg/kg bw methylphenidate twice daily resulted in reduced basal serum insulin levels, enhanced response to a glucose load 20 minutes following challenge, and then return to baseline insulin levels, which remained lower than control levels. Serum prolactin levels were consistently decreased in males and females treated with  $\geq 3$  mg/kg bw twice daily [**no dose-response relationship was evident**]. Twice daily treatment of neonates with  $\geq 35$  mg/kg bw delayed vaginal opening [**body weights not shown for females**] and reduced the number of estrous cycles following treatment. Mean  $\pm$  SEM day of vaginal opening ( $38.2 \pm 2.3$ ) was similar when methylphenidate treatment was started at 21 days of age as when methylphenidate was started at 5–7 days of age, but there was no longer a significant difference from the control value and the numbers of estrous cycles were reduced only during treatment. Because effects on gonadotropin levels were inconsistent, the study authors concluded that they were not likely related to effects on puberty and estrous cycling. Estrous cycle effects are also discussed in Section 4.2.

**Strengths/Weaknesses:** Strengths include use of multiple doses and appropriate age dosing for comparison with human childhood therapeutic use. The study provides data on estrous cycling in addition to vaginal patency. The availability of extensive dose-response data is a strength. A weakness is that body weights were not reported at vaginal opening. Because variability indices were not reported, it is not clear if the study had sufficient power to detect hormone changes. Some group sizes were small (5 or 6) or not specified, and it is not known whether sample sizes represent multiple samples per litter, which can inflate the Type I error rate.

**Utility (Adequacy) for CERHR Evaluation Process:** The study can be used for assessing delayed puberty effect; however, the use of the extensive hormone data is hampered by a lack of dose-related effects. Confidence in the data is reduced due to small sample sizes and the inability to link sample sizes to number of litters.

**Table 31. Postnatal Methylphenidate Treatment Studies in Rats**

Methylphenidate administration	Parameters examined	Results
0, 1, 3, 10, 35, or 100 mg/kg bw, sc, twice daily for 21 days in 5–7-day-old males and females (n not specified). Blood was collected for serum hormone measurements 24 hours following the last treatment (n = 5–16).	Body weight during treatment <b>[data only shown for males]</b>	↓ at ≥35 mg/kg bw
	Body weight 1 year after treatment	↔ <b>[Data not shown]</b>
	Naso-anal length during treatment <b>[data only shown for males]</b>	↓ at ≥35 mg/kg bw
	Naso-anal length 1 year after treatment	↔ <b>[Data not shown]</b>
	LH	↓ at ≥1 mg/kg bw (M) and at 3 and 10 mg/kg bw (F)
	FSH	↓ at ≥10 mg/kg bw (M)
	Prolactin	↓ at ≥3 mg/kg bw (M and F)
0, 0 (pair-fed), 35, or 100 mg/kg bw, sc, twice daily for 18 days in 18–21-day-old males (n not specified).	Growth hormone	↑ at 1 mg/kg bw (F) and ↓ at 3, 10, and 100 mg/kg bw (F)
	Body weight during treatment	↓ at ≥35 mg/kg bw similar to pair-fed controls
	Naso-anal length during treatment	↓ at ≥35 mg/kg bw similar to pair-fed controls ↓ at 100 mg/kg bw compared to both controls
0, 35, or 100 mg/kg bw, sc twice daily for 21 days in 5–7-day-old females (n = 5–11/group).	Age at vaginal patency	↑ by 3.6 days at 35 mg/kg bw and 4.7 days at 100 mg/kg bw
	Number of estrous cycles after treatment ended	↓ by 2 cycles at 35 mg/kg bw and 4.4 cycles at 100 mg/kg bw
0 or 35 mg/kg bw, sc, twice daily for 30 days in 21–23-day-old females (n = 9/group).	Age at vaginal patency	↔ <b>[Although the mean day of vaginal opening was similar to the value obtained with treatment initiation at 5–7 days.]</b>
	Number of estrous cycles during treatment	↓ by 3.1 cycles
	Number of estrous cycles after treatment ended	↔
	LH	↑ at 100 mg/kg bw
0, 1, 3, 10, 35, or 100 mg/kg bw, sc, twice daily for 21 days to 5–7 day-old males. LH-RH (20 ng) challenge given by iv 24 hours later and blood collected for serum LH measurement (n = 6/group).	LH	↓ at 35 mg/kg bw (10 min) and 100 m/kg bw (10 min and 1 hr)
	FSH	↓ at ≥35 mg/kg bw (10 min)
	Growth hormone	↓ at ≥35 mg/kg bw (most time points) but ↑ at 16–18 hr.
Single dose of 0, 35, or 100 mg/kg bw, ip, to 25–27-day-old males. Blood collected for serum hormone measurements over period of 10 minutes to 7 days (n not specified).	LH	↓ at ≥35 mg/kg bw (before and 10 and 60 minutes after glucose load)
	Insulin	↑ at 3 and 100 mg/kg bw (20 minutes after glucose load)

↑ = statistically significant increase, ↓ = statistically significant decrease, ↔ = no effect, M = males, F = females. From Greeley and Kizer (163).

**Teo et al. (49)**, from Celgene Corporation, treated pregnant Sprague-Dawley rats with *d*-methylphenidate (purity 98–102%) or *d,l*-methylphenidate (chiral purity 50:50) given orally in 2 daily doses 6 hours apart. **[The route (oral) is indicated only in the Discussion section; another paper by these authors (48) used gavage treatment and the Expert Panel assumes gavage treatment for this study as well.]** In a dose range-finding study, doses of *d*-methylphenidate were 2, 20, and 100 mg/kg bw/day and doses of *d,l*-methylphenidate were 4, 40, and 200 mg/kg bw/day. A control group was treated with the sterile water vehicle. There were 8 rats in each dose group, half of which were treated on GD 7–17 (plug = GD 0) and scheduled for cesarean section on GD 20 and half of which were treated on GD 7–PND 6, permitted to litter, and followed during the lactation period. The top two doses of each methylphenidate preparation produced clinical signs of toxicity in the dams that continued into the lactation period. There were reductions in body weight gain in all groups except the control and the 2 mg/kg bw/day *d*-methylphenidate groups. Adverse affects on pup body weight were identified at 100 mg/kg bw/day *d*-methylphenidate in the litters delivered by cesarean section, and at 100 mg/kg bw/day *d*-methylphenidate and 40 mg/kg bw/day *d,l*-methylphenidate in the litters delivered naturally. **[There was insufficient detail in the reporting of the dose range-finding study to evaluate other outcome parameters or to determine LOAEL, NOAEL, or benchmark dose.]**

In the main study, 25 pregnant rats/dose group were given *d*-methylphenidate at 0, 2, 6, or 20 mg/kg bw/day or *d,l*-methylphenidate 40 mg/kg bw/day. Animals were given these doses in 2 equal treatments **[presumed gavage]** separated by 6 hours on GD 7–PND 20 (plug = GD 0, birth = PND 1). Pups were weaned on PND 21 and 25 male and female offspring per dose group were followed as the F<sub>1</sub> generation, using at least 1 pup/sex/litter where possible. The rest of the offspring were killed and necropsied. The F<sub>1</sub> animals were evaluated using a passive-avoidance test (beginning on PND 23) and a water-filled M-maze (on PND 70). Females were evaluated for vaginal patency beginning on PND 28 and males were evaluated for preputial separation beginning on PND 39. At approximately 90 days of age, one F<sub>1</sub> male and female/litter were cohabited for 21 days after which males were killed and necropsied. Females were killed and necropsied on GD 20. Data were analyzed using ANOVA with post-hoc Dunnett test or Kruskal-Wallis with Dunn test, depending on homogeneity of variance.

Clinical signs (hyperactivity and aggression) were noted in the F<sub>0</sub> dams given 6 mg/kg bw/day *d*-methylphenidate. Additional clinical signs were noted at 20 mg/kg bw/day *d*-methylphenidate and at 40 mg/kg bw/day *d,l*-methylphenidate. **[Clinical signs were evaluated by CERHR using the benchmark dose<sup>2</sup> approach. The most sensitive sign in presumed pregnant rats was hyperactivity with a BMD<sub>10</sub> of 3.9 mg/kg bw/day and a BMDL of 3.6 mg/kg bw/day. In lactating rats, the most sensitive sign was repetitive sniffing with a BMD<sub>10</sub> of 3.4 mg/kg bw/day and a BMDL of 3.2 mg/kg bw/day.]** There was a higher incidence of clinical signs at 40 mg/kg bw/day *d,l*-methylphenidate than 20 mg/kg bw/day *d*-methylphenidate, although the amount of the active enantiomer (*d*-methylphenidate) was identical in both treatments. Maternal body weight gain and feed consumption (absolute and relative) were reduced to a similar degree by 20 mg/kg bw/day *d*-methylphenidate and 40 mg/kg bw/day *d,l*-methylphenidate, with no significant effect by pairwise comparison at 2 or 6 mg/kg bw/day *d*-methylphenidate **[Evaluation**

---

<sup>2</sup> The BMD<sub>10</sub> is the benchmark dose associated with a 10% effect, estimated from a curve fit to the experimental data. The BMDL represents the dose associated with the lower 95% confidence interval around this estimate. Benchmark doses are used commonly in a regulatory setting; however, they are used in this report when the underlying data permit their calculation, and are only supplied to provide one kind of description of the dose-response relationship in the underlying study. Calculation of a benchmark dose in this report does not mean that regulation based on the underlying data is recommended, or even that the underlying data are suitable for regulatory decision-making.

**by CERHR of the decrease in feed consumption from GD 7–20 using the benchmark dose approach gave a BMD<sub>10</sub> of 23 mg/kg bw/day and a BMDL of 19 mg/kg bw/day. The F<sub>0</sub> weight data were not provided in a form suitable for benchmark dose calculation.]**

Duration of gestation was significantly prolonged by about 0.5 days in the groups given *d*-methylphenidate 20 mg/kg bw/day and *d,l*-methylphenidate 40 mg/kg bw/day. There were no treatment-related effects on number of live or stillborn pups, pup survival during the lactation period, or pup weight at birth or during the lactation period. There were no notable findings in pups necropsied on PND 21. Body weight and feed consumption in the F<sub>1</sub> males in the *d,l*-methylphenidate 40 mg/kg bw/day group were decreased for several individual weeks and overall in the PND 1–71 time period. There was no effect on body weight or feed consumption for any of the doses of *d*-methylphenidate and female F<sub>1</sub> body weight was not affected by any of the treatments during PND 1–71. There were no treatment-related effects on day of preputial separation or vaginal patency, and no effects on passive-avoidance test or water-filled M-maze performance [**data were not shown**]. Terminal body weights were decreased in F<sub>1</sub> males in the *d*-methylphenidate 20 mg/kg bw/day and *d,l*-methylphenidate 40 mg/kg bw/day groups. Relative weight of the testis was increased in the *d,l*-methylphenidate 40 mg/kg bw/day group, but not in any of the *d*-methylphenidate groups. Mating of the F<sub>1</sub> animals showed no treatment-related effects on number of pregnant animals, corpora lutea, or implantations, and no alterations in live or dead fetuses/litter, resorptions, sex ratio, or fetal weight.

The authors estimated from AUC values that the top dose of *d*-methylphenidate used in this study was 5.6 times the human therapeutic dose. The decrease in weight in F<sub>1</sub> males was evaluated as consistent with the decrease in feed consumption, although no explanation could be given for the lack of effect in females. *d*-Methylphenidate at this dose was considered not to have adverse effects on reproductive parameters after exposure during pregnancy and lactation.

**Strengths/Weaknesses:** A strength of this study was that it was conducted according to the FIFRA style. Sample sizes were adequate in both the dose-range finding study and the main study. The oral route is a strength because it is relevant to human exposure, although it limits comparison to other studies. A weakness is that it is unclear if individual data were available and if GLP quality assurance was used. No data were shown for behavioral assessments, puberty measures, estrous cycles, or sperm. More detail is needed on the F<sub>1</sub> mating protocols to be sure they were of sufficient sensitivity to detect adverse effects. Very few neurological examinations were conducted and for those examinations performed (passive-avoidance, water maze), no data were provided.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is valuable for assessing fertility after developmental exposure.

**McDougall et al. (164)**, in a study partially supported by an ASI research grant, examined behavioral sensitization associated with methylphenidate treatment in developing rats. A series of studies was conducted in which Sprague-Dawley rats were ip injected with methylphenidate [**purity not specified**] or saline during pretreatment periods on PND 16–20 or PND 10–14. During the pretreatment period, the frequency of line crosses (a measure of horizontal locomotor activity) and stereotyped sniffing was assessed for 40 minutes, 5 minutes after the rats were injected. Following 1 or 7 abstinence days, sensitization of locomotor activity and stereotyped sniffing was assessed in rats receiving a challenge dose of methylphenidate or saline. Five minutes after receiving the challenge dose, rats were observed for 40 minutes. An increase in line crosses or sniffing in rats pretreated and challenged with methylphenidate compared to rats pretreated with saline and challenged with methylphenidate was considered to be a sensitization

response. Data were analyzed by ANOVA and Student *t*-test or Tukey test. A summary of pretreatment and challenge doses, days of treatment, and sensitization results for the three main experiments is listed in Table 32. Treatment groups consisted of 7–8 rats from different litters, with approximately equal numbers of males and females.

During pretreatment periods, it was found that methylphenidate caused dose-dependent increases in line crosses and stereotyped sniffing. During the pretreatment period, potency of doses for inducing line crossing was 5 > 10 > 20 > 2.5 mg/kg bw/day, with statistical significance obtained at 5 and 10 mg/kg bw/day. Potency of doses for inducing stereotyped sniffing during the pretreatment period was 20 > 10 > 5 > 2 mg/kg bw/day, with statistical significance obtained at the top two doses. The study authors stated that locomotor response was sensitized in rats pretreated with 2.5–20 mg/kg bw/day methylphenidate and challenged with 2.5 mg/kg bw methylphenidate. Numerous pretreatment and challenge doses induced sensitization of stereotyped sniffing in both age groups following a 1-day abstinence period. Following a 7-day abstinence, the authors stated that sensitization remained only in rats pretreated with the 20 mg/kg bw/day dose. **[However, it appears that sensitization also occurred in rats pretreated with 10 mg/kg bw/day and challenged with 2.5 mg/kg bw methylphenidate (see Table 32).]** The study authors concluded that methylphenidate treatment produces sensitization in young rats, but that the sensitization decreases over time, by contrast with adult rats in which sensitization may persist for months. The authors interpreted this lack of long-term sensitization in young rats as a prediction that methylphenidate in children will not increase the likelihood of stimulant abuse.

**Table 32. Sensitization Responses in Rats Treated with Methylphenidate**

Pretreatment		Challenge		Sensitization response <sup>a</sup>	
Dose (mg/kg bw/day)	PND	Dose (mg/kg bw)	Test Day (PND)	Line crosses	Stereotyped sniffing
2.5	16–20	2.5	22	↑	↔
5.0		5.0		↔	↑
10		10		↓	↑
20		20		↓	↑
2.5	16–20	2.5	28	↔	↔
5.0		5.0		↔	↔
10		10		↔	↔
20		20		↓	↑
2.5		2.5	22	↔	↔
5.0				↑	↔
10.0				↑	↑
20.0				↑	↑
2.5	10–14		28	↔	↔
5.0				↔	↔
10.0				↔	↑
20.0				↔	↑
20		2.5	16	↔	↑
		20		↔	↑
		2.5	22	↔	↔
		20		↔	↑

<sup>a</sup>Change following challenge in methylphenidate pretreatment group compared to corresponding saline pretreatment group. ↑, ↓, ↔ statistically significant increase, decrease, no effect  
From McDougall et al. (164).

**Strengths/Weaknesses:** A strength of this study is the multiple-dose and litter-based design. Group sizes were adequate, with internal replication between experiments. Testing for sensitization using challenge doses is a strength. A weakness is that conclusions regarding age-dependent effects (adult vs juvenile) may not be valid, as no adult data were presented. Conclusions regarding addiction potential also need supporting data. It is unclear if treated animals were growth retarded and maturation was delayed, an important consideration because immature rats have distinct developmental activity profiles. It is a weakness that the statistical design collapsed males and females without correction for repeated samples from a litter, and that there was no mention of masking of the subjective behavioral assessment to treatment status. The very short neonatal exposure period limits the applicability of the data.

**Utility (Adequacy) for CERHR Evaluation Process:** The study has adequate design and reporting, but interpretation for use in the evaluation process is not straightforward.

**Brandon et al. (165)**, in a study supported by the National Institute on Drug Abuse, evaluated the adult effects of the treatment of adolescent Sprague-Dawley rats with methylphenidate. Five-week-old animals (12 per treatment group [**sex not specified**]) were treated with methylphenidate HCl [**purity not specified**] 10 mg/kg bw/day or saline ip for 7 days. The animals were challenged as 8-week-old adults with cocaine 7.5 mg/kg bw ip following which they were evaluated for activity (ambulation and rearing) in a rodent cage fitted with photocells. The experiment was repeated using a 5 mg/kg bw/day dose of methylphenidate HCl and a 15-mg/kg bw cocaine challenge, and using a 2 mg/kg bw/day dose of methylphenidate HCl and a range of cocaine challenges (3.75–30 mg/kg bw). Adolescent treatment with 5 or 10 mg/kg bw/day methylphenidate caused a significant increase in locomotor activity in response to cocaine; however, 2 mg/kg bw/day methylphenidate treatment during adolescence was not different from saline in sensitizing the animals to the subsequent cocaine challenge as adults. The 2 mg/kg bw/day adolescent treatment, however, sensitized the animals as adults trained to poke their noses in a hole to receive a 75 µg/kg bw infusion of cocaine. Adult animals pretreated as adolescents with methylphenidate demonstrated a larger number of nose-pokes and self-administered a larger amount of cocaine than did adult animals pretreated as adolescents with saline. Based on a cited study, the authors stated that the 2 mg/kg bw/day methylphenidate dose approximated therapeutic exposures in children based on plasma concentration. The sensitization in adolescence to the self-administration of low doses of cocaine in adult life was interpreted as consistent with “alterations in brain substances mediating the increased incentive value of low reinforcers...our results also suggest that adolescent exposure to [methylphenidate] may potentially increase future vulnerability to low doses of cocaine.” A long-lasting reduction in synthesis of the dopamine transporter in the prefrontal cortex and nucleus accumbens was postulated as a mechanism of this sensitization effect.

**Strengths/Weaknesses:** Strengths of this study include use of multiple doses and appropriate ages at dosing. Weaknesses include no reporting of gender or growth and maturation endpoints. It is unclear if baseline activity (prior to challenges) was evaluated. It is also unclear if a litter-based design was used, which is important even if the dam was not treated. The short dosing duration and the ip dosing limit the applicability of the data.

**Utility (Adequacy) for CERHR Evaluation Process:** The study is potentially useful in addressing addiction potential. However, the incomplete data reporting, the short dosing duration, and the late onset of dosing detract from the utility of this study in the evaluation process.



### 3.2.3 Postnatal neurochemical effects

**Wagner et al. (166)**, supported by US Public Health Service (PHS), treated neonatal Sprague-Dawley rats with two daily sc doses of methamphetamine hydrochloride, *d*-amphetamine sulfate, or methylphenidate. The total dose of each stimulant was 12.5, 25, or 50 mg/kg bw/day. A control group was given injections of the saline vehicle. Neonates were treated from PND 10–40, and were raised in litters of 10 that were constructed from pooled and redistributed PND 3 pups (without regard to sex). At least two litters were used per treatment group. Pups were killed 2 weeks after the last treatment and brains were dissected to provide samples of caudate, midbrain, hypothalamus, pons-medulla, and telencephalon. Dopamine concentration was determined in caudate samples using HPLC, and norepinephrine concentrations were determined in other regions using alumina adsorptions with spectrofluorometric analysis. Statistical comparisons were made using one-way ANOVA. Caudate dopamine was reduced by *d*-amphetamine 50 mg/kg bw/day and by methamphetamine 25 and 50 mg/kg bw/day. There were no alterations associated with methylphenidate treatment. The authors concluded that the lack of alteration in catecholamine levels was consistent with findings in the brains of adult rats and monkeys after methylphenidate treatment.

**Strengths/Weaknesses:** Strengths of this study include appropriate ages of animals at treatment and avoidance of a split-litter design. The randomized postnatal pup distribution minimized genetic litter effects. Weaknesses are that no growth or maturation parameters were stated, methods for measuring norepinephrine may not have been sensitive, and no information was provided on dopamine or norepinephrine turnover. The hypothesis being tested was unclear. There were only two litters per treatment and an unknown number of samples per litter (the reported degrees-of-freedom (93,24) suggest up to 4 samples per litter). The failure to specify the statistical design is a weakness. The number of significant changes is 3 of 66, which is less than predicted by a Type I error probability of 0.05.

**Utility (Adequacy) for CERHR Evaluation Process:** This statistical problems of this study limit its utility for the evaluation process.

**Brandon et al. (167)**, in a study supported by the National Institute on Drug Abuse, examined midbrain dopamine neuron activity in adolescent rats treated with methylphenidate. Five-week-old male Sprague-Dawley rats were randomly assigned to groups that received saline or 2.0 mg/kg bw/day methylphenidate [**purity not specified**] by ip injection for 7 days. [**The number of rats treated was not specified.**] Extracellular single-unit recordings were taken in anesthetized rats 1–3 days or 14–21 days following dosing to evaluate activity of dopamine neurons in the ventral tegmental area. Statistical significance of results was analyzed by Student *t*-test. Methylphenidate treatment resulted in a significantly increased dopamine neuronal firing rate, an increased trend for percent spikes emitted as bursts, and significant increases in burst frequency and spikes per burst during the 1–3 day withdrawal period. During the 14–21 day withdrawal period, methylphenidate-treated rats displayed attenuated dopamine neuronal activity, as indicated by reduced firing rate and increased interspike interval. Autoreceptor-mediated inhibition of firing, as measured by response to the dopamine receptor agonist quinpirole, was equivalent in saline- and methylphenidate-treated rats during both time periods. The study authors concluded “Adolescent exposure to methylphenidate induces neuronal changes associated with increased addiction liability in rats.”

**Strengths/Weaknesses:** Strengths include the large sample size and an adequate experimental design for the hypothesis being tested; however, the basis for dose selection is unclear. More detail on methodology would have been helpful. The use of the ip route and cumulative dosing in naïve rats make comparison to human exposures difficult.

**Utility (Adequacy) for CERHR Evaluation Process:** The unique experimental methods and short-duration exposure limit the utility of these data for the evaluation process.

**Kuczenski and Segal (168)**, supported by PHS, the Veterans Administration, and the University of California, administered methylphenidate to adolescent male Sprague-Dawley rats by gavage. Animals were obtained at 28 days of age and habituated to the laboratory environment for 10 days. They began gavage treatment with saline at 38 days of age and treatment with methylphenidate at 41 days of age. Animals had guide cannulas placed stereotactically in the dorsal hippocampus and nucleus accumbens. One day before experimentation, dialysis probes were placed through the cannulas to permit acclimation. **[Animals were used for assessments of locomotor activity as well as brain neurochemistry and it is not possible to tell whether the same animals were used for both endpoints, or the ages at which guide cannulas were placed and neurochemistry experiments performed.]** Acute doses of 1.0, 2.5, or 5.0 mg/kg bw methylphenidate were given by gavage. The 1.0 and 2.5 mg/kg bw doses were selected to produce blood levels similar to those obtained clinically, and the 5.0 mg/kg bw dose was estimated to produce blood levels higher than those achieved clinically **[blood levels were not measured, but were estimated based on previous work in rats. Clinical blood levels were considered to be 8–40 ng/mL]**. There were 6–10 animals/treatment group, tested during the dark phase of a reverse dark-light cycle. Hippocampus norepinephrine concentration was increased by all doses of methylphenidate, peaking 40 minutes after the treatment (samples were collected every 20 minutes). Peak hippocampus norepinephrine concentration after the 5.0 mg/kg bw dose was about 20 nM compared to a baseline concentration of about 5 nM **[estimated from a graph]**. Nucleus accumbens dopamine was increased only after the 5.0 mg/kg bw dose, peaking 60 minutes after treatment at about 22 nM compared to a baseline value of about 16 nM **[estimated from a graph]**. Total activity (estimated from videotaping of animals over 9 hours) decreased when methylphenidate was given at 0.75, 1.0, 2.5, or 3.0 mg/kg bw/dose every 3 hours for 3 doses. The authors concluded that there was an association between the increase in hippocampal norepinephrine and decrease in locomotor activity, based on these endpoints occurring in the same dose range, but that a role for dopamine in the nucleus accumbens could not be documented.

**Strengths/Weaknesses:** A strength of this study is use of multiple doses and experimental procedures that were adequate for the hypotheses being tested. Group sizes were adequate and there was statistical control for multiple comparisons. The dose regimen was chosen with consideration of species differences in pharmacokinetics. A weakness is that dosing was late for evaluation of adolescence. Gender was not stated and growth was not evaluated. It is unclear if the association between neurotransmitters and behavior was evaluated statistically.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is adequate for the evaluation process; however, the lack of dose-related effects of methylphenidate alone on behavior coupled with the use of either acute or repeated exposure to young adult rats limits the usefulness of these data.

### **3.2.4 Unpublished studies**

Information for additional studies that were apparently not published was presented in drug labels for methylphenidate. Although the lack of study reports does not allow review by the Expert Panel, the information is presented below for completeness.

Dosing of rats with 45 mg/kg bw/day methylphenidate (4 times the maximum recommended human dose based on surface area) throughout pregnancy and lactation resulted in reduced

offspring body weight gain, but no other postnatal developmental effects; the no effect level for pre- and postnatal development was identified as 15 mg/kg bw/day, a value equal to the maximum recommended human dose on a mg/m<sup>2</sup> basis (10).

Increased fetal skeletal variations were observed, but there was no evidence of specific teratogenic activity following oral dosing of rats with 75 mg/kg bw/day methylphenidate during organogenesis; maternal toxicity was observed at that dose, which is 7 times the maximum recommended human dose on a mg/m<sup>2</sup> basis (10). The no effect level for embryo-fetal development was identified as 25 mg/kg bw/day, 2 times the maximum recommended human dose on a mg/m<sup>2</sup> basis.

Decreased postnatal pup weight gain and survival and maternal toxicity were observed in a reproductive study where rats were orally dosed with 58 mg/kg bw/day methylphenidate throughout gestation and lactation; the dose was 30 times and 6 times the maximum recommended human dose on a mg/kg bw and mg/m<sup>2</sup> basis, respectively (5).

In a study where 7-day-old rats were orally administered methylphenidate for 9 weeks, neurobehavioral assessment during adulthood revealed decreased spontaneous locomotor activity in males and females of the 50 mg/kg bw/day group (6 times the maximum recommended human dose based on mg/m<sup>2</sup>) and deficient acquisition of a learning task in females of the 100 mg/kg bw/day group (12 times the maximum recommended human dose on a mg/m<sup>2</sup> basis (10). The no effect level for juvenile neurobehavioral development was identified at 5 mg/kg bw/day, half the maximum recommended human dose on a mg/m<sup>2</sup> basis.

Spina bifida incidence was increased in fetuses of rabbits orally dosed during organogenesis with 200 mg/kg bw/day racemic methylphenidate, 40 and 100 times the human MRHD on a mg/m<sup>2</sup> and mg/kg bw basis, respectively (7, 10). The no effect level for embryo-fetal development was identified at 60 mg/kg bw/day, 11 times the maximum recommended human dose based on surface area.

**[The Expert Panel notes that descriptions in secondary sources such as product labels do not contain sufficient detail to contribute to the evaluation process.]**

### 3.3 Utility of Developmental Toxicity Data

Human data are not sufficient to evaluate developmental toxicity following prenatal exposure to methylphenidate. Human data on childhood exposure to methylphenidate are sufficient for evaluating effects on heart rate, blood pressure, tics, and risks of developing substance abuse disorders. There are insufficient data to determine the effects of childhood methylphenidate exposure on seizures and psychotic symptoms.

The database is sufficient to evaluate the effects of prenatal methylphenidate exposure in rats and rabbits. A rat and rabbit study by Teo et al. (48) included an assessment of prenatal mortality and external, visceral, and skeletal malformations. Data are sufficient to evaluate postnatal growth and survival following prenatal and lactational exposure of rats to methylphenidate (49). There was one multiple-dose study examining growth in immature animals exposed to methylphenidate (163), but the drug was administered by the sc route, which is not relevant to human therapeutic exposure. There are insufficient data for evaluating developmental neurotoxicity in animals.

### 3.4 Summary of Developmental Toxicity Data

#### 3.4.1 Human Data

No conclusions could be drawn from two human studies of methylphenidate exposure during pregnancy (70, 71) due to study design limitations such as lack of a comparison group, no control of confounding factors, multiple exposures to other drugs, and/or inadequate analyses that grouped methylphenidate data with data for other drugs.

Nine controlled studies examining side effects in children were identified (72-80). Side effects observed more often in the methylphenidate group compared to the placebo group in at least three of the studies (number of studies reporting effects) included appetite problems (6), stomachache (4), insomnia (4), crying (3), and headache (3). Side effects that were reported in only one of the studies included drowsiness, increased blood pressure (discussed below), irritability, anxiety, high activity, dizziness, nail biting, and withdrawal. Some authors noted that certain side effects may actually be related to ADHD. One study that evaluated clinical chemistry and hematology parameters in methylphenidate-treated children for up to 48 months reported no adverse effects (82).

Studies examining the acute effects of therapeutic methylphenidate doses on growth hormone levels reported increases in growth hormone levels that returned to baseline levels following dosing (36, 83), an effect that also occurs in adults (84). An acute decrease in prolactin was also reported following methylphenidate dosing (36). Diurnal concentrations of growth hormone and prolactin were measured in subjects receiving methylphenidate therapy (20–120 mg/day) for 3 months to 4 years, while they were on therapy, and during an 11-day to 10-week abstinence period (85). During periods with and without methylphenidate treatment, patterns of diurnal growth hormone and prolactin release were similar with normal fluctuations throughout the day and peak hormone release during sleep. One study demonstrated standard growth hormone provocation curves in children treated with *d*-amphetamine prior to methylphenidate treatment (83). However, after 6–8 months therapy with 5–35 mg/day methylphenidate, there were “tendencies” for delayed growth hormone response to acute *d*-amphetamine treatment consisting of an initial fall in concentration, with or without a subsequent rise. In a study comparing growth hormone responses to a clonidine challenge in children before and after a minimum of 3 months treatment with  $\geq 0.3$  mg/kg bw/day methylphenidate, methylphenidate treatment was found to inhibit clonidine-induced increase in growth hormone levels (86).

A number of controlled studies evaluated cardiovascular effects in children treated with methylphenidate or placebo over a period of 1 week or more. The time period between dosing and testing was not clear in many studies. Four studies reported increased heart rate (3–16 beats per minute) (87, 89, 90, 92), while no increases in heart rate were reported in two other studies (88, 91). Three studies reported blood pressure effects including an increase in systolic (6.2 mm Hg) and mean arterial blood pressure (4.4 mm Hg) (90) and an increase in diastolic blood pressure (1.9–14 mm Hg) (87, 92); no increases in blood pressure were reported in three other studies (88, 92). A dose-response comparison of these studies is not possible because units of dosing (e.g. mg/day vs. mg/kg bw/day) were not consistent between studies. However, two studies provided some information on possible dose-response relationships. In the Ballard et al. study (90), increases in heart rate and blood pressure were correlated with weight-adjusted dose, which ranged from 0.13–0.89 mg/kg bw. Children in the Brown and Sexson study (92) received twice daily doses of 0.15, 0.3, or 0.5 mg/kg bw; increased heart rate [by CERHR analysis] was noted at  $\geq 0.3$  mg/kg bw and increased blood pressure at 0.5 mg/kg bw.

Possible effects of stimulant medications on seizures were evaluated in three studies. In a study where 40 children with “minimal brain dysfunction” received placebo or 20–40 mg/day methylphenidate for 6 weeks, 11 children had abnormal EEGs prior to drug treatment and methylphenidate therapy did not increase the frequency of abnormal EEGs (87).

Case reports have described the development of psychotic symptoms (e.g., hallucinations, delusions, mania) in children treated with methylphenidate. A retrospective chart review study reported that 9 of 98 children treated with stimulant medications (7 on methylphenidate and 2 on pemoline) developed psychotic symptoms and 2 were later diagnosed with bipolar disorder (101). The Expert Panel is not aware of controlled studies examining relationships between stimulant treatment and psychosis in children.

It has been reported that a large proportion of children with Tourette disorder have comorbid ADHD (reviewed by Leckman (102)). Since the appearance of a 1974 case report describing development of Tourette disorder in a 9-year-old boy treated with methylphenidate (103), a number of papers describing tics or Tourette disorder in association with stimulant therapy were published (Table 26). However, 5 controlled studies with methylphenidate doses up to 0.6 mg/kg bw or 60 mg/day did not demonstrate increased incidence of tic onset or worsening of symptoms compared to placebo or baseline levels (74, 77, 80, 104, 105).

Concerns have been raised that stimulant treatment in childhood can increase the risk for developing substance abuse disorders later in life. Two studies from the same group demonstrated associations between stimulant treatment (69% of subjects treated with methylphenidate) and tobacco or cocaine dependency in adulthood (126, 127#3053); however, the Expert Panel found the studies to be unreliable for drawing conclusions due to limitations such as inadequate correction for severity of ADHD, apparent errors in the reporting of data, and questionable statistical procedures. In studies found to be of better quality for evaluating risks of substance abuse, the type of stimulant treatment was not specified in one study (123) and stimulant therapies in the other studies included methylphenidate in 80% (124) or 100% (128) of subjects. None of the studies found compelling evidence that prolonged treatment of ADHD with stimulants in childhood increased the risk of tobacco or cigarette use in adolescence (123, 124) or alcohol or substance abuse in adolescence (123, 124) or adulthood (124, 128). A study in which children with reading disorders were treated with methylphenidate for 12–18 weeks, a time period much shorter than typical treatment periods for ADHD, also found no increased risk of substance use disorder in adulthood (130). One of the studies found associations between ADHD and/or conduct disorders and substance use (128). Numerous studies examining possible associations between ADHD, independent of treatment, and substance abuse were not considered by the Expert Panel. The Panel notes a review by Wilens (132) that concluded, “There is a robust literature supporting a relationship between ADHD and SUD [**substance use disorders**]. Noncomorbid ADHD appears to confer an intermediate risk factor for SUD, although conduct and bipolar disorder appear to heighten the risk of early onset of SUD. . .”

The effects of methylphenidate on growth of children were evaluated in 20 studies summarized in Table 28 and in the 1992 Multimodal Treatment Study of ADHD (159). Studies reported variable results. However, the weight of evidence suggests that methylphenidate treatment can slow height and weight gain in children, but that rebound growth appears to occur, especially following drug holidays.

### **3.4.2 Experimental Animal Data**

Key studies on methylphenidate experimental animal developmental toxicity are summarized in Table 33. The most useful study for evaluating prenatal endpoints was conducted in rats and

rabbits by Teo et al. (48). These investigators gavaged 25 rats/group with 0, 2, 6, or 20 mg/kg bw/day *d*-methylphenidate or 40 mg/kg bw/day *d,l*-methylphenidate administered in 2 divided doses on GD 7–17. Dams were killed on GD 20 for microdissection of half the litters and skeletal evaluation of the other half. Clinical signs were observed in dams dosed with 6 and 20 mg/kg bw/day *d*-methylphenidate and 40 mg/kg bw/day *d,l*-methylphenidate group, with some signs occurring more often in the 40 mg/kg bw/day *d,l*-methylphenidate group than in the 20 mg/kg bw/day *d*-methylphenidate group. Also noted in the  $\geq 6$  mg/kg bw/day *d*-methylphenidate and 40 mg/kg bw/day *d,l*-methylphenidate groups were reductions in feed intake and body weight gain during treatment. **[CERHR Benchmark dose<sup>3</sup> modeling for maternal weight gain during the treatment period or from the onset of treatment to GD 20 resulted in BMD<sub>10</sub> values of 26–32 mg/kg bw/day and BMDL values of 18–21 mg/kg bw/day.]** There were no treatment-related alterations in corpora lutea or implantations per dam or in litter values for live or dead fetuses, resorptions, sex ratio, fetal body weight, fetal malformations, or variations. Ossification was delayed in the 20 mg/kg bw/day *d*-methylphenidate and 40 mg/kg bw/day *d,l*-methylphenidate groups when analyzed on a per fetus, but not per litter basis. **[CERHR Benchmark dose modeling of *d*-methylphenidate resulted in BMD<sub>10</sub> values in the 31–36 mg/kg bw/day range and BMDL values in the 23–24 mg/kg bw/day range for the various fetal ossification delays.]**

Teo et al. (48) gavaged 20 rabbits/group with 0, 4, 20, or 100 mg/kg bw/day *d*-methylphenidate or 200 mg/kg bw/day *d,l*-methylphenidate administered in 2 divided doses on GD 6–18. Does were killed on GD 29 for microdissection and evaluation of fetuses for skeletal malformations. Clinical signs were observed in does dosed with 100 mg/kg bw/day *d*-methylphenidate and 200 mg/kg bw/day *d,l*-methylphenidate, with some clinical signs occurring more often in the 200 mg/kg bw/day *d,l*-methylphenidate group. There were no adverse effects on mean number of corpora lutea, implantations, live or dead fetuses/litter, resorptions, sex ratio, or fetal alterations at any dose level.

The most useful study for evaluating postnatal endpoints was conducted by Teo et al. (49). These investigators dosed 25 pregnant rats/dose group with *d*-methylphenidate 0, 2, 6, or 20 mg/kg bw/day or *d,l*-methylphenidate 40 mg/kg bw/day, given in 2 divided treatments **[presumed gavage]** on GD 7–PND 20 (plug = GD 0, birth = PND 1). Pups were weaned on PND 21 and 25 male and female offspring per dose group were followed as the F<sub>1</sub> generation, using at least 1 pup/sex/litter where possible. The rest of the offspring were killed and necropsied. Clinical signs (hyperactivity and aggression) were noted in the F<sub>0</sub> dams given 6 mg/kg bw/day *d*-methylphenidate. Additional clinical signs were noted at 20 mg/kg bw/day *d*-methylphenidate and at 40 mg/kg bw/day *d,l*-methylphenidate, with a higher incidence of clinical signs at 40 mg/kg bw/day *d,l*-methylphenidate. Maternal body weight gain and feed consumption (absolute and relative) were reduced to a similar degree by 20 mg/kg bw/day *d*-methylphenidate and 40 mg/kg bw/day *d,l*-methylphenidate. **[CERHR benchmark dose<sup>3</sup> modeling for decreased feed consumption from GD 7–20 resulted in a BMD<sub>10</sub> of 23 mg/kg bw/day and a BMDL of 19 mg/kg bw/day. Body weight data were not provided in a form suitable for benchmark dose calculation.]** Duration of gestation was prolonged by about 0.5 days with 20 mg/kg bw/day *d*-methylphenidate and 40 mg/kg bw/day *d,l*-methylphenidate. There were no treatment-related

---

<sup>3</sup> The BMD<sub>10</sub> is the benchmark dose associated with a 10% effect, estimated from a curve fit to the experimental data. The BMDL represents the dose associated with the lower 95% confidence interval around this estimate. Benchmark doses are used commonly in a regulatory setting; however, they are used in this report when the underlying data permit their calculation, and are only supplied to provide one kind of description of the dose-response relationship in the underlying study. Calculation of a benchmark dose in this report does not mean that regulation based on the underlying data is recommended, or even that the underlying data are suitable for regulatory decision-making.

effects on number of live or stillborn pups, pup birth weight, and pup weight or survival during the lactation period. There were no notable findings in pups necropsied on PND 21. The only treatment-related reductions in body weight gain and feed consumption occurred in F<sub>1</sub> males of the 40 mg/kg bw/day *d,l*-methylphenidate group during the PND 1–71 time period. Terminal body weights were decreased in F<sub>1</sub> males dosed with 20 mg/kg bw/day *d*-methylphenidate and 40 mg/kg bw/day *d,l*-methylphenidate. There were no treatment-related effects on day of preputial separation or vaginal patency, and no effects on passive-avoidance test or water-filled M-maze performance **[data were not shown]**. Mating of the F<sub>1</sub> animals showed no treatment-related effects on number of pregnant animals, corpora lutea, or implantations, and no alterations in live or dead fetuses/litter, resorptions, sex ratio, or fetal weight. The authors estimated from AUC values that the top dose of *d*-methylphenidate used in this study was 5.6 times the human therapeutic dose. The decrease in weight in F<sub>1</sub> males was evaluated as consistent with the decrease in feed consumption, although no explanation could be given for the lack of effect in females. *d*-Methylphenidate at this dose was considered not to have adverse reproductive effects. **[Results of the F<sub>1</sub> mating study are repeated in Section 4.2 for comparison to other studies with reproductive endpoints; because exposure of the F1 animals was through treatment of their dams during pregnancy and lactation, this study is a developmental study, albeit one with reproductive endpoints.]**

A series of experiments by Greeley and Kizer (163) provided some useful information, although the studies were conducted with high doses administered through the sc route, a scenario that is not relevant to therapeutic human exposures. The studies involved twice daily sc administration of 1 or more dose levels between 2 and 200 mg/kg bw/day delivered as two divided doses to Sprague-Dawley rats during ~PND 5–26. Growth (body weight and naso-anal length) was reduced in rats treated with  $\geq 70$  mg/kg bw/day methylphenidate on ~PND 5–26, but there was no effect on naso-anal length 1 year following treatment. Inhibited growth appeared to result from anorexigenic properties of methylphenidate at 70 mg/kg bw/day, but additional factors were apparently involved at 200 mg/kg bw/day. It did not appear that growth was inhibited due to reduction in growth hormone because decreases were noted only in female rats, while growth was restricted in both sexes. Other effects of methylphenidate treatment included reduced prolactin at  $\geq 6$  mg/kg bw/day **[no dose-response effect noted]** and decreased basal insulin and enhanced response to glucose challenge at 70 mg/kg bw/day. Dosing of females with 70 or 200 mg/kg bw/day methylphenidate on ~PND 5–26 resulted in delayed vaginal opening. Although not statistically significant, a delay in vaginal opening in rats given 70 mg/kg bw/day methylphenidate on ~PND 21–51 was similar to the value observed in the younger rats. Effects of methylphenidate on estrous cycling are summarized in Section 4.2.

Single dose studies by Pizzi et al. (161, 162) also demonstrated reversible inhibition of growth in immature rats sc injected with  $\geq 35$  mg/kg bw/day methylphenidate.

Effects of behavioral sensitization following methylphenidate exposure in immature rats were examined by McDougall et al. (164) and Brandon et al. (165). McDougall reported sensitized locomotor and stereotypy responses following a methylphenidate challenge in PND-22 rats pretreated ip with methylphenidate  $\geq 2.5$  mg/kg bw/day (locomotor) and  $\geq 5.0$  mg/kg bw/day (stereotypy) on PND 16–20; by PND 28, there was no evidence of locomotor sensitization and stereotypic sensitization was observed only in rats pretreated with  $\geq 10$  mg/kg bw/day. Pretreatment of PND-10–14 rats with 20 mg/kg bw/day methylphenidate resulted only in sensitization of stereotypic responses following methylphenidate challenge. In studies using a cocaine challenge, Brandon et al. (165) reported that ip pretreatment of 5-week-old rats with  $\geq 5$  mg/kg bw/day methylphenidate for 7 days resulted in increased locomotor response following the challenge. Pretreatment of 5-week-old animals with 2 mg/kg bw/day methylphenidate resulted in

greater self administration of cocaine. While McDougall et al. (164) concluded that their study did not suggest a greater likelihood of substance abuse following methylphenidate treatment, Brandon et al. (165) concluded that their study suggested a greater vulnerability to low doses of cocaine following adolescent exposure to methylphenidate.

Posnatal neurochemical effects of methylphenidate were evaluated in a small number of studies. One study limited by statistical procedures found no effects on brain dopamine levels in rats 2 weeks after dosing with up to 50 mg/kg bw/day methylphenidate sc on PND 10–40 (166). Acute gavage dosing of 41-day-old rats with methylphenidate resulted in an increases in hippocampus norepinephrine level at  $\geq 1$  mg/kg bw and increase in nucleus accumbens dopamine level at 5.0 mg/kg bw; an association was found between decreased norepinephrine and reduced activity following administration of  $\geq 0.75$  mg/kg bw methylphenidate every 3 hours for a total of 3 doses(168). Alterations in activity of dopamine neurons in the ventral tegmental area were demonstrated for up to 21 days following treatment of 5-week-old rats with 2 mg/kg bw/day methylphenidate for 7 days (167).

### **Questions for the Expert Panel**

Are human data sufficient for an evaluation of the developmental toxicity of methylphenidate following prenatal exposure?

If so, what are the relevant exposure conditions and endpoints?

Are human data sufficient for an evaluation of developmental toxicity of methylphenidate following exposure of children?

If so, what are the relevant exposure conditions and endpoints?

Are experimental animal data sufficient for an evaluation of the developmental toxicity of methylphenidate following prenatal or lactational exposure or other exposures of immature animals?

If so, what are the relevant experimental animal models, exposure conditions, and endpoints?

If the experimental animal data are sufficient for an evaluation, are the data assumed relevant, relevant, or not relevant?

Note: The definitions of the term sufficient and the terms assumed relevant, relevant, and not relevant are in the CERHR guidelines at <http://cerhr.niehs.nih.gov/news/guidelines.html>.



**Table 33. Summary of Animal Developmental Toxicity Studies**

Species/ strain	Enantiomer/ Exposures	Maternal effect level	Critical developmental effects	Developmental effect level	Reference
Sprague- Dawley rats	<i>d</i> - methylphenidate / gavage 0, 2, 6, 20 mg/kg bw/day <sup>a</sup> on GD 7–17	LOAEL = 6 mg/kg bw/day (decreased body weight gain) NOAEL = 2 mg/kg bw/day. <b>[BMD<sub>10</sub><sup>b</sup> = 26–32 mg/kg bw/day; BMDL = 18–21 mg/kg bw/day]</b>	Ossification delay (only on a per fetus but not per litter basis)	LOAEL = 20 mg/kg bw/day (maternal blood level = 463 ng/mL) NOAEL = 6 mg/kg bw/day <b>[BMD<sub>10</sub> 31–36 mg/kg bw/day; BMDL = 23–24 mg/kg bw/day]</b>	Teo et al. (48)
Sprague- Dawley rats	<i>d</i> - methylphenidate / presumed gavage 0, 2, 6, or 20 mg/kg bw/day <sup>a</sup> on GD7–PND 20	LOAEL = 20 mg/kg bw/day (decreased feed intake and weight gain) NOAEL = 6 mg/kg bw/day <b>[BMD<sub>10</sub> of 23 mg/kg bw/day; BMDL of 19 mg/kg bw/day (for feed intake, the only endpoint with acceptable data for modeling)]</b>	Decreased terminal body weight in adult male offspring	LOAEL = 20 mg/kg bw/day NOAEL = 6 mg/kg bw/day	Teo et al. (49)
Sprague- Dawley rats	Enantiomer not specified. Subcutaneous 0, 2, 6, 20, 70, or 200 mg/kg bw <sup>a</sup> on ~PND 5–26	N/A	Decreased body weight and naso-anal length during treatment	LOAEL = 70 mg/kg bw/day	Greeley and Kizer (163)
			Decreased prolactin	LOAEL = 6 mg/kg bw/day	
			Decreased growth hormone in females only	LOAEL = 6 mg/kg bw/day	
			Decreased basal insulin but enhanced response to glucose load	LOAEL = 70 mg/kg bw/day	
Sprague- Dawley rats	Enantiomer not specified. Subcutaneous 0, 70, or 200 mg/kg bw <sup>a</sup> on ~PND 5–26	N/A	Delayed vaginal opening and decreased number of estrous cycles following treatment	LOAEL = 70 mg/kg bw/day	Greeley and Kizer (163)

Species/ strain	Enantiomer/ Exposures	Maternal effect level	Critical developmental effects	Developmental effect level	Reference
New Zealand White rabbits	<i>d</i> -methylphenidate / gavage 0, 4, 20, or 100 mg/kg bw/day on GD 6–18	LOAEL = 100 mg/kg bw/day (clinical signs) NOAEL = 20 mg/kg bw/day	No adverse developmental effects	NOAEL = 100 mg/kg bw/day (maternal blood level = 39 ng/mL)	Teo et al. (48)

<sup>a</sup>Doses were given in two divided doses and the values are presented as total daily dose.

<sup>b</sup>The BMD<sub>10</sub> is the benchmark dose associated with a 10% effect, estimated from a curve fit to the experimental data. The BMDL represents the dose associated with the lower 95% confidence interval around this estimate. Benchmark doses are used commonly in a regulatory setting; however, they are used in this report when the underlying data permit their calculation, and are only supplied to provide one kind of description of the dose-response relationship in the underlying study. Calculation of a benchmark dose in this report does not mean that regulation based on the underlying data is recommended, or even that the underlying data are suitable for regulatory decision-making.

N/A = non-applicable

## 4.0 REPRODUCTIVE TOXICITY DATA

### 4.1 Human Data

No studies on human reproductive effects of methylphenidate were located.

### 4.2 Experimental Animal Data

**Morrissey et al. (64)** reviewed results of reproductive organ weight findings and sperm morphology and vaginal cytology examinations (SMVCE) conducted at the end of 50 NTP 13-week toxicity studies in rats and mice. The purpose of the review was to evaluate SMVCE as a screen for reproductive toxicants. Methylphenidate HCl was one of the chemicals reviewed and the 13-week dietary methylphenidate study in rats and mice is discussed in detail in Section 2.2.2. Results of the SMVCE analysis appear to also be discussed in an introduction of an NTP reproductive toxicity study on methylphenidate (169). According to Morrissey et al. (64), the only reproductive effects reported in male rats were an increase in relative epididymis weight and percent abnormal sperm at doses of 125, 500, and/or 2000 ppm [**the specific doses at which each effect was observed was not specified**]. Effects reported in mice were decreases in absolute cauda epididymis and testis weight and increased relative testis weight at doses of 125, 500, and/or 2000 ppm. Percent normal sperm was not affected in mice and there was no effect on sperm density or motility in rats or mice. In contrast, the NTP (169) reported that no sperm effects were observed in rats and that sperm motility was significantly reduced in all treated mouse groups (68.7% motility in treated group versus 57.5, 60.1, and 60.7% in each respective treatment group). The NTP (169) reported that disrupted estrous cycles, consisting of predominantly diestrus stage, occurred in 7/10 rats exposed to 2000 ppm. No disruption of estrous cycles was reported for mice. The NTP report concluded, “These data show that these levels of Methylphenidate in the diet of Swiss mice caused effectively no change in reproductive endpoints, despite changes in liver weights and male body weights.”

**[The Expert Panel notes that methylphenidate produced concordant results in both the rat and mouse 13-week studies. Concordance was defined as an effect on absolute testis or epididymal weights or any SMVCE parameter regardless of whether changes in body weight had occurred during the study. The positive results in rats and mice were not reproducible in the subsequent NTP continuous breeding study (see below (169)).]**

**Strengths/Weaknesses:** A strength of this study is that morphology assessments were conducted by a single designated laboratory. Samples were coded and a sufficient number of sperm were examined in each sample (~500). The study was conducted under standardized protocols and GLP. A weakness is that sample size in the 13-week studies was only 10 animals/sex/dose group, whereas the Reproductive Assessment by Continuous Breeding (RACB) study uses 20/sex/dose. Dosing was not well-timed relative to reproductive maturation. The increase in abnormal sperm in the 13-week rat methamphetamine study was small (0.18%). Without additional information on the 13-week mouse study, it is difficult to determine whether reproductive effects were secondary to general toxicity (although the reference states that doses that caused severe depression of body weight or body weight gain were not selected). Furthermore, the Morrissey reference does not state which doses altered organ weights and SMVCE parameters (the high dose was 2000 ppm). Data are not presented in the Morrissey reference; therefore, it is difficult to thoroughly evaluate the results and fully appreciate the magnitude of the changes observed. The Morrissey study (64) and NTP study (169) were conducted in different strains of mice.

**Utility (Adequacy) for CERHR Evaluation Process:** The critical reproductive organ weight, sperm morphology, and estrous cycle data are presented here only as descriptions from secondary sources, whereas the complete study data need to be examined in order to determine whether reproductive toxicity can be identified in this study. It is also necessary to have a full description of the protocols for

evaluating the reproductive toxicity endpoints. Therefore, this study is not useful for the CERHR process.

**Greeley and Kizer (163)** examined vaginal opening and estrous cycling in Sprague-Dawley rats sc injected twice daily with saline or methylphenidate at 35 or 100 mg/kg bw for 21 days at 5–7 days of age (n = 5–11/group) or 35 mg/kg bw for 30 days at 21–23 days of age (n = 9/group). The study is described in detail in Section 3.2.2 and Table 31. In the 5–7-day-old rats, methylphenidate significantly delayed vaginal opening from  $34.4 \pm 0.5$  (SEM) days of age in controls to  $38 \pm 0.7$  days in the 35 mg/kg bw group and  $39.1 \pm 1.1$  days in the 100 mg/kg bw group. The numbers of estrous cycles in the 30-day period following treatment were significantly reduced from  $5.2 \pm 0.5$  in the control group to  $3.2 \pm 0.2$  in the 35 mg/kg bw group and  $0.8 \pm 0.3$  in the 100 mg/kg bw group. Methylphenidate treatment started at 21–23 days of age did not significantly delay vaginal opening. **[However, the mean  $\pm$  SEM day of vaginal opening was within the same range as the younger age group. The values were:  $35.1 \pm 0.6$  days of age in control vs.  $38.2 \pm 2.3$  days of age in the 35 mg/kg bw group.]** In the older group, the numbers of estrous cycles were reduced during treatment ( $5.4 \pm 0.3$  in control versus  $2.3 \pm 0.2$  in treated), but there was no effect on estrous cycling following treatment. Measurement of LH and FSH levels did not result in a clear pattern of effect, leading study authors to conclude that effects on those gonadotropins were not a likely cause of estrous cycle changes. Doses that delayed vaginal opening and estrous cycling were also found to inhibit growth.

**Strengths/Weaknesses:** A strength is that this study is one of the few to directly dose neonatal pups with methylphenidate. This study is valuable in that it probes two sensitive periods for sexual differentiation in the rat. A weakness is that there is no information describing how pups were assigned to treatment groups and whether the authors controlled for litter effects. Litter effects could be a large confounder in this study. Although the group size is small, it appears adequate for detecting relevant effects. Methylphenidate was administered to rat pups by sc injection, which is not a relevant route of human therapeutic exposure. The 100 mg/kg dose clearly exceeded the maximum tolerated dose, as rat pups (5–7 days of age) given methylphenidate for 21 days weighed ~40% less than controls. Pups given 35 mg/kg methylphenidate weighed ~15% less than controls. It is difficult to discern whether methylphenidate has direct effects on vaginal opening and hormone levels or effects are secondary to delayed development and altered growth rates at high doses of methylphenidate. For graphed data, sample sizes were not given. Rat pups were given a single dose of methylphenidate and killed at various times thereafter for the determination of growth hormone, FSH, LH, and PRL levels. The dose-response relationships for these hormones were mostly poor or nonexistent in the neonatal rat pups given 0, 1, 3, 10, 35, or 100 mg/kg bw/day methylphenidate. Concentrations of LH, FSH, and growth hormone were highly variable in the juvenile animals given bolus doses of 35 or 100 mg/kg bw methylphenidate. Hormone concentrations may vary due to diurnal variation, variations in growth/maturation rate, or inappropriate sampling of hormones, particularly hormones that are episodically released. It is difficult to determine if the FSH/LH assays were sensitive to treatment due to missing information in the protocols and results. Insulin levels were decreased by methylphenidate at rest and 10 and 60 minutes after glucose administration, whereas serum insulin was markedly increased 20 minutes after glucose treatment. The mechanism for this effect is not understood. It would be useful to replicate this result because sample sizes at 20 minutes were 5 or 6 compared with samples of 9–12 for most other time points examined.

**Utility (Adequacy) for CERHR Evaluation Process:** The original data from this study would need to be examined and the literature consulted to determine whether the delay in vaginal opening was secondary to growth retardation. Determining whether the toxic effect is secondary to growth retardation is an important point to consider in a CERHR evaluation. Therefore, this study is not useful.

**The NTP (169)** conducted a continuous breeding study to examine the reproductive toxicity of methylphenidate in mice. In the GLP study, male and female Swiss CD-1 mice were fed diets containing 0, 0.012, 0.05, or 0.1% methylphenidate hydrochloride. Authors estimated respective methylphenidate doses of 0, 18.2, 75.7, and 160.2 mg/kg bw/day in males and 0, 17.7, 76.0, and 150 mg/kg bw/day in females. Doses were selected based on effects reported in the literature and the goal was to minimize possible confounding due to hepatic toxicity or body weight effects. Purity of methylphenidate hydrochloride was >99%. **[Though not specified, it is assumed that the racemic form of the drug was administered.]** Stability and levels of methylphenidate in feed were verified. The control group contained 40 mating pairs and each treatment group, 20 mating pairs each. Animals were exposed to methylphenidate during a 7-day pre-cohabitation period, a 98-day cohabitation period, and during the 21-day nursing period for the last litter produced. **[Though not clearly explained in the protocol, CERHR is aware that this type of study involves removing all but the last litter produced so that the animals can continue mating].** After the last litter was weaned, the animals from the high-dose group were given diets containing the same levels of methylphenidate hydrochloride as their parents (0.1% or 151.7 mg/kg bw/day in males and 171.4 mg/kg bw/day in females). Upon reaching sexual maturity, male and female F<sub>2</sub> control and high-dose animals (~20/group/sex) were mated within respective treatment groups for 7 days in order to evaluate fertility. Statistical analyses include Cochran-Armitage and Fisher exact test to evaluate fertility; Kruskal-Wallis, Jonckheere, and Wilcoxon-Mann-Whitney U tests to evaluate numbers of litters, live pups, and organ weights; F-test and *t*-test to evaluate pup weight (co-varied with litter size); and Jonckheere, Shirley, and Dunn test to evaluate body weight and food intake.

Due to deaths of mice in each dose group, reproductive parameters were examined in 30–37 pairs of F<sub>0</sub> controls and 15–19 F<sub>0</sub> pairs/treatment group. Methylphenidate treatment of F<sub>0</sub> mice did not significantly affect fertility, cumulative days to litter, number of litters/pair, litter size, live pups, or live pup sex or weight. Methylphenidate did not affect food intake in male or female F<sub>0</sub> mice. F<sub>0</sub> female body weight was not affected, but body weights of males in the 0.1% group were significantly lower at weeks 6, 10, and 14. Sperm motility vaginal cytology evaluations (SMVCE) and necropsies were conducted in 10 F<sub>0</sub> mice/sex from the control and 0.1% dose groups **[presumably after weaning of the F<sub>1</sub> litters]**. Vaginal smears conducted for 12 days prior to necropsy revealed no effect of 0.1% methylphenidate on estrous cycle length or frequency of stages. Absolute and adjusted (to body weight) liver weights were increased in F<sub>0</sub> females from the 0.1% groups. Treatment with 0.1% methylphenidate had no effect on epididymal sperm motility or density; percentage of abnormal sperm was reduced in the 0.1% group. Body weight was significantly reduced in males treated with 0.1% methylphenidate. There was no effect on absolute weight of seminal vesicles, right epididymis, right testis, cauda epididymus, or prostate gland. Absolute and relative liver weight were increased in males of the 0.1% group. No histopathological evaluations were conducted in F<sub>0</sub> mice.

There were no significant effects on postnatal survival, weight gain, or food intake in F<sub>1</sub> pups. In the reproductive assessment of F<sub>1</sub> mice, 17/20 control pairs and 18/19 pairs in the 0.1% methylphenidate group were fertile. Treatment of F<sub>1</sub> mice with 0.1% methylphenidate had no significant effects on mating, fertility, live pups/litter, or pup sex or weight. All surviving F<sub>1</sub> animals underwent an SMVCE analysis and were necropsied at the end of the study **[presumably following birth of the F<sub>2</sub> litters]**. Monitoring of estrous cycles for 12 days prior to necropsy revealed no effect of 0.1% methylphenidate on length of estrous cycle or frequency of estrous phases. Terminal body weight of F<sub>1</sub> females in the 0.1% group was not affected. Absolute and relative liver and ovary weights and absolute kidney weights were increased in F<sub>1</sub> females of the 0.1% group. In F<sub>1</sub> males of the 0.1% group, there was no adverse effect on epididymal sperm motility, density, or morphology and testicular sperm count. Terminal body weights of males in the 0.1% group were not affected. Organ weight changes in F<sub>1</sub> males of the 0.1% group included an increase in absolute and relative liver weight, and decrease in

absolute and relative seminal vesicle weight. No histopathological evaluations were conducted in F<sub>1</sub> mice.

**[The Expert Panel notes that contrary to Morrissey's (64) results in rats, the NTP study (169) demonstrated that epididymal sperm abnormalities were significantly decreased relative to concurrent controls. The NTP authors concluded that there were no changes in murine reproductive endpoints at <1000 ppm in the diet.]**

**Strengths/Weaknesses:** Strengths include verification of dietary concentrations and stability of methylphenidate. Sample sizes were sufficient and statistical analyses were appropriate. In the introduction to the NTP study (169), the authors reference a subchronic mouse study, wherein dietary doses of >125 ppm methylphenidate decreased sperm motility and doses >250 ppm increased liver weights. It is unclear if this references the same data set as Morrissey et al. (64). The NTP references dose levels of 125 and 250 ppm in the previous methamphetamine subchronic study. While 125 ppm appears as a dose level in the Morrissey study, 250 ppm does not (perhaps this dose level was not selected for SMVCE monitoring). In addition, the NTP introduction references a decrease in mouse sperm motility, whereas the Morrissey study referenced differences in reproductive organ weights in mice.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is very useful in the evaluation process.

**Teo et al. (49)**, from Celgene Corporation, treated pregnant Sprague-Dawley rats with *d*-methylphenidate (purity 98–102%) or *d,l*-methylphenidate (chiral purity 50:50) given orally in two daily doses 6 hours apart. **[The route (oral) is indicated only in the Discussion section; another paper by these authors (48) used gavage treatment and the Expert Panel assumes gavage treatment for this study as well.]** In the main study, discussed in Section 3.2.2, 25 pregnant rats/dose group were given *d*-methylphenidate at 0, 2, 6, or 20 mg/kg bw/day or *d,l*-methylphenidate 40 mg/kg bw/day. Animals were given these doses in 2 equal treatments **[presumed gavage]** separated by 6 hours on GD 7–PND 20 (plug = GD 0, birth = PND 1). Pups were weaned on PND 21 and 25 male and female offspring per dose group were followed as the F<sub>1</sub> generation, using at least 1 pup/sex/litter where possible. Females were evaluated for vaginal patency beginning on PND 28 and males were evaluated for preputial separation beginning on PND 39. At approximately 90 days of age, 1 F<sub>1</sub> male and 1 F<sub>1</sub> female/litter were cohabited for 21 days, after which males were killed and necropsied. Females were killed and necropsied on GD 20. Data were analyzed using ANOVA with post-hoc Dunnett test or Kruskal-Wallis with Dunn test, depending on homogeneity of variance.

Clinical signs (hyperactivity and aggression) were noted in the F<sub>0</sub> dams given 6 mg/kg bw/day *d*-methylphenidate. Additional clinical signs were noted at 20 mg/kg bw/day *d*-methylphenidate and at 40 mg/kg bw/day *d,l*-methylphenidate. There was a higher incidence of clinical signs at 40 mg/kg bw/day *d,l*-methylphenidate than at 20 mg/kg bw/day *d*-methylphenidate, although the amount of the active enantiomer (*d*-methylphenidate) was identical in both treatments. Duration of gestation was prolonged by about 0.5 days in the groups given *d*-methylphenidate 20 mg/kg bw/day and *d,l*-methylphenidate 40 mg/kg bw/day. There were no treatment-related effects on number of live or stillborn pups, pup survival during the lactation period, or pup weight at birth or during the lactation period. There were no notable findings in pups necropsied on PND 21. Body weight gain and feed consumption in the F<sub>1</sub> males in the *d,l*-methylphenidate 40 mg/kg bw/day group were decreased for several individual weeks and overall in the PND 1–71 time period. There was no effect on body weight or feed consumption for any of the doses of *d*-methylphenidate, and female F<sub>1</sub> body weight was not affected by any of the treatments during PND 1–71. There were no treatment-related effects on day of preputial separation or vaginal patency. Terminal body weights were decreased in F<sub>1</sub> males in the *d*-methylphenidate 20 mg/kg

bw/day and *d,l*-methylphenidate 40 mg/kg bw/day groups. Relative weight of the testis was increased in the *d,l*-methylphenidate 40 mg/kg bw/day group, but not in any of the *d*-methylphenidate groups. Mating of the F<sub>1</sub> animals showed no treatment-related effects on number of pregnant animals, corpora lutea, or implantations, and no alterations in live or dead fetuses/litter, resorptions, sex ratio, or fetal weight. Doses of *d*- and *d,l*-methylphenidate were 40 and 27 times the maximum daily human therapeutic dose, respectively. The authors estimated from AUC values that the top doses of *d*-methylphenidate and *d,l*-methylphenidate used in this study were 5.6 and 11.9 times the human therapeutic dose. The decrease in weight in F<sub>1</sub> males was evaluated as consistent with the decrease in feed consumption, although no explanation could be given for the lack of effect in females. *d*-Methylphenidate at this dose was considered not to have adverse reproductive effects. **[The Expert Panel notes that dosing of the F<sub>1</sub> animals in the study of Teo et al. (49) occurred only through treatment of their dams during pregnancy and lactation. This study is, then, a developmental toxicity study. The study is presented here, however, because many of the endpoints were reproductive in nature. The study is presented in this section for comparison with the available reproductive toxicity studies, but the conclusions derived from this study are presented in Section 3. The Expert Panel notes that aside from decreased gestational body weight gains, minimal clinical signs (dilated pupils and increased vocalization in *d,l*-methylphenidate dams only) and effects on F<sub>1</sub> male body weight gains and terminal body weights at 20 and 40 mg/kg bw/day *d*- or *d,l*-methylphenidate, respectively, neither compound produced significant adverse effects in F<sub>0</sub> or F<sub>1</sub> rats.]**

**Strengths/Weaknesses:** This study had sufficient group sizes, appropriate controls, and appropriate statistical analyses. The investigators controlled for litter effects. Chemical purity and stability were verified. A weakness is that there were no toxicokinetic measurements taken during lactation. Pups were only exposed to methylphenidate through maternal milk on PND 1–20. This feature, coupled with interspecies differences in developmental stage at birth, makes it difficult to extrapolate this dose regimen to children who are given methylphenidate directly. Also, there was some confusion in the study text describing *d,l*-methylphenidate-associated maternal body weights (Section 3.2.2.). The passage begins by describing a decrease in maternal body weight gains at 40 mg/kg bw/day *d,l*-methylphenidate during the dosing and gestation periods. Later, the text states, “Weights were significantly greater for the 40 mg/kg bw/day *d,l*-methylphenidate groups on GD 12–15,” which is inconsistent with Figure 2 of the study. The study text also states, “No differences were seen in body weight gains between the 40 mg/kg bw/day *d,l*-methylphenidate and vehicle control groups.” The study interval for this statement is not identified (e.g., lactation body weight gains?). Aside from the passages describing maternal body weight effects, the text was clearly presented.

**Utility (Adequacy) for CERHR Evaluation Process:** This study is useful for the evaluation process, although limited based on the weaknesses identified above.

#### 4.3 Utility of Reproductive Toxicity Data

There are no data for evaluating reproductive toxicity in humans. Based on an NTP (169) study examining fertility in two generations of mice exposed to methylphenidate through diet, the Expert Panel determined there are sufficient data for evaluating reproductive toxicity in mice. A study conducted in rats (49) provided some information about reproductive toxicity in F<sub>1</sub> offspring following *in utero* and lactational exposure to methylphenidate, but was not sufficient for examining reproductive toxicity in rats because there was no exposure of F<sub>0</sub> males and females prior to mating.

## 4.4 Summary of Reproductive Toxicity Data

### 4.4.1 Human Data

No human data were located.

### 4.4.2 Experimental Animal Data

In an NTP continuous breeding study (169), male and female Swiss CD-1 mice were fed diets containing 0, 0.012, 0.05, or 0.1% methylphenidate hydrochloride [**presumably *d,l*-enantiomers**]. Authors estimated methylphenidate doses of 0, 18.2, 75.7, and 160.2 mg/kg bw/day in males and 0, 17.7, 76.0, and 150 mg/kg bw/day in females. The control group contained 40 mating pairs and the treatment groups 20 mating pairs each. Animals were exposed to methylphenidate during a 7-day pre-cohabitation period, a 98-day cohabitation period, and during the 21-day nursing period for the last litter produced. After the last litter was weaned, the offspring from the high-dose group were given diets containing the same levels of methylphenidate hydrochloride as their parents (0.1% or 151.7 mg/kg bw/day in males and 171.4 mg/kg bw/day in females). Upon reaching sexual maturity, male and female F<sub>2</sub> control and high-dose animals (~20/group/sex) were mated within respective treatment groups for 7 days in order to evaluate fertility. Estrous cycles and sperm parameters were examined in F<sub>0</sub> and F<sub>1</sub> mice of the 0.1% methylphenidate group. Methylphenidate treatment had no effect on fertility, live pups/litter, pup sex or weight, estrous cycles, or sperm motility, density, or morphology in F<sub>0</sub> and F<sub>1</sub> mice; cumulative days to litter and number of litters/pair in F<sub>0</sub> mice; or mating of F<sub>1</sub> mice.

Teo et al. (49) treated Sprague-Dawley rats with 0, 2, 6, or 20 mg/kg bw/day *d*-methylphenidate (purity 98–102%) or 40 mg/kg bw/day *d,l*-methylphenidate given orally [**presumed gavage**] in 2 daily doses 6 hours apart from GD 7–PND 20. Pups were weaned on PND 21 and 25 male and female offspring per dose group were followed as the F<sub>1</sub> generation, using at least 1 pup/sex/litter where possible. Maternal and typical developmental toxicity findings are reported in Section 3.2 [**The Expert Panel notes that because exposure of the F<sub>1</sub> animals was entirely through treatment of their dams, all the findings in the study can be considered developmental. The study is presented in this section for comparison with the available reproductive toxicity studies, but the conclusions derived from this study are presented in Section 3.**] Duration of gestation was prolonged by about 0.5 days in the F<sub>0</sub> dams given *d*-methylphenidate 20 mg/kg bw/day and *d,l*-methylphenidate 40 mg/kg bw/day. There were no treatment-related effects on day of preputial separation or vaginal patency in F<sub>1</sub> rats. Mating of the F<sub>1</sub> animals showed no treatment-related effects on number of pregnant animals, corpora lutea, or implantations, and no alterations in live or dead fetuses/litter, resorptions, sex ratio, or fetal weight.

One study provided information on vaginal opening and estrous cycling in rats sc dosed with 0, 70, or 200 mg/kg bw methylphenidate given in 2 divided doses on ~PND 5–26, though the panel notes that the study was conducted with a route that is not relevant to therapeutic human exposures (163). Methylphenidate significantly delayed vaginal opening from 34.4 ± 0.5 (SEM) days of age in controls to 38 ± 0.7 (70 mg/kg bw) and 39.1 ± 1.1 (200 mg/kg bw) days of age in the treatment groups. The numbers of estrous cycles in the 30-day period following treatment were significantly reduced from 5.2 ± 0.5 in the control group to 3.2 ± 0.2 (70 mg/kg bw) and 0.8 ± 0.3 (200 mg/kg bw) in the treatment groups. A second group of rats was treated with 70 mg/kg bw methylphenidate for 30 days beginning at 21–23 days of age. Though not significant, vaginal opening was delayed, and occurred at the same approximate time period as the younger group (38.2 ± 2.3 days); numbers of estrous cycles were reduced only during treatment. The Expert Panel notes that it is difficult to discern whether methylphenidate has direct effects on vaginal opening and hormone levels or effects are secondary to delayed development and altered growth rates at high doses of methylphenidate.



### **Questions for the Expert Panel**

Are human data sufficient for an evaluation of the male or female reproductive toxicity of methylphenidate?

If so, what are the relevant exposure conditions and endpoints?

Are experimental animal data sufficient for an evaluation of the male or female reproductive toxicity of methylphenidate?

If so, what are the relevant experimental animal models, exposure conditions, and endpoints?

If the experimental animal data are sufficient for an evaluation, are the data assumed relevant, relevant, or not relevant?

Note: The definitions of the term sufficient and the terms assumed relevant, relevant, and not relevant are in the CERHR guidelines at <http://cerhr.niehs.nih.gov/news/guidelines.html>.

## **5.0 SUMMARIES, CONCLUSIONS, AND CRITICAL DATA NEEDS**

To be completed at Expert Panel meeting.

- 5.1 Developmental Toxicity
- 5.2 Reproductive Toxicity
- 5.3 Summary of Human Exposures
- 5.4 Overall Conclusions
- 5.5 Critical Data Needs

## 6.0 REFERENCES

1. Kimko, H. C., Cross, J. T. and Abernethy, D. R. Pharmacokinetics and clinical effectiveness of methylphenidate. *Clin Pharmacokinet* 1999; 37: 457-70.
2. Novartis. Focalin™ product labeling. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2001.
3. ChemIDplus. Methylphenidate. Available at <http://chem2.sis.nlm.nih.gov/chemidplus/ProxyServlet?objectHandle=DBMaint&actionHandle=default&nextPage=jsp/chemidlite/ResultScreen.jsp&TXTSUPERLISTID=000113451>. National Library of Medicine. 2004.
4. Novartis. Ritalin® and Ritalin-SR® product labeling. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2001.
5. Celltech. Metadate®CD product labeling. Rochester, NY: Celltech Pharmaceuticals, Inc.; 2003.
6. Mallinckrodt. Methylin® and Methylin®ER product labeling. St. Louis, MO: Mallinckrodt, Inc.; 2002.
7. ALZA. Concerta® extended-release tablets product labeling. Mountain View, CA: ALZA Corporation; 2003.
8. NTP. Toxicology and carcinogenesis studies of methylphenidate hydrochloride (CAS no. 298-59-9) in F344/N rats and B6C3F1 mice (feed studies). Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Toxicology Program; 1995.
9. FDA. Electronic Orange Book: Approved drug products with therapeutic equivalence evaluations. Available at <http://www.fda.gov/cder/ob/default.htm>. Food and Drug Administration Center for Drug Evaluation and Research. 2004.
10. Novartis. Ritalin®LA extended-release capsules product labeling. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2001.
11. Celltech. Metadate®ER tablets product labeling. Rochester, NY: Celltech Pharmaceuticals, Inc.; 2002.
12. Mallinckrodt. Methylin® chewable tablets product labeling. St. Louis, MO: Mallinckrodt, Inc.; 2003.
13. Woodworth, T. DEA congressional testimony before the: committee on education and the workforce: subcommittee on early childhood, youth and families. Available at <http://www.dea.gov/pubs/cngrtest/ct051600.htm>. U.S. Drug Enforcement Administration. 2000.
14. UN. Psychotropic substances. Available at <http://www.incb.org/e/index.htm?> United Nations International Narcotics Control Board; 2002.
15. Searight, H. R., Burke, J. M. and Rottnek, F. Adult ADHD: evaluation and treatment in family medicine. *Am Fam Physician* 2000; 62: 2077-86, 2091-2.
16. Markowitz, J. S. and Patrick, K. S. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. *Clin Pharmacokinet* 2001; 40: 753-72.
17. Madras, B. K., Miller, G. M. and Fischman, A. J. The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). *Behav Brain Res* 2002; 130: 57-63.
18. Santosh, P. J. and Taylor, E. Stimulant drugs. *Eur Child Adolesc Psychiatry* 2000; 9 Suppl 1: I27-43.
19. NIDA. InfoFacts: methylphenidate (Ritalin). Available at <http://165.112.78.61/Infofax/ritalin.html>. National Institute on Drug Abuse. 2003.
20. Teter, C. J., McCabe, S. E., Boyd, C. J. and Guthrie, S. K. Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. *Pharmacotherapy* 2003; 23: 609-17.
21. Johnston, L. D., O'Malley, P. M., Bachman, J. G. and Schulenberg, J. E. Monitoring the future-national survey results on drug use, 1975-2003: Volume I, Secondary school students. Bethesda, MD: National Institute on Drug Abuse; 2003.
22. Greenhill, L. L., Halperin, J. M. and Abikoff, H. Stimulant medications. *J Am Acad Child Adolesc Psychiatry* 1999; 38: 503-12.
23. AAP. American Academy of Pediatrics Committee on Children with Disabilities, Committee on Drugs: Medication for children with an attention deficit disorder. *Pediatrics* 1987; 80: 758-60.
24. AAP. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. *Pediatrics* 2001; 108: 1033-1044.
25. CHADD. AD/HD in Women: Information & Resource Sheet #10. Available at [http://www.help4adhd.org/documents/Women\\_PDF.pdf](http://www.help4adhd.org/documents/Women_PDF.pdf). National Resource Center on ADHD. 2004. website.
26. NCGI. The National Center for Gender Issues and ADHD at <http://www.ncgiadd.org/>. 2004. website.

27. Winsberg, B. G., Kupietz, S. S., Sverg, J., Hungund, B. L. and Young, N. L. Methylphenidate oral dose plasma concentrations and behavioral response in children. *Psychopharmacology (Berl)* 1982; 76: 329-32.
28. Teo, S. K., San, R. H., Wagner, V. O., Gudi, R., Stirling, D. I., Thomas, S. D. and Khetani, V. D. D-Methylphenidate is non-genotoxic in in vitro and in vivo assays. *Mutat Res* 2003; 537: 67-79.
29. Solanto, M. V. Clinical psychopharmacology of AD/HD: implications for animal models. *Neurosci Biobehav Rev* 2000; 24: 27-30.
30. Greenhill, L. L. Pharmacologic treatment of attention deficit hyperactivity disorder. *Psychiatr Clin North Am* 1992; 15: 1-27.
31. FDA. Ritalin LA: Clinical Pharmacology and Biopharmaceutics Reviews(s), Medical Review, and Statistical Review. Center for Drug Evaluation and Research; 2001.
32. FDA. Focalin: Chemistry Review(s), Clinical Pharmacology and Biopharmaceutics Reviews(s), and Medical Review. Center for Drug Evaluation and Research; 2001.
33. Chan, Y. P. M., Swanson, J. M., Soldin, S. S., Thiessen, J. J., Macleod, S. M. and et al. Methylphenidate hydrochloride given with or before breakfast. Part 2. Effects on plasma concentration of methylphenidate and ritalinic acid. *Pediatrics* 1983; 72: 56-59.
34. Srinivas, N. R., Hubbard, J. W., Quinn, D. and Midha, K. K. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. *Clin. Pharmacol. Ther.* 1992; 52: 561-568.
35. Wargin, W., Patrick, K., Kilts, C., Gualtieri, C. T., Ellington, K., Mueller, R. A., Kraemer, G. and Breese, G. R. Pharmacokinetics of methylphenidate in man, rat and monkey. *J Pharmacol Exp Ther* 1983; 226: 382-6.
36. Shaywitz, S. E., Hunt, R. D., Jatlow, P., Cohen, D. J., Young, J. G. and et al. Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. *Pediatrics* 1982; 69: 688-694.
37. Srinivas, N. R., Quinn, D., Hubbard, J. W. and Midha, K. K. Stereoselective disposition of methylphenidate in children with attention-deficit disorder. *J Pharmacol Exp Ther* 1987; 241: 300-6.
38. Hungund, B. L., Perel, J. M., Hurwic, M. J., Sverd, J. and Winsberg, B. G. Pharmacokinetics of methylphenidate in hyperkinetic children. *Br J Clin Pharmacol* 1979; 8: 571-6.
39. Greenhill, L. L., Perel, J. M., Rudolph, G., Feldman, B., Curran, S., Puig-Antich, J. and Gardner, R. Correlations between motor persistence and plasma levels in methylphenidate-treated boys with ADHD. *Int J Neuropsychopharmacol* 2001; 4: 207-15.
40. Coffey, B., Shader, R. I. and Greenblatt, D. J. Pharmacokinetics of benzodiazepines and psychostimulants in children. *J Clin Psychopharmacol* 1983; 3: 217-25.
41. Aoyama, T., Kotaki, H., Sasaki, T., Sawada, Y., Honda, Y. and Iga, T. Nonlinear pharmacokinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers. *Eur J Clin Pharmacol* 1993; 44: 79-84.
42. Modi, N. B., Wang, B., Noveck, R. J. and Gupta, S. K. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. *J Clin Pharmacol* 2000; 40: 1141-9.
43. Kollins, S. H. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. *J Clin Psychiatry* 2003; 64 Suppl 11: 14-8.
44. Markowitz, J. S., Morrison, S. D. and DeVane, C. L. Drug interactions with psychostimulants. *Int Clin Psychopharmacol* 1999; 14: 1-18.
45. Hubbard, J. W., Srinivas, N. R., Quinn, D. and Midha, K. K. Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder. *J. Pharm. Sci.* 1989; 78: 944-947.
46. Teo, S., Stirling, D., Thomas, S., Hoberman, A., Kiorpes, A. and Khetani, V. A 90-day oral gavage toxicity study of D-methylphenidate and D,L-methylphenidate in Sprague-Dawley rats. *Toxicology* 2002; 179: 183-96.
47. Davids, E., Zhang, K., Tarazi, F. I. and Baldessarini, R. J. Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. *Psychopharmacology (Berl)* 2002; 160: 92-8.
48. Teo, S. K., Stirling, D. I., Hoberman, A. M., Christian, M. S., Thomas, S. D. and Khetani, V. D. D-methylphenidate and D,L-methylphenidate are not developmental toxicants in rats and rabbits. *Birth Defects Res Part B Dev Reprod Toxicol* 2003; 68: 162-71.

49. Teo, S. K., Stirling, D. I., Thomas, S. D., Hoberman, A. M., Christian, M. S. and Khetani, V. D. The perinatal and postnatal toxicity of D-methylphenidate and D,L-methylphenidate in rats. *Reprod Toxicol* 2002; 16: 353-66.
50. Bakhtiar, R. and Tse, F. L. Toxicokinetic assessment of methylphenidate (Ritalin((R))) enantiomers in pregnant rats and rabbits. *Biomed Chromatogr* 2004; 18: 275-81.
51. Teo, S. K., Stirling, D. I., Thomas, S. D., Evans, M. G. and Khetani, V. D. A 90-day oral gavage toxicity study of d-methylphenidate and d,l-methylphenidate in beagle dogs. *Int J Toxicol* 2003; 22: 215-26.
52. Srinivas, N. R., Lim, H. K., Hubbard, J. W. and Midha, K. K. Evidence that dogs do not model enantioselective pharmacokinetics of dl-methylphenidate in humans. *J. Pharm. Sci.* 1991; 80: 707-708.
53. Schachter, H. M., Pham, B., King, J., Langford, S. and Moher, D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. *Cmaj* 2001; 165: 1475-88.
54. Schmidt, R. A., Glenny, R. W., Godwin, J. D., Hampson, N. B., Cantino, M. E. and Reichenbach, D. D. Panlobular emphysema in young intravenous Ritalin abusers. *Am Rev Respir Dis* 1991; 143: 649-56.
55. Gunby, P. Methylphenidate abuse produces retinopathy. *Jama* 1979; 241: 546.
56. Mizutani, T., Lewis, R. A. and Gonatas, N. K. Medial medullary syndrome in a drug abuser. *Arch Neurol* 1980; 37: 425-8.
57. Mehta, H., Murray, B. and LoJudice, T. A. Hepatic dysfunction due to intravenous abuse of methylphenidate hydrochloride. *J Clin Gastroenterol* 1984; 6: 149-51.
58. Sherman, C. B., Hudson, L. D. and Pierson, D. J. Severe precocious emphysema in intravenous methylphenidate (Ritalin) abusers. *Chest* 1987; 92: 1085-7.
59. Foley, R., Mrvos, R. and Krenzelok, E. P. A profile of methylphenidate exposures. *J Toxicol Clin Toxicol* 2000; 38: 625-30.
60. Kollins, S. H., MacDonald, E. K. and Rush, C. R. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. *Pharmacol Biochem Behav* 2001; 68: 611-27.
61. Kita, T., Wagner, G. C. and Nakashima, T. Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. *J Pharmacol Sci* 2003; 92: 178-95.
62. HSDB. Methylphenidate. Available at <http://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?/.temp/~PMHaIx:1>. National Library of Medicine. 2002.
63. NIOSH. RTECS report for 2-piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride (CAS#: 298-59-9). Available at <http://www.cdc.gov/niosh/rtecs/tm3abf10.html>. National Institute of Occupational Safety and Health. 2002.
64. Morrissey, R. E., Schwetz, B. A., Lamb Jr, I. V., Ross, M. D., Teague, J. L. and Morris, R. W. Evaluation of Rodent Sperm, Vaginal Cytology, and Reproductive Organ Weight Data from National Toxicology Program 13-Week Studies. *Fundam Appl Toxicol* 1988; 11: 343-358.
65. Walker, A. P. and Dumars, K. W. Commonly Used Pediatric Drugs, Sister Chromatid Exchanges and the Cell Cycle. *Am J Hum Genet* 1977; 29:
66. Matthews, E. J., Spalding, J. W. and Tennant, R. W. Transformation of BALB/c-3T3 cells: V. Transformation responses of 168 chemicals compared with mutagenicity in Salmonella and carcinogenicity in rodent bioassays. *Environ Health Perspect* 1993; 2: 347-482.
67. Selby, J. V., Friedman, G. D. and Fireman, B. H. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. *Cancer Res* 1989; 49: 5736-47.
68. Dunnick, J. K. and Hailey, J. R. Experimental studies on the long-term effects of methylphenidate hydrochloride. *Toxicology* 1995; 103: 77-84.
69. Fukui, R., Svenningsson, P., Matsuishi, T., Higashi, H., Nairn, A. C., Greengard, P. and Nishi, A. Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice. *J Neurochem* 2003; 87: 1391-401.
70. Debooy, V. D., Seshia, M. M., Tenenbein, M. and Casiro, O. G. Intravenous pentazocine and methylphenidate abuse during pregnancy. Maternal lifestyle and infant outcome. *Am J Dis Child* 1993; 147: 1062-5.
71. Heinonen, O. P. Birth defects and drugs in pregnancy. ed. Littleton, MA: Publishing Sciences Group Inc; 1977.
72. Rapoport, J. L., Quinn, P. O., Bradbard, G., Riddle, D. and Brooks, E. Imipramine and methylphenidate treatments of hyperactive boys. A double-blind comparison. *Arch. Gen. Psychiatry* 1974; 30: 789-793.
73. Conners, C. K. and Taylor, E. Pemoline, methylphenidate, and placebo in children with minimal brain dysfunction. *Arch Gen Psychiatry* 1980; 37: 922-30.

74. Barkley, R. A., McMurray, M. B., Edelbrock, C. S. and Robbins, K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. *Pediatrics* 1990; 86: 184-92.
75. Handen, B. L., Feldman, H., Gosling, A., Breaux, A. M. and McAuliffe, S. Adverse side effects of methylphenidate among mentally retarded children with ADHD. *J Am Acad Child Adolesc Psychiatry* 1991; 30: 241-5.
76. Fine, S. and Johnston, C. Drug and placebo side effects in methylphenidate-placebo trial for attention deficit hyperactivity disorder. *Child Psychiatry Hum Dev* 1993; 24: 25-30.
77. Ahmann, P. A., Waltonen, S. J., Olson, K. A., Theye, F. W., Van Erem, A. J. and LaPlant, R. J. Placebo-controlled evaluation of Ritalin side effects. *Pediatrics* 1993; 91: 1101-6.
78. Schachar, R. J., Tannock, R., Cunningham, C. and Corkum, P. V. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. *J Am Acad Child Adolesc Psychiatry* 1997; 36: 754-63.
79. Kent, J. D., Blader, J. C., Koplewicz, H. S., Abikoff, H. and Foley, C. A. Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. *Pediatrics* 1995; 96: 320-325.
80. Efron, D., Jarman, F. and Barker, M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. *Pediatrics* 1997; 100: 662-6.
81. Connor, D. F. Preschool attention deficit hyperactivity disorder: a review of prevalence, diagnosis, neurobiology, and stimulant treatment. *J Dev Behav Pediatr* 2002; 23: S1-9.
82. Satterfield, J. H., Schell, A. M. and Barb, S. D. Potential risk of prolonged administration of stimulant medication for hyperactive children. *J Dev Behav Pediatr* 1980; 1: 102-7.
83. Aarskog, D., Ferang, F., Klove, H., Stoa, K. F. and Thorsen, T. Effect of the stimulant drugs, dextroamphetamine and methylphenidate on secretion of growth hormone in hyperactive children. *J. Pediatr.* 1977; 90: 136-139.
84. Brown, W. A. and Williams, B. W. Methylphenidate increases serum growth hormone concentrations. *J Clin Endocrinol Metab* 1976; 43: 937-9.
85. Schultz, F. R., Hayford, J. T., Wolraich, M. L., Hintz, R. L. and Thompson, R. G. Methylphenidate treatment of hyperactive children: effects on the hypothalamic-pituitary-somatomedin axis. *Pediatrics* 1982; 70: 987-992.
86. Hunt, R. D., Cohen, D. J., Anderson, G. and Clark, L. Possible change in noradrenergic receptor sensitivity following methylphenidate treatment: growth hormone and MHPG response to clonidine challenge in children with attention deficit disorder and hyperactivity. *Life Sci* 1984; 35: 885-97.
87. Knights, R. M. and Hinton, G. G. The effects of methylphenidate (Ritalin) on the motor skills and behavior of children with learning problems. *J Nerv Ment Dis* 1969; 148: 643-53.
88. Greenberg, L. M. and Yellin, A. M. Blood pressure and pulse changes in hyperactive children treated with imipramine and methylphenidate. *Am. J. Psychiatry* 1975; 132: 1325-1326.
89. Aman, M. G. and Werry, J. Methylphenidate in children: effects upon cardiorespiratory function on exertion. *Int J Ment Health* 1975; 4: 119-131.
90. Ballard, J. E., Boileau, R. A., Sleator, E. K., Massey, B. H. and Sprague, R. L. Cardiovascular responses of hyperactive children to methylphenidate. *J. Am. Med. Assoc.* 1976; 236: 2870-2874.
91. Brown, R. T., Wynne, M. E. and Slimmer, L. W. Attention deficit disorder and the effect of methylphenidate on attention, behavioral, and cardiovascular functioning. *J Clin Psychiatry* 1984; 45: 473-6.
92. Brown, R. T. and Sexson, S. B. Effects of methylphenidate on cardiovascular responses in attention deficit hyperactivity disorder adolescents. *J Adolesc Health Care* 1989; 10: 179-83.
93. Kelly, K. L., Rapport, M. D. and DuPaul, G. J. Attention deficit disorder and methylphenidate: a multi-step analysis of dose-response effects on children's cardiovascular functioning. *Int Clin Psychopharmacol* 1988; 3: 167-81.
94. Safer, D. J. Relative cardiovascular safety of stimulants used to treat attention-deficit hyperactivity disorder. *J Child Adolesc Psychopharmacol* 1992; 2: 279-90.
95. Gross-Tsur, V., Manor, O., van der Meere, J., Joseph, A. and Shalev, R. S. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? *J Pediatr* 1997; 130: 670-4.
96. Hemmer, S. A., Pasternak, J. F., Zecker, S. G. and Trommer, B. L. Stimulant therapy and seizure risk in children with ADHD. *Pediatr Neurol* 2001; 24: 99-102.
97. Lucas, A. R. and Weiss, M. Methylphenidate hallucinosis. *Jama* 1971; 217: 1079-81.

98. Young, J. G. Methylphenidate-induced hallucinosis: case histories and possible mechanisms of action. *J Dev Behav Pediatr* 1981; 2: 35-8.
99. Bloom, A. S., Russell, L. J., Weisskopf, B. and Blackerby, J. L. Methylphenidate-induced delusional disorder in a child with attention deficit disorder with hyperactivity. *J Am Acad Child Adolesc Psychiatry* 1988; 27: 88-9.
100. Koehler-Troy, C., Strober, M. and Malenbaum, R. Methylphenidate-induced mania in a prepubertal child. *J Clin Psychiatry* 1986; 47: 566-7.
101. Cherland, E. and Fitzpatrick, R. Psychotic side effects of psychostimulants: a 5-year review. *Can J Psychiatry* 1999; 44: 811-3.
102. Leckman, J. F. Phenomenology of tics and natural history of tic disorders. *Brain Dev* 2003; 25(Suppl 1): S24-S28.
103. Golden, G. S. Gilles de la Tourette's syndrome following methylphenidate administration. *Dev Med Child Neurol* 1974; 16: 76-8.
104. Law, S. F. and Schachar, R. J. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? *J Am Acad Child Adolesc Psychiatry* 1999; 38: 944-51.
105. Tourette's\_Syndrome\_Study\_Group. Treatment of ADHD in children with tics: a randomized controlled trial. *Neurology* 2002; 58: 527-36.
106. Denckla, M. B., Bemporad, J. R. and MacKay, M. C. Tics following methylphenidate administration. A report of 20 cases. *Jama* 1976; 235: 1349-51.
107. Golden, G. S. The effect of central nervous system stimulants on Tourette syndrome. *Ann Neurol* 1977; 2: 69-70.
108. Fras, I. and Karlavage, J. The use of methylphenidate and imipramine in Gilles de la Tourette's disease in children. *Am J Psychiatry* 1977; 134: 195-7.
109. Shapiro, A. K. and Shapiro, E. Do stimulants provoke, cause, or exacerbate tics and Tourette syndrome? *Compr Psychiatry* 1981; 22: 265-73.
110. Lowe, T. L., Cohen, D. J., Detlor, J., Kremenitzer, M. W. and Shaywitz, B. A. Stimulant medications precipitate Tourette's syndrome. *Jama* 1982; 247: 1729-31.
111. Erenberg, G., Cruse, R. P. and Rothner, A. D. Gilles de la Tourette's syndrome: effects of stimulant drugs. *Neurology* 1985; 35: 1346-8.
112. Price, R. A., Leckman, J. F., Pauls, D. L., Cohen, D. J. and Kidd, K. K. Gilles de la Tourette's syndrome: tics and central nervous system stimulants in twins and nontwins. *Neurology* 1986; 36: 232-7.
113. Sverd, J., Gadow, K. D. and Paolicelli, L. M. Methylphenidate treatment of attention-deficit hyperactivity disorder in boys with Tourette's syndrome. *J Am Acad Child Adolesc Psychiatry* 1989; 28: 574-9; discussion 580-2.
114. Borcharding, B. G., Keysor, C. S., Rapoport, J. L., Elia, J. and Amass, J. Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability? *Psychiatry Res* 1990; 33: 83-94.
115. Lipkin, P. H., Goldstein, I. J. and Adelman, A. R. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. *Arch Pediatr Adolesc Med* 1994; 148: 859-61.
116. Gadow, K. D., Sverd, J., Sprafkin, J., Nolan, E. E. and Ezor, S. N. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. *Arch Gen Psychiatry* 1995; 52: 444-55.
117. Gadow, K. D., Nolan, E., Sprafkin, J. and Sverd, J. School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. *J Dev Behav Pediatr* 1995; 16: 167-76.
118. Castellanos, F. X., Giedd, J. N., Elia, J., Marsh, W. L., Ritchie, G. F., Hamburger, S. D. and Rapoport, J. L. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. *J Am Acad Child Adolesc Psychiatry* 1997; 36: 589-96.
119. Gadow, K. D. Methylphenidate Treatment of Adhd in Children with Tourette Syndrome. Crisp Data Base National Institutes Of Health
120. Varley, C. K., Vincent, J., Varley, P. and Calderon, R. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications. *Compr Psychiatry* 2001; 42: 228-33.
121. Chilcoat, H. D. and Breslau, N. Pathways from ADHD to early drug use. *J Am Acad Child Adolesc Psychiatry* 1999; 38: 1347-54.
122. Beck, L., Langford, W. S., MacKay, M. and Sum, G. Childhood chemotherapy and later drug abuse and growth curve: follow-up study of 30 adolescents. *Am. J. Psychiatry* 1975; 132: 436-438.

123. Biederman, J., Wilens, T., Mick, E., Spencer, T. and Faraone, S. V. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. *Pediatrics* 1999; 104: e20.
124. Barkley, R. A., Fischer, M., Smallish, L. and Fletcher, K. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. *Pediatrics* 2003; 111: 97-109.
125. Fischer, M. and Barkley, R. A. Childhood stimulant treatment and risk for later substance abuse. *J Clin Psychiatry* 2003; 64 Suppl 11: 19-23.
126. Lambert, N. M. and Hartsough, C. S. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. *J Learn Disabil* 1998; 31: 533-44.
127. Lambert, N. M. Stimulant treatment as a risk factor for nicotine use and substance abuse. In: P. S. Jensen and J. R. Cooper, ed.^eds. *Attention Deficit Hyperactivity Disorder*. ed. Kingston, NJ: Civic Research Institute, 2002:
128. Paternite, C. E., Loney, J., Salisbury, H. and Whaley, M. A. Childhood inattention-overactivity, aggression, and stimulant medication history as predictors of young adult outcomes. *J Child Adolesc Psychopharmacol* 1999; 9: 169-84.
129. Loney, J., Kramer, J. R. and Salisbury, H. Medicated versus unmedicated ADHD children: adult involvement with legal and illegal drugs. In: J. P.S. and C. J., ed.^eds. *Attention Deficit Hyperactivity Disorder*. ed. Kingston, NJ: Civic Research Institute, 2002: 1-16.
130. Mannuzza, S., Klein, R. G. and Moulton, J. L., 3rd. Does stimulant treatment place children at risk for adult substance abuse? A controlled, prospective follow-up study. *J Child Adolesc Psychopharmacol* 2003; 13: 273-82.
131. Wilens, T. E., Faraone, S. V., Biederman, J. and Gunawardene, S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. *Pediatrics* 2003; 111: 179-85.
132. Wilens, T. Attention deficit hyperactivity disorder and substance abuse disorders-the nature relationship, subtypes at risk, and treatment issues. In: J. P.S. and C. J., ed.^eds. *Attention Deficit Hyperactivity Disorder*. ed. Kingston, NJ: Civic Research Institute, 2002: 1-17.
133. Safer, D., Allen, R. and Barr, E. Depression of growth in hyperactive children on stimulant drugs. *N Engl J Med* 1972; 287: 217-20.
134. Safer, D. J. and Allen, R. P. Factors influencing the suppressant effects of two stimulant drugs on the growth of hyperactive children. *Pediatrics* 1973; 51: 660-7.
135. Safer, D. J., Allen, R. P. and Barr, E. Growth rebound after termination of stimulant drugs. *J. Pediatr.* 1975; 86: 113-116.
136. Quinn, P. O. and Rapoport, J. L. One-year follow-up of hyperactive boys treated with imipramine or methylphenidate. *Am J Psychiatry* 1975; 132: 241-5.
137. Gross, M. D. Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine. *Pediatrics* 1976; 58: 423-31.
138. McNutt, B., Ballard, J. E. and Boileau, R. The effects of long-term stimulant medication on growth and body composition of hyperactive children. *Psychopharmacol Bull* 1976; 12: 13-5.
139. McNutt, B. A., Boileau, R. A. and Cohen, M. N. The effects of long-term stimulant medication on the growth and body composition of hyperactive children [proceedings]. *Psychopharmacol Bull* 1977; 13: 36-8.
140. Millichap, J. G. Growth of hyperactive children treated with methylphenidate. *J Learn Disabil* 1978; 11: 567-70.
141. Millichap, J. G. Dr. Gross's Findings Supported. *Pediatrics* 1978; 61: 146-7.
142. Satterfield, J. H., Cantwell, D. P., Schell, A. and Blaschke, T. Growth of hyperactive children treated with methylphenidate. *Arch. Gen. Psychiatry* 1979; 36: 212-217.
143. Loney, J., Whaley-Klahn, M. A., Ponto, L. B. and Adney, K. Predictors of adolescent height and weight in hyperkinetic boys treated with methylphenidate [proceedings]. *Psychopharmacol Bull* 1981; 17: 132-4.
144. Kalachnik, J. E., Sprague, R. L., Sletator, E. K., Cohen, M. N. and Ullmann, R. K. Effect of methylphenidate hydrochloride on stature of hyperactive children. *Dev Med Child Neurol* 1982; 24: 586-95.
145. Mattes, J. A. and Gittelman, R. Growth of hyperactive children on maintenance regimen of methylphenidate. *Arch Gen Psychiatry* 1983; 40: 317-21.



146. Greenhill, L. L., Puig-Antich, J., Novacenko, H., Solomon, M., Anghern, C., Florea, J., Goetz, R., Fiscina, B. and Sachar, E. J. Prolactin, growth hormone and growth responses in boys with attention deficit disorder and hyperactivity treated with methylphenidate. *J Am Acad Child Psychiatry* 1984; 23: 58-67.
147. Klein, R. G. and Mannuzza, S. Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height. *Arch Gen Psychiatry* 1988; 45: 1131-4.
148. Klein, R. G., Landa, B., Mattes, J. A. and Klein, D. F. Methylphenidate and growth in hyperactive children. A controlled withdrawal study. *Arch Gen Psychiatry* 1988; 45: 1127-30.
149. Spencer, T., Biederman, J., Wright, V. and Danon, M. Growth deficits in children treated with desipramine: a controlled study. *J Am Acad Child Adolesc Psychiatry* 1992; 31: 235-43.
150. Zeiner, P. Body growth and cardiovascular function after extended treatment (1.75 years) with methylphenidate in boys with attention-deficit hyperactivity disorder. *J Child Adolesc Psychopharmacol* 1995; 5: 129-38.
151. Schertz, M., Adesman, A. R., Alfieri, N. E. and Bienkowski, R. S. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. *Pediatrics* 1996; 98: 763-9.
152. Spencer, T. J., Biederman, J., Harding, M., O'Donnell, D., Faraone, S. V. and Wilens, T. E. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? *J Am Acad Child Adolesc Psychiatry* 1996; 35: 1460-9.
153. Rao, J. K., Julius, J. R., Breen, T. J. and Blethen, S. L. Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy. *Pediatrics* 1998; 102: 497-500.
154. Lahat, E., Weiss, M., Ben-Shlomo, A., Evans, S. and Bistrizter, T. Bone mineral density and turnover in children with attention-deficit hyperactivity disorder receiving methylphenidate. *J Child Neurol* 2000; 15: 436-9.
155. Rapport, M. D. and Moffitt, C. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. *Clin Psychol Rev* 2002; 22: 1107-31.
156. Sund, A. M. and Zeiner, P. Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children? *Nord J Psychiatry* 2002; 56: 53-7.
157. Lisska, M. C. and Rivkees, S. A. Daily methylphenidate use slows the growth of children: a community based study. *J Pediatr Endocrinol Metab* 2003; 16: 711-8.
158. Poulton, A. and Cowell, C. T. Slowing of growth in height and weight on stimulants: a characteristic pattern. *J Paediatr Child Health* 2003; 39: 180-5.
159. MTA-Cooperative-Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. *Arch Gen Psychiatry* 1999; 56: 1073-86.
160. MTA-Cooperative-Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. *Pediatrics* 2004; 113: 762-9.
161. Pizzi, W. J., Rode, E. C. and Barnhart, J. E. Methylphenidate and growth: demonstration of a growth impairment and a growth-rebound phenomenon. *Dev Pharmacol Ther* 1986; 9: 361-8.
162. Pizzi, W. J., Rode, E. C. and Barnhart, J. E. Differential effects of methylphenidate on the growth of neonatal and adolescent rats. *Neurotoxicol Teratol* 1987; 9: 107-11.
163. Greeley, G. H., Jr. and Kizer, J. S. The effects of chronic methylphenidate treatment on growth and endocrine function in the developing rat. *J Pharmacol Exp Ther* 1980; 215: 545-51.
164. McDougall, S. A., Collins, R. L., Karper, P. E., Watson, J. B. and Crawford, C. A. Effects of repeated methylphenidate treatment in the young rat: sensitization of both locomotor activity and stereotyped sniffing. *Exp Clin Psychopharmacol* 1999; 7: 208-18.
165. Brandon, C. L., Marinelli, M., Baker, L. K. and White, F. J. Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats. *Neuropsychopharmacology* 2001; 25: 651-61.
166. Wagner, G. C., Schuster, C. R. and Seiden, L. S. Neurochemical consequences following administration of CNS stimulants to the neonatal rat. *Pharmacol Biochem Behav* 1981; 14: 117-9.
167. Brandon, C. L., Marinelli, M. and White, F. J. Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons. *Biol Psychiatry* 2003; 54: 1338-44.

168. Kuczenski, R. and Segal, D. S. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. *J Neurosci* 2002; 22: 7264-71.
169. NTP. Methylphenidate HCl reproduction and fertility assessment in swiss CD-1 mice when administered via feed. Research Triangle Park, NC: National Toxicology Program, National Institute of Environmental Health Sciences; 1989.